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ABSTRACT
In order to study a complex biological phenomenon such as tumor cell metastasis, one must focus on
examining discrete aspects of the process which are amenable to experimentation. In this thesis, I made
use of xenograft and spontaneous in vivo mouse models of prostate cancer to approach this problem
from two perspectives. First, I sought to identify genes which were involved with metastasis. Second, I
focused on the mechanistic elements involved with tumor cell intravasation into lymphatics. The results
from this work have shown that loss of Protein 4.1B, a 4.1/ezrin/radixin/moesin (FERM) domain-
containing cytoskeletal protein, is a frequent event in prostate cancer. The significance of this finding was
confirmed by experimental ablation of 4.1B, which enhanced tumor progression and metastasis, at least
in part, by protecting cells against apoptosis. This thesis has also shown that metastatic dissemination to
lymph nodes is mediated primarily by peritumoral lymphatic vessels, which surround the tumor at the
invasive margins. In contrast, inhibition of intratumoral lymphatics did not affect metastatic spread,
indicating that these vessels were unnecessary for tumor cell dissemination. The genetic and
mechanistic findings from this thesis were consistent across both model systems examined, and are also
in concordance with observations made in human clinical prostate cancer. Thus, the results of this work
have contributed small pieces of knowledge to our overall understanding of how tumors initiate, and
frequently complete, the elaborate and often lethal process of spreading throughout the body.
Thesis Supervisor: Richard Hynes
Title: Professor of Biology
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CHAPTER 1. INTRODUCTION
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Metastasis: Guiding Principles
The term "metastasis" derives from the Greek word methistanai, meaning "change of the state." In the
context of cancer, it is used to describe the process by which malignant cells from a primary tumor
disseminate to other parts of the body. While it is estimated that metastasis is ultimately responsible for
90% of cancer-related deaths, the task of undergoing a "change of the state" is not an easy one, even for
transformed cells. In order to metastasize, a tumor cell must possess or acquire the ability to surmount a
variety of obstacles-challenges that include de-adhesion from the primary tumor, intravasation into blood
or lymphatic vasculature, survival in circulation, extravasation, and growth at a secondary site. With so
many barriers that need to be overcome, it is almost a wonder that tumors ever succeed at metastasis.
This is likely accomplished, at least in part, through persistence: Each gram of primary tumor is believed
to release up to 4 x 106 malignant cells into circulation daily, and even a single cell, if endowed with the
appropriate capabilities, has the potential to be fatal [Butler and Gullino, 1975]. But what is it exactly that
makes a cancer cell metastatic? As will become evident, the problem of understanding how a tumor
embarks upon and completes its metastatic journey involves asking at least two fundamental questions:
Where is the malignant cell going? And where did it come from?
A discussion about where tumor cells are going, or in other words, where they eventually metastasize to,
invariably begins with the theories set forth by Stephen Paget. For it was Paget, an English surgeon at
the turn of the twentieth century, who first popularized the "seed and soil" theory for metastasis in his
1889 paper, "The Distribution of Secondary Growths in Cancer of the Breast"' [Paget, 1889]. In his
paper, he argued that the patterns of metastasis observed for tumors were non-random and could be
explained by organ-specific factors that favored colonization by certain tumor cell types but not others. In
other words, just as a seed cannot flourish unless sown into fertile soil, a metastatic tumor cell ("the
seed") cannot proliferate unless surrounded by an organ that provides a hospitable growth environment
("the soil"). In the case of breast cancer, that appropriate soil would be found in the lungs, bones, brain
and liver-all common sites of metastasis for this tumor. For other cancer types, the right soil might exist
within different organs. In this way, Paget was among the first to realize that the determinants of organ-
specific metastasis rested not only on the tumor cell itself, but also, from a wider standpoint, on how it
interacts with its surrounding microenvironment.
Paget's views, to some extent, are contrasted by those proposed by James Ewing, an American
pathologist who argued in 1929 that patterns of blood flow, rather than "seed and soil," were the major
factors that affected site-specific metastasis [Ewing, 1919]. As tumor cells in circulation are thought to
arrest in the first or second capillary bed they encounter, how different organs are connected by blood
1 Although Paget is widely credited for his "seed and soil" hypothesis, the idea likely originated from Fuchs, in his 1882
paper, "Das Sarkom des Uvealtractus." In fact, Paget states in his paper that "the chief advocate of this theory of the
relation between the embolus and the tissues which receive it is Fuchs." (http://en.wikipedia.org/wiki/Stephen_Paget)
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flow could potentially impact the eventual site of metastasis from a particular tumor. In fact, it is now
believed that both Paget's and Ewing's hypotheses are likely true. A survey of eight different tumor types
undertaken by Weiss et al., in 1992, revealed that venous blood flow patterns could account for the
distribution of metastases observed in 68% of cases [Weiss, 1992]. In the roughly one-third of patients
where Ewing's hypothesis did not apply, "seed and soil" was likely to be important. In any case,
mechanical factors such as blood flow patterns almost certainly determine where tumor cells will end up.
But whether these cells will eventually form metastases may depend on whether their microenvironment
supports, or at least tolerates, the continued growth of these malignant cells.
As mentioned previously, any discussion about where tumors metastasize to, should be accompanied by
an examination of where these cells first came from. This can entail several aspects, not only limited to
where a metastatic cell physically started its journey, but also including the cell type from which it
originated, and the patterns of genetic and epigenetic changes that differentiate it from normal. In regard
to the location from which metastatic dissemination begins, it has already been mentioned that blood flow
patterns at the site of origin are important. But Ewing's hypothesis might also be extended to include the
lymphatic system, a common route of metastasis for many tumors. Indeed, the existence of this second
system of fluid transport has been known since around 1650, when the lymphatic system was co-
discovered by Thomas Bartholin and Olaus Rudbeck. And perhaps even more so than blood vessels, the
patterns of lymphatic drainage determine where tumors will metastasize: Invasion invariably begins at
the draining, or sentinel, lymph node, and spreads outwards based upon afferent and efferent lymphatic
connections. If the sentinel lymph node is free of metastasis, the other 500-600 lymph nodes in the
human body will almost certainly be un-invaded[Nathanson, 2003; Wittekind, 2000]. Given that the
presence of lymph node metastases has important prognostic implications in the clinic, and that
lymphatics provide an additional route by which tumors can enter venous circulation, attention will be
focused on this important subject in the later chapters of this thesis.
We have already mentioned that Paget's original hypothesis emphasized the role of soil in the
propagation of metastases at the final site of invasion. A corollary to this might surmise that the
microenvironment, or stroma, that surrounds a primary tumor might also affect metastatic proclivity at the
site of origin. This stroma comprises cellular components including fibroblasts, immune cells, endothelial
cells and endothelial-associated cells. These different cell types could potentially communicate with each
other, and/or with tumor cells, through a variety of signals, including cytokines, matrix molecules and
other secreted factors. In fact, recent work has shown that the outcomes of these interactions can affect
metastasis by enhancing the innate aggressiveness of the tumor cell, by inducing the local growth of
blood and lymphatic vessels, and even perhaps by establishing a pre-metastatic niche at future sites of
invasion [Gupta and Massague, 2006]. Therefore, the perception of metastasis as a solitary journey
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undertaken by a single rogue cell can be regarded as overly simplistic and perhaps, these days, even
antiquated.
By now we have discussed how factors extrinsic to the malignant cell might affect metastasis, and it is
important to turn our attention to how intrinsic factors might also govern the process. In a sense, this also
involves asking a metastatic cell where it came from-how it originally developed, whom it is immediately
descended from, and how it became malignant. Genome-wide gene expression analyses have certainly
revolutionized the way some of these questions are now viewed and studied, as will be discussed below,
though some of the most thought-provoking principles about metastasis were originally conceived by
Isaiah J. Fidler in the 1970s and 1980s. Work by Irving Zeidman in the 1950s had already shown that the
number of experimental metastases formed in a mouse is a function of the number of cells introduced into
the animal [Zeidman et al., 1950], but Fidler made efforts to quantitate this process temporally by injecting
radiolabeled B16 melanoma cells [Fidler, 1970]. And, in fact, he found that metastasis is an exceeding
rare occurrence: less than 0.01% of these cells formed secondary growths in mice, and most cells were
eliminated from the animal soon after they were introduced. He also observed that the metastatic
phenotype was heritable, as cells derived from metastatic nodules following intravenous injection
exhibited enhanced metastatic potential when subsequently re-introduced into mice [Fidler, 1973]. These
observations led Fidler to propose that metastases were formed not by random cells that existed within
the bulk of the primary tumor, but, instead, by rare cells that were somehow more adept than their peers
at completing all the necessary steps of the process. By extension, this also suggested that primary
tumors were heterogeneous, composed of cells that differed drastically in their ability to colonize other
tissues.
Fidler proved these hypotheses using a modified version of the Luria-DebrOck fluctuation test [Fidler and
Kripke, 1977]. In the 1940s, Salvador Luria and Max DebrOck had observed that mutations arose
randomly in bacteria, and independently of selective pressure, rather than in response to it [Luria and
Delbruck, 1943]. In the original fluctuation test, Luria and DebrOck had shown that, within a population of
bacteria, some members were resistant to phage infection, and that these had pre-existed prior to
selection. This important concept has implications for evolution and, as Fidler demonstrated, for
metastasis. Similar in approach to the Luria-DebrOck fluctuation test, Fidler made single cell clones of his
B16 melanoma cells and showed that these clones differed widely in metastatic ability when injected into
mice [Fidler and Kripke, 1977]. This demonstrated that metastatic variants pre-existed within the original
population of cells even prior to challenge. And what was responsible for this? As in the case of resistant
bacteria and natural selection, the driving force was random variation. Indeed, subsequent work by Fidler
later showed that highly metastatic tumor cells exhibited greater genetic instability than did poorly
metastatic cells, and, overall, tumor cells are thought to be much more genetically unstable than normal
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cells [Fidler, 2003]. These findings have laid the conceptual groundwork for some of the experiments
described in the first few chapters of this thesis.
Also important has been the advent of microarray technology, which has transformed the way we study
tumor biology. Gene expression analyses have aided not only in the discovery of genes responsible for
tumor progression and metastasis, but have also enhanced our ability to make predictions concerning
clinical outcome in ways that-some may argue-are improvements over traditional methods of
histological evaluation and diagnosis. The ability to "fingerprint" tumors using array analysis has also
allowed researchers to uncover many hidden connections. While recent gene expression studies have
suggested that distant metastases resemble their primary tumors of origin [Ramaswamy et al., 2003;
Sorlie et al., 2003; van't Veer et al., 2002], other studies have indicated that the expression of specific
genes is altered in metastatic cells [Clark et al., 2000; Kang et al., 2003; Minn et al., 2005; Xu et al., 2006;
Yang et al., 2004]. These two observations are not mutually exclusive. A model incorporating both these
findings has speculated that cells derived from metastases and from their corresponding primary tumors
share an overall gene expression pattern that confers the ability to complete some, but not all, of the
steps required for metastasis[Hynes, 2003; Kang et al., 2003]. On top of this, the altered expression of a
limited number of additional genes may render a sub-population of cells fully competent for metastasis,
without changing its overall similarity to the primary tumor.
This model could help explain why a tumor's cell of origin and its accompanying differentiation program
could affect its metastatic proclivity. For instance, it has long been known that epithelial tumors often
metastasize to lymph nodes, whereas sarcomas rarely do; also, melanomas tend to be highly metastatic
tumors [Friedl and Wolf, 2003; Gupta et al., 2005]. It is possible that, based on their developmental
history and the accompanying signaling pathways and transcription factors that are activated/repressed,
certain tumors may be more prone to metastasize than others. In other words, these tumors may sit at a
knife's edge when it comes to metastasis, perhaps requiring few genetic or epigenetic changes to render
them capable of completing the process. In the case of melanomas, these tumors are derived from
melanocytes, which arose from migratory neural crest cells. It is therefore plausible that this history of
migratory behavior might, upon transformation, subsequently reappear and drive the metastatic process.
The Path of the Metastatic Cell
The journey taken by a metastatic cell from a primary tumor to a secondary site is thought to be complex,
involving the coordinated expression of dozens, if not hundreds, of genes. As will be discussed in the
next chapter, many of the models developed to study metastasis over the past few decades have been
suited for observing some, but not all, of the steps of this process. Consequently, the findings gleaned
from these studies have been, in a way, fragmentary-some are relevant to the earlier stages of
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metastasis, others to the later stages, and few studies have tracked the process from beginning to end. It
is therefore useful, when examining the path of the metastatic cell, to divide this journey into two halves:
those events that occur prior to entrance into circulation, and those that happen afterwards.
Early stages of metastasis: cell migration
In most cases, the appearance of a primary tumor precedes metastatic dissemination, although in certain
instances, patients are diagnosed with distant metastases in the absence of a recognizable primary
tumor 2 [Schmidt-Kittler et al., 2003]. In the more conventional situation, the metastatic process begins
when cancer cells detach from the primary tumor and invade blood vessels or lymphatics. This may be a
passive process where cells are simply sloughed off from the primary tumor or an active one involving
directed migration [Condeelis and Segall, 2003; Wyckoff et al., 2004]. The way a tumor cell migrates, at
least in part, may depend on the tissue from which it originates. Cells from connective tissue tumors such
as fibrosarcomas and gliomas tend to migrate individually, for instance, whereas those from melanomas
and carcinomas often migrate collectively [Friedl and Wolf, 2003]. In addition, highly differentiated
epithelial tumors may initially display collective migration, only to de-differentiate and exhibit single cell
invasion, a process termed epithelial-to-mesenchymal transition (EMT) [Thiery, 2002]. Indeed, genes that
promote EMT-including Twist [Yang et al., 2004]; Slug and Snail transcription factors [Kurrey et al.,
2005]; and components of the TGF-P signaling pathway [Oft et al., 2002; Siegel et al., 2003]-have all
been reported to enhance the earliest stages of metastasis. E-cadherin, which is often lost during EMT,
is thought to suppress cell migration and tumor progression[Perl et al., 1998].
The mechanisms by which cells migrate under normal physiological situations, such as during
embryogenesis, wound healing and immune-cell trafficking, are likely also to be relevant during the
earliest stages of metastasis. In large part, the surrounding extracellular matrix (ECM) and the integrity
of cell-cell junctions likely affect how tumor cells accomplish this[Friedl and Wolf, 2003]. Mesenchymal, or
elongated, single cell migration tends to occur in the presence of dense matrix networks. This sort of
movement typically involves cell polarization and extension of a pseudopod at the leading edge, followed
by contraction and movement of the trailing edge. A host of proteins, including cell surface receptors and
cytoskeletal proteins, are almost certainly involved. In order to establish the proper traction and adhesive
contacts needed to "pull" a cell forward, transmembrane proteins such as the heterodimeric family of
integrins are necessary to negotiate interactions with ECM components like fibronectin, collagen and
laminin [Webb and Horwitz, 2003]. This process is also aided by other cell surface receptors such as
cadherin proteins, which primarily mediate homophilic interactions; the selectins, which bind proteins
containing cell-surface carbohydrates; and certain members of the immunoglobulin-like superfamily of
2 This cancer of unknown primary (CUP) scenario is reported to occur in up 7% of patients who are initially found to
possess systemic spread without a clearly discernible primary tumor.
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proteins-the CAMs, or cell adhesion molecules-which exhibit both homo- or hetero-philic binding
capabilities [Hynes and Lander, 1992].
The formation of adhesive contacts leads to clustering of these receptors, particularly of integrins, into
focal complexes that incorporate actin-associated proteins such as a-actinin, talin, vinculin, paxilin and
tensin . Integrin signaling can activate pro-migratory pathways by signaling through molecules such as
focal adhesion kinase (FAK), which promotes cell movement through Src [Hood and Cheresh, 2002].
Pl3-kinase is also often activated, and this leads to the synthesis of 3-phosphoinositides, which are bound
by and cause re-localization of PH domain-containing proteins such as Akt to the plasma membrane
[Comer and Parent, 2002; Funamoto et al., 2002]. At least one downstream consequence of this is
activation of Rho family proteins such as Cdc42 and Racl, which have long been observed to induce
cellular protrusions such as filopodia and lamellipodia, respectively [Ridley et al., 2003]. Cdc42 has also
been reported to activate proteins such as WASP, while Racl can activate WAVE (through a variety of
adaptor proteins), and both of these can enhance the activity of Arp2/3, a critical protein which nucleates
and catalyzes filamentous actin polymerization at the leading edge of the cell [Webb and Horwitz, 2003;
Yamaguchi et al., 2005]. Not surprisingly, many of these cellular components have been implicated in
metastasis, as have numerous other proteins which have been found to be involved with cell migration
[Wang et al., 2005].
Interestingly, this cycle of cellular extension and retraction is not the only form of movement that can
contribute to metastasis. Perhaps more relevant to tumors in vivo is a second form of migration where
rounded cells are observed to "burrow," or adopt an amoeboid morphology [Friedl and Wolf, 2003]. This
is likely to be the favored mode of cellular movement under less adhesive conditions, as is often seen in
vivo or in three-dimensional cultures, where focal contacts are lacking. Although the signaling pathways
responsible for amoeboid migration have not been fully elucidated, it is known that the activity of
cytoskeletal proteins such as RhoA and ezrin 3 are required, while that of Racl is not [Sahai and Marshall,
2003]. In addition, amoeboid migration occurs independently of protease activity, in contrast to
mesenchymal migration, which has been observed to rely on the activity of matrix metalloproteinases
(MMPs). This is, perhaps, not surprising, given that the latter form of movement is thought to occur
primarily within dense ECM networks that, unless proteolyzed, may impede cell migration.
Early stages of metastasis: stromal factors
Certainly, every tumor cell possesses the innate molecular machinery to make migratory behavior
possible. But what are the stimuli and cues that actually elicit pro-invasive signaling pathways and gene
expression programs from otherwise non-migratory cells? In some cases, malignant cells in a primary
3 Ezrin and other related ERM proteins are described in greater detail in Chapter 3.
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tumor may be driven to metastasis in order to escape insults such as hypoxia, and, indeed, the presence
of a hypoxic gene expression signature has been reported to correlate with increased metastatic behavior
[Chi et al., 2006]. In most cases, however, directed migration-whether amoeboid or mesenchymal-
tends to occur in response to attraction, either towards a gradient of cytokines (chemotaxis) or matrix
molecules (haptotaxis) [Moore, 2001]. One recent illustration of this is a study performed by Wyckoff et
al, who imaged rat mammary adenocarcinomas and reported that metastatic cells were more likely to
polarize towards blood vessels than were non-metastatic cells[Wyckoff et al., 2004; Wyckoff et al., 2000].
This enhanced polarization was explained by increased expression of EGF receptor on the surface of
aggressive cells, which made them chemotactic to EGF released by macrophages lining the blood
vessels.
Based on this observation, a logical question might be: Why were there macrophages present in the
tumor to begin with? Interestingly, further work showed that these immune cells themselves had been
summoned by, the tumors, which secreted the macrophage chemotactic factor CSF-1 [Wyckoff et al.,
2004]. And so it would seem as if, at least in this experimental system, tumor-stromal communication
occurring through a series of paracrine factors initiated the metastatic process.
While the nature of these sorts of interactions, for the most part, still remain to be characterized, it is now
believed that the importance of tumor-stromal interlocution is the rule, rather than the exception, in
cancer. Within the tumor microenvironment, there are certainly many opportunities for this to take place,
as immune cells and cancer-associated fibroblasts (CAFs) are frequently observed in close proximity to
malignant cells. These CAFs have been reported to exhibit an "activated" phenotype characterized by
expression of cr-smooth muscle actin, as well as enhanced migration and abnormal secretion of cytokines
and ECM [Cunha et al., 2003]. Importantly, transplantation/co-injection experiments have demonstrated
that CAFs appear to be stably activated and can induce de novo tumorigenic growth in non-tumorigenic
prostate epithelial cells[Olumi et al., 1999], or increased tumorigenicity in human MCF-7 breast cancer
cells[Orimo et al., 2005]. In the latter case, CAFs in breast cancer were found to enhance angiogenesis
and tumor growth by secreting the chemokine SDF-1/CXCL12[Orimo et al., 2005]. This mobilized and
recruited endothelial precursor cells which were derived from the bone marrow and expressed the
receptor CXCR4.
Secretion of cytokines such as VEGF-A, VEGF-C, TGF-p, FGF, HGF, EGF, IGF and PDGF by stromal
cells has also been reported [Cunha et al., 2003]. Not surprisingly, the presence of these cytokines can
help drive several malignant processes, including the induction of tumor EMT (by TGF-p, EGF, HGF
and/or IGF), and neovascularization [Christofori, 2006]. In particular, HGF ligand binding to c-Met
receptor on tumor cells has long been known to induce scattering and an invasive phenotype [Christofori,
2006], while enhanced IGF signaling has been reported to promote metastasis in a mouse model of
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pancreatic cancer [Lopez and Hanahan, 2002]. TGF-3 also appears to be centrally important during
cancer progression, although it can act as both a positive and a negative regulator of tumorigenesis. For
instance, although TGF-P can suppress the growth of certain tumor cells, its upregulation in fibroblasts
has been shown to induce mammary carcinomas [Kuperwasser et al., 2004]. Genetic deletion of TGF-p
type II receptor specifically in fibroblasts was also associated with upregulated HGF, and induction of
spontaneous prostate and forestomach carcinomas in mice [Bhowmick et al., 2004]. In addition,
transgenic expression of constitutively active TGF-3 type I receptor in mammary tumors has been
reported to enhance metastasis [Siegel et al., 2003]. Thus, the effects of TGF-P as both a positive and
negative regulator of tumorigenesis are likely cell-type and cell-context dependent.
A similar dual effect on tumor progression and metastasis has been observed in the case of MMPs, which
are secreted by both tumor and stromal cells. MMPs act not only to degrade the surrounding ECM but
also to activate latent cytokines as well as other MMPs. Furthermore, MMPs can release matrix-bound
growth factors (e.g. VEGF-A and FGF) that can induce invasive behavior and vasculogenesis, though
cryptic collagen IV fragments released by MMP-9 can also possess potent anti-angiogenic
activity[Hamano et al., 2003]. Experimentally, spontaneous mouse mammary tumor formation was
enhanced by fibroblasts that overexpressed MMP-1 and MMP-7, but was inhibited when fibroblasts had
lost MMP-11 (reviewed in [Lynch and Matrisian, 2002]). Transgenic expression of MMP-3 in mammary
tumors has also been reported to promote EMT through disruption of E-cadherin-p-catenin
interactions[Sternlicht et al., 1999].
As illustrated previously in the case of macrophages, inflammatory cells of the innate immune system are
now regarded as critical, if not indispensable, mediators of tumor progression[Coussens and Werb, 2002].
Immune cells are major sources of growth factors and cytokines that can induce tumor invasion and
neovascularization. Tumor and/or stromal fibroblastic secretion of chemokines and other cytokines such
as VEGF-A and CSF are key to recruiting specific leukocyte populations. Macrophages, in particular, are
chemotactic to VEGF-A, M-CSF and monocyte chemotactic protein chemokines [Cursiefen et al., 2004].
In addition, neutrophils are also chemotactic to chemokines such as CXCLI/MIP-2 and are important for
angiogenesis[Scapini et al., 2004]. Finally, natural killer cells have been found to aid progression of pre-
neoplastic mammary lesions through secretion of MMPs [Bissell and Radisky, 2001].
Early stages of metastasis: intravasation and egress
In many cases, the net outcome of these varied interactions is an enhanced propensity on the part of
malignant cells to invade into, or intravasate, blood or lymphatic vasculature. While the process of
intravasation has been especially difficult to study, intravital microscopy has recently allowed real-time
observation of tumor cells entering into blood or lymphatic circulation [Hoshida et al., 2006; Wyckoff et al.,
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2000]. To some extent, the chicken chorioallantoic membrane (CAM) assay has also made possible the
ability to quantitate this process indirectly, by detecting the number of tumor cells that migrate through
blood and lymphatic vasculature from a source (the upper CAM) to a specific destination (the lower
CAM). Studies using this model have shown, for instance, that intravasation of human breast, prostate
and fibrosarcoma tumor cells into blood vessels requires the proteolytic activity of MMP-9 and urokinase
plasminogen activator [Kim et al., 1998].
Successful completion of the intravasation stage of metastasis can also be assayed by detecting
circulating tumor cells in the blood, both in animal models and in human patients. In fact, viable tumor
cells have been isolated in the blood of patients bearing nearly all types of cancer, including the most
common forms of carcinomas [Allard et al., 2004]. The presence of these circulating cells can be
detected by RT-PCR, immunohistochemistry or by culturing these cells in vitro. Although the prognostic
value of these detection methods has remained controversial, and mouse model studies have reported
that circulating tumor cells are often apoptotic and less malignant than cells present at the primary site
[Swartz et al., 1999], the entrance of tumors into the vasculature is, nonetheless, a necessary step for
metastasis. Indeed, experimentally increasing the propensity by which tumors intravasate through
vasculature-for instance, by elevating the expression of the EMT-inducing transcription factor Twist-
has been reported to yield increased metastasis [Yang et al., 2004].
In the later chapters of this thesis and also in the appendix, we address additional issues concerning how
tumor cells might be induced to enter blood and/or lymphatic circulation. Although lymphatic vessels are
more permeable than blood vessels and are, therefore, believed to be more susceptible to intravasation
by tumors, we will also explore potential molecular mechanisms that might influence this process4
Finally, the impact of the tumor microenvironment will be examined in greater detail within the latter parts
of this thesis5
Later stages of metastasis: arrest and survival in a new microenvironment
Once a tumor cell has successfully entered the throughways of the circulatory system, how does it know
where to stop? As mentioned previously, size restriction is likely to be important, at least in most
instances: While the diameter of capillaries ranges from 3-8 um and permits the trafficking of red blood
cells, which are approximately 7 um in diameter and deformable, the size of most tumor cells is on the
order of 20 um [Chambers et al., 2002]. Thus, the mechanical aspects of Ewing's hypothesis likely come
into play. However, in other cases, tumor cells have been reported to attach to the wider walls of pre-
and post-capillary vessels [Al-Mehdi et al., 2000; Wong et al., 2002]. Size restriction, at least in these
instances, seems unlikely to account for these observations.
4 Please see Appendix F: "Lymphatic or Hematogenous Dissemination: How Does a Metastatic Tumor Cell Decide?".
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Certainly, the entrance and exit of cells from circulation are not unprecedented events. Immune cells are
specialists at performing these feats, and heterotypic interactions mediated initially by selectin receptors,
then subsequently by integrins and CAMs, allow exit, or extravasation, of leukocytes from circulation
[Robinson et al., 1999]. At least the initial stages of the extravasation process, including the rolling of
individual cells along a monolayer of endothelial cells, followed by arrest, can be modeled in vitro through
use of a flow chamber. Such experimental systems have revealed, for instance, that carbohydrate-
containing cell surface proteins are critical for the arrest of circulating prostate and breast cancer cells
and, possibly, also for homotypic adhesive interactions that may facilitate the formation of tumor cell
aggregates [Glinsky et al., 2003]. In addition, these and similar results have suggested that selectins play
roles in tumor metastasis, and, indeed, several in vivo tumor studies have shown this to be the case. For
instance, spontaneous pancreatic tumors overexpressing L-selectin were found to metastasize to lymph
nodes, while tumors without L-selectin did not metastasize [Qian et al., 2001]. Mice lacking either P-
and/or L-selectin were also resistant to metastasis by colon adenocarcinoma cells [Borsig et al., 2002],
while carcinoma cells expressing elevated levels of E-selectin displayed enhanced metastasis [Krause
and Turner, 1999]. Similarly, mis-expressing or inhibiting6 selectin ligands on tumor cells has been
reported to affect their ability to disseminate [Borsig et al., 2002]. These selectin-ligand interactions likely
enhance binding not just between tumor cells and the endothelium, but also between tumors and
platelets/leukocytes. The consequences of this may be the formation of micro-emboli that help arrest
tumor cells in the vasculature, or protect them against attack from the immune system [Borsig et al.,
2002].
Numerous other tumor-endothelial interactions are likely important for extravasation. For instance, phage
homing studies as well as gene expression analyses have identified molecular differences among
vascular beds present in different organs, and the unique assortment of receptors/ligands on the surface
of specific endothelial cells likely biases the types of interactions which occur [Croix et al., 2000;
Ruoslahti, 2002]. For instance, trans-migration of tumor cells through bone marrow endothelial cells has
been shown to require interactions between the receptor CD44 and its ligand hyaluronan; between
integrin a4-1l (VLA-4) and V-CAM; and also between integrin aL(32 (LFA-1) and I-CAM [Simpson et al.,
2001]. Tumor expression of the integrins a3pl and a6P4 has also been implicated in binding laminin on
the surface of lung endothelial cells [Guo and Giancotti, 2004; Wang et al., 2004], and recent studies
have identified metadherin as an additional receptor for enhancing lung metastasis [Brown and Ruoslahti,
2004]. Finally, the cytoskeletal protein ezrin has been reported to be necessary for tumor cell
extravasation in the lung [Khanna et al., 2004].
Please see Appendix F: "Tumor-Lymphatic Interactions in an Activated Stromal Microenvironment".
6 Through pre-treatment of cells with sialidase or glycoproteases, which cleave sialylated mucins
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Although we have devoted some amount of attention to mechanisms by which tumor cells exit circulation,
others have noted that extravasation may not be a necessary step for metastasis. As will be mentioned
in Chapter 2, fluorescently-labeled fibrosarcoma and breast cancer cells have been observed to form
intravascular metastatic colonies in the pre-capillary arterioles of the lung [Al-Mehdi et al., 2000; Wong et
al., 2002]. Extravasation was rarely seen with these cells, which were wholly contained within vascular
channels. These findings appear to contradict those of others, who have reported that as many as 80%
of B16 melanoma cells extravasated into the lung parenchyma within three days after intravenous
injection [Cameron et al., 2000; Luzzi et al., 1998].
Regardless of whether tumor cells have extravasated or not, one consistent observation from all these
reports is that, in the majority of cases, these cells do not progress to form metastases. Of course, the
difficulties associated with successful metastatic colonization have been known for some time, although it
still remains unclear which step(s) of the process are rate-limiting. Given that primary tumors are capable
of sending millions of cells into circulation daily, it is believed that the latter stages of metastatic
dissemination are responsible for this inefficiency. Tumor cell survival within a new microenvironment
likely presents a major challenge, and apoptosis may account for the rapid clearance of most malignant
cells following arrest in the vasculature. Indeed, inhibiting apoptosis-through expression of anti-
apoptotic genes such as Bcl2, Bcl-XL and XIAP in tumors-has been reported to enhance metastasis
[Martin et al., 2004; Mehlen and Puisieux, 2006]. Downregulation of caspase-8 or upregulation of the
receptor TrkB has also been found to increase metastasis by conferring tumor cell resistance to anoikis, a
form of apoptosis that results when cells are detached from a substratum [Douma et al., 2004; Stupack et
al., 2006]. In addition, some have observed that apoptosis may occur when malignant cells express
integrins that are inappropriate for a novel microenvironment and are, therefore, likely to be unligated
[Stupack et al., 2006]. Clearly, there are many mechanisms that can lead to cell death, and this is almost
certainly a rate-limiting step for any metastatic cell.
Later stages of metastasis: flourishing in a novel microenvironment
Even after a tumor cell has reached its final destination and has managed to avoid undergoing apoptosis,
it faces additional challenges, one of which is to initiate malignant growth at the secondary site. Paget's
hypothesis is especially relevant at this stage, and tumors that resist apoptosis but are incapable of
proliferating have been observed to lie dormant as solitary cells in experimental systems [Cameron et al.,
2000]. In humans, bone marrow aspirates have revealed the presence of micrometastases in 20-40% of
human carcinomas, and these may also represent viable tumor cells that have lodged in the bone without
undergoing extensive proliferation [Pantel et al., 1999]. Whether such cells can ever form malignant
growths is currently unclear, although in some instances, it has been suggested that primary tumors may
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suppress the growth of distant metastases, a phenomenon mediated, at least in part, by the plasmingen
fragment angiostatin [O'Reilly et al., 1994].
Even those cells that manage to proliferate in a novel microenvironment are confronted with numerous
obstacles. Cameron et al., have observed, for instance, that while most injected B16 melanoma cells
arrested in the lung and extravasated, only 1 in 40 cells initiated growth as micrometastases, and, even
then, only 1 in 100 micrometastases progressed to form macrometastases, with the remainder being
cleared from the lung [Cameron et al., 2000; Luzzi et al., 1998]. What is responsible for the inefficiency of
the very last stage? Perhaps the inability to induce angiogenesis may be one reason, although this
possibility remains to be validated.
The presence of cytokines at a secondary site which are favorable to the metastatic cell would certainly
confer a growth and/or survival advantage, and, as we have already mentioned before, may be a major
determinant of organ-specific metastasis. The ability to respond to these favorable signals, while ignoring
potentially unfavorable ones [Xu et al., 2006], may be a property associated with a cell's gene expression
program. This was recently demonstrated in studies where variants of the MDA-MB-231 human breast
cancer cell line were isolated from either bone or lung metastases [Kang et al., 2003; Minn et al., 2005].
When re-introduced into mice, these cell line derivatives exhibited increased metastasis specifically to the
organ from which they had been isolated. Microarray analyses revealed unique gene expression
signatures that differentiated cells with different metastatic proclivities, and the causal role of specific
genes in conferring organ-specific biases was confirmed by experimental overexpression or
underexpression. For instance, cells which did not ordinarily metastasize to bone could be manipulated
to do so by overexpressing the genes ILl 1, osteopontin, and either CXCR4 or CTGF [Kang et al., 2003].
Similarly, lung metastasis could be specifically enhanced by upregulating sets of other genes, including
SPARC 7, V-CAM1, IL13R-a2, MMP1/2, among others, while downregulation of V-CAM1 or IL13R-a2 was
found to decrease lung metastasis [Minn et al., 2005]. Although the precise organ-specific signals that
biased metastatic outcome were not as clear from these studies, at least in the case of the bone
microenvironment, high levels of TGF-P may have necessitated the expression of specific genes to
respond to this cytokine [Kang et al., 2003].
Finally, as chemokines are often used to direct immune cells to lymph nodes and other organs, it is not
surprising that tumor cells have been found to make use of these signals to "home" to specific sites.
While these cytokines may act over long distances, thus being more akin to hormones, and may affect
some of the earliest steps of metastasis, such as directed cell migration, chemokines are likely also to
promote cell proliferation at the secondary site[Homey et al., 2002]. This reinforces the notion that a
certain logic may underlie the pattern of metastatic tropism exhibited by a particular tumor, and that this
7 We test the role of SPARC in prostate and breast cancer metastasis/tumorigenesis in Chapter 4.
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pattern can be deciphered, at least in part, by analyzing the distribution of specific chemokine receptor-
ligand pairs. The first and most notable demonstration of this was performed by Muller et al., who
showed that CXCL12/SDF-1 was preferentially expressed in the lymph nodes, lung, liver and bone
marrow[Muller et al., 2001]. These are all common sites of metastasis for breast cancers, which express
the SDF-1 receptor CXCR4. Inhibiting the interaction between this receptor-ligand pair in vivo reduced
the ability of MDA-MB-231 breast cancer cells to metastasize to both lung and lymph nodes.
Furthermore, the chemokine CCL21 was also found to be highly expressed in lymph nodes, and its
receptor, CCR7, is often present on the surface of breast cancer and melanoma cells. Indeed, work by
others has shown that overexpressing CCR7 in B16 melanoma cells can augment lymph node
metastasis[Wiley et al., 2001]. Finally, activated lymphatic endothelial cells may secrete increased levels
of CCL1, which could possibly be a chemotactic signal for CCR8-expressing tumor cells[Alitalo et al.,
2004].
Metastasis: Outstanding Questions
Some of the first genes believed to be involved with metastasis were identified years ago using laborious
experimental approaches such as cDNA subtraction techniques and microcell-mediated chromosomal
transfer. The finding that chromosomal DNA from non-metastatic cells could suppress the metastatic
potential of aggressive cells has, long ago, suggested the existence of metastasis suppressor genes.
Indeed, several candidates fitting this description have been cloned over the years, including nm23, KAI1
(CD82), KiSS-1, MKK4 (SEK1) and BRMS1 [Yoshida et al., 2000]. While numerous studies have since
found that many of these genes are frequently lost in a variety of human metastatic tumors, their precise
functions, for the most part, still remain to be determined [Maurer et al., 1999; Welch et al., 2000].
However, one very recent report has shown that KAI1 on the surface of tumor cells forms an
intermolecular interaction with a protein known as DARC, a seven-pass transmembrane receptor
expressed on the endothelium[Bandyopadhyay et al., 2006]. The outcome of this interaction, amazingly,
was tumor cell senescence in vitro. Even more remarkably, further experiments revealed that
upregulation of KAI1 on melanoma cells suppressed metastasis in wild-type, but not DARC-deficient,
mice[Bandyopadhyay et al., 2006]. This is perhaps just one illustration of the complex types of cellular
interactions that take place during metastasis, a process that will surely appear even more complex as
the functions of additional metastasis-related genes become known in greater detail.
Whole genome expression analyses have certainly increased the pace by which potential metastasis-
and tumorigenesis-related genes are identified, though further work will be needed in order to understand
how networks of genes are co-regulated and how these might synergize during metastatic progression.
This might be especially useful for differentiating between two classes of metastasis genes: those that
initially pre-dispose a tumor to metastasis, and those that, perhaps, specifically function later in the
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process. In other words, in the first case, expression of metastasis pre-disposition genes might be an
indirect consequence of a tumor's developmental history and/or of cross-talk with certain signaling
pathways commonly upregulated early on during tumorigenesis, such as the MAP kinase pathway [Gupta
and Massague, 2006]. These are likely genes which are expressed both by the primary tumors and by
distant metastases, and may confer growth advantages at both sites, an observation that was noted by
Minn et al., for instance, who reported that genes involved with lung-specific metastasis could enhance
primary tumor growth [Minn et al., 2005]. Predisposition to metastasis might also be an inherited
characteristic, and at least one DNA mapping study has reported that Sipal, a gene found within the
metastasis efficiency modifier locus Mtesl, might encode a protein that functions as an enhancer of
breast cancer metastasis[Park et al., 2005]. As was mentioned, the other class of metastasis genes-
those that further enhance the aggressiveness of tumors already pre-disposed to spread-probably
arises out of genomic instability and random mutation, and are likely to be uniquely expressed in
metastases. Some of these include RhoC, GPR56 and Twist, just to name a few which have been
identified at this Institute [Clark et al., 2000; Xu et al., 2006; Yang et al., 2004], and this list will almost
certainly continue to grow.
At the same time, many other lingering questions about metastasis will remain until better imaging
technologies allow direct observation of this process at higher resolution. For instance, one important
question concerns the phenomenon of EMT and whether this transition is relevant to metastasis.
Although EMT is generally believed to be accompanied by increased cellular migration and/or invasion, a
complete epithelial-to-mesenchymal transition is rarely observed in human clinical tumors, even those
that metastasize [Christofori, 2006]. Related to this is another aspect of metastasis that has traditionally
been difficult to observe: the process of intravasation from the primary tumor. Certainly, the mechanical
aspects of intravasation, as well as the genes involved, need to be better defined, and this may someday
help explain why certain tumors are capability of disseminating only through the lymphatic route, while
others are endowed with the ability to intravasate into blood vessels. Indeed, we will focus further
attention on this question below and in Chapters 5 and 6 of this thesis. In addition, improved imaging of
the metastatic process may help address which of the numerous steps involved are rate-limiting. It might
also help determine whether metastasis occurs early or late during tumorigenesis, a question some have
attempted to answer using comparative genome hybridization techniques [Schmidt-Kittler et al., 2003].
Finally, the varied roles and interactions of the tumor microenvironment in determining metastatic
outcome need to be better defined. For instance, the immune system can act both positively and
negatively to affect tumor progression and metastasis; therefore, an important area of research involves
determining how this balance might be tilted in one direction versus another [Coussens and Werb, 2002].
Also currently unclear is the importance of stem or progenitor cells during tumorigenesis and metastasis,
and this will almost certainly become an area of extensive focus in the years to come.
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Prostate Cancer Metastasis
This is a thesis about how prostate cancer metastasizes, although it is possible, and perhaps even likely,
that some of our findings may be pertinent to other cancer types. The prostate is a non-essential organ;
thus, among the approximately 230,000 men who are diagnosed with prostate cancer every year8, many
choose to have the organ removed by prostatectomy. Nevertheless, nearly 30,000 patients die annually
from prostate cancer, making this malignancy the second leading cause of cancer-related deaths in men.
In nearly all cases, these deaths are a result of disseminated-and essentially incurable-metastatic
disease.
And so this thesis seeks to apply some of the principles of Fidler and Paget and Ewing to address both
the genetic and mechanistic determinants that affect prostate cancer progression and metastasis. The
subsequent chapters are structured in the following manner:
In Chapter 2, I will elaborate upon the animal models commonly used to study
prostate cancer in the laboratory. I will also describe the systems we used for
the majority of our experiments, including the process by which we derived
prostate cancer cells that differed in metastatic potential. Finally, I will discuss
the gene expression analyses performed on these tumors in our attempt to
identify gene candidates that affect the metastatic process.
In Chapter 3, I will provide an overview of the Protein 4.1 family of proteins, of
which one member-Protein 4.1B, or DAL-1-was significantly downregulated in
highly metastatic prostate tumors. This will be followed by a description of our
experimental results which validate 4.1 B as a suppressor of the metastasis in two
different in vivo mouse models of prostate cancer.
In Chapter 4, I will provide an overview about SPARC, another candidate
metastasis suppressor which was identified in our screen. This will be followed
by a discussion about our attempts to test the role of this protein in spontaneous
mouse models of prostate and breast cancer.
In Chapter 5, I will briefly describe the factors which might be involved during
tumor cell intravasation. I will relate an observation we made in the course of our
studies, which suggested that hematogenous dissemination of tumor cells was
Source: American Cancer Society, 2005.SSource: American Cancer Society, 2005.
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dependent upon lymphatic spread. This observation was the impetus for
experiments described in Chapter 6.
In Chapter 6, I will review the process of lymphangiogenesis, both under normal
and abnormal conditions. I will also describe our attempts to inhibit prostate
cancer lymphangiogenesis, a set of experiments that evolved into a mechanistic
study of how prostate tumors disseminate to lymph nodes. Finally, I will discuss
the unexpected results that came out these experiments and their implications.
In Chapter 7, I will summarize the work described in this thesis, the unanswered
questions that came out of these studies, as well as potential avenues of future
research that could be undertaken to answer them.
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CHAPTER 2.
DERIVATION AND ANALYSIS OF METASTATIC VARIANTS
OF THE HUMAN PROSTATE CANCER CELL LINE PC-3
The work in this chapter was conceived by Sunny Wong, Herbert Haack and Richard Hynes.
PC-3 cell lines were isolated from derivatives originally generated by Herbert Haack. Bioinformatics
analysis was assisted by Steve Shen and Charlie Whittaker. The contents of this chapter were written by
Sunny Wong, with editing by Richard Hynes.
Chapter 2
INTRODUCTION
Mouse Models of Prostate Cancer
The major deterrent for studying metastasis stems from difficulties in observing and modeling the process
in an experimentally tractable system. Without a doubt, the question of how tumors metastasize remains
an amazingly challenging problem: the process is ephemeral, prone to stochasticity, difficult to observe
directly, and immensely complex, both in terms of the complicated networks of genes involved, as well as
the cellular interactions needed for metastasis to occur. While mouse models can approximate many of
the steps of metastasis, even now, they provide a relatively low resolution view of what is actually taking
place. Perhaps the best way to begin approaching this complex problem is to focus on specific genes or
steps involved in the process. In this regard, the choice of a suitable model system to utilize is especially
key.
Prostate cancer (CaP) is a disease of old age, and as such, mice do not ordinarily develop CaP, as they
are more likely to succumb to other cancers or malignancies earlier in life[Shappell et al., 2004]. The
sorts of experimental manipulations that do produce prostate cancer in mice generally fall into two
categories: prostate cells (often transformed) can be introduced, or xenografted, from an outside source;
or the animal itself can be genetically manipulated either through deletion or mis-expression of a gene (or
genes) to develop prostate cancer spontaneously. Both types of manipulations have their advantages
and disadvantages. While xenograft models provide the experimenter with systems that can readily be
manipulated and are often less prone to variability, they are also, by their very nature, highly artificial
methods for studying CaP. Spontaneous models, on the other hand, can offer more realistic views of
prostate cancer, yet this realism comes at an experimental price: they are not easily manipulated, the
tumors take longer to progress, and the variability inherent in these systems is often quite high. An ideal
approach, therefore, might involve initially testing hypotheses using the first model, then validating
findings in the second. Of course, the ultimate goal is to determine whether the findings that come out of
these studies are relevant to the human situation and whether they bear even some degree of universal
truth-a lofty standard, no doubt, but nonetheless, a critical one.
Xenograft Transplantation Models of Prostate Cancer
Xenograft models have traditionally involved injecting established cancer cell lines into immunodeficient
mice. Three of the most frequently used human prostate adenocarcinoma cell lines were all derived in
the late 1970s, and include PC-3 and DU-145 cells, which are both androgen-independent; and LNCaP
cells, which are androgen-dependent[Horoszewicz et al., 1980; Kaighn et al., 1979; Mickey et al., 1977].
All three were derived from metastases that had arisen, respectively, in the lumbar vertebra, the brain and
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in the left supraclavicular lymph node of human clinical patients. When injected subcutaneously
underneath the skin, these cells have all been reported to form tumors, but in most cases, metastasis is
rare or infrequent[Horoszewicz et al., 1980; Mickey et al., 1977; Stephenson et al., 1992]. Although
intravenous injection of tumor cells into the bloodstream can often yield systemic metastases, such an
approach is useful only for modeling the later stages of the process, subsequent to intravasation of cells
into the bloodstream. In addition, while metastases in the lungs and liver often arise from intravenous
injection of tumor cells, other physiologically relevant sites such as lymph nodes are rarely invaded.
A better model for tumor progression involves injecting cancer cells not underneath the skin, but rather,
directly into the anatomical site most akin to the tissue of origin of these cells-in this case, into the
mouse prostate. Such an approach, known as an orthotopic injection, has been reported to yield
aggressive primary tumors for both PC-3 and LNCaP cells that frequently metastasize to the draining
para-aortic/lumbar lymph nodes and, in the case of PC-3 cells, to lungs[Pettaway et al., 1996; Rembrink
et al., 1997; Stephenson et al., 1992]. Although it remains unclear why prostate tumors metastasize more
efficiently when introduced into the orthotopic, rather than subcutaneous, site, part of the explanation may
have to do with prostate-specific stromal factors that evoke the invasive phenotype. Indeed, many recent
studies have focused attention on the role of the tumor microenvironment in promoting cancer
progression, as described in Chapter 1. In addition, experiments showing that stromal cells can promote
tumorigenesis and metastasis when co-injected with malignant cells are in concordance with the
hypothesis that the prostate microenvironment is a crucial regulator of tumor aggressiveness(Cunha et
al., 2003].
However, even injecting tumor cells into the prostate presents certain problems and limitations. Because
the cells are in fluid suspension when introduced as a single bolus injection, there is an absence of cell-
cell contacts and supporting tissue architecture[Wang et al., 1999]. As a result, an element of artificiality
is introduced. In addition, such an approach fails to reproduce the earliest step in metastasis-that is, the
de-adhesion of invading cells away from the bulk of the primary tumor. Injecting tumor cells into the
prostate, or any organ, for that matter, may also have other unforeseen consequences. In experiments
where the dispersal of luciferase-expressing PC-3 cells was tracked following intramuscular injection,
cells were found not long afterwards in numerous sites, including the femur, lungs and liver[Rubio et al.,
2000]. This was likely not attributable to metastasis, at least as one normally envisions the process, but
rather, to the leakage of cells away from the primary site of injection. Clearly, better systems are needed
to model more precisely the many steps of the metastatic cascade.
To begin to address some of these concerns, An et al., in 1998 described a method for grafting solid PC-
3-derived tumors into the prostate[An et al., 1998]. Termed "surgical orthotopic implantation" (SOI), this
technique involves transplanting solid fragments of tumor material harvested from subcutaneous tumors
Chapter 2
into the ventral or dorsal lobes of the prostate. The resulting primary tumors were reported to display an
enhanced propensity to metastasize to the lymph nodes and lungs, in some cases even beyond the
capacity previously observed for orthotopic injection[An et al., 1998; Hoffman, 1999]. When green
fluorescent protein-labeled PC-3 cells were implanted by SOl, micrometastases were also observed in
visceral organs such as the liver and kidneys, as well as in various parts of the mouse skeleton, including
the skull, ribs, pelvis, femur and tibia[Yang et al., 1999]. The presence of skeletal metastases was an
especially important observation, given that CaP frequently metastasizes to bone in human patients, but
rarely does so in animal models, as will be discussed later. SOI has also been touted as a technique that
circumvents problems previously seen when tumor cells are artificially dispersed following injection, and,
in addition, provides a three-dimensional microenvironment where the metastatic potential of a tumor can
be realized, and where all the relevant steps in this process can be recreated[Hoffman, 1999]. Therefore,
SOI may provide the most accurate xenograft model of human prostate cancer in the mouse.
Spontaneous Mouse Models of Prostate Cancer
In spite of the many advantages offered by xenotransplant models, these are also, by their very nature,
highly artificial systems. Spontaneous tumor models of CaP likely provide more realistic approximations
of prostate cancer progression in the mouse, and, ideally, the genes most commonly deregulated in
human CaP would also yield tumors when mis-expressed in mice. In human prostate cancer,
abnormalities in chromosome region 8p12-8p22 are found in 80% of cases, while disruptions in region
10q are also associated with 50-80% of malignancies[Abate-Shen and Shen, 2000]. The homeobox
transcription factor Nkx3.1 is important for prostate development and maps to the region on 8p, while the
lipid phosphatase PTEN is found at 10q. Indeed, mice heterozygous for either Nkx3.1 or PTEN develop
prostate intraepithelial neoplasia (PIN), although the lesions are relatively mild and non-invasive, and the
time to onset is long-typically, > 12 months, with some variation depending on genetic
background[Bhatia-Gaur et al., 1999; Kwabi-Addo et al., 2001]. PTEN' - mice that also lack the tumors
suppressors p27, Nkx3.1 or Ink4a/Arf generally displayed enhanced progression of carcinogenesis,
higher grade lesions and reduced survival, relative to mice mutant for any single one of these genes[Park
et al., 2002]. However, progression to metastatic disease was not observed[Wang et al., 2003].
Subsequent studies involving Cre-mediated homozygous deletion of PTEN in the mouse prostate have
reported the development of androgen-dependent adenocarcinomas by 9 weeks of age[Wang et al.,
2003]. These tumors possessed upregulated Akt activity, and metastasized to the lymph nodes and lung
by 12 weeks of age, but again, bone metastases were not seen.
Transgenic overexpression of oncogenes specifically in the prostate has also yielded prostate tumors. As
upregulation of insulin growth factor (IGF) and of the Akt pathway are often observed in CaP, it is not
surprising that overexpression of either IGF-1 or myristoylated Akt resulted in prostate
Chapter 2
carcinogenesis[DiGiovanni et al., 2000; Majumder et al., 2003]. In the case of Akt transgenic mice, PIN
was observed in the ventral prostates and was later shown to depend, at least in part, upon activation of
S6 kinase, a component of the TOR pathway[Majumder et al., 2004]. These lesions, however, never
progressed to invasive carcinomas even after 78 weeks of age[Majumder et al., 2003]. In the case of
IGF-1 transgenic mice, PIN and focal areas of adenocarcinoma were seen in both the dorsal and ventral
prostate lobes of mice at 6 months of age, and this was associated with upregulated activity of PI-3
kinase, an upstream activator of Akt[DiGiovanni et al., 2000]. However, as before, there was also no
evidence of metastatic spread.
The TRAMP Prostate Cancer Model
Although there has been recent emphasis on developing tumor models that recapitulate, at least in part,
the genetic abnormalities most often deregulated in human cancers [Dyke and Jacks, 2002], perhaps the
most widely used spontaneous model of CaP involves transgenic overexpression of a gene that has
never caused prostate cancer in any human individual. First described by Greenberg et al., in 1995, the
Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) model relies upon the prostate-specific, rat
probasin-promoter-driven expression of the Simian virus 40 (SV40) large T antigen[Greenberg et al.,
1995]. SV40 inhibits the tumor suppressors pRb and p531, and transgenic expression of this gene in
various organs, including the mouse mammary glands and pancreas, has reliably yielded tumors. In the
TRAMP model, mice develop multi-focal prostate hyperplasia beginning at 10 weeks of age, and these
foci progress to PIN and metastatic carcinomas after another 14-30 weeks [Gingrich et al., 1996]. The
tumors themselves begin as androgen-dependent lesions but can manifest hormone-independent
disease after androgen ablation therapy [Gingrich et al., 1997]. Although the precise time to onset varies
significantly with genetic background, with pure C57BL/6 TRAMP mice displaying the slowest rate of
spontaneous tumor progression and FVB/TRAMP mice exhibiting the fastest rate2, metastases to the
lymph nodes and lungs have been reported in older mice[Gingrich et al., 1997], and, at least in one case,
extensive spinal metastases were observed[Gingrich et al., 1996].
The TRAMP model has also been useful for studying the modifying effects of other genes that, when mis-
expressed on their own, either do not cause prostate cancer in the mouse, or lead to relatively mild
tumorigenic phenotypes. For instance, mice heterozygous for PTEN, when also bearing the TRAMP
transgene, displayed accelerated tumor progression relative to wild-type TRAMP mice[Kwabi-Addo et al.,
2001]. Similarly, overexpression of the apoptosis inhibitor Bcl2 in TRAMP prostates enhanced the onset
of carcinogenesis[Bruckheimer et al., 2000]. Hepsin, a transmembrane serine protease, is upregulated in
90% of prostate cancers, and, interestingly, probasin-promoter-driven overexpression of this gene in the
1 Inhibition of these two tumor suppressors has been shown to be necessary but insufficient for transformation. Therefore,
other as-yet unknown factors are likely affected by expression of SV40 large T antigen.
2 http://thegreenberglab.fhcrc.org/protocols/TRAMPBreedingScheme.pdf
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prostate caused a weakening of the basement membranes that normally separate the epithelial and
stromal layers[Dhanasekaran et al., 2001; Klezovitch et al., 2004]. Laminin and collagen staining
appeared disorganized and fragmentary, but these mice did not develop prostate cancer. However, when
hepsin overexpression was combined with a mouse model similar to TRAMP (LPB-Tag, which does not
metastasize), doubly transgenic animals developed macrometastases to the lung and liver[Klezovitch et
al., 2004]. Furthermore, at least 24% of 21 week old animals bore metastases to the bone.
Absence of Bone Metastasis in Mouse Models of Prostate Cancer
While each of these systems clearly has its own unique advantages and disadvantages, a common
drawback of all these models, with perhaps the exception of Hepsin-Tag doubly transgenic mice, is the
relative absence of bone metastases. Even in the case of the Hepsin experiments, the remarkable
metastatic phenotypes observed were elicited only after significant overexpression of the transgene in the
mouse prostate, which normally does not express any detectable levels of Hepsin[Klezovitch et al., 2004].
In other models, microscopic deposits of tumor cells in the bone were reported only after exhaustive
approaches were taken to detect metastases or, otherwise, these were extremely rare events-certainly,
a far cry from what is typically seen in the clinic, where 90% of human CaP patients with hematogenous
spread have been reported to possess osseous invasion[Bubendorf et al., 2000]. The paucity of bone
metastasis seen in the mouse models remains a major hurdle in the field. The hepsin experiments, and
possibly others, have suggested that proper tumor-stromal interactions-both at the primary tumor and at
the site of invasion-may not be taking place to encourage the formation of skeletal metastases in mice.
This would be consistent with Paget's "seed and soil" hypothesis, as described in Chapter 1.
In contrast, others have speculated that anatomical differences in the plexus of veins that surround the
prostate and urogenital systems (Batson's plexus) may account for the absence of bone metastases in
rodents[Resnick, 1992; Shiraid and Ito, 1992]. In humans, well-developed anastomoses between the
pelvic and vertebral vein systems may allow shunting of venous blood directly from the prostate to the
spine, and, therefore, tumor cells could potentially reach the bone without having to enter systemic
circulation. Indeed, radiolabelled tracers introduced into the human prostatic plexus of veins have been
observed to reach the lower lumbar spine without having to pass through the inferior vena cava[Shiraid
and Ito, 1992]. In rodents, the venous communications between the pelvic and vertebral systems are not
as extensive. In addition, others have also hypothesized that high abdominal pressure in humans may
re-direct the flow of blood towards the vertebral plexus, whereas rodents display relatively reduced
abdominal pressure, owing to their non-erect posture[Shiraid and Ito, 1992]. Compellingly, several
studies have shown that temporary occlusion of the inferior vena cava can re-direct the flow of abdominal
blood and of intravenously-injected tumor cells towards the vertebral column[Harada et al., 1992;
Nishijima et al., 1992; Shevrin et al., 1988]. Occluded animals frequently developed spinal lesions and, in
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some cases, hind limb paralysis, while non-occluded control animals bore lung metastases, but in no
cases was skeletal invasion observed. Bone tumors have also been reported when PC-3 or LNCaP cells
were introduced by direct intra-tibial injection into the bone[Corey et al., 2002]. These results, therefore,
seem to lend support to hypotheses first put forth by James Ewing, who proposed in the 1920s that
patterns of blood flow, rather than "seed and soil," were the major determinants of organ-specific
metastasis. Likely, both his and Paget's hypotheses are valid and are certainly not mutually exclusive, as
distinct processes are likely to influence the patterns of metastasis at different temporal points of
progression.
Experimental Approach
Metastasis is unquestionably a complicated process, and, given the available systems for studying
prostate cancer progression in mice, we elected to begin our studies by focusing on the SOI xenograft
approach. The major advantage of using SOl--that it models the earliest steps of metastasis-made this
technique especially attractive, despite the fact that it is probably the most technically difficult of all the
methods described thus far for introducing tumor cells into the mouse. Using SOI, we decided to carry
out a screen to identify genes important for the metastatic process. This was similar to the screen
described previously by Clark et al., where metastatic variants of a melanoma cell line were derived and
analyzed by microarrays to identify potential metastasis genes3 [Clark et al., 2000]. We decided to focus
our studies on derivatives of the cell line PC-3, mostly because these cells grow well in culture and when
implanted in vivo. The rest of this chapter describes the derivation and initial characterization of these
cell lines, as well the gene expression analyses that were performed on them. In subsequent chapters,
we make use of these cells and the SOI technique to validate our gene candidates, as well as to study
how prostate cancer spreads via the lymphatics and bloodstream. In all cases, we have turned to the
TRAMP spontaneous tumor model to make additional observations in an attempt to test our findings from
the SOI model. Whenever possible, we have also tried to view our results and their implications in light of
what others have previously reported for human clinical prostate cancer. We believe that this
combination of approaches is especially important, given the complexity and heterogeneity of this
disease.
RESULTS
Establishment of an orthotopic xenograft mouse model of prostate cancer progression
As described earlier, tumor fragments derived from the human prostate adenocarcinoma cell line PC-3
can be introduced into immunodeficient mice using surgical orthotopic implantation (SOI) to generate a
3 For additional details, please refer to Chapter 1.
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metastatic model of prostate cancer[An et al., 1998]. We began our studies by establishing this model in
our laboratory and by adapting this technique to obtain reproducible results. It was also important that, by
familiarizing ourselves with SOI, we could develop a set of expectations for this mouse model, both in
terms of its advantages as well as its limitations. Finally, to study metastasis, it was necessary to develop
methods for quantitating the spread of tumor cells. Some of these methods are described briefly below
and in more detail in the Materials and Methods section (Appendix A).
We found that, typically, subcutaneous tumors from which fragments are derived for SOI required about 3
weeks of growth in CD-1 nude immunodeficient mice before transplantation (Figure 1A). Once implanted,
mice began to appear moribund as a consequence of the primary tumor approximately 2 months
afterwards and did not usually survive beyond 100 days post-surgery. Although we initially implanted
tumors into both the mouse dorsal and ventral prostate lobes (Figure 1 B), in later work, we implanted
exclusively into the dorsal prostate for convenience and consistency of technique. Both approaches
yielded palpable primary tumors that developed macroscopic lymph node metastases (Figures 1A and
2A). The para-aortic/lumbar lymph nodes were frequently invaded, as were the more distal renal lymph
nodes. Injection of methylene blue into the prostate led to accumulation of the dye in the lumbar lymph
nodes, indicating that these nodes directly drained the prostate (Figure 2B). In rare instances,
metastases were also observed in the mediastinal lymph nodes and in the superficial inguinal lymph
nodes, though these sites were not routinely examined.
The SOI technique also yielded tumors that formed lung micrometastases (Figure 3), though in no cases
have we observed macrometastases in the lung, in other visceral organs, or in bone. By hematoxylin-
and-eosin staining, the micrometastases in the lung were readily distinguishable from the rest of the lung
parenchyma by their pleiomorphic nuclei, and were roughly classified according to the two-dimensional
size of the metastatic cluster (Figure 3A). Metastatic deposits were observed both within the parenchyma
and, in rare instances, within the lumens of blood vessels (Figure 3B). These metastatic cell clusters
appeared not to have extravasated, a phenomenon first described by Al-Mehdi et al., for fibrosarcomas
cells and, subsequently, by others for breast cancer [Al-Mehdi et al., 2000; Glinsky et al., 2003; Wong et
al., 2002]. In at least one case, we observed a single row of tumor cells growing within a blood vessel,
which was also noted by Al-Mehdi et al. Though these lung micrometastases were readily apparent, we
further confirmed the prostatic origin of these cells by staining sections for the prostate-specific cell
surface antigen STEAP (Figure 3B)[Hubert et al., 1999].
We found that we could recover viable tumor cells that had been circulating in hematogenous blood from
animals implanted by SOI. This was accomplished by drawing whole blood from the right ventricles of
tumor-bearing mice shortly after sacrifice, and cell number was quantitated by performing a colony
formation assay on cultured blood (Figure 8A). We had also attempted other techniques to identify and
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count rare tumor cells in circulation, including those based on flow-cytometry and human-specific
quantitative Alu PCR, but both of these methods were difficult to carry out, had problems with high
background, were plagued by poor and/or inconsistent detection of positive control test samples, and,
importantly, did not differentiate between viable and non-viable tumor cells. Therefore, we used the
colony formation assay to quantitate tumor cells in the blood, and initial control studies indicated that as
few as -5 tumor cells spiked into 100 ul of blood could be recovered, and that the plating efficiency of our
different PC-3 cell lines was roughly equivalent (data not shown).
Finally, we found that we could recover, culture and expand tumor cells that had been previously
implanted by SOI into mice. These were derived from the primary tumors, or from lymph node or lung
metastases. Although, in most cases, these cells appeared morphologically similar to the starting PC-3
parental cell population, we confirmed the human origin of these cells by positive staining for a human-
specific Class I MHC molecule (Figure 4A) and by negative staining for a mouse-specific MHC molecule
marker (H-2K(b)/H-2D(b)) (Figure 4A). The human-specific antibody could also be used to identify
individual tumor cells that had metastasized to lymph nodes (Figure 4B).
Overall, these preliminary studies were useful for establishing the SOI technique for prostate cancer in
our laboratory, for determining how best to obtain reproducible results from this system, and for
developing methods to quantitate the degree of metastatic spread both via the lymphatic and
hematogenous routes. This is perhaps the greatest advantage of SOI for modeling how prostate cancer
spreads--the multiple points of assay possible in a system that can also be readily manipulated to assess
how perturbations in specific genes might affect different steps of the metastatic process. We make use
of these assays, as well as others, in the following sections and chapters of this thesis to elucidate some
of the genetic and mechanistic underpinnings of prostate cancer progression.
Derivation of the "core" PC-3 metastatic variant cell lines
Although numerous metastatic variants have been derived by us and others from PC-3 parental
cells[Pettaway et al., 1996; Stephenson et al., 1992], the core cell lines used for the bulk of these studies
included pMicro-1, pMicro2-#78 (also known as #78) and pMicro2-#82 (also known as #82)(Figure 5A).
Derivation of these cells was initiated by Dr. Herbert Haack, a former postdoctoral researcher in the lab.
PC-3 parental cells from American Type Culture Collection (ATCC) were injected subcutaneously into
Balb/c nude immunodeficient mice on April 13, 2001. The subcutaneous tumors were harvested on June
1, 2001, and subsequently implanted by SOI into the ventral prostates of C57BL/6 nude immunodeficient
mice. One of these mice (designated 6-1B or mouse 1 1V) developed a 300 mg tumor with lymph node
macro-metastases when sacrificed on August 14, 2001, and single cells were dissociated from the lungs
and put into culture. The cells that grew out of this culture were originally named 8-14A lung, and later,
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pMicro-1, to indicate that they had been derived from micrometastases in the lung. pMicro-1 cells were
then injected subcutaneously on November 1, 2001, into CD-1 nude immunodeficient mice, and tumor
material was implanted into the dorsal or ventral prostates of CD-1 nude mice on December 13, 2001.
From these implanted mice, mouse #78D (12-13D) was sacrificed on March 16, 2002, and mouse #82V
(12-13H) was sacrificed on March 18, 2002. Each of these mice had developed bulky primary tumors
with lymph node macro-metastases, and their lungs were placed into culture to isolate metastatic cells.
The cells that grew out of the lungs of mouse #78D were named #78 cells; those that grew out to the
lungs of mouse #82V were called #82 cells. Therefore, both #78 and #82 cells were derived from tumor
cells present in the lung at the time of sacrifice, though no macroscopic lung metastases have yet to be
observed from this orthotopic metastasis model.
Initial characterization of the "core" PC-3 metastatic variant cell lines
The core cell lines used in our studies-pMicro-1, #78 and #82-appeared morphologically
indistinguishable in vitro. In all three cases, the cells attached slowly, but firmly, to tissue culture plates
and did not spread well, often displaying phase enhancement at the cell borders under light microscopy.
The three cell lines exhibited similar rates of growth compared to each other and to parental PC-3 cells
under normal growth conditions in vitro (Figure 5B). When tested for migratory and invasive behavior
towards serum, the cell lines also did not differ (data not shown). However, when injected as
subcutaneous tumors into CD-1 nude immunodeficient mice, all three of the core cell lines formed
significantly larger tumors than PC-3 parental cells that had either been injected into CD-1 or Balb/c
immunodeficient mice (Figure 5C).
The overall gross genomic content of these cells was assessed by propidium iodide (PI) staining and flow
cytometry. PC-3 parental cells, like most cancer cell lines, are aneuploid, and by PI staining, two major
populations were identified that differed in overall genomic content by roughly a factor of two (Figure 6A,
top graph, red peaks). Interestingly, the core selected cell lines possessed approximately identical
genomic contents among themselves, but their ploidy levels fell between the two major populations
identified within PC-3 parental cells. Comparisons made with other cell types indicated that, as expected,
normal mouse lymphocyte cells displayed a low genomic content (Figure 6A, bottom graph, blue peaks),
while an additional PC-3 "lymph node" line (pMacro), which was derived from a mediastinal lymph node
macro-metastasis, possessed a high genomic content that exceeded even the ploidy of the highest PC-3
parental population (Figure 6A, bottom graph, green peaks). As a control for flow cytometry, when the
PC-3 parental and #78 cells were pre-mixed prior to analysis, each of the peaks representing the two
different cell lines could still be distinguished (Figure 6B). Furthermore, fifteen individual cell clones were
isolated from the heterogeneous PC-3 parental cell population, and each of these was analyzed for
genomic content. Not surprisingly, in most cases, the ploidy of these clones overlapped with one of the
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two major peaks seen for the parental cells (data summarized in Figure 6C), though in some instances, a
mixture of more than one clone may have yielded additional peaks.
Characterization of the core PC-3 metastatic variant cell lines by surgical orthotopic implantation
Solid tumor material derived from subcutaneous tumors from each of the three core cell lines was grafted
into the dorsal prostates of CD-1 nude immunodeficient mice. After 2-3 months post-implantation, mice
were sacrificed when they appeared moribund, and blood, lungs, tumors and lymph nodes were
collected. Although the ages of the mice at the time of sacrifice differed slightly, the majority of lung
metastases and the most severely invaded lymph nodes tended to be observed in mice that were
analyzed 70-80 days after implantation (data not shown). In addition, a great majority of the para-
aortic/lumbar lymph nodes recovered after SOI displayed either macroscopic or microscopic tumor
metastases (see Chapter 6). Lymph nodes which were >30 mg in mass were designated as
"macroscopic metastases" because they were found, in all cases, to contain significant levels of tumor
invasion, as assessed by histology4 (see Chapter 6). In fact, those lymph nodes that exceeded >80 mg in
mass were, in nearly all instances, completely replaced by tumor material. Therefore, the mass of the
lymph nodes was a good measure of the degree by which tumors had metastasized via the lymphatic
route, while the number of lung metastases could be used to measure the extent of hematogenous
spread.
Quantitation of the masses of the draining para-aortic lumbar and renal lymph nodes revealed significant
differences between the #78 and #82 cell lines. While orthotopic tumors derived from both cell lines
yielded macroscopic para-aortic/lumbar lymph node metastases at about the same frequency (-70% of
tumors), the average mass of the lumbar lymph nodes for #82 tumors was about two-fold greater than
that of #78 tumors (176 mg. versus 90 mg., respectively; p = 0.038) (Figure 7A). When the masses of the
more distal renal lymph nodes were assessed, there was a three-fold difference: Renal nodes from #82
tumors had an average mass of 150 mg, whereas those from #78 tumors had an average mass of 54 mg
(Figure 7A). However, this difference approached, but did not exceed, statistical significance (p = 0.064)
because of increased scatter in the data.
In terms of quantitating hematogenous dissemination, #82 tumors, on average, yielded approximately
twelve-fold more lung metastases than did #78 tumors (on average, 71 micrometastases per animal
versus 6 micrometastases, respectively; p = 0.0071) (Figure 7B). There were no statistically significant
differences in terms of primary tumor size at the time of analysis (p = 0.66) (Figure 7B) or the number of
viable circulating tumor cells recovered from the blood of these animals (p = 0.67) (Figure 8A). As a
rough measure of the efficiency by which tumors formed micro-metastases in the lung, the total number
4 By comparison, uninvaded lymph nodes typically do not exceed 10 mg in dry mass.
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of lung metastases for a given cell line was divided by the total number of circulating tumor cells in the
blood (from only those animals which had both measurements taken). In this regard, #82 cells formed
6.1 lung micrometastases for every tumor cell recovered from the blood, whereas #78 cells formed only
0.44 lung metastases for every tumor cell recovered-or roughly, a fourteen-fold difference (Figure 8B).
When the sizes of micrometastases in the lung were assessed, approximately 7% of those metastases
derived from #82 tumors were greater than 20-cell clusters (n = 78/1136 total lung metastases observed),
whereas 0% of metastases from #78 tumors exceeded that size (n = 0/112) (Figure 9A).
The data for the various assessments of metastasis are summarized in Figure 9B. Interestingly, the
immediate precursor of both these cell lines, pMicro-1, displayed an intermediate metastatic phenotype
between those of highly metastatic #82 cells and poorly metastatic #78 cells, but, in most cases, did not
differ significantly from either cell line in any of the parameters used to assess metastasis. This would
imply that pMicro-1 may have actually consisted of a metastatically heterogeneous population of cells,
from which the #78 and #82 cell populations were subsequently isolated through in vivo passage. It is
also reasonable to believe that additional passaging of #78 or #82 cells in vivo might yield cell lines that
possess even more extreme metastatic characteristics.
Gene expression analysis of the core PC-3 metastatic variant cell lines
To identify genes that might be responsible for prostate cancer metastasis, we performed gene
expression analysis on our selected set of core PC-3 metastatic variant cell lines. We elected to profile
these cells, and not other variants of PC-3, for several reasons. First, the metastatic tendencies of the
core set of pMicro-1, #78 and #82 cells were well-characterized in our orthotopic system, and had yielded
significantly different invasive behaviors that could not merely be explained by differential growth of the
primary tumor. In addition, many of the other cell lines, including the parental PC-3 cells and others, did
not grow readily in mice, either as subcutaneous or orthotopic tumors. And importantly, our ploidy
analysis revealed that the overall genomic content of the core metastatic variant cells most resembled
one another, while exhibiting gross differences from those of other cells, such as PC-3 parentals.
Although the gene expression effects manifested from chromosome-wide duplications and deletions are
unclear, it is possible that hundreds, if not thousands, of genes irrelevant to the metastatic phenotype
might be mis-expressed among cell lines that differed at such a drastic genomic level. Therefore, these
were all justifications for our decision to focus on our three core cell lines.
We used RNA from three independent subcutaneous tumors derived from each cell line for gene
expression profiling. Subcutaneous tumors, rather than cells grown in vitro, were previously used to
profile melanoma cell lines that differed in metastatic potential, and may be less susceptible to random
fluctuations in gene expression than cells grown in tissue culture (personal communication, Dr. E. A.
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Clark). As expected, clustering analysis performed by dChip revealed that the gene expression profiles of
independent replicate tumor samples were more closely related to one another than to tumors derived
from other cell lines (Figure 10A). Among genes which were differentially expressed between highly
metastatic #82 and poorly metastatic #78 cells, there was a notable enrichment for those whose protein
products were classified by gene ontology to affect cell adhesion, matrix assembly and cytoskeletal
regulation (Figures 10B-C; for complete list, please see Appendix E). Some of these genes upregulated
in highly metastatic #82 cells included carcinoembryonic antigen-related cell adhesion molecule 5
(CAECAM5); thrombospondin-1; and cysteine-rich, angiogenic inducer 61 (CYR61). Genes
downregulated in highly metastatic cells included connexin 43; bone morphogenetic protein 2 (BMP2);
Rho GDla; and matrix metalloproteinase 1 (MMP1). Interesting, at least three members of the insulin
growth factor ,(IGF) signaling pathway (IGF binding protein-3 and -6; and IGF 1 receptor) were also
among the top genes upregulated in highly metastatic cells, as was the gene encoding interleukin 8, a
pro-angiogenic factor previously found to be overexpressed in breast cancer cells that preferentially
metastasized to bone[Kang et al., 2003].
However, we were particularly struck by two genes that came out of this analysis: erythrocyte membrane
protein band 4.1-like 3 (also known as 4.1B, or DAL-1; ID# NM_012307); and secreted protein, acidic,
cysteine-rich (also known as SPARC, osteonectin or BM-40; ID# NM_003118). Both these genes were
severely downregulated in highly metastatic #82 cells relative to #78, were represented at the "top" of our
list with multiple probe sets, and have previously been assigned cell biological functions that could affect
the metastatic phenotype[Framson and Sage, 2004; Sun et al., 2002]. Coincidentally, 4.1B had recently
been identified by a former M.I.T. post-doctoral researcher in our laboratory, Dr. Joseph McCarty, as a
novel interactor of integrin P38, and another former M.I.T. post-doctoral researcher in Dr. Tyler Jacks's
laboratory, Dr. Joseph Kissil, had generated 4.1B-deficient mice[McCarty et al., 2005; Yi et al., 2005].
Thus, not only was 4.1B the second most downregulated gene in our highly metastatic cells, but also
there was biological justification for its possible role in metastasis, as well as reagents readily available to
test that hypothesis. We took this fortuitous convergence of events as a good sign and proceeded to
characterize the role of 4.1 B in prostate cancer progression and metastasis, as described in Chapter 3.
For many of the same reasons, we also examined whether SPARC, a matrix protein component, was
involved, and the results of that work are described in Chapter 4.
DISCUSSION
The results from this chapter lay the foundation for subsequent studies in this thesis in three ways: we
validated the SOI system as a reliable model for studying prostate cancer progression; we derived and
characterized three metastatic variant cell lines that were used for the majority of our studies; and we
performed gene expression analysis on these cells to identify candidates that might be causal for the
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different metastatic phenotypes. Therefore, we now have the techniques and approaches needed to
study metastasis; in the following chapters, we make use of these tools.
As expected, our experience with SOI has shown that this system is technically challenging and, in total,
requires between 3-4 months before results can be obtained. In spite of this, we found it highly
advantageous that SOI readily yields primary tumors in the prostate which often metastasize via the
lymphatic and hematogenous routes. The fact that we could also isolate and quantitate viable, circulating
tumor cells in the blood was another benefit; however, aside from lymph nodes, we have not yet detected
any macrometastases from this system. It is unclear exactly why this is the case, but a likely explanation
is that additional time is needed for these metastases to develop. Indeed, we have previously seen that
intravenous injection of PC-3 cells can yield macroscopic lung and even bone metastases after 3 months
(data not shown). Although animals implanted by SOI can often live up to 3 months, it is unclear when
the primary orthotopic tumor actually begins to metastasize during this period. As will be discussed in
Chapter 5, hematogenous dissemination of tumor cells was observed only after lymphatic spread;
consequently, entrance of tumor cells into the blood might occur quite late. In any case, we found the
SOl system to be a manageable model of CaP, and, because it recapitulates even the earliest steps of
metastasis, this system has allowed us to obtain some interesting and pertinent results, as will be
described in the subsequent chapters.
We derived the core cell lines used in our studies by repeated in vivo passaging using the SOI model.
pMicro-1 cells were descendent from PC-3 parental cells, and, in turn, gave rise to #78 and #82 cells. In
vivo characterization of these cells revealed that #82 cells were highly metastatic, that #78 cells were
relatively poorly metastatic, and that pMicro-1 cells displayed an intermediate metastatic phenotype
between these two. These results were slightly surprisingly, given that we had originally expected the
metastatic potential of these cells to increase with each round of in vivo passage; in other words, we had
initially expected #78 and #82 cells to be equally or more metastatic than their common predecessor,
pMicro-1. We speculate that pMicro-1 may be a mixed population of highly and poorly metastatic cells,
and, since we had derived both #78 and #82 by nondiscriminately culturing dissociated cells that were
present in the lung, #82 cells may have consisted of actual pulmonary micro-metastases, whereas #78
cells may have been derived from cells that had merely been circulating in the blood within the lungs at
the time of sacrifice. However, we had also realized that knowledge concerning the precise origins of
these cells was not critical for completing the goals of our later studies. What was essential was that we
had derived a set of related cell lines that differed significantly in metastatic potential, and that, as shown
from the ploidy experiments, these cells did not vary so drastically at the genomic level that pinpointing
the right gene(s) responsible for metastasis would be impossible.
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We therefore proceeded to examine these three cell lines by gene expression analysis. We derived RNA,
then eventually cDNA and cRNA, from three independent subcutaneous tumors for each of our three cell
lines. Although we had originally carried out gene expression profiling on the pMicro-1 cell line, it later
became unclear how this data could be useful for our studies, since the metastatic potential of pMicro-1
was neither relatively high nor low, and, in most cases, did not differ significantly between either #78 or
#82 cells. The expression of metastasis-related genes might therefore be reflective of this intermediate
phenotype in two ways: a gene (or genes) may also display an intermediate level of expression between
that of #78 and #82; or, if a network of genes was responsible for metastasis, the expression of some of
these genes might be identical to that of #78, while others might be identical to that of #82. If the latter
explanation were true, the net phenotype would still be an intermediate metastatic potential for pMicro-1.
Because we could not distinguish between these possibilities, we focused primarily on genes whose
expression levels differed significantly between the #78 and #82 cell lines. Our list of candidate genes
was enriched for those which encoded proteins believed to be involved with cell cytoskeleton, matrix and
adhesion. In particular, 4.1B/DAL-1 and SPARC were both severely downregulated in highly metastatic
#82 cells relative to #78 cells, making them putative suppressors of metastasis. Although 4.1B/DAL-1
was originally identified as a potential tumor suppressor for lung adenocarcinomas and
meningiomas[Tran et al., 1999], the effect of this cytoskeletal protein on tumor metastasis has not yet
been reported. In contrast, the matrix component SPARC has been previously associated with a variety
of cell biological processes, including tumorigenesis and metastasis, but these findings have also often
been inconsistent or contradictory with results from other studies[Framson and Sage, 2004]. For these
and other reasons previously described, we chose to examine further the effects of both 4.1B and
SPARC on prostate cancer progression and metastasis. The results from this work will be described in
the following two chapters.
We were also intrigued by the observation that hematogenous dissemination of tumor cells following SOI
correlated with lymphatic invasion, as will be discussed in Chapter 5. This suggested that tumor cells
might be entering systemic circulation not by intravasating directly into venous capillaries but, rather, by
utilizing a circuitous route involving the lymphatic system. Although we were not successful in either
proving or disproving this hypothesis, we were able to gain some insights into how tumor cells entered
lymphatic circulation, particularly by identifying the types of vessels that were either dispensable or
indispensable for the process, as described in Chapter 6. As intravasation is one of the earliest steps in
metastasis, these studies have validated the use of surgical orthotopic implantation as a model where
even the most initial stages of tumor cell dissemination can be studied.
Chapter 2
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Figure 1. Surgical orthotopic implantation (SOI) can be used to model prostate
cancer in mice. (A) A schematic of the SOI technique is shown (top), where solid
tumor pieces derived from subcutaneous tumors are implanted into the prostate
orthotopic site of CD-1 nude immunodeficient mice. The mouse dorsolateral prostate,
unimplanted (top left photo, arrow, photo courtesy of Dr. A. Donjacour) or mock-
implanted (bottom left photo, arrow) with a fluorescently-labeled tumor. After 2-3
months post-implantation, a mouse bearing a typical orthotopic tumor (white arrow) with
para-aortic lumbar lymph node metastases (green arrows) is shown (right photo). (B)
The mouse prostate consists of three pairs of lobes-ventral, lateral and dorsal-and is
located beneath the bladder and seminal vesicles.
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Figure 2. The para-aorticllumbar lymph nodes drain the prostate and are frequent
sites of metastasis. (A) An illustration isshown depicting the location of commonly
invaded lymph nodes relative to the prostate (left). Typical lumbar and renal lymph
node metastases are shown (right). (B) Dye tracking studies using Methylene Blue
injected into the prostate indicate that the organ is directly drained by the lumbar
lymph nodes (K, kidney; LN, lymph node)
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Figure 3. Orthotopic prostate tumors develop lung micro-metastases. (A)
Micrometastases are visible by hematoxylin-and-eosin (H&E) staining and are
characterized by enlarged nuclei relative to the surrounding lung parenchyma.
Metastases consisting of at least 3 cellswere counted and grouped by size into the
classifications shown. (B) Lung micro-metastases were sometimes seen growing withinblood vessel lumens without extravasating (top panels). Lung micro-metastases visibleby H&E (bottom left) can be confirmed by immunohistochemical staining for theprostate-specific cell surface antigen STEAP (bottom right).
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Figure 4. The human origin of PC-3 cells passaged in vivo can be confirmed by
immunohistochemistry. (A) PC-3 parental cells, aswell asan example of a PC-3
variant cell line passaged in vivo (sMet*), both stain positively with an antibody against
a human-specific Class I MHC molecule (HLA-A/B/C) but not with an antibody against a
mouse-specific MHC molecule (H-2K(b)/H-2D(b)). The opposite istrue for mouse
fibroblast cells (B) The human-specific HLA-A/B/C antibody identifies both human
cells in the orthotopic primary tumor (left), aswell as isolated tumor cellsthat had
metastasized to the draining lymph nodes (right) in frozen sections
(*The sMet cell line was derived by H.H. from an axillary lymph node metastasis from a PC-3 subcutaneous tumor.)
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Figure 5. The "core" PC-3 variant cell lines were derived by in vivo passaging of
tumor cells using surgical orthotopic implantation. (A) The PC-3 variant cell line
pMicro-1 wasderived from PC-3 parental cells, while #78 and #82 cellswere both
derived from pMicro-1. Additional details about cell line derivation are described in
the Materials and Methods (Appendix A), and Results sections (B) The cell lines
displayed uniform growth ratesin vitro. (C) When injected as subcutaneoustumorsinto
CD-1 immunodeficient mice, the core PC-3 variant cells--pMicro-1, #78 and
#82-displayed indistinguishable rates of growth. PC-3 parental cells exhibited
markedly reduced rates of growth when injected into either CD-1 or Balb/c
immunodeficient mice.
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Figure 6. The genomic content of the "core" PC-3 variant cell lines resembled one
another's but was distinct from other cell lines or cell types. (A) Flow cytometry-
based ploidy analysis revealed that the core PC-3 variant cell lines ("pMicro-selected")
possessed a similar genomic content, which was distinct from that of parental PC-3 cells
(top left). An overlay of the ploidy results indicates the relative genomic content of
various cell types (bottom left). (B) When PC-3 parental (PC-3P) cells and #78 cells
were intentionally pre-mixed prior to analysis, peaks representing the two cell lines
could be distinguished. (C) From the parental PC-3 cells, fifteen individual clones
were analyzed for genomic content and classified as having high or low ploidy. In
some cases, a mixture of both was detected.
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Figure 7. The core PC-3 variant cell lines exhibited differing metastatic abilities
after being implanted into the prostate. (A) The fixed masses of the para-
aorticllumbar (left) and renal lymph nodes (right) for mice bearing orthotopic prostate
tumors are shown for the three core PC-3 variant cell lines: #78, pMicro-1 and #82.
(B) The number of lung micrometastases (left) and the fresh masses of the orthotopic
primary tumors (right) are shown for the three cell lines. (horizontal bars, mean; ***, p <
0.04)
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Circulating Tumor
Cells
#78 pMicrol #82
Total Lung Total Blood
Cell Line N Mets Colonies RatIo Fold
pMicro2-82 10 662 108 6.13 61
pMlcro-1 7 304 203 1.50 15
pMacro 3 391 273 1.43 14
pMicro2-78 7 66 155 0.43 4
Parental 2 33 120 0.28 3
PC-3M 2 27 263 0.10 1
Total 31 1483 1022
Figure 8. Circulating viable tumor cells in the blood can be detected and quantitated
in order to assess lung metastatic efficiency. (A) A typical colony formation assay is
used to quantitate tumor cells circulating in whole blood (left). The number of
circulating tumor cells in the blood of animals bearing orthotopic tumors derived from
the three core cell lines is shown (right). (horizontal bars, mean) (B) Shown isa table
summarizing the number of mice from which both lung metastasis and circulating
tumor cell data were collected ("N"), the total number of circulating tumor cells counted
from these mice (in 100 ul of blood), the accompanying total number of lung
metastases observed, and the efficiency of lung metastasis (expressed as the total
number lung metastases divided by the total number of circulating tumor cells in the
blood). The relative efficiency was obtained by normalizing all results to that of PC-3M,
which was set to 1 ("Fold").
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Figure 9. The core PC-3 variant cell lines exhibited differences in various
parameters for metastasis following implantation into the prostate. (A) Depicted is
the size distribution of lung metastasis clusters observed for the three core PC-3 variant
cell lines. (B) Shown is a table summarizing various parameters of tumor growth and
metastasis following orthotopic implantation of the three cell lines. All resultswere
normalized relative to those of #78 cells, which were set to 1.
B
#78 pMicro-1 #82
Average lung metastases per mouse 1.0 7.2 11.8
Average lung mets > 5 cell clusters per mouse 1.0 10.4 19.0
Average size of primary tumor 1.0 0.7 0.9
Average size of lumbar lymph nodes 1.0 1.5 2.0
Average size of renal lymph nodes 1.0 1.9 2.8
Average number of blood colonies per mouse 1.0 1.5 0.7
Average lung metastases per blood colony 1.0 3.4 13.9
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Figure 10. Candidate metastasis genes were identified by comparing the gene
expressions of subcutaneous tumors derived from the three core PC-3 variant cell
lines. (A) Unsupervised hierarchical clustering of the gene expression profiles of the
three cell lines. (B) The 38 genesthat differed by >2.5-fold expression between poorly
metastatic #78 tumors and highly metastatic #82 tumors are shown, as analyzed by D-
Chip (above the line, genes downregulated in highly metastatic cells; below the line,
genes upregulated in highly metastatic cells).
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Figure 10. Candidate metastasis genes were identified by comparing the gene
expressions of subcutaneous tumors derived from the three core PC-3 variant cell
lines (cont). (C) Shown isa list of notable geneswhose expression levelswere also
significantly changed, but to a lesser extent than those in (A) (above the line, genes
upregulated in highly metastatic cells; below the line, genes downregulated in highly
metastatic cells). For a complete list of differentially expressed genes, please see
Appendix E.
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CHAPTER 3.
PROTEIN 4.1B SUPPRESSES PROSTATE CANCER
PROGRESSION AND METASTASIS
The work in this chapter was conceived by Sunny Wong and Richard Hynes. Antibodies and
overexpression constructs for 4.1 B and/or integrin 18 were generated by and/or obtained from Joseph
McCarty. 4.1B-deficient mice were generated by and obtained from Joseph Kissil. Bioinformatics
analysis was assisted by Steve Shen. The contents of this chapter were written by Sunny Wong, with
editing by Richard Hynes.
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INTRODUCTION
The Protein 4.1 Superfamily of Proteins
Protein 4.1 B is a member of the Protein 4.1 superfamily of proteins, which is characterized by the
presence of a conserved N-terminal 4.1/ezrin/radixin/moesin (FERM) domain. These proteins serve to
connect transmembrane glycoproteins such as CD44 to the actin cytoskeleton, and have been shown to
affect numerous cellular processes, including polarization, migration and proliferation, among other
functions[Bretscher et al., 2002]. Based on sequence homology, the Protein 4.1 superfamily of proteins
can be further divided into five subgroups: Protein 4.1 molecules, ERM proteins, talin-related molecules,
protein tyrosine phosphatase (PTPH) proteins, and novel band 4.1-like 4 (NBL4)(Figure 1A)[Sun et al.,
2002]. Given their roles in numerous cellular processes, it is not surprising that several members of these
subgroups have also been implicated in tumor progression. In particular, the ERM-like protein merlin (the
product of the NF2 gene) is a critical suppressor of meningiomas and schwannomas[Gutmann et al.,
1997], while another ERM protein, ezrin, has recently been shown to enhance metastasis of bone and
soft tissue sarcomas[Khanna et al., 2004; Yu et al., 2004a]. Roles for protein 4.1 subgroup members in
tumorigenesis, however, are less clear, though 4.1B is believed to be a tumor suppressor that is
commonly lost in a variety of cancers, as will be discussed later.
In total, the Protein 4.1 superfamily of proteins consists of greater than 40 members in mammals, and
related proteins are also present in Drosophila and C. elegans, though the FERM domain is found only in
multi-cellular organisms[Polesello and Payre, 2004]. Most of the mechanistic and structural studies that
have been performed have focused on the ERM subgroup of proteins, which consists of three members:
ezrin, radixin and moesin'. Each of these proteins possesses a FERM domain, a central coiled-coil a-
helical domain, and a C-terminal actin-binding domain (C-ERMAD)[Sun et al., 2002]. Since the FERM
domains of ERM and Protein 4.1 proteins display high degrees of sequence homology, many of the
properties exhibited by ERM FERM domains are predicted to be similar to those of Protein 4.1 FERM
domains, though, in most cases, these predictions await experimental validation. However, it is important
to note that, aside from their FERM domains, Protein 4.1 and ERM proteins are actually quite
divergent[Sun et al., 2002]. Therefore, while these molecules may exhibit some common features due to
their homologous FERM domains, such as localization and interaction partners, they are also likely to
possess different functions within the cell.
1 Merlin is related to the ERM proteins and is often also considered a member of this subgroup, although it lacks a C-
terminal actin-binding domain. Merlin activity is also regulated differently than the ERM proteins, as will be discussed in
the subsequent sections.
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Functional Regulation of ERMI4.1 Proteins 2
Crystallographic studies on the FERM domain of moesin have revealed a clover-leaf structure consisting
of three subdomains: F1, F2 and F3[Edwards and Keep, 2001]. While F1 is structurally similar to
ubiquitin, F2 bears homology with acyl-CoA-binding proteins. At the sequence level, F3 exhibits
homology with phosphotyrosine binding (PTB), pleckstrin homology (PH) and EnabledNASP homology I
(EVH1) domains. At least in the case of ERM proteins, these three subdomains appear critical for
mediating both intra- and inter-molecular interactions. In the first scenario, the N-terminal FERM domain
can fold upon itself and bind the C-terminal end of the same protein, thereby adopting a "closed"
conformation that conceals binding sites for F-actin and other proteins including CD44, ICAM-1/2, ERM-
binding phosphoprotein 50 (EBP50) and Rho-GDI (Figure 1B) [Bretscher et al., 2002]. In the second
scenario, the FERM domain of any ERM protein is capable of interacting with the C-terminus of any other
ERM protein, and this extended, "open" conformation thus exposes all the binding sites previously
concealed. Conversion from the closed to open conformation can be induced by Rho kinase-mediated
phosphorylation of a C-terminal threonine residue, or by binding of lipid phosphatidylinosital (4,5)-
bisphosphate (PIP2) to the FERM domain[Yonemura et al., 2002]. In many cases, induction of the open
conformation activates ERM proteins and re-localizes them from the cytoplasm to cortical actin
protrusions at the plasma membrane.
As one might expect, overexpression of truncated ERM proteins can act as dominant active or dominant
negative mutants. Introduction of the C-terminal half of ezrin or radixin into cells induces abnormally long
membrane protrusions, presumably by locking endogenous ERM proteins into an extended, open
conformation and exposing actin-binding sites[Henry et al., 1995]. Conversely, overexpression of the N-
terminus of ezrin[Crepaldi et al., 1997] or introduction of antisense oligonucleotides targeted against ERM
proteins can inhibit microvilli formation and reduce adhesion of cultured cells[Takeuchi et al., 1994].
As mentioned previously, the Rho pathway is critical for inducing the open (active) conformation of the
ERM proteins and, interestingly, may act in a positive feedback loop. Lysophosphatidic acid (LPA)
treatment of cells can activate Rho proteins, which leads to downstream induction of Rho kinase. Rho
kinase, in turn, phosphorylates ERM proteins, which weakens the intramolecular interactions between the
FERM and C-ERMAD domains[Matsui et al., 1998; Shaw et al., 1998]. This allows the protein to adopt
an active conformation that exposes binding sites for Rho-GDI, an inhibitor of Rho-GTP[Takahashi et al.,
1997]. The net effect is that active ERM proteins compete Rho-GDI away from their substrates, thus
allowing prolonged activity of Rho-GTPases. As predicted from this model, overexpression of Rho-
GTPases has been shown to activate ERM proteins and to cause their redistribution to the plasma
membrane, while inhibition of Rho activity with C3-ADP-ribosyltransferase (C3) can block LPA-induced
2 Merlin regulation differs in some respects and is discussed in more detail in the next section.
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ERM protein activation[Yonemura et al., 2002]. In addition, expression of the radixin FERM domain is
sufficient to activate Rho. Thus, ERM proteins act both upstream and downstream of Rho-
GTPases[Matsui et al., 1998].
ERM self-folding can also be disrupted through binding of lipids such as PIP2 to their FERM domains.
This Rho-independent mechanism of activation was hypothesized when in vitro studies suggested that
PIP2 could activate recombinant ERM proteins[Anderson and Marchesi, 1985] and cause binding to
purified CD44 in the absence of phosphorylation[Hirao et al., 1996]. In addition, unphosphorylated ERM
proteins were observed to localize to the microvilli of A431 skin epithelial carcinoma cells following
induction by EGF, even in the presence of the kinase inhibitor staurosporine[Yonemura et al., 2002]. A
mutant form of ezrin containing an alanine substitution in place of threonine at the C-terminal
phosphorylation site was also observed to localize to the plasma membrane after EGF induction. Indeed,
titration of PIP2 by micro-injecting cells with the antibiotic neomycin-which binds polyphosphoinositides,
particularly PIP2, with high affinity-re-localized ERMs from the plasma membrane to the cytoplasm and
caused break-down of microvilli[Yonemura et al., 2002]. Finally, crystal-structure analysis of the radixin
FERM domain in complex with inositol-(1,4,5)-triphosphate (IP3) has allowed direct observation of lipid
binding[Hamada et al., 2000]. Thus, these studies have shown that both lipids and phosphorylation can
activate ERM proteins by affecting their conformation.
Merlin: A Potent Tumor Suppressor
Merlin is perhaps the most well-studied member of the Protein 4.1 superfamily, although even now, there
is a great deal that remains unknown about this important protein. Merlin is a tumor suppressor and the
product of the NF2 gene, which is named after the human disorder that arises-neurofibromatosis type
2-when merlin is absent or non-functional. Patients suffering from neurofibromatosis type 2 are
predisposed to multiple tumors of the central nervous system, including schwannomas, meningiomas and
ependymomas[Gutmann et al., 1997]. The disorder is dominantly inherited, loss of heterozygosity of NF2
is frequent, and the tumor suppressive role of merlin is evident in that mice heterozygous for this protein
develop metastatic osteosarcomas and lymphomas[McClatchey et al., 1998]. Like other ERM proteins,
merlin possesses an N-terminal FERM domain that forms intramolecular interactions with its own C-
terminal domain-this is the active, tumor suppressive form that localizes to adherens junctions in
confluent fibroblasts[Lallemand et al., 2003; Sherman et al., 1997; Sun et al., 2002]. While loss of merlin
does not appear to affect proliferation directly, mutant cells seem incapable of sensing normal contact
growth inhibition and exhibit diffuse localization of adherens junction components like (3-
catenin[Lallemand et al., 2003]. In support of its role as a tumor suppressor, overexpression of merlin
can induce cellular apoptosis[Lutchman and Rouleau, 1995; Sherman et al., 1997], while expression of
various truncated forms of merlin (FERM domain only, or full length protein minus the FERM domain) can
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act as dominant negatives against the endogenous protein. These dominant negatives, as expected,
have been found to induce Schwann cell hyperplasia in vivo[Giovannini et al., 1999], and to confer
anchorage-independent growth and insensitivity to contact inhibition in NIH-3T3 cells in vitro [Johnson et
al., 2002].
As in the case of ERM proteins, merlin activity is conformation-dependent. Under conditions of high cell
density, growth factor withdrawal and/or attachment to extracellular matrix, merlin is normally
hypophosphorylated, folded up and inhibitory of cell growth[Lallemand et al., 2003; Morrison et al., 2001].
Although the exact mechanism by which merlin suppresses proliferation remains unclear, interaction with
the receptor CD44 appears critical, and the hypophosphorylated, active form of merlin has also been
shown to inhibit the Racl pathway[Kissil et al., 2003; Morrison et al., 2001]. Under growth permissive
conditions, merlin is phosphorylated, possibly by Rho kinase or by p21-activated kinase (Pak-1), which
opens up and inactivates the molecule[Kissil et al., 2002; Matsui et al., 1998]. In its extended
conformation, merlin can interact with CD44 directly via its FERM domain or indirectly through head-to-tail
associations with ERM proteins, particular ezrin[Morrison et al., 2001; Sun et al., 2002]. In addition, the
open and inactive conformation of merlin exposes binding sites for actin and for other proteins, including
f1ll spectrin and paxillin. Therefore, the sum of these interactions might provide not only a link between
CD44 and the cytoskeleton to promote cell adhesion and polarity, but also a way to keep merlin in its
inactive (and non-growth inhibiting) state.
Given the ample genetic evidence implicating merlin as a potent tumor suppressor, it is reasonable to
expect that related proteins might also affect the cancer progression pathway. Indeed, ezrin has been
reported to be necessary for Rho kinase/ROCK-mediated transformation of fibroblasts[Martin et al.,
2002], and recent studies have shown that ezrin is also a critical and positive regulator of osteosarcoma
and rhabdomyosarcoma metastasis[Khanna et al., 2004; Yu et al., 2004a]. Among the Protein 4.1
subgroup of proteins, relatively less is known about the normal functions of its members, which are
characterized by an N-terminal FERM domain, a central spectrin-actin binding domain (SABD), and a C-
terminal domain (CTD), as well as three unique domains (U1-U3). However, among this subgroup of
proteins-which currently consists of 4.1R, 4.1G, 4.1N and 4.1 B-and based on a growing number of
studies, 4.1B has emerged as a leading tumor suppressor candidate in a variety of cell types.
Protein 4.1/DAL-1: A Putative Tumor Suppressor?
4.1B was first identified using differential display RT-PCR as a gene whose expression was reduced in
human non-small cell lung carcinomas (NSCLC)[Tran et al., 1999]. The protein which was first cloned,
unexpectedly, turned out to be a truncated version of 4.1 B-this was originally named Deleted in
Adenocarcinoma of the Lung-I, or DAL-1. Translation of DAL-1 initiates at Methionine 110, relative to
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full-length 4.1 B, and, consequently, this proteins lacks the 4.1B N-terminal U1 domain and the entire
CTD[Gutmann et al., 2001]. DAL-1 also has internal deletions in portions of the U2 and U3 subdomains,
and, interestingly, possesses a short stretch of unique amino acids in its FERM domain (Figure 1C-D). In
a limited number of studies so far, no differences in function have been discerned between 4.1B and
DAL-1; thus, the two are, at present, regarded interchangeably in the literature.
In terms of results obtained from human clinical studies, there is good reason to believe that 4.1B/DAL-1
could function as a tumor suppressor. The gene is located at chromosome position 18p11.3, a region
that is lost in 38% of lung, brain and breast tumors[Tran et al., 1998]. 4.1B expression has also been
reported to be downregulated in up to 70% of meningiomas and in up to 55% of breast cancers, while 18p
is a frequent site of loss-of-heterozygosity in a variety of cancers[Charboneau et al., 2002; Gutmann et
al., 2000; Gutmann et al., 2001; Kittiniyom et al., 2001]. 4.1B is also widely expressed, particularly in the
brain, lungs and intestine, and has been observed to be downregulated in a spontaneous mouse model of
colorectal cancer, as well as during the transition from adenoma to carcinoma in a spontaneous model of
pancreatic cancer[Ohno et al., 2004; Terada et al., 2005]. Finally, 4.1B expression has been reported to
be absent from several breast and lung cancer cell lines[Tran et al., 1999].
Protein 4.1BIDAL-1: In vitro Studies
Several studies have shown that experimental overexpression of 4.1B can suppress growth and, in some
cases, induce apoptosis in human breast cancer, non-small cell lung cancer and meningioma
cells[Charboneau et al., 2002; Jiang and Newsham, 2006; Robb et al., 2005]. Although the mechanism
by which 4.1 B induces apoptosis remains unclear, one report has recently observed that overexpression
of 4.1B increases caspase-8 activity in MCF-7 cells, and that inhibitors of caspase-8 can block 4.1B-
mediated apoptosis[Jiang and Newsham, 2006]. Others have reported that overexpression of 4.1 B
induces Racl-dependent JNK signaling, which leads to growth suppression of meningioma cells[Gerber
et al., 2006]. Truncation studies have also suggested that the U2 region of 4.1 B contains the minimal
growth suppressive domain when tethered to the membrane by FERM domain-mediated protein-protein
interactions[Robb et al., 2005]. However, the growth inhibitory effects of 4.1 B are not universal and may
be cell-type-specific. For instance, overexpression of 4.1B inhibits the growth of some subclones of MCF-
7 breast cancer cells, but not others, and 4.1B has been reported not to affect the growth of
schwannomas[Charboneau et al., 2002; Gutmann et al., 2001].
Conceivably, expression or activity of known interactors of 4.1 B-including CD44, the tumor suppressor
TSCL1, other 4.1 proteins, merlin and potentially ERM proteins-could modulate its activity (Figure 1 B)
[Sun et al., 2002]. In most cases, binding likely occurs through the FERM domain, though recent work
from our lab has also shown that the C-terminal domain of 4.1 B can interact with another potential tumor
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suppressor, integrin P8 [McCarty et al., 2005a]. In most cases, the functional significance of these
interactions is unknown. One exception is that 4.1B binding to the core domain of protein arginine N-
methyltransferase 3 (PRMT3) has been reported to inhibit the ability of PRMT3 to methylate substrates in
vitro [Singh et al., 2004]. Whether PRMT3 activity is important for 4.1B-mediated suppression of
tumorigenesis remains unclear. Finally, it is worth noting that, in contrast to other members of the ERM
and Protein 4.1 sub-families, 4.1B does not bind actin[Gutmann et al., 2001].
In terms of sub-cellular localization, 4.1B has been observed both in the cytoplasm and at the plasma
membrane, either in a non-specific "honeycomb" pattern or enriched at points of cell-cell
contact[Charboneau et al., 2002; Gutmann et al., 2001; Tran et al., 1999]. Localization of 4.1B, therefore,
likely varies among different cell types, and may also be influenced by components of the surrounding
extracellular matrix. For example, 4.1B was reported to co-localize with integrin 18 only when the cells
were plated on the 18 ligand, LAP (the latency-associated peptide of TGF-f,)[McCarty et al., 2005a]. In
terms of cell adhesion and migration, one study has shown that overexpression of 4.1 B in MCF-7 cells
increased the strength, but not the rate, of cellular attachment to various matrix molecules[Charboneau et
al., 2002]. In another study, overexpression of 4.1B somewhat inhibited cell motility (down -20%) in
schwannoma cells[Gutmann et al., 2001]. Clearly, further characterization of this protein in different
cellular contexts is needed to validate and extend these observations.
Protein 4.1BIDAL-1: In vivo Studies
Knock-out mice lacking 4.1B have been generated by Yi, et al., and mutant animals are healthy and
viable, without any detectable predisposition to spontaneous tumor formation above background levels[Yi
et al., 2005]. In addition, 4.1 B mouse embryonic fibroblasts were also reported to exhibit no differences
in proliferation compared with wild-type fibroblasts. Thus far, the only phenotype observed in null animals
has been a relatively minor one: Mammary glands from 4.1 B/ female mice displayed a 60% increase in
Ki67-positive epithelial cells during pregnancy, but not during the lactating or involution stages[Kuns et al.,
2005]. In some rare instances, we have observed 4.1B / mice experiencing seizures (J.L.K. and S.Y.W.)
and premature death, which may, in some ways, resemble what has been reported in mice bearing a
conditional deletion of integrin av in neurons[McCarty et al., 2005b]. Unfortunately, this phenotype is not
fully penetrant in 4.1B-deficient animals. Consequently, the absence of any readily apparent and
reproducible phenotypes in these mice has precluded efforts to assign a physiological or cellular function
to this protein. While this may be due to genetic redundancy and/or compensation by other Protein 4.1
subgroup members, another possibility is that loss of 4.1B may yield very subtle phenotypes, discernible
only under specific assay conditions. For instance, absence of 4.1 B may not affect tumor initiation or
predisposition in mice, but can it affect the later stages of cancer progression to metastasis?
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As described in the previous chapter, using a screen to identify genes that might be responsible for
prostate cancer metastasis, we found that 4.1B was significantly downregulated in highly metastatic
tumor cells. As was also mentioned, loss of 4. 1B has been associated with a variety of human clinical
tumors, and several studies have shown that overexpression of 4.1B suppresses growth in vitro. None of
these studies, however, examined the effects of 4.1B on tumorigenesis in vivo. In the following section, I
describe our work validating the role of 4.1B in prostate cancer progression and metastasis. Notably, I
use both a spontaneous model and a xenotransplant orthotopic model of prostate cancer to validate that,
indeed, 4.1B can act as a suppressor of tumor progression in vivo. Finally, I show that 4.1B is also
frequently downregulated in human clinical prostate cancer.
RESULTS
Downregulation of Protein 4.1B increases the metastatic propensity of human prostate
adenocarcinoma cells in a xenotransplant orthotopic model of prostate cancer
As described in the previous chapter, in a screen for genes that might be responsible for prostate cancer
metastasis, we found that Protein 4.1B expression was downregulated in highly metastatic PC3-#82 cells,
relative to poorly metastatic PC3-#78 cells (Figure 2A). This was originally observed by gene expression
analysis of RNA from subcutaneous tumors, using the software program D-Chip. As 4.1B was the
second most downregulated gene in #82 cells, and the purported functions of the Protein 4.1 subgroup of
proteins appear relevant to processes such as migration and proliferation-steps which are certainly
involved with metastasis-we decided to examine this gene further. We began by confirming the
microarray results by performing quantitative real-time PCR on both subcutaneous tumors and on cells
cultured in vitro. We found that in either case, as with our gene expression analysis, 4.1B RNA was
severely reduced in highly metastatic #82 cells, relative to poorly metastatic #78 and medium metastatic
pMicro-1 cells (Figure 2B). This result was subsequently confirmed at the protein level by Western blot
against 4.1B in total soluble lysates from tissue culture cells, which detected doublet bands around 125
kDa (Figure 2C). In this case, we found that 4.18 was abundant in #78 cells and in PC-3 parental cells,
which were purchased from ATCC and had not been passaged in vivo. In addition, 4.1B appeared to be
expressed at an intermediate level in pMicro-1 cells and was almost completely lost both in #82 cells and
in highly metastatic PC-3M cells obtained from Dr. I.J. Fidler (Figures 2C-D). Thus, our results for 4.1B at
the RNA and protein levels coincided and, together, showed that 4.1B was selectively lost in aggressive
prostate cancer cells.
The fact that 4.1B expression was inversely associated with metastatic potential suggested that this
protein might act as a potential suppressor of prostate cancer progression and metastasis. We first
approached this hypothesis by determining whether experimental ablation of 4.1B expression was
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sufficient to enhance the metastatic ability of poorly metastatic cells. To downregulate 4.1 B, we
generated #78 cell lines expressing stable siRNAs targeted against this gene and found that cells
expressing any of four different siRNAs (DL1-DL4) exhibited significant reductions in 4.1B protein and
RNA levels in vitro (Figure 3A). This inhibition was also maintained after these cells had been injected as
subcutaneous tumors. For the rest of our studies, we decided to focus on the two cell lines displaying the
most severe ablation of 4.1B (#78-DL1 and #78-DL2) and used as controls #78 cells expressing an empty
vector (pSIRISP) or an siRNA against GFP (siGFP). We found no significant differences in proliferation
among the cell lines in vitro, either in the presence or absence of serum (Figure 3B), and subcutaneous
tumors derived from these cells also grew at similar rates (Figure 3C). This is in concordance with our
findings that #78 and #82 cells did not differ in proliferation, despite expressing varying levels of 4.1B.
We next xenotransplanted #78 tumors expressing siRNAs against 4.1B or control plasmids into the
dorsolateral lobes of the prostate using surgical orthotopic implantation (SOI). Approximately 2-3 months
after implantation, mice were analyzed when they appeared moribund, and, at the time of dissection, the
average masses of the orthotopic primary tumors in the prostate did not differ among the cell lines (Figure
4A). However, the average masses of the draining para-aortic/lumbar lymph nodes were significantly
larger in mice implanted with 78-DL1 and -DL2 tumors, relative to those implanted with control tumors
(Figure 4B, p = 0.039). In many cases, histological examination revealed that lymph nodes from mice
implanted with 78-DL1 and -DL2 tumors were completely infiltrated with tumor cells (n = 46 nodes
examined), whereas nodes from animals implanted with control tumors more frequently exhibited only
partial, if any, invasion (Figure 4C, n = 42 nodes examined, p < 0.0001).
Partial invasion of lymph nodes by control tumors commonly involved subcapsular infiltration of malignant
cells, without deeper penetration into the interior of the node. This was also often a site where many
tumor cells appeared apoptotic, as assessed by TUNEL staining (Figure 4D, top, arrows). In contrast,
TUNEL staining was rare in nodal regions which were completely replaced by tumor cells (Figure 4D,
bottom), as was often the case with DL1- and DL2-expressing tumors, though central areas of necrosis
were sometimes stained in exceptionally large nodal metastases (not shown). Mice implanted with
siRNA-expressing tumors also possessed more lung metastases than those implanted with control
tumors, though these differences did not reach statistical significance due to the small number of animals
that had exhibited systemic spread (Figure 4E). Overall, these results indicate that 4.1 B suppresses
prostate cancer metastasis, and that downregulation of 4.1 B is sufficient to increase the metastatic
potential of poorly metastatic #78 cells.
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Protein 4.1B interacts with integrin 08
To try and elucidate how high levels of 4.1B might be suppressing metastasis in PC-#78 cells, we
attempted to confirm known binding partners of this protein, in an effort to place it within the context of
potential signaling pathways. Notable 4.1B-interacting proteins have been reported to include CD44,
merlin, calmodulin, TSLC1, PRMT3, 14-3-3 proteins, P-ll spectrin, microtubules, as well as other ERM
and 4.1 proteins. In nearly all cases, however, rather than being 4.1 B-specific interactors, these binding
partners likely interact with all members of the 4.1 subgroup of proteins via either their FERM or SABD
domains. Recently, studies by Dr. Joseph McCarty in our lab identified the 4.1B C-terminal domain as a
novel interactor of integrin 38 in a yeast two-hybrid screen. Follow-up work showed that, in fact, 38
interacted with all 4.1 subgroup proteins through their CTDs. As P8 has been shown to suppress the
growth of tumor cells through activation of TGF-P[Mu et al., 2002], we sought to confirm the 4.18B-38
interaction in PC-3 cells, as well as to test whether this interaction affected cell growth and/or survival.
We began by determining whether PC-3 cells expressed integrin (8 and its heterodimeric binding partner,
av. Neither integrin subunits were detectable by Western blot on soluble whole cell lysates (data not
shown), so we attempted to immunoprecipitate either the av or 138 subunits, and to determine whether
their respective binding partners ((8 or av, respectively) were enriched by co-immunoprecipitation (co-IP).
We found that immunoprecipitation of (8 could co-IP endogenous av integrin from PC-3 cells, as
assessed by Western blot (Figure 5A). This was also true in mouse TRAMP prostate cancer cells (data
not shown). In the reverse experiment, immunoprecipitation of av integrin did not co-IP 138, although this
may have been due to technical reasons (data not shown). A summary of the antibodies most useful for
detecting mouse or human avP8 in different applications is shown in Figure 5B.
Upon confirming that PC-3 cells expressed avi38, we next determined whether 4.1 B could interact with
integrin 38. Initial studies focused on #78 cells, as they were known to express avI8 as well as high
levels of 4.1 B; however, in no cases were we successful at co-IP experiments involving endogenous
proteins (data not shown). Therefore, we co-expressed both 4.1 B and integrin P8 fused with the epitope
tags myc and V5, respectively, to their C-termini. Following co-transfection of cells, immunoprecipitation
of integrin 138 using an antibody against V5, followed by Western blot detection of the myc tag yielded a
single band of the expected size for the 4.1B-myc fusion protein (Figure 5C). This experiment lends
support to the possibility that 4.1 B and integrin (8 can interact in prostate tumor cells. Although
endogenous co-IP of these proteins was unsuccessful, this was not surprising, given that protein-protein
interactions in vivo are often weak in nature, thereby easily disruptable by detergent solublization of
protein lysates. Therefore, it is possible that endogenous 4.1B and integrin 38 can interact in our cells,
but this interaction may occur at a level that is below our current limits of detection.
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Once we were able to confirm the 4.1B-18 interaction, we were interested in determining whether
overexpression of either of these genes could impact cell growth and/or morphology. Early attempts to
overexpress 4.1B stably in PC-3 cells were unsuccessful, and, therefore, both myc-tagged 4.1B and V5-
tagged integrin 38 were cloned into separate doxycycline-inducible vectors, which were delivered into #82
cells by viral infection. Induction of 4.1 B and P8 expression upon addition of doxycycline was confirmed
by Western blot (Figure 6A). Subsequently, the growth of induced versus non-induced cells was assayed
in the presence or absence of serum. In either situation, we found no significant differences in growth
between non-induced cells and cells induced to express 4.1B (Figure 6B-C and data not shown).
Induction of 08 expression did result in an apparent 20% reduction in cell number, but given that these
cells had been induced and grown for 6-7 days prior to quantitation, the differences appeared quite subtle
(Figure 6B and data not shown). However, these findings were complicated by the observation that
inducible gene expression for either 4.1B or P8 was apparent in only about one-third of cells, as assessed
by immunofluorescence staining (Figure 6D).
Protein 4.1B suppresses tumor progression in a spontaneous model of prostate cancer
As discussed previously, xenotransplant models offer convenient approaches for studying tumorigenesis
in vivo; however, these approaches only recapitulate some of the steps of cancer progression and are, by
their nature, relatively artificial systems. We were therefore interested in confirming and extending our
observations--that 4.1 B suppresses metastasis following SOl xenotransplantation-in a spontaneous
model of prostate cancer. For this, we utilized the transgenic adenocarcinoma of the mouse prostate
(TRAMP) tumorigenesis model, where transgenic overexpression of SV40 large T antigen in the prostate
causes spontaneous prostate cancer development in the mouse. Whereas normal prostate ductal
structures consist of a single layer of cytokeratin 8-positive luminal cells surrounded by occasional
cytokeratin 5-positive basal cells (Figure 7A), tumor development in TRAMP mice involves expansion of
the luminal cell compartment, loss of differentiation and cell polarization, and finally, invasion through the
basement membranes and metastasis (Figure 7B) [Abate-Shen and Shen, 2000]. This progression is
believed to be gradual, occurring in a step-wise fashion, and has been described by a grading system, as
will be described shortly.
To determine if 4.1B could modulate TRAMP tumor progression, we first obtained 4.1B knock-out mice
and confirmed the absence of the protein by performing Western blot on brain and prostate lysates from
4.1 B-' or 4.1BB' " animals (Figure 8A). We then crossed these animals into a TRAMP background and
analyzed the mice after 26 weeks of age. We found that 11/19 (58%) of 4.1 B-';TRAMP ÷' mice developed
a variety of palpable carcinomas in the prostate, compared to 2/26 (7.7%) of 4.1+'-;TRAMP+- mice (p =
0.0002, Figures 8B and 8D). As was seen in our xenotransplant model, 4.1B-deficient TRAMP
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tumorigenic prostates also displayed an increased propensity to metastasize to para-aortic/lumbar lymph
nodes, relative to 4.1B-heterozygous TRAMP prostates. The presence of metastatic tumor cells in the
nodes was confirmed by staining lymph node sections with antibodies against the epithelial marker
cytokeratin 8 (Figure 8C). The overall results from these experiments are summarized in Figure 8D.
We next micro-dissected and sectioned the tumorigenic TRAMP prostates from all mice. Histopathologic
grading of these sections, using the system described by Hurwitz et al.[Hurwitz et al., 2001], was blindly
performed by a pathologist from our lab, Dr. Marc Barry. Sections were scored on a scale of 1-6, with '1'
being normal prostate and '6' representing poorly differentiated adenocarcinoma, with intermediate
grades denoting precursor lesions of varying severity (Figure 9A). Since tumorigenic prostates often
exhibited heterogeneity even within the same section, two grades were assigned for each prostate lobe of
each animal: a highest grade and a predominant grade. For instance, in the section shown in Figure 9B,
a highest grade of 6 was awarded for the focal areas of undifferentiated adenocarcinoma observed, while
a predominant grade of 4 was also assigned. We found that, regardless of genotype, nearly all mice
developed tumors. However, using either grading approach on either the ventral or dorsolateral lobes of
the prostate, we invariably found that 4.1B-'-;TRAMP+/ mice developed the highest, least differentiated,
and most aggressive grades of prostate cancer at a significantly increased frequency relative to
heterozygous TRAMP mice (Figures 9C, p = 0.003). These results indicate that loss of 4.1B is sufficient
to enhance the progression of spontaneous prostate cancer to metastatic disease.
To understand how absence of 4.1B promotes tumor progression, we stained sections for proliferation
and apoptotic markers (Ki67 and TUNEL, respectively). Because cancer progression in the TRAMP
model is believed to proceed in a step-wise fashion, beginning at Grade 1 and increasing with severity
over time, we reasoned that if proliferative or apoptotic differences were manifested in the lower-graded
prostatic lesions, that would affect the rate of progression to Grade 6 adenocarcinoma. Therefore, we
began by staining 26-week old, Grade 4-matched prostate sections with Ki67 antibody and by TUNEL
(Figure 10A). We found no differences between 4.1B'1 or 4.1B */_ TRAMP prostates for either proliferation
or apoptosis, and we also found no differences when we stained 26-week old, Grade 5-matched sections
(Figure 10B). However, especially for the 4.1 B- prostates, these samples were biased in that many
tumors had already progressed to Grade 6 and could not be used for this analysis; in other words, what
was actually analyzed was the remaining prostates that had not progressed to the higher grades. To
perform a more unbiased study, we removed and sectioned prostates from a younger cohort of 22-week
old TRAMP mice for both genotypes. At this age, prostates from both 4.1B -'- and 4.1 B / mice had mostly
progressed to Grades 3-4 severity, but had not yet reached Grade 6 (Figure 10C). Although there was
again no statistically significant difference in proliferation (p = 0.15), we found that 4.1 B-;TRAMP
prostates displayed about 50% fewer apoptotic cells, compared to heterozygous TRAMP mice (Figures
10D-E, p < 0.001). These results suggest that absence of 4.1 B, at the very least, protects prostatic
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precursor lesions from undergoing cell death at 22 weeks, which may facilitate enhanced progression to
higher and more invasive tumorigenic grades by 26 weeks.
Characterization of 4.1B in murine TRAMP prostate cancer cells
TRAMP prostate cancer cell lines were derived by Foster, et al. (1997), and were isolated from a single
spontaneous TRAMP prostate primary tumor. Three cell lines were established, TRAMP-C1, -C2 and -
C3; and while TRAMP-C1 and -C2 cells were reported to form colonies in soft agar and subcutaneous
tumors when injected into syngeneic animals, TRAMP-C3 cells displayed longer doubling times in vitro,
did not form colonies in soft agar and were non-malignant in animals (Figure 11A). We obtained TRAMP-
C1 and -C3 cells from American Type Culture Collection (ATCC) and began by confirming that TRAMP-
C1, but not TRAMP-C3, cells formed soft agar colonies (Figure 11B). In concordance with our
xenotransplant and spontaneous tumor results, we also found that 4.1B protein levels were specifically
reduced in malignant TRAMP-C1 cells, relative to non-malignant TRAMP-C3 cells (Figure 11C), while
levels of the related proteins, 4.1G and 4.1N, were unchanged. We next performed immunofluorescence
staining for 4.1 B on both cell lines, and observed that while non-aggressive TRAMP-C3 cells generally
exhibited uniformly high levels of this protein, aggressive TRAMP-C1 cells displayed remarkable
heterogeneity (Figure 11D). While most cells had lost expression of 4.1 B, a significant minority still
retained expression and "co-existed" in a mixed population.
We next sought to determine whether ablation of 4.1B expression could increase the aggressiveness of
TRAMP-C3 cells-in essence, making them more akin to TRAMP-C1 cells. Stable expression of any of
three siRNAs targeted against mouse 4.1B effectively ablated expression of the protein (Figure 12A), and
this was confirmed by immunofluorescence (Figure 12B). The two cell lines with the most significant
reductions in 4.1B protein levels (C3-mDL1 and -mDL4) were tested for their ability to form colonies in
soft agar; however, regardless of whether the TRAMP-C3 cells expressed high or low levels of 4.1 B, as
before, no colonies were seen (data not shown). These cells also exhibited no growth differences in the
presence or absence of serum and/or testosterone (data not shown). Therefore, ablation of 4.1B
expression did not appear to be sufficient for inducing the malignant phenotype from non-malignant cells,
at least not in the assays we attempted.
In light of these results, we decided to ask a less ambitious question: If loss of 4.1B could not induce a
malignant phenotype de novo in TRAMP-C3 cells, could loss of 4.1B enhance the aggressiveness of
already-malignant TRAMP-C1 cells? Because a subpopulation of TRAMP-C1 cells was found by
immunofluorescence to express high levels of 4.1 B, we decided to clone and expand members of this
subpopulation. We began by isolating 30 single cell clones derived from the heterogeneous bulk
population and by testing each of these clones by immunofluorescence for 4.1B expression (Figure 13A).
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In most cases, these cloned TRAMP-C1 subpopulations expressed uniformly high, low or intermediate
levels of 4.1 B, as expected, though in some rare instances, heterogeneous expression was observed-
these subpopulations may have been derived from more than one clone, or they might be genetically
unstable. For 8 independent clones (four expressing high levels of 4.1 B, four expressing low levels, as
determined by immunofluorescence), we further validated these observations by Western blot (Figure
13B). Interestingly, even among cells that expressed uniformly high/intermediate levels of 4.1 B,
localization of the protein varied significantly, ranging from diffuse localization in the cytoplasm (Clone 1),
to membrane enrichment at sites of cell-cell contact (Clone 29) (Figure 13C). In non-malignant TRAMP-
C3 cells, 4.1B localization was also found in circular, actin-rich structures (Figure 13D). siRNA-mediated
ablation 4.1 B appeared to have no apparent effect on these structures, which superficially resembled
podosomes, although this inference awaits further validation.
To determine if varying levels of endogenous 4.1 B affected soft agar colony formation, we subjected 29 of
our 30 clones to this assay. We found that the ability of these cells to initiate anchorage-independent
growth varied drastically, even though these clones were derived from an aggressive, albeit
heterogeneous, starting population. The results, which are shown in Figure 14A and are sorted by soft
agar colony size, ranged from cells that had not proliferated (-), to those that had undergone only a
couple of rounds of cell division (+/-), to those that had formed larger colonies (+ and ++) after two weeks.
Unfortunately, no correlation was evident between the level of endogenous 4.1 B expression and soft agar
colony size. We did notice, however, that among those cells that had formed colonies, two general types
of morphologies could be distinguished: The colonies either took on a reflective appearance with a
smooth outer border ("smooth"), or they appeared dense and possessed an uneven outer edge ("jagged")
(Figure 14B). When we compared colony morphology with 4.1B expression, we found that 6/9 clones
that had formed smooth colonies expressed high levels of 4.1 B, whereas 7/10 clones that had formed
jagged colonies expressed low levels of the protein (Figure 14B). This suggested to us that, perhaps to
some degree, high levels of 4.1B might be associated with a smooth colony morphology, and, conversely,
absence of 4.1B might be associated with a jagged morphology.
We tested this hypothesis by ablating 4.1B using stable siRNAs in five TRAMP-C1 cell clones which had
exhibited both high levels of 4.1B protein and a smooth, soft agar colony morphology (Clones 8, 9, 14, 17
and 27). Although we succeeded in downregulating this gene in all five independent clones (Figure 14C),
we did not observe any differences in either the size or morphology of the colonies formed in soft agar,
relative to that of control-infected cells (data not shown). The sum of these results suggests that although
4.1B is downregulated in highly aggressive TRAMP-C1 cells, loss of this protein is neither sufficient to
convert non-aggressive cells into aggressive cells, nor is it capable of augmenting the aggressiveness of
already-malignant cells. Our results, however, do not rule out the possibility that other assays might
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identify phenotypic differences directly affected by 4.1 B expression. This, as well as other interpretations
of our results, will be elaborated upon in the Discussion section.
Expression of Protein 4.1B is often downregulated in human clinical prostate tumors
We have just shown that loss of 4.1B can enhance tumor progression and metastasis in two independent
mouse models of prostate cancer; however, an important question still remains: Does loss of this gene
actually occur in human clinical patients? Although it is not possible to test whether 4.1B has a direct
causal effect in tumor suppression in human samples, nonetheless, it would be reassuring and in
concordance with our experimental findings if loss of 4.1 B were a frequently observed event during
human prostate cancer progression. That would at least imply that 4.1B might function as a potential
negative modulator of tumorigenesis in humans.
As mentioned previously, several studies have reported downregulation of 4.1 B in various tumor types
relative to their corresponding normal tissues, but none have implicated this protein, thus far, in prostate
cancer. We therefore began by examining the Oncomine gene expression database for studies where
4.1B expression was significantly changed. We were pleased to discover that among a total of five
independent data-sets comparing prostate cancer versus normal/benign tissue, four showed significant
downregulation of 4.1 B in the tumors (in all cases, p < 0.001) (Figures 15A-B). These data-sets were
originally collected by Welsh et al. (2001)[Welsh et al., 2001], Singh et al. (2002)[Singh et al., 2002], Yu et
al. (2004)[Yu et al., 2004b], and LaPointe et al. (2004)[Lapointe et al., 2004]. In particular, in the study by
LaPointe et al. (2004), 4.1B expression was significantly downregulated in prostate tumor samples
relative to normal prostate tissues (Figure 15B, p < 0.001), and further downregulated in lymph node
metastases compared to prostate tumors (p < 0.001).
Recent studies have shown that the genes encoding the Ets family transcription factors ERG and ETV1
are frequently translocated in as many as 80% of human prostate cancers. In the majority of cases,
these genes were fused to the coding sequence of TMPRSS2, causing androgen-regulated
overexpression of the chimeric proteins in tumors. Interestingly, Oncomine analysis revealed that
prostate tumors with ERG overexpression exhibited significantly lower levels of 4.1 B expression, relative
to tumors that did not overexpress Ets family transcription factors (Figure 16, p = 0.0001; data originally
from LaPointe et al. (2004)). Although, again, this is not proof that one protein inversely regulates the
expression of the other, it suggests that there might exist a link between 4.1B and ERG. Overall, we have
found that four out of a total of five independent human clinical prostate cancer data-sets exhibited very
significant downregulation of 4.1B expression in tumors. This would appear to be in concordance with
our findings from two in vivo mouse tumor models that loss of the tumor suppressor 4.1B is a relevant
and important event during progression of human prostate cancer.
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DISCUSSION
Although Protein 4.1 B was originally identified as a protein whose expression was reduced in human non-
small cell lung carcinomas[Tran et al., 1999], subsequent studies have shown that downregulation occurs
across many different tumor cell types, including colorectal, breast and renal clear cell carcinomas. 4.1B
protein has also been reported to be lost in up to 70% of sporadic meningiomas and in 55% of ductal
carcinomas in situ, and has been observed to be downregulated during tumorigenesis in spontaneous
mouse models of pancreatic and intestinal cancer[Gutmann et al., 2000; Kittiniyom et al., 2001; Ohno et
al., 2004; Terada et al., 2005]. While in vitro experiments have suggested that 4.1B might act as a tumor
suppressor, these results have awaited experimental validation in vivo.
We have shown here that Protein 4.1 B acts as a negative modulator of the aggressive tumor phenotype
in two different in vivo models of prostate cancer. In a screen for genes involved with metastasis, we
found that 4.1B expression was significantly reduced in highly metastatic human prostate
adenocarcinoma cells, and that downregulation of 4.1 B in poorly metastatic cells was sufficient to
increase their metastatic potential in our xenotransplant orthotopic model. Furthermore, we showed that
prostates from 4.1B-' TRAMP mice displayed increased progression to invasive, undifferentiated
adenocarcinomas, relative to those from 4.1 B+ TRAMP mice, in a spontaneous tumor model of prostate
cancer. In both systems, tumorigenic cells lacking 4.1B appeared to exhibit reduced apoptosis, which
may have accounted for enhanced invasion. 4.1B expression was also downregulated in tumors relative
to normal tissues in four independent studies of human clinical prostate cancer, and was also significantly
reduced in prostate samples displaying high ERG expression. These results suggest that downregulation
of 4.1 B is a frequent event in human prostate cancer that may contribute to a malignant tumor phenotype.
Our in vivo findings are in concordance with studies that have suggested that overexpression of 4.1 B can
induce apoptosis in vitro for some tumor cell types[Charboneau et al., 2002; Gutmann et al., 2001; Jiang
and Newsham, 2006; Robb et al., 2005; Tran et al., 1999]. However, we have yet to observe any
apparent in vitro consequences associated with manipulating 4.1B levels in either PC-3 or TRAMP cells.
In experiments where 4.1B was overexpressed, the growth suppression phenotype has been reported to
be cell-type-specific. High 4.1B, for instance, inhibited growth of meningiomas but not
schwannomas[Gutmann et al., 2001], and suppressed proliferation of some MCF-7 breast cancer cell
clones but not others[Charboneau et al., 2002]. Our own negative results from overexpression of 4.1B
may have been complicated by the fact that only a minority of cells were induced by doxycycline to
express 4.1 B. Yet, at the same time, the lack of any observable differences in growth also agreed with
our findings that siRNA-mediated ablation of 4.1 B did not affect cell proliferation; that our original #78 and
#82 cells did not grow differently; that both 4.1B' and 4.1 B*"-mice initiated TRAMP tumors similarly and
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did not display significant differences in proliferation; and that mouse embryonic fibroblasts deficient in
4.1B have not been observed to exhibit any growth phenotypes in vitro [Yi et al., 2005].
In light of these results, we believe that 4.1 B likely exerts its apoptotic and/or proliferative effects in a cell
type- and/or context-specific manner. It is possible that 4.1 B sensitizes prostate cells to apoptosis under
specific conditions, and, in future work, it will be critical to determine how to challenge these cells
appropriately in vitro, such that the 4.1B-associated phenotypes are manifested. Along these lines, we
explored the possibility that the interaction between 4.1B and a potential tumor suppressor, integrin P8,
might be important for regulating cell proliferation and apoptosis. While we were able to confirm this
interaction in our PC-3 cells, we have not yet been able to attribute any biological significance to this
observation. As with 4.1B, overexpression of integrin 138 in our cells did not affect proliferation, and no
effects were seen when cells were grown on plates coated with Qav38 ligands, including vitronectin and
LAP (data not shown). Because avp8 has been reported to contribute to protease-mediated processing
and activation of TGF-1 [Cambier et al., 2005; Mu et al., 2002], we examined whether varying levels of
4.1B in PC-3 cells could affect the activity of 18 and, thus, the ratio of activated to non-activated TGF-1
secreted into the medium. Our preliminary results were inconclusive, as the amount of TGF-1 found in
cell-conditioned media was quite low and consisted almost entirely of non-activated TGF-P (data not
shown). Clearly, it will be important to examine further the significance of the 4.1 B interaction with 138, as
well as its interactions with other known binding partners, including CD44 and merlin.
In addition, it will also be interesting to determine whether varying the levels of 4.1B has any effects on
the TRAMP tumor cell lines and, if so, how these effects are mediated. Although we found that
aggressive TRAMP-C1 cells showed downregulation of 4.1B relative to poorly aggressive TRAMP-C3
cells, we were unable to attach any functional significance relating 4.1 B expression with cell phenotype.
We found that loss of 4.1 B was insufficient for converting non-malignant TRAMP-C3 cells into malignant
cells, and also insufficient for increasing the malignancy of already-malignant TRAMP-C1 cells. Again, it
is very possible that we may not have sufficiently challenged the cells in a manner that would elicit
phenotypes that hinged on 4.1B expression. For example, while cells suspended in soft agar did not
display any apparent differences in morphology or growth, perhaps growing cells in a more realistic three-
dimensional environment (e.g. collagen gels or Matrigel) might have yielded a noticeable phenotype. As
TRAMP-C1 cells have been observed to form tumors when injected into syngeneic (C57BI/6)
hosts[Foster et al., 1997], we have also attempted to inject subclones derived from TRAMP-C1 cells
expressing either high or low levels of 4.1 B. Unfortunately, preliminary results were complicated by the
fact that tumor formation was inconsistent for all cell clones tested and occurred only after a long latency
period (> 2 months, data not shown). Therefore, it may be imperative to develop more reproducible
assays to test these cells.
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Another avenue of future research will be to determine in more detail how loss of 4.1B protects tumor
cells from apoptosis in vivo. Based on the distribution of tumor grades found at 26 weeks for TRAMP
prostates from 4.1B'- and 4.1B+1 / mice (Figure 9C), it appears, at least from a preliminary analysis, that
heterozygous prostate tumors tended to accumulate at Grade 4, whereas knock-out prostate tumors
proceeded more efficiently to the higher Grades 5 and 6. The finding that there was reduced apoptosis in
Grade 4-matched 22-week old prostates is in concordance with the hypothesis that the Grade 4-to-Grade
5 transition during tumor progression might be a rate-limiting step in heterozygous mice. However, since
we did not examine apoptosis in lower-graded sections, we cannot rule out the possibility that 4.1B might
also be acting earlier in tumorigenesis. This is an issue that can easily be resolved through analysis of
additional TRAMP mice.
Similarly, in our xenotransplant orthotopic model of prostate cancer, additional mice may need to be
examined, and possibly at earlier time-points, to determine how the presence or absence of 4.1 B affects
the most initial stages of tumor colonization in the lymph node. In this study, we have observed that #78
tumors with high 4.1B expression did not metastasize efficiently to the draining lymph nodes and, thus,
exhibited incomplete-and, in many cases, subcapsular-invasion of the nodes. In contrast, tumors with
low 4.1B expression (#78-DL1 and -DL2) yielded lymph nodes which often consisted almost entirely of
tumor material. The differences in the degree of lymph node infiltration made it difficult to make direct
(and accurate) comparisons of apoptosis frequency between cell lines, although there did appear to be
increased cell death in nodes that possessed subcapsular invasion. This observation, however, does not
distinguish between cause and effect for apoptosis and subcapsular invasion. In other words, cells which
are apoptosis-prone might be restricted to grow merely as subcapsular metastases (apoptosis "causes"
partial invasion); on the other hand, as the subcapsular spaces are where afferent lymphatics connect
with lymph nodes and are usually the initial sites of tumor colonization, this might also be a site where,
and/or a period when, increased apoptosis is normally seen (partial invasion "causes" apoptosis).
Therefore, it remains unclear in our SOI model whether loss of 4.1 B enhances the arrival of tumor cells to
the node, and/or whether it augments the ability of malignant cells to colonize the node once they have
arrived. As mentioned previously, examining mice at earlier timepoints may resolve this issue by allowing
more direct comparisons to be made between cell lines of differing metastatic ability.
In conclusion, our findings from this chapter have validated the role of 4.1B as a negative modulator of
prostate cancer progression in vivo. The additional observation that 4.1B is significantly downregulated in
four out of five studies of human clinical prostate cancer is consistent with the idea that loss of 4.1B is an
important and physiologically relevant event during progression of this disease. It will be critical in future
work to understand, at a molecular level, the mechanism by which 4.1B suppresses tumorigenesis, and
also to confirm the human clinical gene expression results at the protein level. As translocation of Ets
family transcription factors has emerged as a common phenomenon in clinical prostate cancer[Tomlins et
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al., 2005], it will also be interesting to determine whether 4.1 B expression is directly regulated by Ets
family members such as ERG, which can both induce or suppress gene transcription in a context-
dependent manner[Hsu et al., 2004; Sementchenko and Watson, 2000].
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Figure 1. The Protein 4.1 superfamily can be divided into five subgroups and is
characterized by a conserved FERM Domain. (A) These subgroups include protein
4.1 proteins, ERM proteins (to which Merlin is related), talin-related molecules, protein
tyrosine phosphatase (PTPH) proteins and novel band 4.1-like 4 (NBL4) (reproduced
from Sun et al., 2002). (FERM, 4.1/ezrin/radixin/moesin domain; CCR, coiled coil
region; ABD, actin binding domain; CTD, C-terminal domain; PTP, protein tyrosine
phosphatase domain)
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Figure 1. The Protein 4.1 superfamily can be divided into five subgroups and is
characterized by a conserved FERM Domain. (B) Regulation of 4.1 subgroup proteins
may resemble that of ERM proteins, which normally adopt a "closed," inactive
conformation. Phosphorylation by Rho kinase or binding of PIP2 "activates" and unfolds
these proteins, exposing interaction sites for other proteins. Listed above are known
binding partners of Protein 4.1 B.
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Figure 1. The Protein 4.1 superfamily can be divided into five subgroups and is
characterized by a conserved FERM Domain (cont). (C) DAL-1 isa truncated form of
Protein 4.1B lacking the N-and C-terminal domains, aswell asportionsof interior
domains (reproduced from Sun et al., 2002). (D) An amino acid sequence comparison
between DAL-1 and 4.1B is shown. Residues found only in 4.1B are not highlighted.
Those found in both 4.1B and DAL-1 are highlighted dark gray. Residues found only in
DAL-1 are colored light gray (reproduced from Gutmann et al., 2001). (CTD, C-terminal
domain; ABD, actin-binding domain; CCR, coiled coil region; PTP, protein tyrosine
phosphatase domain)
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Figure 2. Derivation of metastatic variant prostate cancer cell lines and identification of
4.1B as a protein that is downregulated in highly metastatic cells. (A) Highly metastatic #82
cells and poorly metastatic #78 cellswere isolated after repeated in vivo passaging of human
PC-3 cells using surgical orthotopic implantation. (B) Quantitative RT-PCR results from RNA
derived from subcutaneous tumors (middle bars, "independent subcutaneous") and from tissue
culture cells (right bars, "in vitro") confirmed microarray results (left bars, "microarray") showing
that 4.1B expression is downregulated in #82 cells (arrows, beige bars), relative to #78 cells
(blue bars) and pMicro-1 cells(purple bars). All results shown are denoted asfold change,
normalized to #82 cells. (C) Western blotting for 4.1B confirms its absence in #82 cells (top),
with GAPDH asa loading control (bottom). (D) Western blotting for Protein 4.1 subgroup
proteins shows specific lossof 4.1B in #82 and PC-3M cells 4.1G and 4.1N levelswere mostly
unchanged. (Parental, PC-3 cellsoriginally purchased from ATCC)
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Figure 3. Stable downregulation of 4.1B expression in poorly metastatic #78 does not affect
tumor growth in vitro or in vivo. (A) #78 cells expressing any of four different siRNAsagainst
4.18 (DL1-4) exhibited stable downregulation of 4.1B expression in vitro, relative to cells
expressing vector only (pSIR) or an siRNA against GFP (siGFP), as assessed by Western blot (top
two rows). siRNA-mediated inhibition of 4.1B expression was maintained in subcutaneous
tumors (bottom row). (B) Proliferation of #78 cells expressing DL1 (blue bars) or DL2 siRNAs
(purple bars) was unchanged relative to that of #78 cells expressing siGFP control (hatched
line). Cell numberswere assessed every 24 hoursafter plating for4 days, in the presence (left
graph) or absence (right graph) of serum.
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Figure 3. Stable downregulation of 4.1B expression in poorly metastatic #78 does
not affect tumor growth in vitro or in vivo (cont). (C) Growth of these cells as
subcutaneous tumors was also not significantly changed.
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Figure 4. Downregulation of 4.1B increases the metastatic potential of poorly metastatic
#78 cells. (A) The average massof the orthotopic prostate primary tumorsdid not differ
among cell lines. (B) The average massof lymph nodesfrom mice bearing DL1- and DL2-
expressing tumorswas significantly larger than that of mice bearing control tumors. (C) The
average percent area of the para-aortic lymph nodes infiltrated by tumor cells was significantly
increased in mice bearing orthotopic tumors expressing DL1 or DL2 siRNAs, relative to those
with controls. (D) Lymph nodes from mice bearing control #78 tumors(top row) commonly
possessed areas of subcapsular tumor invasion, where apoptotic cells were frequently observed
(arrows), while nodes from mice bearing DL1- and DL2-expressing #78 orthotopic tumors were
often completely infiltrated by tumor cells, with few apoptotic cells present (bottom row). (E)
The number of lung micrometastases arising from the different orthotopic tumors is shown.
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Figure 5. Protein 4.1B interacts with integrin 08 in PC-3 cells. (A)
Immunoprecipitation of endogenousintegrin P8 also pulled down endogenousintegrin
av, its(z subunit interactor, in PC-3 cells (B) Shown isa list of antibodiesthat have
been successfully used to detect avp8 in mouse or human cells, organized by
application. The graph depicts flow cytometric analysisof mouse TRAMP-C3 cells
stained with anti-av (blue) antibody or with control antibodiestunstained (red and
green).
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Figure 5. Protein 4.1B interacts with integrin P38 in PC-3 cells (cont). (C) Co-
transfected myc-tagged Protein 4.1B and V5-tagged integrin 18 were overexpressed in
PC-3 cells (bottom), and were shown to interact by co-immunoprecipitation with anti-V5
antibody, followed by Western blot against myc-tag (bottom). (IP, immunoprecipitation;
WB, Western blot; Pre, pre-cleared beads)
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Figure 6. Inducible overexpression of either myc-tagged 4.1B or VS-tagged integrin 1
8 does not affect proliferation in PC-3 cells. Both coding sequenceswere cloned
downstream of a Tet responsive element (TRE) that is rendered transcriptionally active
in the presence of doxycycline (DOX). (A) Inducible overexpression of 4.1B was
observed by Western blot upon addition of doxycycline in two independently infected
#82 cell lines ("old" and "new"), and as assessed by antibodies against the myc epitope
tag (top left) or against 4.1B (bottom left). Similarly, V5-tagged P8 was inducibly
overexpressed upon addition of doxycycline, as assessed by detection of the V5 epitope
tag (right). 87
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Figure 6. Inducible overexpression of either myc-tagged 4.1B or V5-tagged integrin I
8 does not affect proliferation in PC-3 cells. (cont). (B) Cells induced (white bars) or
not induced (black bars) to overexpress4.1 B, RFP or luciferase did not exhibit
significant differences in cell number, 6-7 days after addition of doxycycline, as
assessed by manual cell counting and normalized to the non-induced control.
Inducible overexpression of 38 showed a slight (-20%) reduction in cell number. (C)
Cell counting results were confirmed visually by staining plated cellswith crystal violet
following 6-7 days +/- doxycycline.
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Figure 6. Inducible overexpression of either myc-tagged 4.1B or V5-tagged integrin B
8 does not affect proliferation in PC-3 cells. (cont). (D) Immunofluorescence
staining for myc- or V5-epitope tags revealed that only about one-third of induced cells
displayed visually detectable overexpression of either 4.1 B (left) or integrin P8 (right).
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Figure 7. The transgenic adenocarcinoma of the mouse prostate (TRAMP) tumor
model allows study of spontaneous prostate cancer development and progression.
(A) TRAM P-negative 4.1B-/- (KO) or 4.1B+/- (Het) dorsolateral prostates (D.P.) were
stained with antibodies against the basal cell marker cytokeratin 5 (green) or the luminal
cell marker cytokeratin 8 (red), imaged at low (top rows) or high magnification (bottom
row). (B) TRAMP prostate tumors initiate spontaneously and likely involve overgrowth
of luminal cells, followed by lossof attachment to the basement membrane, and
invasion. (Figure reproduced from Abate-Shen and Shen, 2000.)
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Figure 8. 4.1B-1- mice develop aggressive adenocarcinomas in the TRAMP
spontaneous tumor model of prostate cancer. (A) Western blotting for 4.1 B (top) or
4.1G (bottom) in brain or prostate tissues shows that 4.1B is specifically lost in knock-out
animals (B) 4.1B-/-;TRAMP+/- mice more commonly developed a variety of palpable,
high-grade carcinomas in the prostate (arrows), including (starting from upper left and
proceeding clockwise) compound, multi-lobed carcinomas; ventral-lobed carcinomas;
anterior-lobed carcinomas; and dorsal-lobed carcinomas
Oi f
Nodal Metastasis Uninvaded Lymph Node
Cytokeratin-8
H&E
4.1B +1-; TRAMP+I/- 4.18 4--; TRAMP+/- p-value
Incidence of Grade 6 Carcinoma 4/26 (15.4%) 11/19(58%) 0.003
Incidence of Palpable Grade 6 Carcinoma 2/26(7.7%) 11/19(58%) 0.0002
Incidence of Lymph Node Metastasis 2/26 (7.7%) 6/19 (32%) 0.04
Figure 8. 4.1B-I- mice develop aggressive adenocarcinomas in the TRAMP
spontaneous tumor model of prostate cancer (cont). (C) These tumors frequently
invaded the draining para-aortic/lumbar lymph nodes, as observed directly by
hematoxylin-.and-eosin staining (bottom) or by staining for the epithelial marker
cytokeratin 8 (top). The results of these tumor studies and their statistical significance
are summarized in (D).
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Figure 9. 4.1B-deficient animals develop higher grade and less differentiated
prostate adenocarcinomas. (A) Histopathologic grades (minimum, 1; maximum, 6)
were assigned to TRAMP prostates according to the system described by Hurwitz et al
(2001). Higher graded section exhibited increased luminal cell expansion, loss of
normal tissue architecture, and reduced differentiation. (B) TRAMP prostateswere
assigned two grades per section per lobe: a highest grade and a predominant grade.
An H&E-stained prostate section is shown with highest focal areas of grade 6 and with a
predominant grade of 4.
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Figure 9. 4.1 B-deficient animals develop higher grade and less differentiated
prostate adenocarcinomas (cont). (C) The ventral (VN) and dorsolateral (DL) lobes of
26-week old 4.1 B-/-;TRAM P and 4.1 B+/-;TRAM P prostates were separately evaluated
with both scoring systems In either case, 4.1B-/- mice developed the highest grade
carcinomas (Grade 6, red bars) more frequently than did 4.1B+/- mice (right graphs).
The same result was also true if each entire prostate was assigned a single highest
grade, based on the highest grade assigned to any one constituent lobe (left graph).
Significance values for these analyses are shown.
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Figure 10. 4.1B-/-;TRAMP+/- prostates exhibited reduced apoptosis relative to those
of 4.1B heterozygous mice. (A) Typical grade 4 ventral (left) and grade 5 dorsal (right)
prostate sections are shown following staining with the proliferation marker Ki67 (top) or
by TUNEL, using the Apoptag detection kit (bottom). (B) Quantitation of staining results
for Ki67 and TUNEL (apoptag) is shown for 26-week-old mice.
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Figure 10. 4.1B4-;TRAMP+/- prostates exhibited reduced apoptosis relative to those
of 4.1B heterozygous mice (cont). (C) Prostate sections from a cohort of 22-week-old
TRAMP mice were also graded.
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Figure 10. 4.1B-I-;TRAMP+/- prostates exhibited reduced apoptosis relative to those
of 4.1B heterozygous mice (cont). (D) 22-week-old grade 4 ventral prostate sectionsfrom 4.1B-/-;TRAMP+/-prostates showed reduced staining by TUNEL (left), compared to
prostates from 4.1B heterozygous TRAMP mice (right). (E) Quantitation of these resultsis shown.
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Figure 11. Protein 4.1B levels are reduced in aggressive TRAMP tumor cell lines.
(A) The malignant TRAMP-C1 and non-malignant TRAMP-C3 mouse prostate cell lines
were derived by Foster et al. (1997), from a single TRAMP primary tumor. (B)
Aggressive TRAMP-C1 cellsformed coloniesin soft agar, but TRAMP-C3 cells
remained as single cells PC3-#78 cellsalso formed colonies
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Figure 11. Protein 4.1B levels are reduced in aggressive TRAMP tumor cell lines
(cont). (C) 4.1B protein levelswere specifically reduced in malignant TRAMP-C1 cells
(Cl), relative to non-malignant TRAMP-C3 cells (C3), as assessed by two different
antibodies against 4.1B (4.1B PE and 4.1B JM). (D) Immunofluorescence staining of
TRAMP cells using the 4.1B-PE antibody revealed that 4.1B was non-uniformly
downregulated in aggressive TRAMP-Cl cells.
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Figure 12. Stable siRNAs can downregulate murine 4.1B in non-malignant TRAMP-
C3 cells. (A) Western blotting showsthat 4.1B was specifically downregulated in cells
expressing any of three different siRNAstargeted against mouse 4.1B, relative to that of
control cells expressing the vector only (pSIRISP) or an siRNA against GFP (siGFP). (B)
Immunofluorescence staining revealed that cellsexpressing mDL1 or mDL4 siRNAs
exhibited reduced 4.1B protein relative to that of cells expressing control vectors.
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Figure 13. TRAMP-C1 cells expressing uniformly high or low 4.1B protein can be
cloned from the original heterogeneous population. (A) Thirty clones derived from
malignant TRAMP-Cl cellswere analyzed for 4.1B expression by immunofluorescence
using the 4.1B-PE antibody. Most clones exhibited uniformly high, low or intermediate
levels of expression (red, green or purple boxes, respectively). In a few instances,
heterogeneous expression was still observed (gray boxes).
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Figure 13. TRAMP-C1 cells expressing uniformly high or low 4.1B protein can be
cloned from the original heterogeneous population (cont). (B) In eight different
clones, immunofluorescence staining intensity for 4.1B was confirmed by Western blot.(C) The cloned cell lines exhibited differences in 4.1B localization, ranging from both
cytoplasmic and membrane localization (Clone 8), to membrane-only localization(Clone 29), cytoplasmic-only localization (Clone 1), and no expression (Clone 20).
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Figure 13. TRAMP-C1 cells expressing uniformly high or low 4.1B protein can be
cloned from the original heterogeneous population (cont). (D) Co-staining for 4.1B
and actin revealed that 4.1B protein was often co-localized with circular actin-rich
structures in TRAMP-C3 cells (top two photographs). siRNA expression of mDL1 ablated
4.1B protein but did not affect these actin-rich structures(bottom photograph).
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Figure 14. TRAMP-C1 cell clones exhibit differences in colony size and morphology
when suspended in soft agar. (A) Cell clones were grouped according to the size of
the colonies formed when plated in soft agar (purple column), which ranged from single
cells (-) to small colonies (+/-) and larger (+ and ++).
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Figure 14. TRAMP-C1 cell clones exhibit differences in colony size and morphology
when suspended in soft agar (cont). (B) Cell cloneswere grouped according to
colony morphology in soft agar (purple column), which varied between clones that had
formed colonieswith either a smooth or uneven ("jagged") outer edge. (C) 4.1B protein
expression was ablated with stable siRNAs (mDL1 or mDL2) in five independent clones
expressing high levels of 4.1B and exhibiting a smooth soft agar colony morphology.
Downregulation of 4.1 B did not alter colony size or morphology in these cells
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Figure 15. 4.1B expression is reduced in human clinical prostate cancer relative to
normal prostate tissue. (A) 4.1B is significantly downregulated in prostate tumors
relative to normal/benign prostate tissues in data-sets obtained from Welsch et al.
(2001); Singh et al. (2002); and Yu et al. (2004), as analyzed by Oncomine. In all
graphs, blue bars represent non-tumorigenic/benign prostate tissue, while red bars
represent prostate cancer.
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Figure 15. 4.1B expression is reduced in human clinical prostate cancer relative to
normal prostate tissue (cont). (B) 4.1B expression is significantly downregulated
during human clinical prostate cancer progression, from normal prostate tissue, to
prostate cancer and finally to prostate cancer metastases (raw data originally from
LaPointe et al. (2004) and analyzed by Oncomine).
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Figure 16. 4.1B expression is inversely associated with expression of the ETS family
transcription factor ERG in human clinical prostate cancer. Oncomine analysis of data
collected by LaPointe et al., (2004) revealed that, among patients bearing tumorswith ERG
overexpression (red bars), 4.1B levels are significantly reduced (upper left graph, p = 0.0001),
compared to those of patients bearing tumorswithout overexpression of ETS family
transcription factors (blue bars). To a lesser extent, 4.1N levels are also inversely associated
with ERG overexpression (upper right graph), while expression of 4.1R is positively associated
with ERG (lower right graph). Each bar represents gene expression results from a single human
patient, and, within each group ("no ETS overexpression" or "ERG overexpression), patients
were ranked from lowest to highest expression for a particular gene (e.g. 4.1B or 4.1 N).
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CHAPTER 4.
A DIRECT TEST FOR THE ROLE OF SPARC IN
SPONTANEOUS PROSTATE AND BREAST CANCER
PROGRESSION
The work in this chapter was conceived by Sunny Wong and Richard Hynes. SPARC-deficient mice were
obtained from E. Helene Sage. The contents of this chapter were written by Sunny Wong, with editing by
Richard Hynes.
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INTRODUCTION
SPARC: A Multi-Functional Conundrum
Secreted protein, acidic and rich in cysteine (SPARC, also known as osteonectin or BM-40) is an
extensively studied, albeit enigmatic, protein. SPARC is abundant, estimated to account for about 15% of
the non-collagenous extracellular matrix in bone, and widely expressed during development, tissue
remodeling and tumorigenesis[Framson and Sage, 2004; Koblinski et al., 2005]. But while the cell
biological and signaling functions ascribed to SPARC are many, this protein also seems to be necessary
for none of these processes, as the phenotypes manifested in SPARC null mice are relatively minor, as
will be discussed later. Perhaps fitting with its seemingly contradictory "all and none" role, studies
examining the effects of SPARC on tumor progression have produced compelling, although often
contradictory, results: SPARC is upregulated in tumorigenesis; SPARC is downregulated in
tumorigenesis. While compensation may account for the lack of major phenotypes seen in knock-out
mice, and the varied effects manifested by SPARC may be cell type- and context-dependent, a greater
understanding of the mechanism of action of this protein will surely be needed before clarity is brought to
the confounding results observed thus far.
In fact, the gene ontology generally agreed upon for SPARC seems almost contrarian in itself: It is a de-
adhesive protein component of the extracellular matrix (ECM), belonging to a class of molecules known
as matricellular proteins[Murphy-UIIrich, 2001]. This class of proteins also consists of the
thrombospondins and tenascins, which together promote what has been termed an "intermediate" state of
cell adhesion. Such a cell state has been postulated to be ideal for a variety of processes involving cell
movement. One can imagine that a cell which is too-firmly attached to its surrounding matrix-via
mature, integrin-containing focal contacts linked to stress fibers in the cytoskeleton-would hardly be
inclined to migrate[Friedl and Wolf, 2003]. At the same time, complete loss of cell adhesion would
deprive cells of the traction needed for movement and might even lead to cell death. An intermediate
adhesive state, therefore, might be useful. Indeed, SPARC has been shown to induce cytoskeletal
rearrangements and to disassemble focal adhesions for a variety of cell types in vitro, including tumor cell
lines, fibroblasts, endothelial cells and smooth muscle cells[Brekken and Sage, 2001]. A specific receptor
for SPARC has not been isolated; instead, SPARC has been postulated to function as a modulator of
other known ligand-receptor interactions[Murphy-Ullrich, 2001]. At the same time, while SPARC is a
component of the ECM and binds matrix molecules such as collagen and laminin, it is not believed to
contribute directly to the structural integrity of these networks[Brekken et al., 2003].
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Cellular Effects of SPARC
The three major domains present in SPARC are modular and have each been attributed to specific cell
biological effects[Bradshaw and Sage, 2001]. Most of the studies examining the bioactivity of these
individual domains were performed using isolated peptides added to cells in vitro, though there is likely to
be some relevance for these studies in vivo, as matrix metalloproteinases (MMPs) have been reported to
cleave and release fragments of SPARC, with consequent effects on various processes, from cell
proliferation to angiogenesis[Framson and Sage, 2004; Sage et al., 2003]. At the N-terminus of the
protein (amino acids 1-50) is a low-affinity calcium-binding domain that has been reported to inhibit cell
spreading and attachment to matrix[Brekken and Sage, 2001]. A follistatin-like domain is present in the
central portion of SPARC (amino acids 51-130) and may function as a pro-angiogenic molecule.
Importantly, the C-terminal extracellular calcium-binding (E-C) module (amino acids 131-280) consists of
two calcium-binding loops, or EF-hands, that, by themselves, functionally mirror the cell biological effects
observed with full-length SPARC[Framson and Sage, 2004]. These include inhibition of cell proliferation;
rearrangement of the cytoskeleton and disassembly of focal adhesions; and binding to growth factors
such as VEGF and PDGF, as well as to ECM components.
Given the effects of SPARC on cell morphology, it is not surprising that this protein has also been found
to affect gene expression in responding cells, often in ways that lead to upregulation of proteins that
ultimately weaken the integrity of the pericellular matrix environment. In various cell types, physiological
levels of SPARC have been reported to induce the expression of MMPs, including collagenase,
gelatinase and stromelysin, as well as plasminogen activator inhibitor-1[Gilles et al., 1998; Lane et al.,
1992]. At the same time, expression of matrix components, including fibronectin, is decreased[Lane et
al., 1992]. In this way, SPARC may indirectly attenuate cell-cell and cell-matrix interactions. However,
the gene expression effects of SPARC likely reach beyond those that merely affect matrix integrity. The
potentiation of TGF-P signaling is one proposed mechanism by which SPARC has been found to induce
anti-proliferative effects on cells[Francki et al., 1999]. This SPARC-TGF-P connection might occur
through an autocrine loop, as SPARC has been shown to induce TGF-P3 in mesangial cells, while TGF-0
can induce SPARC expression in fibroblasts, keratinocytes, smooth muscle cells and endothelial
cells[Francki et al., 1999; Schiemann et al., 2003]. In MvlMu epithelial cells, SPARC-mediated inhibition
of growth could be prevented by expressing a dominant negative form of Smad3, a necessary
downstream signaling component of the TGF-P pathway. SPARC has also been hypothesized to activate
TGF-P post-translationally, as TGF-1 is initially synthesized as a latent propeptide[Schiemann et al.,
2003].
In concordance with its proposed role as a pro-migratory factor for cells, SPARC has been isolated from
bone extracts as the major chemoattractant for prostate (PC-3 and DU-145) and breast cancer cells
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(MDA-MB-231)[Jacob et al., 1999]. SPARC induced migration and invasion of these cells possibly by
eliciting upregulated MMP-2 expression, and this may, at least in part, underlie the phenomenon of organ-
specific metastasis-in this case, the propensity of prostate and breast tumors to metastasize to bone.
Further work by De et al., has shown that PC-3 cells and another prostate cancer cell line, LNCaP, both
responded to SPARC in Transwell migration assays[De et al., 2003]. In addition, SPARC was found to
induce VEGF expression in the LNCaP cells, and all the cell biological effects seen with SPARC were
inhibitable with blocking antibodies against either integrins av-P3/-15, or VEGFR-2 (Flkl). Thus, there
seem to be several interesting, although somewhat disparate, strands of data from these studies: VEGF,
acting through Flkl, can activate av integrins[Byzova et al., 2000]. Activated av-P33 or -P5 may then
engage SPARC, leading to enhanced cell migration'[De et al., 2003]. Finally, binding of SPARC may
upregulate VEGF, thereby possibly completing an autocrine loop.
SPARC As a Mediator of Angiogenesis
The connection between SPARC and VEGF is of particular interest, given that SPARC, after cleavage by
plasmin or by MMPs, can act as a pro-angiogenic factor[Framson and Sage, 2004]. Crucial to all this is a
(K)GHK sequence-containing peptide that is released upon proteolysis and which has been demonstrated
to promote endothelial cell proliferation both in vitro and in vivo[Lane et al., 1994; Sage et al., 2003]. In
addition to inducing VEGF expression, SPARC has also been reported to downregulate expression of
thrombospondin, a potent inhibitor of angiogenesis[Lane et al., 1992]. In spite of all this, however, a
preponderance of evidence has suggested that, in most instances, SPARC is actually an inhibitor of
angiogenesis. In vitro, SPARC inhibits the proliferation of endothelial cells[Kupprion et al., 1998]. It is
also known to bind to and modulate the activity of several angiogenic factors, including VEGF, PDGF,
FGF-2, TGF-1 and IGF-1[Framson and Sage, 2004]. For instance, VEGF- and FGF-2-induced
angiogenesis is inhibited by direct binding of these cytokines to SPARC, which prevents them from
activating their cognate receptors on the surface of endothelial cells[Kupprion et al., 1998]. In addition,
polyvinyl sponges implanted subcutaneously into SPARC-null mice have been observed to possess
increased vascular and fibroblastic invasion, relative to those implanted into wild-type mice[Bradshaw et
al., 2001]. SPARC-null dermal fibroblasts in this study were also found to secrete significantly higher
levels of VEGF. It is difficult to reconcile many of these findings, except to say that the effects observed
with SPARC-either as an angiogenic or anti-angiogenic factor-are likely influenced by the cell type(s)
under study, as well as by factors such as the protease profile of the local microenvironment.
' Direct binding of axvP3/avP5 to SPARC has not been conclusively proven, and indirect evidence has suggested that G protein-
coupled receptors may also bind to SPARC.
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SPARC As a Mediator of Matrix Integrity and Tumorigenesis
While it is widely believed that SPARC affects the integrity of cellular matrices, particularly those
comprised of collagen fibrils, it is still very unclear how it contributes to the ECM and how a compromised
matrix might affect tumor progression. What is clear is that loss of SPARC impairs collagen fibril
assembly both in vitro and in vivo, and that SPARC knock-out mice possess about 50% less collagen in
their skin[Brekken and Sage, 2001]. The reduction in collagen content has been hypothesized to underlie
many of the non-lethal phenotypes manifested in SPARC-null mice, including reduced tensile strength in
the dermis, cataracts, a kinked tail, severe bone loss in older mice, and abnormal expansion of subdermal
adipocytes[Bradshaw et al., 2003; Framson and Sage, 2004]. SPARC knock-out mice also display
accelerated wound closure, which may be indicative of a more contractible ECM with reduced
collagen/hydroxyproline content[Bradshaw et al., 2002].
In nearly all cases, SPARC-mediated regulation of matrix integrity has been postulated to mediate its
effects on tumor growth, although whether SPARC aids or hampers cancer progression is still a matter of
debate and may be tumor-type-specific. In subcutaneous cancer models, Lewis lung carcinoma cells and
EL4 T-cell lymphoma cells formed larger tumors in SPARC-null mice, relative to wild-type mice[Brekken
et al., 2003]. A similar result was also obtained when PAN02 pancreatic adenocarcinoma cells were
injected[Puolakkainen et al., 2004]. Although a slight difference in apoptosis was seen in the case of
PAN02 cells, and no differences in tumor cell proliferation or angiogenesis were observed, these studies
all noted that there was a significant decrease in tumor encapsulation within SPARC-null animals. In
these mice, Masson's trichrome staining revealed that the abundance of collagen fibrils surrounding the
tumors was sparse, and that the fibrils appeared smaller in diameter, relative to those in wild-type mice.
Thus, SPARC may normally function as a tumor suppressor with a novel mechanism: It may act as a
physical restraint against tumor cell expansion by maintaining a dense collagen network.
However, even this simple explanation-where SPARC and the ECM both negatively affect tumor
progression-has become more complicated with the finding that, contrary to the results discussed just
previously, MMTV-driven Her-2/neu breast cancer cells2 formed smaller tumors when injected into
SPARC knock-out mice, relative to wild-type[Sangaletti et al., 2003]. This study was notable in that
adoptive transfer experiments revealed that leukocyte-secreted SPARC was the major determining factor
for tumor growth. If SPARC+ leukocytes were transplanted into knock-out mice, tumor growth was
increased; conversely, when SPARC- leukocytes were transferred into wild-type mice, tumor growth was
inhibited. Therefore, in this case, it would seem as if SPARC enhanced breast cancer progression. But
what is the underlying mechanism for this effect? Interestingly, Sangaletti et al., went on to show in this
study that leukocytes deficient in SPARC infiltrated deep into the tumor parenchyma, whereas those
2 These Her-2/neu breast cancer cells were wild-type for SPARC.
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which were wild-type for SPARC localized mainly to the periphery. This would imply that immune cell
infiltration into the tumor inhibited growth, a conclusion that was supported by the fact that immune
suppression of SPARC knock-out mice increased tumor size. Therefore, this study suggests that
leukocyte-secreted SPARC may somehow act as a deterrent for immune cell entry into the tumor, and
that the immune system suppresses tumor growth. Differences in macrophage infiltration into tumors
have also been observed in SPARC knock-out mice, relative to wild-type, but the experimental evidence
for this, as well as its implications on tumor growth, have been inconsistent and difficult to
reconcile[Brekken et al., 2003; Puolakkainen et al., 2004]. In any case, SPARC is likely to regulate the
ECM in ways that affect immune cell trafficking to the tumor. How SPARC ultimately affects tumor growth
likely also impinges upon how the immune system influences tumorigenesis[Coussens and Werb, 2002].
SPARC As a Mediator of Tumor Metastasis
Finally, the role of SPARC as a modulator of ECM integrity and cell migration would seemingly make it an
ideal candidate for affecting the final stage of tumor progression to metastasis. Given the often-
contradictory observations already seen with SPARC, it is not surprising that its effects on metastasis are
also confusing. In prostate cancer, SPARC expression was highest in cell lines that metastasized to
bone, leading Thomas et al., to propose that tumor cells which efficiently form bone metastases often
display "osteomimetic" characteristics-in other words, they become similar to those cells that normally
reside and thrive in the bone[Thomas et al., 2000]. This may, in part, explain why certain tumors display
organ-specific metastatic preferences. Downregulation of SPARC expression using anti-sense RNA in
melanoma cells also inhibited their invasive capabilities in vitro, as well as their tumorigenicity and
metastasis in vivo, in concordance with the hypothesis that SPARC promotes metastasis[Ledda et al.,
1997]. However, overexpression of SPARC in breast cancer MDA-MB-231 cells specifically inhibited cell
invasion, but not migration, proliferation or apoptosis[Koblinski et al., 2005]. When SPARC-
overexpressing cells were injected into mice, a slight, but significant, reduction in platelet binding to the
tumor cells was noted, and, though not validated directly, this might be responsible for the reduction seen
in metastasis. In addition, in human clinical ovarian carcinomas, SPARC expression was downregulated
in invasive tumors, and in vitro, SPARC induced apoptosis in the ovarian tumor cell lines[Yiu et al., 2001].
These experimental data, coupled with the fact that SPARC expression has often been found to be both
significantly upregulated and downregulated in different human clinical tumors (Figure lC), imply that
SPARC regulation is important for tumorigenesis. However, the exact nature of its effects on
tumorigenesis remains controversial. Our interest in SPARC grew out of our finding that its expression
was severely downregulated in our highly metastatic PC-3 #82 variant cell line, relative to our poorly
metastatic PC-3 #78 cells. If these differences were functionally important, that would indicate that
SPARC acts as a metastasis suppressor in our orthotopic model of prostate cancer. To begin to
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approach this question, we elected to study spontaneous prostate and breast cancer progression in mice
that either possessed or were deficient in SPARC. Although the role of SPARC in tumorigenesis and
metastasis has been examined in numerous studies using cell culture and xenograft experiments, to date,
none have utilized spontaneous tumor mouse models. Therefore, we felt this was a novel and more
realistic approach for testing the effects of SPARC on cancer progression, relative to what has already
been described in the literature. I will describe the results for these experiments in the next section.
RESULTS
SPARC mRNA and protein are downregulated in highly metastatic #82 prostate cancer cells
In addition to 4.1B/DAL-1, gene expression analysis on metastatic variants of the prostate
adenocarcinoma cell line PC-3 revealed that highly metastatic #82 cells displayed significantly
downregulated expression of SPARC/osteonectin, relative to poorly metastatic #78 cells and medium
metastatic pMicro-1 cells (Figure 1A). To further confirm this result, quantitative real-time PCR was
performed on additional subcutaneous tumors and also on tissue culture cells. In all cases, SPARC
expression was highest in #78 cells, slightly reduced in pMicro-1 cells, and severely downregulated in #82
cells (results summarized in Figure 1A). Gene expression data were also validated at the protein level by
Western blot for SPARC in subcutaneous tumors (Figure 1 B, arrows). Together, these results suggest
that SPARC may be acting to suppress metastasis in our prostate cancer orthotopic model, and that,
therefore, loss of SPARC expression/protein may enhance tumor progression and invasion.
SPARC expression is significantly altered in a variety of tumor types
SPARC expression levels were also examined in different human clinical gene expression studies to
determine if there were data to support our hypothesis that SPARC may function as a tumor/metastasis
suppressor. An initial comparison of tumor versus normal samples from the Oncomine database
revealed that SPARC expression levels were frequently altered in a variety of cancers (Figure 1C). For
example, SPARC was significantly upregulated in liver, colon and B-cell tumors relative to their respective
normal tissues of origin, and downregulated in three studies of prostate cancer, relative to normal
prostate. These seemingly contradictory results appear to parallel those obtained in experimental studies
where SPARC has been reported to act both as a tumor-suppressor and -promoter in different mouse
tumor models[Brekken et al., 2003; Puolakkainen et al., 2004; Sangaletti et al., 2003].
SPARC expression levels were extracted from additional published cancer data-sets for analysis. In a
study by Dhanasekaran et al., microarray profiling of human clinical prostate material yielded gene
expression signatures that could distinguish among samples derived from normal prostate tissue, benign
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prostate hyperplasia (BPH), localized prostate cancer, and prostate cancer metastases [Dhanasekaran et
al., 2001]. Interestingly, our analysis of data from this study revealed that SPARC mRNA was reduced in
samples derived from hormone-refractory prostate cancer metastases, compared to those from normal
prostate, BPH, and localized prostate cancer (Figure 2A). Since this study also recorded a significant
reduction of SPARC in tumors relative to normal prostate tissue, this might indicate that SPARC
downregulation could be important for progression of human prostate cancer, starting from the point of
tumor initiation, to the formation of distant metastases in a variety of organs, including lymph nodes, lung
and bone (Figure 2A).
In studies by van't Veer et al., a gene expression signature consisting of 70 features was found to
distinguish between patients bearing node-negative breast cancers that were either likely ("Poor
Prognosis") or unlikely ("Good Prognosis) to metastasize within 5 years from the time of diagnosis [van't
Veer et al., 2002]. Patients with poor prognosis tended to bear tumors which were estrogen receptor
(ER)-negative and which displayed increased lymphocyte infiltration; patients with BRCA1 germline
mutations also bore tumors that were classified by gene expression to belong to the poor prognosis
group. However, prognosis was not correlated with tumor grade or degree of angioinvasion. Although
this optimized 70 gene expression signature did not include SPARC, subsequent analysis by Smid et al.
(2003) [Smid et al., 2003], and by us revealed that reduced SPARC expression was associated with
patients who had developed metastases within 5 years of diagnosis (Figure 2B). Furthermore, the level
of SPARC expression, by itself, was capable of distinguishing between two groups of patients who
differed, to some extent, in their susceptibility to metastatic disease (Figure 2C). As illustrated by the
Kaplan Meier plot, 67% of patients with tumors that expressed high levels of SPARC remained free of
metastasis within 5 years of diagnosis, whereas only 40% of patients with tumors that expressed low
levels of SPARC remained metastasis-free during the same time-frame. Furthermore, tumors with the
BRCA1 mutation, which also tended to be ER-negative [van't Veer et al., 2002], were found to exhibit
lower SPARC expression relative to tumors without the mutation (Figure 3A). These data would therefore
seem to be in concordance with our hypothesis that SPARC suppresses tumor aggressiveness.
Perhaps even more interestingly, analysis of data obtained by Dr. Lei Xu in our lab revealed that SPARC
expression was specifically reduced in highly metastatic sub-clones (MA and MC series) derived from a
bulk, mixed population of parental A375 melanoma cells (Figure 3B) [Xu et al., 2006]. The MA and MC
cells exhibited increased lung metastasis when injected intravenously into immunocompromised mice;
therefore, it is conceivable that downregulation of SPARC may be responsible, at least in part, for the
aggressive phenotype of these cells. This apparent association of SPARC expression with many of the
specific clinical parameters discussed previously, including tumor initiation, growth and metastasis, was
subsequently tested, as described below, in different mouse models of cancer.
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The role of SPARC in spontaneous prostate cancer formation and progression in TRAMP mice
SPARC heterozygous and knock-out mice bearing a single copy of the TRAMP transgene were evaluated
for tumor formation, using similar procedures as those described previously for 4.1B in Chapter 3. At 26
weeks of age,. there was no difference in the percentage of mice that had developed palpable grade 6
carcinomas for the heterozygous (6/19, 32%) and knock-out (4/13, 31%) mice (Figure 4A). Mice that had
not formed palpable carcinomas, nevertheless, possessed enlarged prostate glands that likely contained
non-invasive precursor lesions, as was the case with the 4.1 B-TRAMP studies. Of those mice that had
developed grade 6 carcinomas, there was no difference in the percentage of animals that had also
developed palpable para-aortic/lumbar lymph node metastases (5/6 for SPARC '; and 3/4 for SPARC')
(Figure 4A). Furthermore, the masses of the urogenital systems did not differ significantly between
genotype (mean = 4,059 mg for SPARC+'' and 3,727 mg for SPARC / , p = 0.74) (Figure 4B). Lastly, the
urogenital mass of mice lacking the TRAMP transgene was also not significantly affected by genotype
(mean = 554 mg for SPARC +/ and 516 mg for SPARC- , p = 0.44) (Figure 4B). Therefore, these results
suggest that the presence or absence of SPARC does not influence prostate cancer progression in the
TRAMP tumor model.
The role of SPARC in spontaneous mammary carcinoma formation and progression in PyMT mice
SPARC heterozygous and knock-out mice bearing a single copy of the MMTV transgene were evaluated
for tumor initiation, rate of growth and metastasis. Beginning at 10 weeks of age, mice were inspected
twice weekly for palpable tumors within any of the 10 mammary glands. These were clearly visible as
small masses underneath the skin, and, over time, 100% of mice developed multiple malignant growths
within the majority of their mammary glands. The earliest age at which a tumor was detected was
recorded and used as a rough estimate of tumor initiation. Using this metric, we found no significant
difference in the time to tumor initiation between SPARC+/- or SPARC / mice, whose tumors were first
observed at an average age of 15.3 weeks and 15.6 weeks, respectively (Figure 5A). As a rough
measure of the rate of tumor growth, mice were sacrificed four weeks after the initial observation of
tumors, and the total mass of all malignant growths that had occurred during that time was also recorded.
In this regard, there was also no significant difference between genotypes, as SPARC +/ mice bore tumors
of an average mass of 5.3 grams, while SPARC- mice bore tumors of an average mass of 4.2 grams (p =
0.2) (Figure 5B). There was also no difference when only tumors at specific sites (e.g. upper right
quadrant, lower left quadrant, etc.) were compared (data not shown). Macroscopic examination of the
lungs at the time of sacrifice revealed no significant differences in the number of metastases present
(Figure 5B). On average, SPARC+'- mice possessed 9.6 lung metastases, while SPARC-'- mice
possessed 23.3 lung metastases (p = 0.17), though the results for the SPARC null mice were partially
skewed by a single animal (out of eight total), which bore >100 lung metastases. In addition, there was
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no correlation between the number of lung metastases observed and either the age of the animal or the
total primary tumor burden (Figure 6). Therefore, and similar to the results seen with prostate cancer,
these data suggest that the presence or absence of SPARC does not influence breast cancer progression
in the MMTV tumor model.
DISCUSSION
As was observed from the Oncomine analysis, as well as from data gleaned from cancer bioinformatics
studies originally performed by Dhanasekaran et al.; van't Veer et al.; and Xu et al.; among others,
expression of SPARC/osteonectin is frequently altered during tumor progression[Dhanasekaran et al.,
2001; van't Veer et al., 2002; Xu et al., 2006]. Our own studies have shown that SPARC expression is
significantly downregulated in highly metastatic prostate cancer cells, implying that SPARC may normally
act to suppress metastasis, and that genetic or epigenetic loss of expression of this gene may allow the
highly metastatic phenotype to manifest itself. Because alterations in SPARC have been linked to a
variety of cell morphological phenotypes, and because SPARC is a component of the ECM, we felt that
this was a protein that was well-positioned to have significant effects on tumor progression and
metastasis. We therefore decided to examine the role of SPARC in the context of spontaneous prostate
and breast cancer development in mice.
Contrary to published tumor studies, thus far, we have found no evidence that SPARC is important during
either prostate or breast cancer progression. However, these findings do not preclude the possibility that
future, more detailed and/or sophisticated analyses may identify an important function for SPARC in
tumorigenesis, particularly in other mouse cancer models. At the very least, it is evident from this initial
study that SPARC plays little, if any, role in two SV40-driven mouse models of tumorigenesis. In TRAMP
mice, the presence or absence of SPARC yielded no differences in urogenital-prostate mass or in the
frequency of high grade prostate cancer formation. There was also no difference in the percentage of
mice that developed local lymph node metastases. As observed previously, metastases were present
only in mice that had developed histologic Grade 6, and often palpable, prostate tumors. In MMTV mice,
the presence or absence of SPARC yielded no differences in time to mammary tumor initiation, rate of
tumor growth or the number of lung metastasis. There was also no correlation between the extent of
metastasis and primary tumor size or the age of the animal.
Given the results previously published identifying SPARC as a causal regulator of tumor progression,
both positively and negatively[Brekken et al., 2003; Puolakkainen et al., 2004; Sangaletti et al., 2003], it is
difficult to explain precisely why SPARC appeared to have no apparent effect in our tumor models. There
are, however, several possibilities that could account for these discrepant results. Perhaps most
importantly, the use of spontaneous mouse tumor models in our studies differed dramatically from the
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experimental approaches of others, who examined the role of SPARC often in tissue culture and in
xenograft models of tumorigenesis. As spontaneous tumor models reproduce every step along the
cancer progression pathway, they are generally regarded as more realistic in vivo systems for studying
cancer, although they are also significantly less amenable to experimental manipulation. Thus, SPARC
may act both positively and negatively at several points along this cancer progression pathway, and the
differential effects may, in some way, cancel out, or at least obfuscate our ability to assign a specific role
for SPARC in tumorigenesis. This is a realistic possibility, considering that SPARC has been observed to
act as a tumor inducer, a tumor suppressor, a pro-angiogenic factor, an anti-angiogenic factor, a
metastasis inducer, as well as a metastasis suppressor[Framson and Sage, 2004]. A possible
explanation for these often-contrasting findings may be that the effects of SPARC are heavily biased by
the tumor microenvironment. Various proteolytic enzymes and MMPs are known to process SPARC
post-translationally[Sage et al., 2003], and the various fragments that are consequently generated, as
well as the stromal context in which they are present, and the tumor cell types that ultimately respond to
them-these are all determinants of the bioactivity of SPARC.
Another important difference in our experimental approach is that we had compared tumor progression in
animals that were either completely heterozygous or completely null for SPARC. This is in contrast with
other published reports utilizing SPARC-deficient mice, which compared fully null animals with fully wild-
type ones[Brekken et al., 2003; Puolakkainen et al., 2004; Sangaletti et al., 2003]. In addition, in studies
where pancreatic carcinoma, T-cell lymphoma and mammary carcinoma cells were injected into these
mice, the tumor cells themselves expressed SPARC. In some cases, this could be useful for
discriminating between tumor-derived and stromally-derived SPARC[Sangaletti et al., 2003]. Two
important questions, therefore, come to mind when we consider why our results might have differed from
those of others: Firstly, does a two-fold reduction in SPARC (wild-type versus heterozygous) affect
tumorigenesis? And secondly, is the source of SPARC (tumor- and/or stromal-derived) important?
Neither of these questions can be fully answered with certainty, but given that SPARC null mice exhibit
few significant phenotypic defects, it is not as likely that SPARC is haploinsufficient during tumorigenesis.
Nonetheless, if SPARC heterozygous mice did, in fact, display some enhancement in tumor formation
relative to wild-type animals 3, the background for our analysis would have been increased, making it more
difficult to observe statistically significant differences in tumor formation.
Similarly, the importance of tumor- versus stromally-derived SPARC remains unclear, though one study
has suggested that leukocyte SPARC-and not tumor-derived SPARC-is all-important for affecting
breast cancer formation[Sangaletti et al., 2003]. As ours was a preliminary study on the role of SPARC in
spontaneous tumor progression, we have not yet analyzed the tumors to determine whether SPARC
affected leukocyte localization within the cancer, and this remains to be examined in future studies. In
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addition, it will also be interesting to determine whether the extracellular matrix within, or encapsulated
around, the tumor was affected by SPARC, as has been previously noted by others[Brekken et al., 2003;
Puolakkainen et al., 2004]. Effects on tumor angiogenesis could also potentially be evaluated.
Interestingly, in studies by Puolakkainen, et al., pancreatic tumors injected into SPARC-deficient mice
were reported to possess fewer pericyte-associated blood vessels[Puolakkainen et al., 2004]. As the
blood vessels in that study were identified using the pan-endothelial marker MECA32, it is tempting to
speculate that these vessels could very well have actually been lymphatic capillaries, which are not
normally surrounded by pericytes. Could SPARC be important for lymphatics? Given that this molecule
affects endothelial cells in vitro and is a component of the ECM, it would not be surprising if SPARC were,
indeed, found to be a regulator of tumor lymphangiogenesis. Future immunohistochemical studies using
the marker LYVE-1 to identify lymphatics in tumors and in surrounding normal tissue of SPARC wild-type
and deficient mice could help determine whether this is the case.
In conclusion, we found no overall difference in spontaneous prostate or breast cancer progression in
SPARC knock-out mice, relative to heterozygous animals. Therefore, this raises the possibility that, at
least in some cases, altered levels of SPARC may be associated with, but not be causative for,
tumorigenesis.. In future studies, it will be important to determine how the tumor microenvironment
influences the activity of SPARC. This may someday provide an explanation for the contrasting effects
that have been reported for this multi-functional protein.
3 No SPARC wild-.type mice were generated from our cross for experimental mice, and the few wild-type mice we did
analyze arose from unrelated matings.
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Figure 1. SPARClOsteonectin expression is frequently downregulated in metastatic
prostate cancer. (A) Expression of SPARC in metastatic variants of PC-3 was
compared using gene expression analysis on subcutaneous tumors ("Microarray"), and
quantitative RT-PCR on subcutaneous tumors ("Subcutaneous"') and on tissue culture
cells ("Tissue Culture"). All expression valueswere normalized relative to that of the
highly metastatic variant, pMicro-#82 (beige bars), whose mRNA levelswere set to one.
(blue bars, #78 samples; purple bars, pMicro-1 samples) (B) Western blot for SPARC
protein (arrows) confirmed the RNA results The other bands present may be non-
specific background bands (C) SPARC expression was significantly upregulated (red)
or downregulated (green) in different tumors, relative to normal tissue, according to
Oncomine.
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Figure 2. SPARC/Osteonectin expression is downregulated in metastatic prostate
and breast cancer. (A) SPARC expression was compared between human clinical
prostate cancer metastases, localized prostate cancer, benign prostate hyperplasia
(BPH) and normal prostate tissue, using data obtained by Dhanasekaran et al. (2001).
Each column represents a single tumor sample whose SPARC gene expression level
was normalized relative to the mean intensity of all samples (red, relative up-regulation;
green, relative down-regulation). (B) SPARC expression was compared between
human clinical breast tumors from patients that had exhibited either "good" or "poor"
prognosis, using data obtained by van't Veer et al. (2002), and later processed by Smid
et al. (2003).
124
A
Chapter 4
EUp
* Down
BPH Metastases
High SPARC
20130 are metastasis
free 5 years after
diagnosis (66.7%)
Low SPARC
24/60 are metastasis
free 5 years after
diagnosis (40%)
p = 0.017
0 1 2 3 4 5
Years After Diagnosis
Figure 2. SPARCIOsteonectin expression is downregulated in metastatic prostate
and breast cancer (cont). (C) Human clinical patients bearing mammary tumorswere
divided into two groups based on relative SPARC expression levels, and the percentage
of patients remaining metastasis-free was plotted for up to 5 years after the initial time of
diagnosis (p = 0.017 by Chi-square test, at the 5 year time-point).
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Figure 4. SPARCIOsteonectin does not affect spontaneous prostate cancer
tumorigenesis or metastasis in TRAMP mice. (A) The incidence of palpable
macroscopic prostate carcinomas (top) and lymph node metastases (bottom) was
compared between SPARC knock-out (KO) and heterozygous (Het) animals at 26 weeks
of age. (B) Urogenital mass of TRAMP-negative (left) and TRAMP-positive (right) mice
was assessed for SPARC knock-out and heterozygous animals at 26 weeks of age.
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Figure 5. SPARClOsteonectin does not affect spontaneous mammary tumor
formation or metastasis in MMTV mice. (A) The rate of MMTV mammary tumor
initiation was compared between SPARC knock-out and heterozygous animals (B) The
total tumor burden (left) and the total number of lung metastases (right) were assessed
for SPARC knock-out and heterozygous animals at the time of sacrifice.
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CHAPTER 5.
HEMATOGENOUS METASTASIS IS ASSOCIATED WITH
LYMPHATIC DISSEMINATION IN A MOUSE MODEL OF
PROSTATE CANCER
The work in this chapter was conceived by Sunny Wong and Richard Hynes. The contents of this chapter
were written by Sunny Wong, with editing by Richard Hynes.
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INTRODUCTION
Blood vessel or lymphatic dissemination?
The formation of distant metastases is the deadliest phase of cancer progression. Although numerous
studies, including our own, have identified genes that affect metastasis after tumors have reached
secondary sites, our knowledge about how cancer cells initially gain access to systemic circulation is
limited. Part of the complexity arises from the fact that, once a migratory cancer cell has detached from
the primary tumor, it may intravasate into either a blood or lymphatic vessel. Either route of dissemination
can lead to venous circulation, as lymphatics drain into the blood, most commonly through the left
lymphatic duct (thoracic duct) or the right lymphatic duct, and then subsequently into the subclavian
veins. Therefore, it is imperative that we understand the physiological and molecular mechanisms that
affect what might be the first decision an invasive cell needs to make: whether it will metastasize via
blood vessels or lymphatics.
To a large extent, this decision likely rests on physical restrictions imposed on invasive tumors, although
active mechanisms for attracting malignant cells to specific types of vasculature have also recently been
postulated (see below). Lymphatics have long been regarded as the "default" pathway for tumor cell
dissemination, and this is likely due to the fact that lymphatic capillaries lack the tight interendothelial
junctions typically seen in blood vessels, as well as the surrounding layers of pericytes/smooth muscle
cells and basement membranes[Alitalo and Carmeliet, 2002]. This inevitably renders lymphatics "porous"
relative to blood vessels, thus making them more susceptible to invasion by tumors. In addition, the
survival of malignant cells might benefit from the passive, low-shear fluid flow characteristic of lymphatics.
However, the increased hemodynamic flow rate, as is observed within blood vessels, might also help to
dislodge individual malignant cells from the primary tumor[Byers et al., 1995].
Accessibility of blood and lymphatic vasculature might be another factor that influences the pathway
taken for metastasis. Induction of angiogenesis, the growth of blood vessels, has been shown to be
necessary for tumors growing beyond 0.4 mm in diameter[Ferrara, 2002; Gimbrone et al., 1972]. On the
other hand, lymphatic vessels appear to be dispensable for primary tumor growth in several experimental
mouse models(Chen et al., 2005; He et al., 2002; Karpanen et al., 2001; Krishnan et al., 2003; Lin et al.,
2005; Shimizu et al., 2004]. Because blood and lymphatic vessels share a common embryonic origin,
and respond to many similar growth factors-VEGF-A, VEGF-C, VEGF-D, FGF2, PDGF-B, HGF and
others[Alitalo et al., 2005]-tumors might be expected to induce lymphangiogenesis concomitant with
angiogenesis. But for reasons unclear, this is often not the case. While proliferating intratumoral
lymphatics have been detected in human melanomas[Dadras et al., 2003], as well as in head and neck
squamous cell carcinomas[Maula et al., 2003], evidence for lymphangiogenesis in other cancers has
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been less well documented. In the absence of intratumoral lymphatics, therefore, only tumor cells at the
invasive margins would be expected to have access to the surrounding lymphatic vasculature. In
contrast, most cancer cells should have ready access to blood vessels, which are present throughout the
tumor.
As mentioned previously, active recruitment of tumor cells towards either blood vessels or lymphatics
may occur through paracrine interactions, for instance involving an EGF-EGFR axis. Studies by Wyckoff
et al., for instance, have shown that metastatic rat mammary adenocarcinoma cells expressing high
levels of EGFR often polarize towards blood vessels, which are lined by macrophages that secrete
EGF[Wyckoff et al., 2004]. Macrophages are often also found in proximity to lymphatic vessels
[Schoppmann et al., 2002; Skobe et al., 2001], and in recent studies, macrophages have even been
observed to transdifferentiate into lymphatics[Kerjaschki, 2005; Maruyama et al., 2005]. In addition,
lymphatic stromal cells have been reported to be a source of EGF and IGF-I[LeBedis et al., 2002].
Lymph node secretion of chemokines such as SCL/CCL21 and CCL1 might also attract tumor cells that
express the receptors CCR7 and CCR8, respectively[Homey et al., 2002]. Overexpression of CCR7 in
B16 melanoma cells has been shown to increase lymph node metastasis[Wiley et al., 2001], while others
have reported that breast cancer cells or melanomas expressing CXCR4 may actively home to lymph
nodes containing CXCL12/SDF-1 ligand[Muller et al., 2001].
How do tumor cells reach systemic circulation?
Related to the topic of how malignant cells exit from the primary tumor is another issue that possesses
far-reaching implications: How do tumor cells actually reach systemic circulation? Resolving this
question is especially important, considering the large number of cancer cells that are thought to be
released into the blood-estimated in one study to be up to -4 x 10^6 cells per gram of primary tumor
daily[Butler and Gullino, 1975]. The obvious and simple answer is that tumor cells enter into blood
circulation through blood vessels; yet, as we have discussed previously, the lymphatic system might
provide a more circuitous, though perhaps less treacherous, route for tumor cell dissemination.
The exact answer, or even a generalized answer, for how tumor cells enter hematogenous circulation has
yet to be determined. A major obstacle arises from difficulties in observing and tracking the movements
of individual tumor cells in vivo, although recent intravital imaging studies have provided views of tumor
cell intravasation into vasculature[Hoshida et al., 2006; Wyckoff et al., 2000]. In addition, there has been
little evidence to prove that tumor cells in lymph nodes can actually reach blood circulation. Even if this
phenomenon does occur, it is unclear how frequently tumor cells choose one pathway over the other. At
the very least, if cancer cells must rely on lymphatics to enter into the blood, a positive correlation
between lymphatic and hematogenous spread should be seen in human tumors. In fact, this is exactly
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the case for a variety of cancers observed in the clinic. For instance, Bubendorf et al. reported that 84%
of patients with node-positive prostate cancer bore evidence of hematogenous dissemination, as opposed
to 16% of patients without local lymph node spread[Bubendorf et al., 2000]. In breast cancer, lymph node
metastasis has been linked with poor prognosis and distant metastasis[Cianfrocca and Goldstein, 2004],
and similar observations have also been noted in pancreatic cancer[Yoshida et al., 2004], ovarian
cancer[Dvoretsky et al., 1988], and head and neck cancer[Leemans et al., 1993], among others. It should
come as no surprise, therefore, that lymph node status is often used as a diagnostic tool to predict the
extent to which a primary tumor has already spread throughout the body.
While it is tempting to speculate that these associations arise from the fact that hematogenous metastasis
is dependent upon lymphatic spread, of course, this hypothesis needs to be proven in an experimental
setting. We initially became interested in answering some of the questions raised in this section, after
observing an apparent association between lymphatic and systemic metastasis in our surgical orthotopic
mouse model of prostate cancer. In the following Results and Discussion sections, I will describe our
findings related to this, as well as an experimental approach for determining how tumor cells might enter
blood circulation. This approach, as well as the results that came out of it, will be discussed in detail in
the following chapter.
RESULTS
Hematogenous Dissemination Is Associated With Lymphatic Metastasis in an Orthotopic Model of
Prostate Cancer
As described in Chapter 2, we utilized surgical orthotopic implantation (SOl) as a method for introducing
human prostate PC-3 cells into immunodeficient mice. An advantage of this model, as was also
previously mentioned, was that the primary tumors developed both lymphatic and systemic metastases,
2-3 months post-surgery (Figure 1). Importantly, we were able to develop techniques to quantitate the
degree of tumor spread to the lymph nodes and to the lung, as well as to count the number of viable
circulating cancer cells in the blood of tumor-bearing mice.
With these three assays for measuring tumor cell presence in the lymph nodes, blood and lungs, we
began noticing certain trends that have, for the most part, held true after analysis of >196 mice
successfully implanted by SOI with our PC-3 cell line derivatives. Interestingly, we observed a strong
correlation between lymphatic and hematogenous dissemination in our mouse orthotopic xenograft model
of prostate cancer (Figure 2). As expected, the lymph nodes directly draining the prostate, the para-
aortic/sub-lumbar lymph nodes, were invaded first by the tumors, followed by the more distant sub-renal
lymph nodes. Mice that bore tumors which had not formed macroscopic metastases in the lumbar lymph
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nodes (- 50% of mice) were unlikely to possess renal lymph node macro-metastases. Not surprisingly,
the appearance of lung micrometastases was well-correlated with the detection of viable circulating tumor
cells in the blood (Figure 2A). Unexpectedly, however, significant numbers of circulating tumor cells
(Figure 2B) and lung metastases (Figure 2C) were observed only in mice that possessed both renal and
lumbar lymph node macro-metastases, regardless of primary tumor size.
This apparent correlation between lymphatic and hematogenous spread can be interpreted in at least
three ways (Figure 3). It is possible that PC-3 tumor cells may be unable to intravasate directly into blood
vessels; thus they must first establish satellite lymph node metastases in order to disperse metastatic
cells via the thoracic duct into the blood. Another possibility is that the primary tumors may be completely
non-invasive until somehow triggered to metastasize via both lymphatics and blood vessels
simultaneously. A third explanation is that distinct sub-populations of tumor cells may be capable only of
metastasizing via either the lymphatic or blood vessel routes, but not both, and that dissemination also
occurs at about the same time. Any of these possibilities would potentially yield an apparent correlation
between lymphatic and hematogenous spread. In the last two scenarios, tumor cells which have reached
lymph nodes may or may not disseminate further into venous circulation.
It is interesting to note that, in our system, subcutaneous tumors rarely metastasize, in spite of the fact
that-at least in the case of PC-3 cells-highly angiogenic and lymphangiogenic tumors are formed
(Figure 4). Although there are numerous reasons why tumors might metastasize from an orthotopic site
but not from an ectopic site, a simple explanation is as follows: Although we have observed microscopic
subcapsular lymph node invasion from subcutaneous tumors, these nodes were not invaded to the
degree that would favor widespread systemic tumor cell dispersal. This hypothesis would be in
agreement with our orthotopic results and would argue that hematogenous dissemination is dependent
upon substantial lymphatic spread. A prediction from this model would therefore be that, if given enough
time, subcutaneous tumors should also be expected to develop systemic metastases-but only after
forming macrometastases in the draining, axillary lymph nodes.
DISCUSSION
We have observed that hematogenous dissemination of tumor cells is associated with lymphatic
metastasis in an orthotopic model of prostate cancer. We have also proposed three explanations that
might explain our findings. In the first possibility, hematogenous dissemination might be dependent upon
lymphatic spread; an alternative explanation is that primary tumors might be induced by an unknown
mechanism to metastasize via both the lymphatic and hematogenous routes simultaneously; and, finally,
a third possibility is that distinct sub-populations of tumor cells may be adept at disseminating via either
vascular routes, but not both, and that this dissemination occurs at roughly the same time. In support of
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the first possibility, Sleeman et al., have noted that the physiology of lymph nodes may actually favor
formation of local metastases that could serve as "bridgeheads" for further dissemination [Sleeman,
2000]. Similarly, others have proposed that lymph nodes might act as initial "selection" sites where tumor
cells with partial metastatic competence could seed and expand, while selecting for increasingly
malignant variants that could later spread to more distant sites [Krishnan et al., 2003]. However, it
remains to be seen whether tumor cells can efficiently enter blood circulation via lymphatics.
If entrance into systemic circulation were dependent on lymphatics, experimental inhibition of lymph node
metastasis should also inhibit hematogenous spread. But, while some have indeed reported such
results[Chen et al., 2005; Krishnan et al., 2003; Lin et al., 2005], others found that inhibiting lymph node
metastasis had no effect on lung metastasis[He et al., 2002; He et al., 2004; He et al., 2005]. These
findings are likely attributable to differences in the cell lines utilized and whether the cells were implanted
orthotopically or ectopically. In another study, resection of MT-100-TC mammary carcinomas along with
draining lymph nodes prevented metastatic recurrence, but removal of the primary tumors alone did
not[Ward and Weiss, 1989]. This would suggest that MT-100-TC cells reached systemic circulation via
lymphatics, a progression the authors termed "metachronous seeding."
In contrast, the presence of hematogenous metastases in the absence of lymphatic spread would clearly
indicate direct dispersal of tumor cells into blood vessels. This is a likely scenario for human patients
harboring bone marrow micrometastases in the absence of other detectable signs of spread, which has
been reported to occur in 20-40% of carcinomas[Pantel and Brakenhoff, 2004]. Interestingly,
comparative genomic hybridization (CGH) analyses have suggested that malignant cells may disseminate
through the blood very early in breast cancer[Schardt et al., 2005; Schmidt-Kittler et al., 2003]. These
cells were also found to be distinct from lymph node metastases by CGH, thus arguing against
metachronous seeding.
Although different tumor types may vary in regard to the mechanisms by which they spread throughout
the body, it is clear that in many human clinical studies, as well as animal models including our own, an
apparent association is observed for hematogenous and lymphatic dissemination. Given the three
possible explanations that might account for these results (Figure 3), in the next Chapter, I will describe
our attempts to use our orthotopic model of prostate cancer to distinguish between these possibilities.
Our approach was to try and selectively inhibit lymphatic metastasis in our system. If hematogenous
spread were dependent upon metastasis to lymph nodes, both pathways should be simultaneously
inhibited. On the other hand, if hematogenous metastasis and lymphatic spread occurred independently,
it is expected that bloodborne dissemination of tumor cells should be unaffected by inhibition of lymph
node metastasis.
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Figure 1. Hematogenous and lymphatic metastasis can be assayed and quantitated
in a surgical orthotopic implantation mouse model of prostate cancer. (A) A
schematic depicting the lymph nodeswhich primarily drain the urogenital system is
shown (left). Para-aortic/lumbar and renal lymph nodes bearing macrometastatic tumor
deposits are often seen after surgical orthotopic implantation (right). (B) A colony
formation assay can be used to quantitate the number of viable circulating tumor cells
in the blood (left), while micrometastasescan be observed and counted in lung sections(right). (Reproduced from Chapter 2)
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Figure 2. Associations between hematogenous and lymphatic metastasis after
surgical orthotopic implantation. (A) The presence of lung metastases was correlated
with the presence of circulating tumor cells in the blood. (B) Significant numbers of
circulating tumor cells in the blood were detected only in mice that bore
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Figure 3. Three possible explanations to explain why, in a mouse model of prostate
cancer, hematogenous spread is observed only in the presence of significant
lymphatic spread. (1) The tumors might be incapable of intravasating directly into
blood vessels, so metastatic cells enter venous circulation indirectly via lymphatics
("metachronous seeding"). Or, the tumor is completely non-metastatic until mobilized
to metastasize via both lymphatic and hematogenous routes at the same time (2).
Similar to (2), it is also possible that distinct
subpopulations of tumor cells may be capable of only metastasizing via either
lymphatic or blood vessel routes, but not both (3). In the last two scenarios, tumor cells
which disseminate through the lymphatic system may or may not eventually reach
blood circulation.
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Figure 4. Circulating tumor cells in the blood are not detected from subcutaneous
tumors. Eighteen mice bearing subcutaneous tumors derived from the core PC-3 cell
line derivatives were found, in all cases, not to possess any tumor cells circulating in the
blood (top graph). This isalso mostly true for mice bearing subcutaneous tumors
derived from A375 melanoma cells (bottom graph).
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CHAPTER 6.
LYMPHANGIOGENESIS IS UNNECESSARY FOR PROSTATE
CANCER METASTASIS
The work in this chapter was conceived by Sunny Wong and Richard Hynes. LYVE-1 antibody was
obtained from Erkki Ruoslahti. The FIt4-Ig expression plasmid was obtained from Kari Alitalo. The
contents of this chapter were written by Sunny Wong, with editing by Richard Hynes.
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INTRODUCTION
Lymphangiogenesis: Background
The study of how lymphatic vessels proliferate, a process known as lymphangiogenesis, is a relatively
young field when compared to the study of angiogenesis, the roughly analogous process involving the
growth of blood vessels. At least partly, this has been due to the absence of reliable markers for
identifying lymphatics, a technical hurdle which has not been overcome until the past decade. But
another explanation likely stems from the fact that the importance of angiogenesis is immediately
obvious: blood vessels are essential for the development and maintenance of virtually every organ in the
body', and studies by Folkman et al., have long focused attention on targeting angiogenesis as a means
of inhibiting tumor progression[Kerbel and Folkman, 2002]. This is not to suggest that lymphangiogenesis
is unimportant; the growth of lymphatic vessels is, in fact, necessary for many physiological processes,
including trafficking of immune cells, re-absorption of macromolecules extravasated from blood vessels,
and regulation of interstitial fluid pressure. But is lymphangiogenesis critical for cancer progression and
metastasis?
Lymphatic vessels are found in almost every organ in the body, with the exception of the central nervous
system, bone marrow and avascular tissues[Alitalo et al., 2005]. Unlike blood vessels, lymphatic
capillaries begin as blind-ended tubes in connective tissues and consist of a single layer of overlapping
endothelial cells which lack tight interendothelial junctions and pericytes, and, at most, are ensheathed by
an incomplete basement membrane[Baldwin et al., 2002]. Individual lymphatic endothelial cells are
anchored to interstitial collagen by reticular fibers (Figure 1A), and, under conditions of elevated tissue
pressure, these reticular fibers stretch, drawing apart the attached cells and permitting the influx of fluid
and macromolecules. Lymph fluid which is absorbed through lymphatic capillaries eventually collects into
the larger lymphatic collecting vessels, which themselves later converge to form the even larger right and
left (thoracic) lymph ducts (Figure 1A). Fluid flow is passive and occurs uni-directionally down pressure
gradients acting against the exterior of the vessels, while back-flow is prevented by a system of semilunar
valves2. Along the way, lymphatic fluid is filtered through at least one lymph node, where a portion re-
enters blood circulation through lymphatico-venous anastomoses; however, the majority of fluid reaches
venous circulation via the thoracic duct[Sleeman, 2000].
In humans, lymphatic endothelial cells first appear in 6-7-week-old embryos, while in mice, these cells
originate at embryonic day 10.5, after the formation of the cardiovascular system[Alitalo et al., 2005]. In
both cases, it is now widely believed that lymphatic vessels arise from the budding of embryonic veins, an
1 Cartilage, epidermis and the cornea are all avascular tissues, and appear to be exceptions to this rule.2 In large lymphatics, lymphatic fluid is actively pumped against a pressure gradient.
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observation that was first noted in the early 1900s by the renowned anatomist Florence R. Sabin3. These
buds sprout from veins located in the jugular, retroperitoneal and perimesonephric areas, and initially
migrate to form primary lymph sacs, from which a primary lymphatic plexus eventually develops[Jussila
and Alitalo, 2002].
Differentiation of endothelial cells along the lymphatic lineage requires the function of the transcription
factor Proxl, a master regulator of the lymphatic phenotype[Petrova et al., 2002]. While mouse embryos
deficient for this gene initiate rudimentary lymphatic buds, these fail to undergo proper lineage
commitment[Wigle et al., 2002]. An important function of Proxl is to upregulate expression of the major
lymphatic receptor, VEGF receptor-3 (VEGFR-3 or Flt4)[Petrova et al., 2002; Wigle et al., 2002],
although, early on, VEGFR-3 is expressed throughout the embryonic cardiovascular network and only
later is its expression restricted to lymphatics[Baldwin et al., 2002]. Mouse knock-out studies have also
identified a host of other factors that, when absent, lead to lymphatic developmental defects. Among
these, Ephrin B2, Foxc2 and neuropilin-2 have all been implicated in lymphatic remodeling[Alitalo et al.,
2005], while the transmembrane glycoprotein podoplanin has been found to be necessary for proper
lymphatic development[Schacht et al., 2003]. In addition, the intracellular proteins Syk and SLP76
appear to regulate the divergence of blood and lymphatic vasculature, and mice deficient for either of
these molecules exhibit abnormal communication between the two vessel types[Abtahian et al., 2003], a
phenotype that resembles a human condition known as congenital arteriovenous malformation[Jain and
Padera, 2003]. The hyaluronan receptor LYVE-1 has also been found to be an early marker of lymphatic
commitment, but knock-out studies have shown that this receptor is unnecessary for proper lymphatic
development[Gale et al., 2006]. Nonetheless, LYVE-1, along with several other proteins, including
podoplanin and, to some extent, VEGFR-3, have all been useful as markers for identifying lymphatics
vessels.
Perhaps the best characterized signaling pathway for lymphangiogenesis is mediated by VEGFR-3
binding to either vascular endothelial growth factor-C or -D (VEGF-C and -D) (Figure 1B). Although the
normal physiological role of VEGF-D still remains relatively unclear, VEGF-C has been found to be
critically important, beginning from the earliest stages of lymphatic development. Mice completely
deficient for VEGF-C do not exhibit sprouting of lymphatic buds from the cardinal vein, while
heterozygous mice develop lymphadema[Karkkainen et al., 2004]. This is a condition characterized by
excessive fluid accumulation and swelling as a consequence of defective lymphatic function, and, in
humans, hereditary lymphadema has been linked to missense mutations in VEGFR-3[Makinen et al.,
2001]. The downstream components of this signaling pathway still remain to be characterized in detail,
although it is known that signaling through VEGFR-3, a receptor tyrosine kinase, leads to activation of
PKC and PI3K[Karkkainen et al., 2002], while inhibition of receptor signaling downregulates the activity of
3 Sabin also bears the distinction of being the first woman elected into the National Academy of Sciences, in 1925.
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the MAP kinase pathway[Makinen et al., 2001]. Not surprisingly, given the central role of VEGFR-3 in
lymphatic development, in vitro experiments have shown that the activity of this receptor can regulate the
growth, survival, migration and morphology of lymphatic endothelial cells[Stacker et al., 2002].
Experimental Studies of Tumor Lymphangiogenesis
In some cases, xenografted tumors have been found to induce lymphangiogenesis, both within the tumor
itself (intratumoral lymphatics) and/or at the periphery (peritumoral lymphatics). Indeed, overexpression
studies using cancer mouse models have been instrumental in identifying and validating factors that can
induce lymphangiogenesis and, oftentimes, enhance lymph node metastasis. The first demonstration of
this involved tumor overexpression of VEGF-C and VEGF-D, both of which increased lymphatic
metastasis[Skobe et al., 2001; Stacker et al., 2001]. As mentioned previously, the predominant receptor
for these cytokines is VEGFR-3, although proteolytic processing of VEGF-C/D by plasmin or by
proprotein convertases can allow efficient binding to VEGF receptor-2 (VEGFR-2 or Flkl), which is
expressed on the surface of both blood vessels and lymphatics [McColl et al., 2003; Siegfried et al.,
2003]. Subsequent studies have also identified additional lymphangiogenesis-promoting factors,
including VEGF-A, FGF2, PDGF-B, HGF and others (reviewed in [Alitalo et al., 2005]). Because
lymphatics and blood vessels share a common embryonic origin, it is not surprising that these factors
have previously been found to possess angiogenic activity.
Transgenic Rip-Tag mice overexpressing VEGF-C in the pancreas have been reported to display de novo
generation of lymphatics near P-cell islets and increased metastasis to the regional mesenteric lymph
nodes[Mandriota et al., 2001]. Similarly, loss of the cell adhesion molecule N-CAM was associated with
upregulated VEGF-C in pancreatic tumors, again yielding increased lymph node metastasis[Crnic et al.,
2004]. The opposite result-reduced lymphangiogenesis-was commonly found when Flt4-mediated
signaling was blocked. This has been accomplished by injecting antibodies against VEGF-D into tumor-
bearing mice[Stacker et al., 2001], by adenoviral delivery of a truncated soluble receptor for Flt4[He et al.,
2002], or by expressing in tumor cells RNAi against VEGF-C[Chen et al., 2005; Wong et al., 2005]. In
many cases, lymphatic spread was also concomitantly inhibited.
Aside from increasing the abundance of lymphatic vessels in proximity to the tumor, activation of local
lymphatic vessels has also been proposed as a way to enhance tumor cell intravasation and lymph node
metastasis. He et al., recently noted that peritumoral lymphatics proximal to subcutaneous LNM35 lung
tumors often displayed an "activated" phenotype-that is, increased vessel sprouting, dilation and
permeability[He et al., 2005]. A similar observation was also made by Hoshida et al., who reported that
tumor overexpression of VEGF-C induced hyperplasia of peritumoral lymphatics in the ear, accompanied
by increased lymphatic flow rate and metastasis[Hoshida et al., 2006]. Others have speculated that
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activated lymphatics might upregulate secretion of chemokines that could attract tumor cells[Alitalo et al.,
2004]. This activated phenotype can apparently be reversed by adenoviral delivery of soluble FIt4[He et
al., 2005], an effect that is reminiscent of tumor blood vessel normalization, which is seen upon
interference with VEGF-A- or Flkl-mediated signaling[Tong et al., 2004].
In addition to affecting lymphatics in their immediate vicinity, tumors have been reported to pre-condition
future sites of metastasis in the lymph node. As observed by Hirakawa et al., carcinogen-induced
squamous cell carcinomas in transgenic mice overexpressing VEGF-A in the skin displayed increased
angiogenesis and lymphangiogenesis, as well as enhanced lymphatic and systemic metastasis[Hirakawa
et al., 2005]. Surprisingly, increased lymphangiogenesis was also seen within draining lymph nodes prior
to, and after, metastatic colonization. This suggests that tumors might somehow prepare the lymph node
for metastasis. Although the exact mechanism underlying this phenomenon remains unclear, lymph-node
lymphangiogenesis could perhaps be mediated directly by binding of VEGF-A to Flk1 on the surface of
lymphatic endothelial cells. Or, VEGF-A might increase the permeability of local blood vessels, and the
consequent extravasation of fluid might serve as a lymphangiogenic signal. Interestingly,
lymphangiogenesis within lymph node metastases was also proposed as a possible way for tumors to
disseminate further throughout the lymphatic system and, subsequently, to systemic sites. At present,
however, the exact implications and generalities of these novel findings remain to be seen.
Stromal Induction of Lymphangiogenesis
The stromal fibroblasts and immune cells that surround tumors can also exert direct effects on lymphatics
by secreting growth factors, remodeling the ECM, and maybe even by incorporating into nascent
lymphatic vessels. Stromal contributions to neovascularization are well-documented and perhaps best
illustrated in transgenic mice made to express GFP under control of the human VEGF-A
promoter[Fukumura et al., 1998]. When these mice were crossed with the PyMT spontaneous mammary
tumor model, the fibroblasts surrounding the neoplasm, but not the tumor cells themselves, were GFP-
positive, suggesting that the main source of VEGF-A was stromally derived. Although it is tempting to
speculate that many principles applying to tumor angiogenesis also apply to lymphangiogenesis-and
many have indeed been shown to be relevant for both processes-it is important to note that angiogenic
tumors do not necessarily induce lymphangiogenesis. Furthermore, lymphangiogenesis has not often
been seen in human clinical tumors, even in those that metastasize to lymph nodes. The reasons for this
are presently unclear.
In addition to VEGF-A, fibroblasts have been known to secrete many potential lymphangiogenic factors,
including VEGF-C, FGF, HGF, IGF and PDGF[Cunha et al., 2003]. In vitro stimulation of normal human
skin fibroblasts with TGF-P and EGF induced secretion of both VEGF-C and VEGF-D [Trompezinski et
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al., 2004]. Cancer-associated fibroblasts (CAFs) in breast cancer were also found to enhance
angiogenesis and tumor growth by secreting the chemokine SDF-1/CXCL12[Orimo et al., 2005]. This
mobilized and recruited endothelial precursor cells which were derived from the bone marrow and
expressed the receptor CXCR4. SDF-1 has also recently been found to be important for retaining pro-
angiogenic bone marrow-derived circulating cells that associated near blood vessels[Grunewald et al.,
2006]. Whether these phenomena occur in other tumors, and whether similar mechanisms are important
for inducing lymphangiogenesis, is still highly controversial.
Since stromal fibroblasts secrete abundant matrix proteins, their influence on the composition and
ordering of the ECM microenvironment likely serves as another signal for blood vessels and lymphatics.
During angiogenesis, endothelial cell matrix receptors such as integrins are upregulated and serve
several important capacities such as enhancing VEGF-mediated signaling through direct association with
Flkl[Soldi et al., 1999]. In the case of lymphatics, cell proliferation in vitro seems dependent on the
matrix molecule fibronectin, which may be supplied in vivo by tumor cells, fibroblasts and/or endothelial
cells [Zhang et al., 2005]. Lymphatic endothelial cell binding to fibronectin leads to direct association
between the integrin 11 subunit and FIt4, which may enhance VEGF-C/D signaling pathways [Wang et
al., 2001]. The integrin heterodimer a911 has also been implicated in the development of lymphatics and
may act to bind ECM components like fibronectin and/or, as recently reported, VEGF-C and -D [Vlahakis
et al., 2005]. Lastly, fibroblast-mediated contraction of the ECM, particularly of collagen networks, is
increased when those cells are activated, and likely contributes to high tumor interstitial fluid pressure
(IFP) [Heldin et al., 2004]. While high IFP is thought to signal the growth of new lymphatics, tumor cells
may also cause the collapse of intratumoral lymphatic vessels [Padera et al., 2002].
Importantly, the role of immune cells in mediating angiogenesis and lymphangiogenesis has recently
received great attention, leading to some valuable insights. Once recruited to tumors, leukocytes release
an abundant cache of cytokines and MMPs that can directly affect lymphatics. In support of this idea, the
degree of inflammation in two studies of human cervical cancer positively correlated with both lymphatic
vessel density and the number of VEGF-C-expressing peritumoral cells[Schoppmann et al., 2002;
Schoppmann et al., 2001]. Many of these cells were CD68+ macrophages that also expressed VEGF-
CNEGF-D and Fit4. Increased inflammatory response, however, was negatively correlated with lymph
node metastasis[Schoppmann et al., 2001]. These findings illustrate the complexities that shape the
metastatic tendencies of a tumor-how, for instance, the stromal inflammatory reaction might wield a
double-edged sword, acting both as a way to promote lymphangiogenesis and as an anti-tumor response.
But what exactly is the mechanism for inflammation-induced lymphangiogenesis? Novel findings have
been obtained from experiments utilizing traditional xenograft models, as well as de novo
lymphangiogenesis models involving either the murine cornea or Matrigel plugs implanted into mice.
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Many of these studies have confirmed the important role of macrophages, which have been found to
secrete many potential lymphatic growth factors, including VEGF-C, VEGF-D, VEGF-A and
FGF[Cursiefen et al., 2004; Jin et al., 2006]. Expression of these factors seems to be induced in these
cells by chemotactic factors such as M-CSF[Eubanks et al., 2003] and possibly by an autocrine loop in a
subpopulation that expresses FIt4[Eubanks et al., 2003; Schoppmann et al., 2002]. In addition,
macrophage secretion of proteinases such as MMP-9 could remodel the ECM, thereby releasing
additional cytokines while providing a hospitable environment for lymphatic proliferation[Carmeliet and
Collen, 1998].
In the cornea, which is normally avascular, inflammation can induce local formation of blood and
lymphatic vessels. Interestingly, CD lb+/LYVE-1+ macrophages have been reported to integrate into
inflammation-induced lymphatics in vivo and could also form lymphatic-like tubes when cultured in
vitro[Maruyama et al., 2005]. These findings were recently supported by studies in human renal
transplants that had exhibited immune rejection, chronic inflammation and lymphatic
proliferation[Kerjaschki et al., 2006]. Circulating lymphatic progenitors derived either from a minor
CD133'VEGFR-3÷CD34÷ subpopulation or from a major CD14÷VEGFR-3'CD31 VEGFR-2- monocyte
population incorporated into lymphatics. However, this was contrasted by findings in the same study
where circulating progenitor cells did not incorporate into lymphatics associated with two cases of human
carcinomas, an observation that had been similarly noted in tumor xenograft models utilizing B16
melanoma or Lewis lung carcinoma cells[He et al., 2004b]. Therefore, at present, these data seem to
suggest that proliferation of pre-existing lymphatics accounts for tumor lymphangiogenesis, though
increased inflammation might coax macrophages to transdifferentiate into lymphatics. Obviously, the
generality of these recent findings, while exciting, remains to be further validated in different systems.
Other as-yet-unknown factors affecting lymphatic growth will almost certainly be elucidated in future
studies. For instance, CXC-ERL+ chemokines can induce angiogenesis by binding the receptors
CXCR2/CXCR1 on blood endothelial cells-do chemokines have any direct or indirect effects on
lymphatics, which express SDF-1 and specifically express the atypical, and perhaps non-signaling,
chemokine receptor D6[Nibbs et al., 2001]? It is also known that blood vessels are molecularly
heterogeneous, exhibiting tissue- and tumor-specific patterns of gene expression[Croix et al., 2000].
Most notably, sprouting angiogenic vessels upregulate the integrins avp3 and avP5, thereby possibly
implicating specific matrix molecules such as vitronectin in angiogenesis[Carmeliet and Collen, 1998].
Since peritumoral lymphatics often appear physiologically distinct from normal lymphatics, these nascent
lymphatics will almost certainly possess an altered gene expression program, and consequently, a unique
reliance on different growth factors and matrix molecules.
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Lymphatic Function in Prostate Cancer and Other Tumors: Clinical and Experimental Studies
As discussed earlier, human clinical tumors arising from various cell types often metastasize to lymph
nodes, and prostate cancer (CaP) is no exception. Indeed, analysis of metastasis patterns for
CaP[Bubendorf et al., 2000; Flocks et al., 1959], as well as lymphatic mapping studies using tracking
dyes in breast cancer and melanoma[Giuliano et al., 1994; Morton et al., 1992], have shown that the
pattern of tumor-to-lymph-node dissemination is non-random. Tumors first invade draining (sentinel)
lymph nodes before seeding more distant nodes[Nathanson, 2003]. If the sentinel node is free of
metastasis, other lymph nodes will also likely be uninvaded[Wittekind, 2000]. Therefore, lymphatic
vessels within or in proximity to tumors mediate dissemination to draining lymph nodes, which may then
allow further seeding to more distant sites.
In the case of CaP, metastasis to regional nodes is correlated with poor clinical prognosis and often
guides the therapeutic course of action[Flocks et al., 1959; Smith et al., 1982]. Typically, pelvic
lymphadenectomy is performed prior to radical prostatectomy to assess lymph node status. In patients
with lymph-node-positive CaP, 75% will possess bone metastases within 5 years regardless of
treatment[Smith et al., 1982]. Although lymphatic vessels can be detected in CaP[Trojan et al., 2004;
Tsurusaki et al., 1999; Zeng et al., 2004], the role of intratumoral lymphatics in mediating lymph node
metastasis has been controversial. While numerous clinical studies have correlated lymphatic vessel
density (LVD) with lymph node metastasis in various cancers, nearly as many have failed to detect such
associations (for a summary of clinical data, see[Jain and Padera, 2002]). In CaP, increased LVD has
been correlated both with lymph node metastasis[Tsurusaki et al., 1999; Zeng et al., 2004] and with
higher Gleason Score[Trojan et al., 2004; Zeng et al., 2004], an indicator of more aggressive tumors.
Consequently, it is unclear whether tumoral lymphatics actually facilitate lymph node metastasis, or are
simply markers of tumors prone to disseminate regardless of LVD.
Importantly, experimental studies have shown that intratumoral lymphatics are often compressed,
physiologically abnormal and non-functional for fluid drainage[Padera et al., 2002; Padera et al., 2004].
This apparent absence of functional intratumoral lymphatics would imply that tumor cells intravasated into
these vessels would encounter blockages and dead ends that actually impede metastasis. The fact that
many tumors metastasize to local lymph nodes despite absence of lymphangiogenesis or functional
intratumoral lymphatics, has led some to propose that it is the peripheral, peritumoral lymphatics at the
invasive margins that are the predominant routes of egress from the primary tumor[Jain and Fenton,
2002; Pepper and Skobe, 2003; Sleeman, 2000]. This view is supported by clinical data showing that the
abundance of peritumoral, but not intratumoral, lymphatics correlated with metastasis in breast and
prostate cancer; and that lymphangiogenesis does not occur in many tumors that nevertheless
metastasize to lymph nodes, including those of the breast, prostate and pancreas [Sipos et al., 2005;
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Trojan et al., :2004; Vleugel et al., 2004; Wong and Hynes, 2006]. In contrast, several clinical studies
have correlated intratumoral lymphatic vessel density (LVD) with metastasis (reviewed by [Achen et al.,
2005; Stacker et al., 2002]). Consequently, the importance of tumor lymphangiogenesis in regard to
metastasis is debatable, and may depend on the organ and/or experimental model in question.
Experimental Goals and Approach
Our interest in tumor lymphangiogenesis, as described in the previous chapter, grew out of our
observation that hematogenous metastasis was associated with lymphatic spread in our orthotopic
mouse model of prostate cancer. We were therefore interested to determine whether these two events
were inter-dependent. We decided to test this possibility by attempting to inhibit lymphatic metastasis
and then determining the consequent effects on systemic spread. If bloodborne dissemination was also
found to be inhibited, that would suggest that a tumor's ability to develop lymphatic metastases was
epistatic to its ability to form systemic metastases. As will become evident in the next section, we were
unable to properly test our hypotheses in this system because we were, ultimately, unsuccessful at
inhibiting lymph node metastasis. However, based on our results, we were able to gain some insights
into the mechanisms by which tumors metastasize to draining lymph nodes. Perhaps most importantly,
we were able to distinguish whether intratumoral and/or peritumoral lymphatics were important for
metastatic dissemination of prostate cancer. I will discuss these and other results, as well as their
implications, in the next two sections.
RESULTS
Stable siRNAs Specifically Reduce VEGF-C or VEGF-A Expression and Protein Secretion.
Our original goal was to inhibit lymphatic metastasis by disrupting tumor lymphangiogenesis in our
surgical orthotopic implantation (SOl) mouse model of prostate cancer. As SOI is a two-step approach
that involves grafting of solid subcutaneous tumor fragments into the mouse prostate, we were able to
assess the efficacy of various lymphatic-inhibitory approaches on both subcutaneous and orthotopic
tumors. We began by confirming that subcutaneous tumors formed by a highly metastatic subline of PC-
3 prostate cancer cells (designated PC3-#82) possessed abundant intratumoral lymphatic vessels.
Lymphatic vessels were identified by immunohistochemical staining for the lymphatic markers LYVE-1
and VEGFR-3/Flt4, and by absence of staining for the blood vessel marker CD34 (Figure 2). Because
blood vessels in some tumors have been reported to express VEGFR-3/Flt4 [Valtola et al., 1999], we
used LYVE-1 to identify lymphatics and CD34 to identify blood vessels for the rest of our studies.
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We next determined that PC3-#82 cells expressed and secreted the lymphangiogenesis-promoting
factors VEGF-C and VEGF-A (Figure 3A-B), but not VEGF-D (data not shown). To examine the
importance of tumor-secreted VEGF-C in promoting lymphangiogenesis, we stably expressed siRNAs
against VEGF-C in PC3-#82 cells. We also generated siRNAs against VEGF-A, which has previously
been reported to stimulate lymphatic growth[Cao et al., 2004; Nagy et al., 2002]. C13 and C14 siRNAs
knocked down VEGF-C mRNA 81% and 88%, respectively, relative to vector control (Figure 3A). A2 and
A3 siRNAs reduced VEGF-A mRNA 67% and 74%, respectively (Figure 3A). Quantitative PCR showed
that VEGF-C siRNAs had little effect on VEGF-A expression, and vice-versa. C14-MM and A3-MM mis-
match (MM) controls exhibited little siRNA efficacy. Relative RNA message levels for VEGF-C/A were
reflected in their relative protein abundance in conditioned media, as assayed by ELISA (Figure 3B).
Cells expressing C14 siRNA accumulated virtually no VEGF-C in conditioned medium after 72 hours,
while cells expressing C13 showed modest accumulation (Figure 3C). VEGF-A protein secretion was not
significantly reduced by either C13 or C14 siRNAs, but was slightly increased in cells expressing the C14-
MM control (Figure 3B).
As an additional approach for ablating lymphatics, we expressed the soluble VEGFR-3/Flt4-human Fc-lg
fusion protein (Flt4-lg) in PC3-#82 cells, as described previously [He et al., 2002; Karpanen et al., 2001].
This secreted chimeric protein should act as a competitive inhibitor for endogenous VEGFR-3 expressed
on the surface of lymphatic endothelial cells, and is expected to bind both VEGF-C and VEGF-D. Indeed,
secretion of Flt4-Ig was confirmed by immunoprecipitating the Fc region of this protein from the
conditioned media of PC3-#82-FIt4-Ig cells, followed by Western blot against VEGFR-3 (Figure 3D).
Tumor-Secreted VEGF-C Is Necessary for Lymphangiogenesis
PC3-#82 cells expressing siRNAs against VEGF-C or VEGF-A, or control siRNAs were injected
subcutaneously into CD-1 immunodeficient mice. We did not see consistent tumor growth effects
correlated with VEGF-C or VEGF-A inhibition (data not shown). Tumors were removed approximately 3.5
weeks post-injection, sectioned and stained for LYVE-1 and CD34. PC3-#82 cells expressing C14 siRNA
showed a >99% reduction in lymphatic vessel density (LVD)(Figure 4A-c and 4B) relative to controls
(Figure 4A-a-b and 4B). Tumors expressing C13, a less effective siRNA against VEGF-C, yielded an
83% reduction in LVD relative to controls (Figure 4B). Interestingly, both siRNAs against VEGF-A (A2,
A3) yielded nearly a 50% reduction in LVD versus controls (Figure 4A-d and 4B; combined p value =
0.052). As both VEGF-A siRNAs were only partially effective in reducing VEGF-A gene expression, it is
possible that more potent VEGF-A siRNAs would have yielded a greater reduction in lymphatics. LVD
quantitation of siRNA- or siRNA control-expressing tumors is shown in Figure 4B. In agreement with
results by others [He et al., 2002; Krishnan et al., 2003], expression of soluble Flt4-Ig (Figure 4A-f)
yielded complete inhibition of lymphangiogenesis versus Ig-Neg control (Figure 4A-e and 4B). In all
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cases, blood vessel density was not consistently affected (Figure 4B, images not shown), though C14-
MM control tumors had somewhat increased angiogenesis. Also, staining appeared slightly lighter in
some tumors expressing siRNA. Taken together, these results indicate that tumor-secreted VEGF-C is
necessary for intratumoral lymphangiogenesis. To a lesser extent, tumor-secreted VEGF-A may also be
important. The lack of reduction in blood vessels, especially by A2 and A3, may reflect the limited mRNA
knock-down, and/or suggest that other angiogenic factors are sufficient for inducing tumor angiogenesis.
Ablation of Prostate Intratumoral Lymphatics Does Not Inhibit Lymph Node Metastasis
PC-3 cells have been reported to metastasize infrequently from subcutaneous tumors[Glinskii et al.,
2003]. In contrast, prostate tumor cells introduced orthotopically metastasize in patterns similar to human
CaP, including invasion of lymph nodes, lung and bone [An et al., 1998; Chang et al., 1999]. To model
the early stages of metastasis, where malignant cells must detach from the primary tumor before
intravasating into vasculature, we used surgical orthotopic implantation to graft a single piece of solid
tumor into the dorsolateral prostate lobes of CD-1 mice4. As expected, the tumors introduced by SOI
developed initially from a single focus in the interluminal spaces of the prostate (Figure 8A-a). Between
2-3 months after implant, -50% of mice developed lymph node macrometastases, and the orthotopic
primary tumors possessed abundant blood and lymphatic vessels (data not shown; similar to Figure 2).
To determine the metastatic effects of ablating lymphatic vessels in orthotopic prostate tumors, we used
SOI to transplant PC3-#82 tumors expressing either VEGF-C siRNA (C14), FIt4-lg, or controls. LVD was
reduced -50% in both C14- and FIt4-lg-expressing tumors (Figure 4C). Although statistically significant
(p = 0.012 for C14 vs. control; p = 0.0046 for Flt4-lg vs. control), this reduction was far less severe than
was seen in subcutaneous tumors. Expression of either C14 siRNA or FIt4-lg in orthotopic tumors did not
affect the incidence of macroscopic lymph node metastasis (Figure 4D), the average mass of
macroscopically invaded lymph nodes (Figure 4D, p = 0.92), or the average size of the primary tumors
(data not shown). For lymph nodes without obvious macrometastases, histological analysis identified
micrometastases in virtually all samples analyzed, regardless of cell line (Figure 6E).
To understand why inhibition of lymphangiogenesis was less effective in orthotopic versus subcutaneous
tumors, we measured by ELISA human VEGF-C protein levels in subcutaneous and orthotopic tumors
expressing C14 or siRNA control. The concentration of human VEGF-C protein in C14 orthotopic tumors
was increased relative to C14 subcutaneous tumors and was positively correlated with LVD in both C14
and control tumors (Figure 5A-B). Reduced siRNA-mediated inhibition of VEGF-C secretion over the
duration of the experiment possibly accounted for less severe inhibition of tumor lymphangiogenesis. In
4 Please refer to Chapter 2, "Xenograft Transplantation Models of Prostate Cancer," for more details on SOI.
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the case of Flt4-Ig-expressing tumors, Western blot for VEGFR3/FIt4 indicated that, in some orthotopic
tumors, expression of the fusion protein was also severely reduced (Figure 5C).
To further ablate orthotopic intratumoral lymphatics, we generated a derivative of PC3-#82 cells that
combined expression of VEGF-C siRNA and FIt4-lg (Flt-C14), in addition to a cell line expressing both
empty-vector controls (Ig-pSIRISP). Specific knock-down of VEGF-C mRNA and secretion of Flt4-Ig, this
time from within the same cell line, were confirmed (Figure 6A). As expected, Flt-C14 subcutaneous
tumors possessed no lymphatic vessels, whereas Ig-pSIRISP control tumors had abundant LYVE-1
staining (Figure 6B). When implanted orthotopically, FIt-C14 tumors (n = 11) exhibited a 92% reduction in
LVD versus controls (n = 8, p <0.001) (Figure 6C). A single FIt4-C14 tumor possessed moderate LVD,
and without this outlier, inhibition of LVD increases to 98% versus control. Interestingly, blood vessel
density was also reduced -35% in Flt-C14 tumors versus Ig-pSIRISP control (Figure 6C).
Despite >92% reduction in intratumoral lymphatics, the incidence of microscopic and macroscopic lymph
node invasion, and the mass of macroscopically invaded lymph nodes were again largely unaffected in
Flt-C14 tumors versus Ig-pSIRISP control (Figure 6D, p = 0.15), or versus other controls used in this
study (Figures 4C and 6D, p = 0.80 for FIt-C14 versus pSIRISP). As before, nearly all local lymph nodes
evaluated harbored micro- or macrometastatic tumor invasion (Figure 6E). Also, we found no significant
correlation between LVD and lymph node metastasis in individual orthotopic tumors whose lymphatics
were ablated (Figure 7). Our data argue that intratumoral lymphangiogenesis is unnecessary for prostate
cancer metastasis to lymph nodes.
Abundance of Pre-Existing Marginal Lymphatics Is Unaffected in Fit-C14 Orthotopic Tumors
At least two possible explanations could account for how orthotopic prostate tumors metastasized
efficiently to lymph nodes despite >98% inhibition of intratumoral lymphangiogenesis in 10/11 FIt-C14
tumors. Formally, it is possible that a minority of lymphatic vessels (<2% of total) is sufficient for
metastasis. A likelier explanation is that marginal lymphatic vessels at the tumor-stromal margin-and
not intratumoral lymphatics-are responsible for mediating lymph node metastasis.
Because orthotopic tumors were analyzed 2-3 months after implantation, the tumors tended to be large
(-1 gram) and almost completely devoid of stromal tissue. To examine tumor interaction with pre-existing
marginal lymphatics, we transplanted Fit-C14 or control tumors by SOl and analyzed them 2-3 weeks
after implantation. In most cases, tumors were not palpable and were found by sectioning through the
dorsolateral prostate (Figure 8A-a). As expected, primary tumors consistently arose from a single focus.
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We stained microscopic Fit-C14 or control orthotopic tumors with LYVE-1 and found that both were in
contact with lymphatics located at the tumor-stromal margin (Figure 8A, b-d, and data not shown for
control tumors). In Fit-C14 tumors, all stages of lymphatic invasion were observed, including tumor
growth up against individual lymphatic vessels without compression (Figure 8A-b); intravasation of tumor
cells into lymphatics (Figure 8A-c); and crushing of vessels (Figure 8A-d). Typically, these marginal
lymphatics delineated the exact region of contact between the expanding tumor periphery and the
surrounding prostatic stroma. Quantitation of marginal lymphatics revealed little difference between FIt-
C14 and control orthotopic tumors (Figure 8B, p = 0.55). However, intratumoral lymphatics were present
in control tumors but completely absent in FIt-C14 tumors (Figure 8B). These results indicate that a
combination of VEGF-C siRNA and FIt4-lg fusion protein selectively inhibited intratumoral
lymphangiogenesis without affecting marginal, possibly pre-existing, lymphatics and suggest that these
vessels at the periphery are sufficient for mediating lymph node metastasis.
Spontaneous TRAMP Tumors Do Not Induce Lymphangiogenesis
To extend our observations, we examined the lymphatics in spontaneous TRAMP (Transgenic
Adenocarcinoma of the Mouse Prostate) tumors. As described previously, TRAMP transgenic mice
express the SV40 large T antigen driven by the prostate-specific rat probasin promoter[Greenberg et al.,
1995], and prostate sections are graded on a scale of 1-6, based on parameters including cell
differentiation and invasion through basement membrane[Gingrich et al., 1999; Hurwitz et al., 2001] s.
Importantly, by 28 weeks, 100% of TRAMP mice have been reported to harbor lymph node and/or lung
metastases[Gingrich et al., 1996]. Local and distal dissemination is predominantly observed only in mice
bearing primary tumors of grade 4 or higher[Hurwitz et al., 2001].
We examined the prostatic lymphatics in eight normal C57BL/6 mice, and fourteen TRAMP mice at
different ages and/or tumor stages. The lymphatics in normal prostates were located in the interluminal
spaces outside individual ductal structures (Figure 9A), and their abundance and location did not differ in
mice between 15-35 weeks of age (data not shown). In TRAMP prostates, PIN develops from the initial
expansion of luminal cells within ductal structures. As with wild type, lymphatics in TRAMP prostates
were consistently located outside of ductal structures and did not infiltrate into tumorigenic areas (Figure
9A). Tumorigenic prostates graded from 1-4 did not exhibit significant differences in LVD versus normal
prostates (Figure 9B). In the most severe cases of prostate cancer (grades 5 and 6), the tumorigenic
regions had overtaken the surrounding stroma, and lymphatic density in the prostate was reduced seven-
fold versus either areas of normal prostate or low grade PIN (Fig. 9A-B, p < 0.001). Since, as mentioned
previously, metastasis to lymph nodes is predominantly seen only in high grade TRAMP tumors[Hurwitz
' Please refer to Chapter 2, "The TRAMP Prostate Cancer Model," for more general information on TRAMP; please refer
to Chapter 3 results, "Protein 4.1B suppresses tumor progression in a spontaneous model of prostate cancer," for
information about grading TRAMP prostate sections.
155
Chapter 6
et al., 2001], it is likely that these spontaneous tumors also utilized pre-existing lymphatics located at the
tumor-stromal border prior to vessel compression and destruction. These results support our findings in
the xenograft SOI model that intratumoral lymphangiogenesis is not required for lymph node metastasis.
Expression of VEGF-C and VEGF-A Are Not Sufficient for Induction of Tumor Lymphangiogenesis
In the course of our studies, we also tested whether A375 melanoma cells expressed lymphangiogenic
growth factors and induced lymphangiogenesis as subcutaneous tumors. As assessed by ELISA, we
could detect VEGF-C secretion by these cells, though at lower levels than PC-3 cells (Figure 10A);
however, we could not detect any VEGF-A from medium conditioned by these cells (Figure 10A). In
addition, we found that highly metastatic variant A375 cell lines also did not express VEGF-A (data not
shown), and, out of eleven subcutaneous tumors derived from A375 cells, none of these possessed
intratumoral lymphatic vessels (Figure 10B). As human VEGF-A isoform 165 has been shown to induce
angiogenesis and lymphangiogenesis[Cao et al., 2004; Nagy et al., 2002], we tested whether
overexpression of this VEGF splice variant could induce lymphatic growth in A375 tumors. Although we
succeeded in generating cells that stably overexpressed VEGF-A and secreted the protein into
conditioned medium (Figure 10A), these cells, again, did not induce lymphangiogenesis when injected as
subcutaneous tumors (data not shown). However, our negative results were complicated by the
observation that VEGF-A-overexpressing A375 cells exhibited downregulated secretion of VEGF-C
(Figure 10A), for unknown reasons, relative to control cells. Interestingly, we did detect LYVE-1 staining
within individual lung metastases following intravenous injection of A375 cells (Figure 10C). Although
some of the vessels stained may have been lymphatics, in many cases, these were often also stained
with CD34 and possessed red blood cells in their lumens. Therefore, it would seem as if LYVE-1 staining
is non-specific in the lung. As one final note, we detected intratumoral lymphatics in subcutaneous
tumors derived from Lewis lung carcinoma cells but not from B16 melanoma cells, and, in a preliminary
study, average LVD in these tumors was unchanged, regardless of whether the cells had been injected
into wild-type mice or mice deficient for all three selectins transmembrane receptors (E-, L- and P-
selectins)(data not shown).
DISCUSSION
Lymph node status has traditionally been used as a prognostic indicator of prostate cancer
aggressiveness, dissemination to distant sites and likelihood of recurrence after therapy[Bubendorf et al.,
2000; Flocks et al., 1959; Smith et al., 1982; Zincke et al., 1982]. Although recent clinical studies have
examined the abundance of lymphatics and/or lymphatic growth factors in CaP, the results have been
difficult to interpret. In most cases, VEGFR-3/Flt4 was upregulated in advanced or node-positive
CaP[Kaushal et al., 2005; Li et al., 2004; Tsurusaki et al., 1999; Zeng et al., 2004]. One study found
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augmented tyrosine phosphorylation of VEGFR-3/Flt4 in advanced versus early stage (node-negative)
CaP[Kaushal et al., 2005], while another found upregulation of a truncated form of VEGFR3/FIt-4, but not
full-length receptor[Stearns et al., 2004]. Furthermore, VEGF-C was upregulated in some cases of
metastatic CaP [Tsurusaki et al., 1999; Zeng et al., 2004] but not others [Kaushal et al., 2005; Stearns et
al., 2004]. VEGF-D was also increased in node-positive versus node-negative CaP in some studies
[Kaushal et al., 2005; Stearns et al., 2004] but unchanged in another[Zeng et al., 2004].
Part of the complexity in analyzing these data arises from the difficulty of distinguishing whether VEGFR-
3/FIt4 was upregulated in tumor-associated lymphatics or in the tumor cells themselves[Kaushal et al.,
2005; Li et al., 2004; Stearns et al., 2004]. Indeed, in vitro studies have shown that CaP cell lines can
express the related receptors VEGFR-1/Fltl [Chevalier et al., 2002; Ferrer et al., 1999] and VEGFR-
2/Flkl [Chevalier et al., 2002; De et al., 2003; Ferrer et al., 1999]. Furthermore, staining for VEGFR-3/Flt4
in one study of CaP exclusively highlighted tumor and epithelial cells, but not endothelial vessels[Kaushal
et al., 2005].
In studies where VEGFR-3/Flt4 staining identified lymphatics associated with CaP, the localization of
these vessels was either reported to be peritumoral[Tsurusaki et al., 1999], or both peri- and
intratumoral[Zeng et al., 2004]. However, VEGFR-3/Flt4 has also been found to be expressed in some
tumor blood vessels[Valtola et al., 1999]. One clinical study of prostate cancer reported lymphatics
primarily in the tumor periphery and in non-tumorigenic stromal regions [Trojan et al., 2004]. Because
lymphatics were significantly reduced in tumors, the authors speculated that CaP progression causes
lymphatic destruction. LYVE-1-positive vessels were also correlated with increased Gleason score
[Trojan et al., 2004], but a detailed study comparing node-positive- with node-negative-CaP using LYVE-1
has not been performed.
Upregulated VEGFR-3/FIt4, VEGF-C and VEGF-D have also been correlated with other parameters of
CaP progression, including Gleason score [Li et al., 2004; Tsurusaki et al., 1999; Zeng et al., 2004] and
PSA level [Li et al., 2004; Tsurusaki et al., 1999]. Consequently, it is difficult to distinguish whether
increased lymphatics actually facilitate nodal metastasis or are simply markers of more aggressive
primary tumors. Similarly, in experimental mouse models, whether lymphangiogenesis is required for
lymph node metastasis may depend on the innate aggressiveness of the tumor in question. It is possible,
that for tumors already adept at colonizing distant sites, pre-existing lymphatics may be sufficient for
lymph node metastasis, whereas less aggressive cancers may require additional vessels to disperse
more cells and increase the probability of metastasis. This may explain why overexpression of insulin-like
growth factor receptor I in pancreatic islet tumors by Hanahan's group yielded aggressive tumors that
metastasized to lymph nodes without significant lymphangiogenesis (as reported by Alitalo, et al.[Alitalo
et al., 2004]).
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Functional studies using assays for microlymphangiography and interstitial fluid pressure have suggested
that intratumoral lymphatics may be nonfunctional[Leu et al., 2000; Padera et al., 2002]. Tumor
compression of intratumoral lymphatic vessels may be responsible for absence of function, though tumor-
induced lymphatics may inherently be physiologically abnormal[lsaka et al., 2004; Padera et al., 2004].
Although this apparent absence of function has been interpreted to suggest that intratumoral lymphatics
are unimportant for metastasis, that hypothesis needs further testing.
In contrast with our results, work by others has shown that inhibiting tumor lymphatics with soluble
VEGFR-3/FIt4-Ig fusion protein can reduce metastasis to lymph nodes both in xenograft models [He et
al., 2002; He et al., 2005; Krishnan et al., 2003; Lin et al., 2005; Papoutsi et al., 2000], and in Rip-Tag
spontaneous tumors [Crnic et al., 2004]. In most studies, both peritumoral and intratumoral lymphatics
were inhibited, though some have suggested that FIt4-lg may have no effect on pre-existing lymphatics
[He et al., 2004a; He et al., 2005; Lin et al., 2005; Papoutsi et al., 2000], or may inhibit peripheral, but not
intratumoral, lymphatics [Crnic et al., 2004]. The varying effectiveness of Flt4-lg may reflect how and
when the inhibitor was administered; its concentration; diffusion to surrounding tissues; abundance of pre-
existing lymphatics; and local concentration of VEGF-C/D ligands. Given that the tumors in our SOI
model arose from a single solid focus (Figure 8A-a), it is possible that diffusion of Flt4-lg was reduced,
when compared to models where tumor cells were injected in suspension. Indeed, several papers have
reported that high-level, systemic expression of Flt4-lg fusion protein can suppress metastasis [Crnic et
al., 2004; He et al., 2005; Lin et al., 2005] and a similar result was also recently achieved by injection of
an antibody against VEGFR-3 [Hoshida et al., 2006]. However, recent work by Pytowski et al. has
suggested that VEGF-C-mediated VEGFR-3 signaling may be unnecessary for maintenance of pre-
existing lymphatics in the mouse tail [Pytowski et al., 2005].
We began these studies with the goal of trying to determine whether tumor cell entrance into blood
circulation was dependent on lymphatic dissemination. That question still remains unresolved, as we
were unable to inhibit lymph node metastasis in our system. Instead, we have shown that intratumoral
lymphangiogenesis can be inhibited in prostate cancer (FIt-C14) without significantly affecting lymph node
metastasis (Figure 11). In early-stage FIt-C14 tumors, we found that despite absence of intratumoral
lymphangiogenesis, the abundance of peritumoral lymphatics was not statistically different from controls,
and in all cases, tumor-intravasated lymphatic vessels were observed. These data suggest that
intratumoral lymphangiogenesis is unnecessary for lymph node metastasis in CaP, and that marginal,
possibly pre-existing, lymphatics are sufficient. He et al. reported that tumor-secreted VEGF-C can
promote dilation and sprouting/hyperplasia in pre-existing lymphatics and that this can be inhibited by
high levels of systemic Flt4-Ig, although the tumor cells still co-opted the pre-existing lymphatics and
lymph node metastases still occurred, albeit at reduced levels [He et al., 2005]. Those results could be
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reconciled with ours if the high levels of FIt4-Ig partially inhibited the intravasation of tumor cells into pre-
existing lymphatics. Another possibility is that, in our system, lymphatic hyperplasia may not be
dependent upon VEGFR3/FIt4-mediated signaling.
We have also obtained corroborative results using the TRAMP spontaneous model of prostate cancer. In
TRAMP, metastasis to lymph nodes is primarily observed only in tumors of grade 4 or higher [Hurwitz et
al., 2001]. In TRAMP prostates, we found that lymphatics were typically located outside the luminal
acinar regions where PIN and adenocarcinoma develop. Peritumoral, but not intratumoral lymphatics,
were seen, and as the tumors invaded through the basement membrane into surrounding stromal regions
(grades 5-6), significantly fewer lymphatics were observed, suggesting destruction of pre-existing
lymphatics and absence of lymphangiogenesis. This is similar to human clinical CaP[Trojan et al., 2004],
and also indicates that pre-existing peritumoral lymphatics are sufficient for lymph node metastasis.
In summary, we have shown that in prostate cancer, lymph node metastasis relies on peritumoral, and
not intratumoral, lymphatics, suggesting that the peritumoral lymphatics that pre-exist before tumor
development may be sufficient for disseminating tumor cells to local and more distal lymph nodes (Figure
11). Our results also suggest that inhibiting lymphangiogenesis may be easier than ablating pre-existing
lymphatics. As targeting lymphatic vasculature has recently been proposed as an anti-metastatic
approach for limiting spread of primary tumors[Achen et al., 2005], this study demonstrates that the need
to target the surrounding marginal lymphatics is especially imperative.
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Figure 1. Lymphatic physiology and growth factors. (A) Lymphatics (green) begin as
blind-ended tubes attached to the matrix via reticular fibers Lymphatic fluid flows
down pressure gradients, from highest to lowest pressure. (B) The protein domain
structures of the various lymphangiogenesis-promoting VEGFs and their receptors are
shown.
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Figure 2. PC34-82 cells form subcutaneous tumors with intratumoral lymphatic and
blood vessels. Serial tumor sections probed with antibodies against LYVE-1 or CD34
show specific, non-overlapping staining for lymphatics or blood vessels, respectively(top panels). This is also evident when the two sections are merged, with lymphatics
colored white and blood vessels black (bottom panel). Serial sections probed with
LYVE-1 and anti-mouse VEGFR-3/Flt4 show coincident staining (middle panels).
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Figure 3. PC3-#82 cell expression and secretion of VEGF-C or VEGF-A can be
reduced by siRNA. (A) Relative mRNA levels for VEGF-C (black) or VEGF-A (gray) were
measured by quantitative PCR, and normalized to pSIRISP vector control. C13 and
C14 cells express siRNAs against VEGF-C. A2 and A3 cells express siRNAs against
VEGF-A. C14-MM and A3-MM (MM = "mismatch") are siRNA specificity controls (B)
siRNAs specifically reduced accumulation of either VEGF-C or VEGF-A protein in
conditioned media, asassessed by ELISA.
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Figure 3. PC3-#82 cell expression and secretion of VEGF-C or VEGF-A can be
reduced by siRNA (cont). (C) Accumulation of VEGF-C protein (top graph), but not
VEGF-A protein (bottom graph), in conditioned media is severely inhibited in PC3-#82
cells expressing C14 siRNA (red), and lessso for C13 siRNA (green), compared to control
(blue). Minimal accumulation of VEGF-C was seen in C14-expressing cells even 72
hours after media change. (D) Secretion of soluble VEGFR-3/Flt4-lg fusion protein in
PC3-#82 cells was confirmed by immunoprecipitating fusion protein from conditioned
medium and by Western blot. (** p < 0.001)
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Figure 4. Tumor-secreted VEGF-C is necessary for tumor lymphangiogenesis. (A)
Subcutaneoustumorswere stained with LYVE-1: (a) pSIRISP control; (b) C14-MM
control; (c) C14 siRNA; (d) A3 siRNA; (e) Ig-Neg control; (f) Flt4-lg. (B) Staining results
for blood vessels (gray bars) and lymphatics (dark bars) were quantitated for siRNA-
expressing subcutaneous tumors (left graph) and for tumors expressing soluble receptor
or control (right graph) (* p = 0.01; ** p < 0.001).
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Figure 4. Tumor-secreted VEGF-C is necessary for tumor lymphangiogenesis (cont).
(C) Quantitation of lymphatic (black) and blood vessels (gray) from orthotopic tumors is
shown (* p < 0.02). (D) Metastasisto the draining (lumbar) and more distant (renal)
lymph nodes was unaffected after the tumorswere implanted by SOI (for lumbar lymph
node mass, p = 0.92 for C14 vs pSIRISP; p = 0.81 for Flt4-lg vs Ig-Neg; and similarly
not significant for renal lymph nodes).
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Figure 5. Durability of siRNA or FIt4-lg expression in orthotopic tumors. (A) Subcutaneous
tumors expressing C14 siRNA had a 71% reduction in VEGF-C protein compared with control,
but only a 44% reduction in orthotopic tumors, asassessed by ELISA. Absolute VEGF-C
concentration was increased in C14 orthotopic versus C14 subcutaneoustumors, but not in
control orthotopic versuscontrol subcutaneous tumors (B) Tumor LVD is plotted against
human VEGF-C concentration of orthotopic primary tumors, revealing a general positive
correlation. Samples expressing C14 siRNA are represented by blackdiamonds, and control
samples are represented by white triangles. Note that a single C14 tumor (#1591) lost siRNA
inhibition against VEGF-C and possessed high LVD. (C) Subcutaneous and orthotopic tumors
were assayed for Flt4-lg fusion protein by Western blot against VEGFR-3/Flt4. Flt4-lg was
expressed at high levels in subcutaneous tumors, but severely reduced or absent in one of two
orthotopic tumorstested, #2360. Ig-Neg are control tumors
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Figure 6. Combined expression of VEGF-C siRNA and Flt4-lg in PC3-#82 cells
effectively reduces orthotopic tumor LVD without markedly affecting lymph node
metastasis (cont). (C) Lymphatic and blood vessels in orthotopic primary tumorswere
quantitated. Combination of FIt4-lg with C14 siRNA inhibited average LVD 100% in
subcutaneous tumors and >92% in orthotopic tumors(n = 11). In 10/11 Fit-C14 orthotopic
tumors, average LVD was reduced >98% ("minus 1"), compared with Ig-pSIRISP control (n =
8). For reference, vessel density for pSIRISP vector control from Fig. 4C is shown. (D)
Metastasisto draining and more distant lymph nodeswas not significantly affected in FIt-
C14 tumors compared with Ig-pSIRISP control (p = 0.15 for lumbar lymph nodes) or
pSIRISP control (p = 0.80; data reproduced from Fig. 4D).
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Line Mass > 30 mg Mass < 30 mg Micrometastases Macrometastases
Flt-C14 6/11 (55%) 5/11 (45%) 3/3 (100%) 9/9 (100%)
Ig-pSIRISP 7/13 (54%) 6/13 (46%) 3/3 (100%) 10/10 (100%)
Flt4-Ig 10/13 (77%) 3/13 (23%) 1/1 (100%) 11/11 (100%)
Ig-Neg 9/13 (69%) 4/13 (31%) 2/2 (100%) 11/11 (100%)
(IC14 12/17 (71%) 5/17 (29%) 1/2 (50%) 13/14 (93%)
pSIRISP 14/21 (67%) 7/21 (33%) 3/3 (100%) 17/17 (100%)
A set of 2-3 lumbar lymph nodes was removed, fixed and weighed. (The collective
mass of lumbar lymph nodes from non-tumor-bearing mice typically does not
typically exceed 10 mg.) Lymph node sets weighing >30 mg were scored as
positive for macrometastasis (Column A). Ten "borderline-positive" lumbar lymph
node sets (mass 30-80 mg) were examined by histology (one H&E section per lymph
node). 8/10 consisted of at least one node with >80% tumor invasion; the remaining
two samples consisted of at least one node with >50% invasion. Since the majority
of lymph node macrometastases greatly exceeded 100 mg in mass, it is likely that
the majority of the node mass (>90%) consisted of metastasized tumor cells. The
incidence of macrometastasis was unchanged in the case of manipulated cell lines
vs. controls (Columns A, B). A representative sample of lymph nodes < 30 mg in
mass was further evaluated by histology (Column C). A single H&E section per
lymph node was examined for micro-metastatic invasion. Overall, 13/14 lymph
node sets were found to possess tumor cells. Column D shows that essentially all
mice bore lymph node metastases (macro or micro), regardless of cell line.
Figure 6. Combined expression of VEGF-C siRNA and FIt4-lg in PC3-#82 cells
effectively reduces orthotopic tumor LVD without markedly affecting lymph node
metastasis (cont). (E) The incidence of macroscopic (> 30 mg) and microscopic lumbar
lymph node metastasis is shown for the cell lines used in thisstudy. In 71/72 animals
examined, metastasis to local lymph nodes was observed.
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Figure 7. Metastasis is not correlated with LVD in indiv idual orthotopic tumors.
Each point represents data from a single tumor/mouse. Different control tumors are
shaded red, while experimental tumorsare shaded green (refer to labelsfor cell line
identification). The upper right box identifies tumors with heavy lymph node metastatic
burdens (> 100 mg mass, or ~-10X the typical mass of uninvaded lymph nodes) and high
LVD. Note that tumors in thiszone consist predominantly of control samples (red
shaded). The lower left box identifiestumorswith low lymph node metastatic burdens
and low LVD. Note that tumors in thiszone predominantly consist of sampleswhere
LVD was experimentally reduced (green shaded). The upper left box identifies tumors
with heavy lymph node metastatic burdens despite low LVD. Note that all samples in
this zone are experimentally manipulated (green shaded). Tumor #1591 (C14) was
subsequently found to have lost siRNA inhibition of VEGF-C (Fig. 5B), while tumor
#2360 showed reduced Flt4-lg protein levels (Fig. 5C).
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Figure 8. Peritumoral lymphatics are found at the tumor-stromal interface of FIt-C14
orthotopic tumors. (A) H&E staining of the prostate 2-3 weeks after SOI reveals a single
focal microscopic tumor (star) surrounded by prostatic ductal acinar structures (a). All
stages of lymphatic invasion were seen in Flt-C14 orthotopic tumors stained with LYVE-
1, including tumor growth against lymphatic vessels (b), i ntravasated vessels containing
tumor cells (c), and compression of vessels (d). Note that, in all cases, peritumoral
lymphatics delineated the tumor-stromal junction ("T," tumor region; "S," stromal
region). (B) Quantitation of peritumoral lymphatics in Flt-C14 and control orthotopic
tumors is shown on the left, and quantitation of intratumoral lymphatics is shown on the
right. Flt-C14 tumors possessed peritumoral, but not intratumoral lymphatics (** p <
0.001)
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Figure 9. TRAMP spontaneous prostate tumors do not induce lymphangiogenesis.
(A) Regions of grade 3 prostate intraepithelial neoplasia (left), or grade 6
undifferentiated adenocarcinoma (right) from TRAMP prostates were stained with LYVE-
1 (top panels) or H&E (middle panels). Normal prostate was also stained with LYVE-1
(bottom panel). Lymphaticswere located in the stroma and excluded from tumorigenic
regions Lymphaticswere mostly absent in regionsof undifferentiated
adenocarcinoma. (B) Quantitation of total lymphatics in normal and TRAMP prostate
sections. Grade 5-6 TRAMP prostates possess significantly fewer lymphatic vessels than
lower grade or normal (grade 1) prostates (p < 0.001).
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Figure 10. A375 melanoma tumors do not induce lymphangiogenesis. (A) A375
control cells secreted VEGF-C (blue bars), but not VEGF-A (purple bars), into
conditioned medium, as assessed by ELISA. Secretion of human VEGF-A could be
detected in A375-h165 cells overexpressing human VEGF-A 165. (B) A375
subcutaneous tumors were angiogenic (right) but not lymphangiogenic (left), regardless
of VEGF secretion.
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Figure 10. A375 melanoma tumors do not induce lymphangiogenesis (cont). (C)
A375 lung metastases exhibited LYVE-1 staining that was often coincident with CD34
staining (top row). Red blood cells could be seen, indicating these were blood vessels
(bottom row). In some cases LYVE-1 staining appeared specific and did not overlap
with CD34 staining (bottom row, arrows).
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Figure 11. Inhibition of peritumoral lymphatics is likely critical for blocking lymph
node metastasis. Various inhibitory approaches can inhibit intratumoral and, in some
cases, peritumoral lymphatics High in vivo expression of Flt4-lg by adenovirus-
mediated gene transfer (adeno-Flt4-1g) is likely more effective at inhibiting peritumoral
lymphatics than tumor expression and secretion of the chimeric protein in our
orthotopic system.
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Summary of Results
The complexity of a biological process such as metastasis necessitates that, with our current technology,
discrete steps or aspects of the problem are analyzed. We decided to focus our studies on prostate
cancer because this is a malignancy that frequently metastasizes, and, indeed, it is the metastases-
rather than the primary tumor-that make this a lethal disease. Among the many questions about how
tumor cells accomplish this process, we decided to focus on three of them in this thesis:
1. What are the genes involved with metastasis?
2. How do tumor cells enter blood circulation?
3. How do tumor cells enter lymphatic circulation?
As these are all questions that seek to address events that occur in vivo, we approached these problems
by using two different mouse models of prostate cancer. In all cases, we began our studies by
xenografting human adenocarcinoma PC-3 cells into the prostate orthotopic site. The major advantage of
xenotransplant mouse models of cancer is that the input cells can readily be manipulated to over- or
under-express genes of interest. However, these approaches do not recapitulate all the steps of
tumorigenesis; the techniques by which tumor cells are introduced are often highly artificial; and tumor
progression is usually observed in immunodeficient mice. Thus, whenever possible, we extended our
observations using the TRAMP spontaneous model of prostate cancer. We also attempted to view our
experimental findings from these two models in the larger context of human clinical prostate cancer: Are
the results we obtained in mice relevant to the human situation? And if so, what are the implications?
We began our studies by deriving from the original PC-3 cell population a set of core cell lines that
differed in metastatic potential. The PC3-pMicro-1 cell population was first isolated, from which two key
cell lines were subsequently derived: PC3-#78 and PC3-#82. Repeated implantation of #78 tumors
using surgical orthotopic implantation (SOI) revealed that these cells were poorly metastatic to lymph
nodes and lung in the orthotopic system; #82 cells, on the other hand, displayed significantly increased
metastatic potential. With knowledge about the in vivo properties of these cells, we performed gene
expression analysis in an attempt to identify genes which were responsible for the differing metastatic
phenotypes. This approach yielded a list of gene candidates that differed between poorly metastatic #78
cells and highly metastatic #82 cells, and we were pleased to find that many of these genes encoded
proteins with known or putative functions related to cell adhesion, migration and invasion. Ultimately, we
decided to pursue further two genes which were both severely downregulated in highly metastatic cells-
Protein 4.1B and SPARC-on the hypothesis that these were potential suppressors of the metastatic
phenotype.
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Protein 4.1 B is a member of the Protein 4.1 superfamily of proteins, and is believed to function as a
cytoskeletal linker that connects transmembrane proteins with the actin cytoskeleton [Sun et al., 2002].
4.1 B possesses an N-terminal FERM interaction domain and is related to ERM proteins, although the
precise physiological functions of this poorly-characterized molecule are currently unknown. In vitro
overexpression experiments, in some cases, have suggested that 4.1 B can function as a tumor
suppressor, and, more importantly, expression of this protein is lost in a variety of human tumors
[Charboneau et al., 2002; Jiang and Newsham, 2006; Robb et al., 2005; Sun et al., 2002; Tran et al.,
1999]. However, mice deficient in 4.1B are viable and phenotypically normal, without any enhanced
predisposition to tumor formation [Yi et al., 2005].
We began examining the role of this protein in prostate cancer metastasis by downregulating 4.1B
expression in poorly metastatic #78 cells, which expressed high levels of the protein. When implanted by
SOl, #78 cells expressing siRNAs against 4.1B exhibited significantly increased metastasis to lymph
nodes relative to controls, whereas the size of the orthotopic primary tumors did not differ. Lymph nodes
from mice bearing siRNA-expressing tumors tended to be fully infiltrated with tumor cells, with low rates of
apoptosis, while nodes from mice bearing control tumors frequently exhibited incomplete, microscopic
subcapsular invasion where tumor cell death was quite apparent. These experiments thus suggest that
downregulation of 4.1 B may have protected tumor cells against apoptosis, which consequently increased
their overall metastatic potential.
In light of these xenotransplant results, we decided to test whether 4.1B was important during
spontaneous prostate cancer progression. Mice lacking this gene were generated by and obtained from
Dr. Joseph Kissil, and these animals were crossed with TRAMP mice, which expressed SV40 large T
antigen in the prostate. We observed that 4.1B-i-; TRAMP+'- mice, on average, developed higher grade,
less differentiated and more aggressive primary prostate tumors than did 4.1B''/; TRAMP +/' littermates or
cousins. In addition, tumors from knock-out mice more frequently metastasized to the draining lymph
nodes than did those from heterozygous mice. Again, we found significant differences in apoptosis: At
22 weeks of age, 4.1 B-deficient, Grade 4 prostatic lesions displayed significantly reduced apoptosis
compared to that of their heterozygous, age- and grade-matched counterparts. We believe that loss of
4.1 B therefore conferred tumors with an increased ability to resist apoptosis, and this ultimately enhanced
their propensity to progress to a metastatic state. As 4.1 B expression is significantly downregulated in
prostate cancer relative to normal tissue in four out of five studies of human clinical prostate cancer, this
again supports our finding that loss of this protein is important during disease progression.
As mentioned previously, we also examined whether SPARC, an extracellular matrix component, was
important during tumor progression and metastasis. Much in vitro and in vivo work has been done on this
protein, although these studies have, often-times, yielded contradictory results implicating SPARC as
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both a tumor/metastasis suppressor and enhancer [Framson and Sage, 2004]. However, we were
interested to find that SPARC levels frequently changed during tumor progression and metastasis, not
just in our own studies, but also in breast and prostate human clinical data. SPARC expression was also
downregulated in highly metastatic A375 melanoma cells relative to poorly metastatic cells, similar to our
results using PC-3 cell line derivatives. Given that the role of SPARC in tumorigenesis has already been
examined in vitro and in several in vivo xenograft cancer studies [Brekken et al., 2003; Koblinski et al.,
2005; Puolakkainen et al., 2004; Yiu et al., 2001], we elected to test its function directly in spontaneous
tumor mouse models of prostate and mammary cancer. For this, we utilized SPARC-deficient mice,
which were obtained from Dr. E. Helene Sage and mated with either TRAMP animals, or with MMTV mice
expressing SV40 in the mammary glands. Surprisingly, we observed no statistically significant
differences in tumor formation or progression in either systems, when comparing SPARC-/ mice with
SPARC+/- littermates and cousins. These results, if also true in humans, would indicate that while levels
of SPARC are frequently altered during tumorigenesis, this is a change which is associated with, rather
than causal for, the tumorigenesis and/or metastasis phenotypes observed.
Over the course of our studies, we also made an interesting observation regarding the patterns of
lymphatic and hematogenous spread that were manifested in the SOI prostate cancer model. We noted
that lung micro-metastases and circulating tumor cells in the blood were detected, in almost all cases,
only in those mice that bore macro-metastases in both the para-aortic/lumbar and para-renal lymph
nodes. Mice that had not displayed macroscopic invasion at both sets of nodes rarely exhibited
hematogenous dissemination of tumor cells. As hematogenous spread has been observed to be
associated with lymphatic metastasis in human clinical prostate cancer and other tumor types [Bubendorf
et al., 2000; Cianfrocca and Goldstein, 2004], this finding could bear important implications for how we
regard some of the earliest steps of the process. At least three explanations could account for these
apparent associations. One possibility is that tumor cells rely on lymphatics to enter systemic circulation.
A second possibility is that tumors metastasize through both the lymphatic and hematogenous routes
simultaneously but independently of one another. A third possibility, related to the second, is that
lymphatic and hematogenous metastasis are independently mediated by distinct sub-populations of tumor
cells.
We tried to differentiate between these three possibilities by attempting specifically to inhibit lymph node
metastasis. If hematogenous dissemination were dependent on lymphatic spread, both routes of
metastasis should be, consequently, inhibited; however, if bloodborne metastasis occurred concomitantly
with, but independently of, lymphatic spread, stopping one route of dissemination should have no effects
on the other. Our approach to inhibiting lymph node metastasis was based on previous findings by others
that VEGF-C is an important lymphangiogenic cytokine, and that blocking the activation of its receptor,
VEGFR-3/Flt4, could reduce tumor metastasis to lymph nodes [Alitalo et al., 2005; He et al., 2002].
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Indeed, we were successful at inhibiting lymphangiogenesis by either ablating tumor expression of VEGF-
C, or by expressing a competitive soluble inhibitor of its receptor. What was surprising, though, was that
inhibiting tumor lymphangiogenesis had no statistically significant effects on lymph node metastasis in our
orthotopic prostate cancer model. Micro- and macro-metastases to the lymph nodes were observed in
nearly all cases, regardless of whether there was an abundance or dearth of intratumoral lymphatic
vessels. Therefore, we concluded that lymphangiogenesis was unnecessary for tumor-to-lymph node
metastasis.
In the absence of lymphangiogenesis, then, how did tumor cells reach the lymph nodes? Work by others
had previously shown that intratumoral lymphatics were non-functional [Padera et al., 2002; Padera et al.,
2004], suggesting that the peritumoral lymphatics at the tumor periphery were the main routes of egress
for metastasis. We explored this possibility by examining orthotopic tumors at an earlier stage, before the
onset of metastasis, when individual microscopic tumor foci were still surrounded by prostatic stromal
tissue at the primary site. We observed that while we were successful at inhibiting intratumoral
lymphatics, the abundance of peritumoral lymphatics was unchanged between our experimental and
control tumors. These results suggest that peritumoral lymphatics that likely pre-existed in the prostate
prior to tumor implantation-and not induced, intratumoral lymphatics-mediated the dissemination of
metastatic cells.
We next turned again to the TRAMP spontaneous model of prostate cancer to try and validate our
xenograft results. We observed that TRAMP prostate primary tumors, which frequently metastasize to
lymph nodes, possessed few intratumoral lymphatics and likely did not induce lymphangiogenesis.
Indeed, lymphatics were present specifically outside the luminal areas where tumors arose and did not
infiltrate into malignant regions. These findings, in concordance with our previous results and with recent
reports by others who noted that lymphangiogenesis does not occur in human clinical prostate, breast
and pancreatic cancer [Sipos et al., 2005; Trojan et al., 2004; Vleugel et al., 2004], suggest that only
peritumoral lymphatics are necessary for lymph node metastasis.
Thus, this thesis has answered, at least in part, two specific, though inter-related, questions regarding
how prostate cancer spreads throughout the body. We identified Protein 4.1B as a gene that potentially
suppresses prostate cancer progression and metastasis. We also determined that tumors likely utilize
peritumoral lymphatics to disseminate to draining lymph nodes. A third question which was posed earlier
in this chapter-that is, how tumor cells enter blood circulation-could not be answered because we were
ultimately unable to inhibit lymphatic metastasis. Therefore, we were unable to test the hypotheses we
formulated to explain the apparent association observed between hematogenous and lymphatic
dissemination. How these hypotheses might be tested in future work is discussed below.
185
Chapter 7
Future Work
In many ways, the work described in this thesis remains ongoing. Although we have shown that loss of
4.1B was associated with reduced apoptosis and increased tumor aggressiveness in vivo, a major
unresolved question remains regarding the mechanism by which this protein functions in the cell. The
development of an in vitro assay to assess 4.1B function will surely be a critical step forward, and this has
become the major focus of our current studies. We have subjected tumor cells expressing high or low
levels of 4.1 B to various apoptotic stimuli, including serum starvation, staurosporine, and
cycloheximide/TNF-a treatment, but in no cases have we seen significant differences in response. These
cells also appear to undergo anoikis at similar rates. As 4.1 B overexpression experiments have been
reported to induce caspase-8-mediated cell death [Jiang and Newsham, 2006], and loss of this caspase
has also recently been shown to be important for metastasis and for avoidance of unligated integrin-
mediated cell death [Stupack et al., 2006], we are planning to focus more of our studies on this pathway.
For instance, we are planning to assay cellular responses to FasL and TRAIL, two ligands which induce
caspase-8-mediated apoptosis. In addition, it might be informative to examine the morphology and
apoptosis rates of our cells when grown in three-dimensional cultures that might better recapitulate in vivo
conditions.
We are also trying to approach this problem from a biochemical angle. As mentioned previously in this
thesis, in order to determine the function of 4.1 B, it will be important to link this protein with a signaling
pathway. Efforts towards this end have already revealed that 4.1B interacts with integrin 08 in prostate
cancer, although the biological significance of this interaction remains unclear. Current work is focused
on determining whether the presence or absence of 4.1 B has effects on the abundance and/or the
activation status of the ERM proteins. Indeed, 4.1B has been reported to interact with all members of this
family, including merlin; however, the outcomes of these interactions are unknown [Sun et al., 2002]. We
are planning experiments to determine, firstly, if these interactions can be confirmed in prostate cancer,
and secondly, to assess whether these interactions might be meaningful. For instance, one experiment
will involve stimulating our cells with a cytokine such as EGF and then determining whether
phosphorylation levels of the ERM proteins are affected by the presence or absence 4.1B. This can
readily be accomplished using antibodies that specifically detect the phosphorylated versions of these
proteins. We are also interested in determining whether 4.1 B has effects on the Rho pathway. It is
interesting to note that both integrin 08 and ERM proteins have been reported to bind Rho-GDI-a
[Bretscher et al., 2002; Lakhe-Reddy et al., 2006], and it is therefore possible that 4.1B might regulate
Rho activity through this protein. Finally, 4.1B has been reported to interact with CD44, a hyaluronan
receptor that has been widely implicated in tumorigenesis, and the functional significance of this
interaction will need to be explored further [Robb et al., 2005].
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There are also some lingering questions regarding the in vivo role of 4.1B during tumor progression and
metastasis, and some of these questions might be answered through analysis of additional animals. In
our TRAMP spontaneous tumor studies, we observed that loss of 4.1 B protected Grade 4 precursor
prostatic lesions from apoptosis at 22 weeks of age, and this may have contributed to enhanced
progression to malignancy. A more thorough study still remains to be performed comparing prostatic
lesions of other grades to determine if 4. 1B might also be acting during some of the earlier or later stages
of tumor progression. Similarly, apoptosis studies should be performed on lymph node metastases from
4.1B-heterozygous and knock-out TRAMP mice.
As we have noted that 4.1 B is significantly downregulated in prostate tumors relative to normal tissues, in
four studies of human clinical prostate cancer, it will be important in future work to confirm these findings
at the protein level. In collaboration with Dr. Marc Barry, working in Dr. Mark Rubin's laboratory at
Harvard, we began a preliminary immunohistochemical study by probing for 4.1B protein in human
prostate tissue arrays. In most cases, we observed strong staining of malignant luminal areas of the
prostate; however, there was no correlation between intensity of staining and tumor severity, based on a
limited number of samples observed. It is likely that background staining may have obscured our results,
as our 4.1 B antibodies are known to detect non-specific human proteins by Western blot. In fact, we
have found that our 4.1 B antibodies are useful for immunofluorescence only when probing mouse cells
such as TRAMP, but not human cells like PC-3. Therefore, in order to determine whether 4.1B protein
levels are downregulated in human prostate cancer, it will either be necessary to generate a cleaner
antibody, or to obtain total protein lysates for Western blot analysis.
In the case of our lymphatic studies, as mentioned above, we were unsuccessful at blocking lymph node
metastasis, and, therefore, we were unable to test our models regarding how tumor cells enter blood
circulation. Although it may be informative to examine why our experimental approaches failed to inhibit
peritumoral lymphatics, perhaps a more interesting and important problem is to determine whether there
are alternative approaches that can be taken to test our original hypotheses. One possibility we have
considered is to remove the draining para-aortic lymph nodes from mice prior to surgical implant of
tumors. The reasoning is that, if the formation of macrometastases at this site were important for
systemic dissemination of tumor cells, the physical removal of these nodes might prevent metastasis to
distant organs such as the lung. While it is unclear how tumor cells might behave in the presence of
lymphatics but in the absence of lymph nodes, our ability to inhibit lymphatic spread could be assessed
by examining the para-renal lymph nodes, which are more distant from the prostate and also appear to be
necessary for systemic spread. Certain controls would also be needed to ensure that removal of the
draining lymph nodes did not significantly affect the immune system, particularly the composition and
abundance of immune cells within the primary tumor. In addition, it would also be necessary to confirm
that the lymphatics present in the prostate are unaffected by lymph node removal.
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Perhaps a more complicated experiment might entail mixing tumor cells that expressed a series of readily
detectable and distinguishable markers, such as fluorescent tags or genomic bar-codes. It would then be
possible to perform relationship studies among tumor cells isolated from the primary tumor, lymph nodes,
blood and lung. For instance, if hematogenous spread were dependent on lymphatics, the systemic
metastases should resemble tumor cells in the lymph nodes more closely than those in the primary
tumor. If the opposite were true-that hematogenous spread occurred directly from the primary tumor
and independently of lymphatic metastasis-then the systemic and lymphatic metastases would not be
expected to resemble one another'. Obviously, the exact approach and controls needed for experiments
such as these would require careful thought and planning.
Concluding Remarks
The results from this thesis have contributed small pieces of knowledge to our overall understanding of
the problem of cancer metastasis. We have examined the genetic basis of this complex process and
have experimentally implicated one gene as a negative regulator of metastasis. We have also studied
the mechanistic aspects of tumor cell dissemination, and determined how some of the earliest steps of
the process are completed. In both instances, there is supporting human clinical data to validate our
results in prostate cancer and, perhaps, in other tumor types as well. This is, in many ways, generally
reassuring, that results obtained in the mouse also appear to be applicable in humans. Whether this is
truly the case remains to be seen, as future work in the field of cancer metastasis will certainly allow us
one day to understand, in far greater detail, the genetic and mechanistic basis of this elaborate and
important disease process.
1 This would be the expected result if metastasis, in least in this experimental system, were a rare and perfectly stochastic
occurrence.
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APPENDIX A. MATERIALS & METHODS
CELL LINES
PC-3 cells were obtained from American Type Culture Collection (ATCC, Manassas, VA) and cultured in
F-12K medium (Kaign's modification, Gibco-lnvitrogen, Frederick, MD) containing 10% fetal bovine serum
(FBS), glutamine and antibiotics. Cells were passaged approximately every 5 days and released with
0.25% trypsin (Gibco-lnvitrogen). Cell freezing was accomplished by re-suspending cells in 90%
complete medium, 5% FBS and 5% dimethyl sulfoxide (DMSO) Hybri-Max (Sigma-Aldrich; St. Louis,
MO). Derivation of PC-3 metastatic variants is described below, and all cells were cultured in complete
PC-3 medium. PC-3M cells were obtained from the lab of Dr. Isaiah J. Fidler (M. D. Anderson Cancer
Center, Houston, TX). TRAMP-C1 and -C3 cells were obtained from ATCC and cultured in Dulbecco's
modified Eagle's medium with high glucose containing 5% FBS, 5% fetal Nu-serum IV (Becton Dickinson,
San Diego, CA), 5 ug/ml insulin and 10 nM dihydrotestosterone. These cells were frozen in 95%
complete medium containing 5% DMSO. Phoenix cells (ATCC) were cultured in Modified Eagle Medium
(DME) supplemented with HEPES, 10% FCS, glutamine and antibiotics. These were frozen in 50%
complete medium, 40% fetal calf serum (FCS) and 10% DMSO. Single cell clones of PC-3 and TRAMP-
C1 were isolated by plating cells at a concentration of 0.3 cells per well in 24-well tissue culture plates.
MOUSE TUMOR MODELS
Subcutaneous Injections and Growth Curves
PC-3 cell lines were grown to near-confluence in T-175 cell culture flasks, removed by trypsin and
collected in 50 ml conical tubes. The cells were pelleted by centrifugation and washed once with normal
growth medium, followed by two washes with chilled PBS buffer. Subsequently, cell numbers were
quantitated by hemocytometer, and the final pellet was re-suspended in chilled PBS at a concentration of
4 x 10^7 cells/mi and moved into a 5 ml polystyrene round-bottom tube (Becton Dickinson). Four- to five-
week-old CD-1 nude immunodeficient mice (Charles River Laboratories, Wilmington, MA) were
anesthetized by avertin/tribomethanol (Sigma) intraperitoneal injection and lain on their side within a fume
hood. The cell suspension was mixed in the tube and drawn up into the barrel of a 1 ml syringe, which
was subsequently capped with a 16-gauge needle (Becton Dickinson). The area of injection-
underneath the skin adjacent to the armpit of the left front paw-was cleaned with alcohol prep pads
(Dynarex Corporation, Orangeburg, NY), after which the needle was inserted and 50 ul of cell suspension
(2 x 10^6 cells) were injected. Formation of a "bleb," or bump, at the site of injection was indicative of a
successful injection. For growth curves, the tumors were measured by calipers every three days for
approximately three weeks following injection. The two-dimensional length and height of the tumor were
recorded, and tumor volume was estimated by the equation: volume = 0.5 x d^2 x D, where "d" was
equivalent to the shorter of the two measurements, and "D" was equivalent to the longer of the two
measurements [Bartolazzi et al., 1995].
Surgical Orthotopic Implantation (SOI)
Subcutaneous tumors were removed for analysis and/or used as donor material for surgical orthotopic
implantation (SOI) approximately 3.5 weeks after injection, as described previously [An et al., 1998;
Chang et al., 1999]. Briefly, a peripheral portion of the tumor was removed and sliced into ~1 mm^3
cubes under a dissecting microscope. CD-1 mice were anesthetized, and the abdominal regions
exposed with an incision along the lower midline. A single tumor fragment was embedded into the right
dorsolateral capsule and secured with 9-0 micro-sutures (Ethicon; Somerville, NJ). The peritoneum and
overlying skin were each closed with one set of 5-0 sutures (United States Surgical; Norwalk, CT). The
entire protocol was performed in sterile conditions inside a fume hood, in accordance with animal care
guidelines. For detailed instructions regarding SOl, please refer to Appendix B.
Preservation of Organs and Analysis (for SOI)
Mice with orthotopic tumors were analyzed when moribund, as judged by bladder/abdominal distension
and/or severe weight loss (typically 2-3 months after implantation). Tumors were removed from the
mouse, cleaned and weighed on a balance. Portions of the tumor were then flash frozen in liquid
nitrogen; fixed overnight in 3.7% formalin buffered in PBS; and/or fixed for 48 hours in Zinc Fixative IHC
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solution (Becton Dickinson), depending on the experiment. Following fixation in formalin or zinc, tumors
were transferred into 70% ethanol for storage. In most cases, visceral organs were fixed overnight in
3.7% formalin, following inflation of the lungs by injecting 1-2 ml of formalin through the mouse trachea.
Bone material was separated from the visceral organs, cleaned and fixed for three weeks in Bouin's
solution (Sigma), before being transferred into 70% ethanol. Lymph nodes were removed, fixed in
formalin overnight and weighed after fixation. A lymph node set was considered macroscopically invaded
if its total mass exceeded 30 mg (by histology, typically >80% of the node is tumor material at this size).
Lymph node sets smaller than 30 mg could not be reliably weighed, and were given a mass of 10 mg and
sectioned. Two sections at different levels were obtained for each node, percent invasion was scored
blindly by a pathologist (Dr. Roderick T. Bronson, R.T.B.), and the higher of the two scores was recorded
for each lymph node. To quantitate lung metastases, the five lobes of the lung were removed after
fixation and randomly minced into -20 pieces. These were then paraffin-embedded, sectioned for
histology at three different levels, and stained by hematoxylin-eosin (H&E). The lung sections at each of
the three levels were examined under microscopy. Tumor cells in the lung were clearly evident, often as
small, dysplastic cell clusters bearing grossly expanded nuclei relative to the lung stroma. A single lung
metastasis was defined as a cluster of at least 3 tumor cells, and the approximate size of each cluster
was recorded: 3-5 cells; 6-10 cells; 11-20 cells; 21-50 cells; or greater than 50 cells. The number of lung
metastases in each mouse was expressed as the sum total of micrometastases observed in the three
sections.
Derivation of Cell Lines (for SOI)
At the time of sacrifice, mice were sprayed down with 70% ethanol. Sterile dissection scissors and
forceps were used to remove the lobes of the lung. The tissue was placed over a 70 um nylon cell
strainer (Becton Dickinson), and, together, these were placed in a 60 mm tissue culture plate containing
complete PC-3 media. Cell straining was accomplished by working the back (blunt) end of a pair of
sterile forceps against the tissue into the nylon mesh. This was done repeatedly until the lung material
was mostly dissociated. The entire procedure was performed in a sterile fume hood, and cells were
grown under normal tissue culture conditions.
Quantitation of Circulating Blood Tumor Cells (for SOl)
Immediately after sacrifice, the tumor-bearing mouse was placed ventral-side up in a fume hood and
cleaned with alcohol wipes. Approximately 0.5-1.0 ml of blood was withdrawn by cardiac puncture from
the right ventricle of the heart, using a 1 ml syringe capped with a 16-gauge needle, inserted at a 30
degree angle into the right lower portion of the rib cage. The blood was immediately transferred into a
Vacutainer (Becton Dickinson) blood collection tube and mixed. From this, 100 ul of blood was removed
and divided between two 10 cmA2 plates containing 10 ml of normal PC-3 cell culture medium. These
cultures were then incubated, undisturbed, for seven days. Afterwards, the plates were gently washed
twice with PBS containing calcium/magnesium to remove the unattached red blood cells and debris. The
remaining cells were fixed on the plate with 3.7% formalin and stained with 0.1% crystal violet solution for
20 minutes. The dye was subsequently removed, and the plates were washed three times with PBS.
Individual tumor colonies appeared as macroscopic spots on the plate, and each colony was confirmed
by visual inspection under a light microscope. The number of confirmed cell colonies was added for the
two plates and expressed as the number of tumor cells circulating in 100 ul of mouse blood at the time of
sacrifice.
Immunohistochemistry - Blood Vessels and Lymphatics
For immunohistochemistry, 2-3 mm thick portions were removed near the periphery of the anterior-facing
end of the tumor. For wild-type and TRAMP prostates, the dorsolateral lobes were dissected. In most
cases, the tissue was fixed in zinc (Becton Dickinson) for 48 hours. For short-term orthotopic analysis,
prostate tissue was fixed in 3.7% formalin overnight. Primary antibodies for immunohistochemistry
included rabbit anti-LYVE-1 (Ruoslahti lab; 1:450)[Laakkonen et al., 2002], goat anti-mouse VEGFR-3
(Clone AF743, R&D Systems, Minneapolis, MN; 1:25) and rat anti-CD34 (Clone RAM34; Becton
Dickinson-Pharmingen; 1:25). Sections were de-waxed, microwaved in Retrievagen buffer (Becton
Dickinson), and stained using standard protocols. Biotin-conjugated secondary antibodies included swine
anti-rabbit Ig (Dako, Glostrup, Denmark) and rabbit anti-rat Ig (Vector Labs; Burlingame, CA), both diluted
1:250. Staining was amplified with Vectastain ABC kit (Vector Labs), developed with Vector VIP
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peroxidase substrate and counter-stained with methyl-green. Lymphatic and blood vessels were
quantitated by counting the number of LYVE-1- or CD34-positive vessels, respectively, in two random,
low-power fields (2.25 mm X 1.7 mm) per tumor. About 30-100% of the tumor area is covered with this
approach, and the LVD from a minimum of seven independent tumors was typically quantitated for each
cell line. In TRAMP and normal prostates, a single low-power field was used for lymphatic quantitation,
typically covering 70-100% of the sample. TRAMP tumor grading was based on a system described by
Hurwitz et al[Hurwitz et al., 2001]. Two pathologists (Dr. Marc Barry (M.B.) and R.T.B.) independently
graded H&E TRAMP sections, and then together arrived at an agreed-upon grade. For short-term SOI
analysis, the length of the tumor periphery at 105X final magnification was quantitated in pixel units by
OpenLab software (Improvision Inc.; Lexington, MA), and the number of lymphatics at the periphery was
normalized to a 1,000 pixel perimeter. We defined "intratumoral" lymphatics as LYVE-1-positive vessels
completely surrounded by tumor cells, and "marginal" or "peritumoral" lymphatics as vessels in contact
with both tumor cells and stroma. For detailed instructions for staining vasculature, please refer to
Appendix D.
TRAMP Mice
Prostate cancer-prone transgenic adenocarcinoma of the mouse prostate (TRAMP) mice expressing
SV40 large T antigen in the prostate were generated by Dr. Norman Greenberg (Fred Hutchinson Cancer
Research Center, Seattle, WA)[Greenberg et al., 1995] and obtained from Dr. Ailin Bai, from Dr. Jianzhu
Chen's lab. The mice were maintained in a pure C57BL/6 background. 4.1B -1-mice were generated by
and obtained from Dr. Joseph Kissil (formerly at MIT, currently at the Wistar Institute, Philadelphia, PA)[Yi
et al., 2005], and were back-crossed into a C57BL/6 background for 2-3 generations. SPARC-/- mice
were obtained from Dr. E. Helene Sage (Hope Heart Institute, Seattle, WA)[Norose et al., 2000] and were
of a mixed background. Primer sequences for genotyping were as follows:
TRAMP: TR-For 5'-CCGGTCGACCGGAAGCTTCCACAAGTGCATTTA-3'
TR-Rev 5'-CTCCTTTCAAGAC CTAGAAGGTCCA-3'
Casein: Cas-For 5'-GATGTGCTCCAGGCTAAAGTT-3'
Cas-Rev 5'-AGAAACGGAATGTTGTGGAGT-3'
4.1 B: G2 5'-CGCCACCGTCTGAGCAGC-3'
G4 5'-GCACGTTTGGTAGCAGTTCCC-3'
PURO-1 300 5'-GCACGACCCCATGCATCG-3'
SPARC: S-For 5'-TCTTTCTTGCAACCCTCTCC-3'
S-Rev 5'-ATTCTCCCATTTCCACCTGG-3'
Neomycin: Neo-For 5'-CTTGGGTGGAGAGGCTATTC-3'
Neo-Rev 5'-AGGTGAGATGACAGGAGATC-3'
For detection of the TRAMP transgene, the TR-For, TR-Rev, Cas-For and Cas-Rev primers was
combined equally, and genomic DNA from mouse ears was amplified with the PCR cycles enumerated
below. The casein positive control should yield an amplification product of 500 bps., while the TRAMP
transgene should yield a product of 600 bps.
TRAMP/Cas Step 1. 94 degrees Celsius, 10 min.
Step 2. 94 degrees Celsius, 1 min.
Step 3. 60 degrees Celsius, 2 min.
Step 4. 72 degrees Celsius, 3 min.
Step 5. Repeat steps 2-4, 30 cycles
Step 6. 72 degrees Celsius, 5 min.
For detection of 4.1 B, a combination of the G2 + G4 primers should yield an amplification product of 300
bps. for wild-type, but no amplification product for the knock-out allele. A combination of the G2 and
PURO-1300 primers should yield an amplification product of 700 bps. for the knock-out allele, and no
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amplification product for wild-type. In most cases, based on our mating scheme (which generated either
4.1B heterozygous or knock-out mice), we multiplexed the G2, G4, TR-For, TR-Rev, Cas-For and Cas-
Rev primers in a single reaction using TRAMP amplification cycles. Heterozygous mice yielded an
amplification product of 300 bps.; knock-out mice yielded no amplification product.
4.1B Step 1. 94 degrees Celsius, 10 min.
Step 2. 92 degrees Celsius, 2 min.
Step 3. 54 degrees Celsius, 1 min.
Step 4. 72 degrees Celsius, 45 sec.
Step 5. Repeat steps 2-4, 30 cycles for G2/G4; 34 cycles for G2/Puro
Step 6. 72 degrees Celsius, 10 min.
(The TRAMP/Cas amplification cycles can also be used)
For detection of SPARC, a combination of the S-For, S-Rev, Neo-For and Neo-Rev primers were used.
After amplification with the cycles enumerated below, SPARC wild-type DNA should yield a product of
121 bps; heterozygous DNA, 121 and 280 bps; and knock-out DNA, 280 bps. In practice, wild-type DNA
also often yielded a weak amplification product of size 280 bps, as shown below:
SP+/+ SP+/- SP-/-
280 bps
121 bps
The amplification cycles are enumerated below:
SPARC Step 1. 94 degrees Celsius, 10 min.
Step 2. 94 degrees Celsius, 20 sec.
Step 3. 64 degrees Celsius, 30 sec.
Step 4. 72 degrees Celsius, 35 sec.
Step 5. Repeat steps 2-4, 4 cycles
Step 6. 94 degrees Celsius, 20 sec.
Step 7. 62 degrees Celsius, 30 sec.
Step 8. 72 degrees Celsius, 35 sec.
Step 9. Repeat steps 6-8, 4 cycles
Step 10. 94 degrees Celsius, 20 sec.
Step 11. 58 degrees Celsius, 30 sec.
Step 12. 72 degrees Celsius, 35 sec.
Step 13. Repeat steps 10-12, 29 cycles
Step 14. 72 degrees Celsius, 2 min.
The following mating scheme was used to generate male experimental 4.1 B/TRAMP mice:
TRAMP*-4.1B *1* x 4.1B /' - TRAMP+'4.1B+. ' (first generation)
TRAMP÷-4.1B * - x 4.1B-' - TRAMP*/-4.1B+ /' or TRAMP'4.1B / (experimental mice)
SPARC-TRAMP mice were generated in a similar manner. Mice were analyzed in their 26 th week of age,
or earlier if they appeared moribund. The urogenital system (bladder, seminal vesicles and all lobes of
the prostate) was dissected in bulk and weighed. The para-aortic/lumbar lymph nodes and all visceral
organs were also removed, and all organs were preserved in either formalin or zinc fixative. Individual
ventral or dorsal lobes of the prostate were later isolated under a dissecting microscope, sectioned for
histology and stained by H&E. All prostate sections were graded on a scale of 1-6, according to the
system described by Hurwitz et al, and were evaluated by R.T.B. and M.B.[Hurwitz et al., 2001]. All
grading was performed blindly, using coded sections. In all cases, palpable tumors were found by
histology to consist of undifferentiated Grade 6 carcinomas. In two cases, non-palpable microscopic foci
of Grade 6 carcinoma were detected upon sectioning. For each section, a highest grade was assigned
based on the area of greatest pathological severity in each section. A predominant grade was assigned
based on the most common grade seen in each section.
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MMTV Mice
Mammary carcinoma-prone polyoma middle T (PyMT or MMTV) mice expressing SV40 large T antigen in
the mammary glands were obtained from Dr. Lei Xu. The mice were obtained in an FVB background and
genotyped using MMTV primer sets with the aid of ReddyMix PCR Master Mix (AbGene, Rochester, NY).
Primer sequences and PCR conditions are described below:
MMTV: IMR0384 5'-GGAAGCAAGTACTTCACAAGGG-3'
IMR0385 5'-GGAAAGTCACTAGGAGCAGGG-3'
Step 1. 94 degrees Celsius, 4 min.
Step 2. 94 degrees Celsius, 30 sec.
Step 3. 62 degrees Celsius, 30 sec.
Step 4. 72 degrees, Celsius, 30 sec.
Step 5. Repeat steps 2-4, 31 cycles
Step 6. 72 degrees, Celsius, 5 min.
The presence of the MMTV transgene results in an amplification product of 550 bps. MMTV mice
deficient or heterozygous for SPARC were generated in the following mating scheme:
MMTV +SPARC+'+ x SPARC' - MMTV+/'SPARC' /- or MMTV/'SPARC . /  (first generation)
MMTV+/SPARC +/- x SPARC& - MMTV'SPARC *'- or MMTV'-SPARC v  (experimental)
Beginning in their 10 th week of age, mice were visually inspected twice a week for macroscopic tumors in
any of their ten mammary glands. Mice were sacrificed and analyzed four weeks after the date when the
first macroscopic tumor was detected. Each of the mammary glands was removed and weighed, then
fixed in formalin. The lungs were inflated and preserved in formalin, and macroscopic lung metastases
were counted under a dissecting microscope.
Proliferation, Apoptosis, Cytokeratins and STEAP
Zinc-fixed prostate lobes from TRAMP mice, and formalin-fixed lymph nodes from mice implanted by SOI
were stained with Ki67 antibody (Sigma) for proliferation and/or by TUNEL for apoptosis (ApopTag Plus
apoptosis detection kit, Chemicon, Temecula, CA). Grade-, age- and lobe-matched TRAMP sections
were quantitated by counting the number of positively stained cells, as well as the total number of cells,
from two different fields per section imaged at 20X magnification, except for Grade 5 sections, which were
imaged at 40X magnification. Grade 4 sections were all derived from the ventral lobes of the prostate,
while Grade 5 sections were all derived from dorsolateral lobes. All staining, image capturing with
OpenLab 5.0.0 software (Improvision), and quantitation were blindly performed, using 4-5 independent
prostate samples per genotype. For cytokeratin staining, zinc-fixed prostate or formalin-fixed lymph node
sections were stained with rat anti-cytokeratin 8 antibody (clone TROMA-1, 1:250, which detects luminal
cells), originally developed by Brulet et al. (Developmental Studies Hybridoma Bank, Iowa City, IA)[Brulet
et al., 1980]; and/or with rabbit anti-cytokeratin 5 antibody (1:5,000, detects basal cells) (Covance,
Princeton, NJ). Rabbit anti-STEAP antibody (Zymed Laboratories, San Francisco, CA) was used at a
dilution of 1:100.
MOLECULAR BIOLOGY
Overexpression Plasmids
The human 4.1 B coding sequence was originally inserted into pcDNA3.1/myc-His vector (Stratagene,
Cedar Creek, TX) by Dr. Joseph McCarty (J.M., formerly at MIT, currently at M. D. Anderson Cancer
Center), using the 5'-BamHI and 3'-Xhol restriction sites, as an in-frame fusion with the myc-His6 tag
coding sequences at the 3' end. The human integrin P8 coding sequence was inserted into
pcDNA3.1N5-His vector (Stratagene) by J.M., using the 5'-BamHI and 3'-Xhol restriction sites, as an in-
frame fusion with the V5-His6 tag coding sequences at the 3' end. The FIt4-lg expression plasmid
(originally "VEGFR-3-lg/pEBS7") was obtained from Dr. K. Alitalo (University of Helsinki, Helsinki,
Finland)[He et al., 2002; Karpanen et al., 2001]. Ig-Neg control plasmid was made by removing the Fit4
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coding sequence and re-annealing the empty vector. A plasmid expressing human VEGF-A (isoform
165, cDNA cloned between EcoRV and BamHI restriction sites), and containing LacZ and Hygromycin
resistance marker ("H165Z") was obtained from Dr. P. D'Amore (Harvard Medical School, Boston, MA).
In addition, an ecotropic receptor-expressing plasmid was obtained from Dr. H. Lodish, MIT. All transient
and stable transfections were performed on adherent cells using Effectene reagent (Qiagen, Valencia,
CA), according to manufacturer's protocols. In the case of FIt4-Ig/Ig-Neg, transfected cells were selected
with 100-200 ug/ml Hygromycin for -3 weeks for stable expression. For the ecotropic receptor,
transfected cells were selected with 800 ug/ml of G418/neomycin for -2-3 weeks.
Tet-Inducible Plasmids
For Tet-induction studies, a retroviral vector expressing trans-activator protein (MSCV-rtTA 1-02G,
obtained from Dr. Patrick Stern (P.S.)) was first transfected with Effectene reagent into Phoenix cells,
from which retroviral supernatant was obtained and used to infect PC-#82 cells expressing ecotropic
receptor. This vector has no selectable marker; instead, infected cells were sorted for GFP expression.
The genes to be inducibly overexpressed were cloned into either the retroviral vector pRevTRE
(Clontech, Mountain View, CA), which contains a hygromycin-resistance marker; or into the lentiviral
vector "Tet-ON" (adapted by P.S. from pRevTRE), which contains a puromycin-resistance marker. The
entire 4.1B-myc-His coding sequence was inserted into Tet-ON using the 5'-Xmal and 3'-EcoRI restriction
sites to generate 4.1B-Tet-ON, while the entire p8-V5-His coding sequence was inserted into pRevTRE
using the 5'-BamHI and 3'-Hpal restriction sites to generate 38-TRE. As controls, pRevTRE containing
the luciferase coding sequence was obtained (Luc-TRE, Clontech) and Tet-ON containing the red
fluorescence protein coding sequence was obtained from P.S. (RFP-Tet-ON). pRevTRE retrovirus
generation involved transfection of the viral plasmid into Phoenix cells, as described previously. Tet-ON
lentivirus generation utilized 293 cells from P.S. and involved co-transfection of the following lentiviral
components (all obtained from P.S.) in the following ratios:
3 gag/pol : 2 VSVg-env : 1 RSV-rev : 6 Tet-On plasmid (2 ug total DNA)
Co-transfections were performed using Effectene reagent, and media were replaced after overnight
incubation at 37 degrees Celsius. Lentivirus-containing supernatant was obtained after another 24-48
hours incubation at 37 degrees Celsius, and used for infection of PC-#82 cells expressing trans-activator
protein. Cells infected with Tet-ON vectors were selected with 2.5 ug/ml puromycin for -1-2 weeks, while
those infected with pRevTRE vectors were selected with 400 ug/ml Hygromycin for -3 weeks.
siRNA Plasmids and Sequences
All siRNAs were inserted into the retroviral vector pSIRISP (W.C. Hahn, Dana Farber Cancer Institute,
Boston, MA)[Masutomi et al., 2003]. The siRNA plasmids were transfected with Effectene into Phoenix
cells (ATCC), and the secreted virus was subsequently used for stable infection of PC3-#82 cells
expressing ecotropic receptor. After infection, cells were selected on puromycin for stable siRNA
expression. All siRNAs were synthesized as long oligonucleotides in the following hairpin configuration:
forward oligo: 5'-CCGGT-(19 bp. sense)-TTCAAGAGA-(19 bp. anti-sense)-TTTTTG-3'; reverse
oligonucleotide: 5'-AATTCAAAAA-(19 bp. sense)-TCTCTTGAA-(19 bp. anti-sense)-A-3'. The
oligonucleotides were annealed and then inserted into the retroviral vector pSIRISP, digested with Agel
and EcoRI. The 19 base-pair siRNA sequences or controls used in this study were as follows:
Against human Protein 4.1B (only 19 bp. core sense sequences shown):
DL1: 5'-GCAATTAGAAGACGATAAA-3'
DL2: 5'-CGAGCTGCCAAGCGTTTAT-3'
DL3: 5'-TCTCGATGGATCAGAATAT-3'
DL4: 5'-GCTCGAATATCAGCAATTA-3'
Against mouse Protein 4.1B (only 19 bp. core sense sequences shown)
mDL1: 5'-CCAGTGGTCTGTTGATATA-3'
mDL2: 5'-CCAAAGTAGTAGTCCATAA-3'
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mDL4: 5'-CGTGACCGGCTTCGAATAA-3'
Against human VEGF-C (only 19 bp. core sense sequences shown)
C13: 5'-ACTGGATGTTTACAGACAA-3'
C14: 5'-GTTCATTCCATTATTAGAC-3'
C14-MM: 5'-GTTCATTCCACCATTAGAC-3'
Against human VEGF-A (only 19 bp. core sense sequences shown)
A2: 5'-GTGAATGCAGACCAAAGAA-3'
A3: 5'-GGAGTACCCTGATGAGATC-3'
A3-MM: 5'-GGAGTACCCACATGAGATC-3'
Against GFP (negative control, only 19 bp. core sense sequences shown)
GFP: 5'-CAAGCTGACCCTGAAGTTC-3'
Real-time PCR / RNA Quantitation
Total RNA was extracted using RNeasy (Qiagen). RNA was digested with DNase (Ambion; Austin, TX),
then re-cleaned with RNeasy. 1 ug of total RNA was reverse-transcribed into cDNA using TaqMan
Reverse Transcription Reagent (Applied Biosystems; Branchburg, NJ). cDNAs were analyzed by
quantitative PCR using SYBR Green PCR amplification kit (Applied Biosystems), measured in a Biorad
iCycler (Hercules, CA). Target-gene message levels were normalized to GAPDH levels, and then to the
control sample. The following primer pairs were used for real-time PCR:
Human 4.1 B: Forward 5'-GCACAGATCTGGAGCCAGGC-3'
Reverse 5'-CTGGTCATGGTCAATGTCTGCA-3'
Human SPARC: Forward 5'-GAGAGCGCGCTCTGCCTGCCG-3'
Reverse 5'-CACCACCTCTGTCTCATCAGGC-3'
Human VEGF-C: Forward 5'-GCCAATCACACTTCCTGCCGA-3'
Reverse 5'-GTTCGCTGCCTGACACTGTGG-3'
Human VEGF-A: Forward 5'-CACTGAGGAGTCCAACATCAC-3'
Reverse 5'-TTCTTGTCTTGCTCTATCTTTCTTTG-3'
Human GADH: Forward 5'-GGAAGGTGAAGGTCGGAGTC-3'
Reverse 5'-CTGGAAGATGGTGATGGGATTTC-3'
Extraction of Tumor RNA and Preparation of Biotinylated cRNA for Microarray Hybridization
Detailed instructions for preparing biotinylated cRNA for hybridization to Affymetrix U133A arrays can be
found below in the "Bioinformatics" section and in Appendix C.
CELL BIOLOGY (IN VITRO)
Growth Curves
Growth curve experiments were performed in either of two ways. For doxycycline induction studies,
1,000 cells were plated on Day 0 in 6-well tissue culture plates. On Day 1, and every other day
subsequently, medium +/- 3 ug/ml doxycycline (Clontech) was added. Manual cell counts by
hemocytometer were performed 6-7 days after induction. Proliferation was also assessed using the
CellTiter 96 proliferation reagent (Promega, Madison, WI) in 96 well plates, where 500 cells were plated
on Day 0 and incubated in the presence or absence of serum or other medium components. Substrate
formation as a function of cell density was assessed after 3 hours incubation at 37 degrees Celsius, with
a VersaMax microplate reader (Molecular Devices, Sunnyvale, CA) at a wavelength of 490 nm. In some
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cases, cell growth was confirmed by staining plates with crystal violet, similar to the method for detecting
blood tumor colonies described previously.
Ploidy Experiments
Tissue culture cells were released with trypsin, washed with PBS and counted. 500,000 cells were
pelleted and re-suspended in 1 ml of 70% ethanol, then incubated overnight at 4 degrees Celsius. The
next day, the cells were pelleted and re-suspended in 1 ml of fresh propidium iodide staining solution (10
mg/ml propidium iodide (Sigma) and 100 units/ml RNase A (New England Biolabs, Ipswich, MA) mixed in
water), then incubated for 30 minutes at room temperature. Cells were then washed twice with PBS and
analyzed by FACScan (Becton Dickinson).
Soft Agar Assay
In a 24-well plate, wells were coated with 500 ul of media containing 0.8% agar, and this was allowed to
solidify at room temperature. Tissue culture cells were released with trypsin, and equalized to a
concentration of 20,000 cells/ml. This suspension was mixed 1:1 with media containing 0.8% agar (final
concentration = 0.4% agar), and 500 ul of this mix were plated over the denser base and allowed to
solidify. Cell colonies were observed under a light microscope over a two-week period.
Immunofluorescence
For detection of 4.1B protein in TRAMP cells, cells were grown in 8-well Lab-Tek Permanox slides (Nalg
Nunc International, Rochester, NY), fixed in 3.7% formalin, permeabilized with 0.3% Triton/PBS and
probed with rabbit anti-4.1B-PE (1:1,500, 30 minutes at room temperature) (Protein Express, Chiba,
Japan). Subsequently, the cells were probed with Alexa Fluor 488-conjugated goat anti-rabbit antibody
(1:100, 30 minutes) (Molecular Probes-Invitrogen, Carlsbad, CA). For detection of the V5 and myc
epitope tags, cells were prepared similarly to above and stained with mouse anti-V5 (1:1,000) or anti-myc
(1:200) (Invitrogen), then detected with Alex Fluor 594-conjuated goat anti-mouse antibody (1:200)
(Molecular Probes-Invitrogen). A rabbit antibody against the MHC Class I antigen HLA-A,B,C (Becton
Dickinson) was used at a dilution of 1:100 to stain all human cells, while a monoclonal antibody against
the MHC Class I antigen H-2Kb/H-2Db (Becton Dickinson) was used at a dilution of 1:100 to stain all
mouse cells.
Inducible Overexpression
Normal growth medium containing 3 ug/ml of doxycycline was added to cells and replaced every 48
hours. Induced gene/protein expression was assayed, > 72 hours after induction.
BIOCHEMISTRY
Immunoblotting
Soluble FIt4-lg was detected by immunoprecipitating conditioned media with Protein A beads (Invitrogen).
The beads were spun, washed and boiled in Laemmli SDS buffer containing 5% P-mercaptoethanol
(Sigma). The protein was run on 8% SDS gel and detected with goat anti-human VEGFR-3 antibody
(Clone AF349; 1:100 diluted; R&D Systems) or rabbit anti-human antibody conjugated to horse-radish
peroxidase (Dako; 1:1000 diluted). Tumor Flt4-lg was detected in tumors by homogenizing in CelLytic-
MT lysis buffer (Sigma), and running supernatant on SDS-PAGE. Antibodies against 4.1 Proteins used
for Western blot included rabbit anti-4.1B (JM)[McCarty et al., 2005]; and rabbit anti-4.1 B (PE), anti-4.1G
and anti-4.1N (all diluted 1:500, Protein Express). Total soluble protein was extracted from tissue culture
cells, or from homogenized frozen tumors or fresh tissue lysates, in NP-40 lysis buffer (50 mM Tris 7.4,
150 mM NaCI, 1% NP-40, 5 mM EDTA) containing protease inhibitor cocktail (Roche, Mannheim,
Germany), then reduced in Laemmli buffer containing 5% P-mercaptoethanol, and separated by 8% SDS-
PAGE. For SPARC, the monoclonal antibody ON1-1 (Zymed Laboratories) was utilized. Detection of
epitope tags was accomplished with monoclonal antibodies against V5 or Myc (1:500, Invitrogen). The
monoclonal GAPDH antibody was obtained from Chemicon. For total soluble protein quantitation, the
Micro BCA Protein Assay kit (Pierce, Rockford, IL) was used.
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VEGF-C and VEGF-A Protein Quantitation
5 X 10^5 PC3-#82 cells were plated into 10 cmA2 plates and grown for 72 hours. Media were replaced,
conditioned for the times specified, collected and spun to remove debris. Frozen subcutaneous and
orthotopic tumors were thawed and homogenized in 1 ml cold CelLytic-MT lysis buffer per gram tumor
material. Lysis buffer contained protease inhibitors (Roche). After homogenization, the lysate was chilled
for > 30 minutes, then spun to remove debris. Total soluble protein was quantitated by BCA protein
assay to normalize ELISA results. The supernatant was diluted 1:4 or 1:10 in PC-3 medium for ELISA.
200 ul of diluted tumor supernatant or undiluted conditioned media were analyzed by human VEGF-A
Quantikine ELISA (R&D Systems); 100 ul of the same were analyzed by human VEGF-C ELISA (IBL,
Tokyo, Japan).
Co-Immunoprecipitation (Co-IP) of Integrin 08 and 4.1B
PC-3 #82-Eco cells were grown to -60% confluence in a 10 cmA2 cell culture plate. The cells were then
transiently co-transfected by Effectene reagent with two of the following plasmids (2 ug of DNA each, 4 ug
total): 4.1 B-myc-pcDNA3.1, integrin P8-V5-pcDNA3.1, lacZ-myc-pcDNA3.1, 4.1B-CTD-myc-pTag3B
and/or 4.1B-FERM-myc-pcDNA3.1. Transfections were performed according to manufacturer's
directions, with the following modifications: DNA and EC transfection buffer were combined in a final
volume of 400 ul, and 32 ul of Enhancer reagent and 100 ul of Effectene reagent were subsequently
added to this mixture. Cells were cultured overnight at 37 degrees Celsius, after which the medium was
replaced, and allowed to incubate for an additional 48 hours. Total cell lysates were extracted with 700 ul
of NP-40 lysis buffer containing protease inhibitors. The lysates were cleared by centrifugation, and the
supernatant was further pre-cleared by incubating with two rounds of unconjugated, equilibrated Protein-
G agarose beads (Invitrogen) for one hour each at 4 degrees Celsius. Meanwhile, monoclonal antibodies
against the V5-epitope tag were conjugated to equilibrated Protein-G agarose beads, using 2 ug of
antibody per co-IP reaction. The antibody-conjugated beads were then added to the twice-pre-cleared
protein supernatant and allowed to incubate overnight at 4 degrees, under steady rotation in a 1.5 ml
Eppendorf tube (Eppendorf, Westbury, NY). The next day, the beads were pelleted by centrifugation and
washed four times with PBS. After the final wash, the beads were resuspended in 30 ul of hot 2X
Laemmli buffer containing 5% P-mercaptoethanol and boiled for 5 minutes. The sample was then
electrophoresed in 8% or 13% SDS-PAGE gels; transferred to Protran BA85 nitrocellulose membrane
(Whatman Inc, Florham Park, NJ); and probed using an anti-myc monoclonal antibody, diluted 1:500, and
subsequently, with a horseradish peroxidase-conjugated anti-mouse secondary antibody, diluted 1:2,000.
BIOINFORMATICS
Microarrays and Bioinformatics
For a detailed description of the preparation of cRNA from tumor material, please refer to Addendix C.
Briefly, total RNA was extracted from flash-frozen subcutaneous tumors (of approximate mass 130-250
mg) using the RNeasy Midi isolation kit (Qiagen). DNA contamination in the preparation was then
removed by DNase digestion (Ambion), and the RNA sample was re-cleaned using the RNeasy Mini kit
(Qiagen). Between 1-3 ug of total RNA was electrophoresed to check for sample integrity, as assessed
by the relative intensity levels of the 26S and 16S RNA bands. Total RNA was reverse-transcribed using
Superscript II reverse transcriptase (Invitrogen), primed with a poly-dT-24 primer, according to Affymetrix
protocols. Second-strand synthesis was performed with DNA polymerase I (Invitrogen), also according to
Affymetrix protocols. The resulting cDNA was purified using Qiagen's PCR purification kit. In vitro
transcription was then performed using the ENZO BioArray RNA transcript labeling kit (Enzo Life
Sciences, Farmingdale, NY), following standard protocols, which produced biotin-labeled cRNA. This
cRNA was subsequently purified using the RNeasy mini kit, and the yield and quality were assessed.
Finally, the cRNA was fragmented and submitted to the Biopolymers core facility for hybridization to
U133A chips (Affymetrix, Santa Clara, CA). Hybridization intensity levels were assessed with the aid of a
GeneArray 2500 scanner (Affymetrix). Data analysis was performed using D-Chip software (Harvard
Medical School, Boston, MA) and, with the help of Dr. Steve Shen, using Gene Pattern 2.0.2 (The Broad
Institute, Cambridge, MA). Oncomine analyses were performed on August 2006, using Oncomine 3.0 at
www.oncomine.org (University of Michigan, Ann Arbor, MI).
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Additional Gene Expression Data-Sets
In most cases, gene expression data from prostate cancer datasets were obtained from the Oncomine
website. In the case of the van't Veer et al. breast cancer study [Veer et al., 2002], gene expression
results were obtained from Dr. Marcel Smid (Josephine Nefkins Institute, Rotterdam, The Netherlands)
who had processed the data using the program Venn Mapper [Smid et al., 2003]. Additional human
clinical patient data from that study were downloaded from the Rosetta Inpharmatics website:
http://www.rii.com/publications/2002/vantveer.html. In the case of the Dhanasekaran et al. prostate
cancer study [Dhanasekaran et al., 2001], gene expression data were downloaded from the
Supplementary Info section at the Nature website: www.nature.com. The A375 melanoma gene
expression data-set was obtained from Dr. Lei Xu from our lab. In some cases, visualization of gene
expression from these data-sets was performed using Tree View 1.60 software (University of California
Berkeley, Berkeley, CA).
Statistics
In most cases, statistics were performed using an unpaired Student's t-test
(http://www.physics.csbsju.edu/stats/llndex.htmI), except in the case of TRAMP tumor incidence data,
which were assessed by Chi-Square (http://www.psych.ku.edu/preacher/isq/chisq.htm). Box plots were
generated after data entry online at: http://www.physics.csbsiu.edu/stats/Index.html. All error bars
shown, +/- SE.
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APPENDIX B. SURGICAL ORTHOTOPIC IMPLANTATION (SOI)
December 1, 2006
All surgical tools are autoclaved or baked overnight prior to surgery, and all manipulations are performed
under sterile conditions in a laminar flow hood. Preferably, keep a set of tools for surgery use only. The
following materials are needed to prepare the tumor fragments for implantation (in most cases, these
materials can be obtained from Samuel Perkins, Inc. (Quincy, MA)):
Dissecting microscope and light source
3 pairs of Dumont jeweler's forceps (#5)
1 pair of dissection scissors (RS-5910; Roboz, Germany)
1 pair of standard forceps
Bard-Parker disposable scalpels (#11) (Becton Dickinson)
F-12K medium (Kaign's modification, Gibco-lnvitrogen)
L-Glutamine (200 mM stock, Gibco-lnvitrogen)
HEPES buffer (1 M stock, Gibco-lnvitrogen)
Phosphate-buffered saline
2 buckets of ice
4 60 mmA2 tissue culture plates
1 Bunsen burner and lighter
70% ethanol
Prior to the procedure, prepare the media as follows: combine 37.5 ml of F-12K medium, 0.5 ml of
glutamine and 12 ml of HEPES. Fill three 60 mmA2 plates with PBS and one plate with media. Chill on
ice. For all subsequent manipulations, sterilize dissecting tools by flaming. Following sacrifice of a
subcutaneous tumor-bearing mouse, lay the animal tumor-side up and spray with ethanol to sterilize the
dissection site. Pinch the skin above the center of the tumor using a pair of standard forceps and begin
cutting away the skin underneath with a pair of dissection scissors. In most cases, the skin should
separate easily from the rest of the tumor. Cut away the muscular tissue between the tumor and the rib
cage, extract the tumor and deposit in one of the plates of PBS. All subsequent manipulations are
visualized under a dissecting microscope set at low magnification. Clean the tumor of stray adipose,
muscle and skin tissue using fine jeweler's forceps. Move the cleaned tumor into a second plate of PBS.
In most cases, the tumor should be oval-shaped at this point. As shown in Figure A, make a cross-
section cut through the tumor approximately 3-4 mm from one end. Afterwards, make a second cross-
section cut 1 mm from the newly formed edge. What should result is a flat circular wedge, 1 mm thick.
Confirm that the tissue appears healthy and free of discoloration, and move this wedge into the third plate
of PBS. From this wedge, peel away the outer, fibrous capsular layer surrounding the periphery of the
tumor using the jeweler's forceps. Next, grip the tumor with the forceps and use the scalpel to cut cubes
of solid tumor material with dimensions of about 1 mmA3. These cubes should then be moved into the
final plate containing the media prepared above.
For surgical orthotopic implantation of these pieces, the following tools are needed:
1 stainless steel instrument tray
3 pairs of Dumont jeweler's forceps (#5)
2 pairs of dissection scissors (RS-5910; Roboz, Germany)
2 pairs standard forceps
1 pair of skin retractors (SC02; Roboz, Germany)
1 pair Iris forceps (Half curved)
1 Castroviejo needle holder (RS-6403; Roboz, Germany)
9-0 Ethilon black monofilament nylon sutures with a BV130-4 Tapered needle
(#2813G, Ethicon)
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5-0 Sofsilk braided silk sutures with a C-1 cutting needle
(#S-1173, United States Surgical, Norwalk, Connecticut)
Dissecting microscope and light source
Lab diapers
Alcohol prep pads (Dynarex, Orangeburg, NY)
PVA surgical spears (Allegiance Healthcare Corp., McGaw Park, IL).
500 ml 70% ethanol
Heating pad
1 ml syringes capped with 26-3/8 gauge needles (Becton Dickinson)
Avertin/tribomethanol (Sigma)
30 ug/ml Buphrenephrine (MIT Division of Comparative Medicine)
Set up the surgical area. Place the instrument tray containing the surgical tools in the hood, as well as
the microscope and light source. Place the heating pad on the microscope stage, and overlay with a lab
diaper. Anesthetize the mouse (30-35 days of age) by intraperitoneal injection of avertin/tribomethanol1 .
Wipe down the abdomen with alcohol pads and lay the animal on its back with its head facing towards
you. Pinch and lift the outer skin, as shown in Figure B, with a pair of standard forceps and make a
midline incision using dissection scissors until reaching the top of the Cowper's glands. Now pinch and
lift the peritoneum layer in a similar manner and make a midline incision through this layer, exposing the
visceral organs. Insert skin retractors underneath the peritoneum on both sides of the midline incision.
Use surgical spears to gently lift out the urogenital system (Figure C). The dorsal prostate (DP) is a clear,
glandular, triangular piece of tissue located just beneath the point where the seminal vesicles meet. The
DP is deeply buried but should be lifted to face upwards during the dissection, and kept in place the entire
time using surgical spears held in one hand.
Make a single 9-0 suture near the right edge of the right lobe of the DP (Figure D(a)). Next, use the
jeweler's forceps to make a small pocket in the tissue (yellow oval), adjacent to the site of the suture
(Figure D(b)). This is accomplished by working the tip of the forcep back and forth against the tissue until
a small gap forms. Next, use the forceps to insert the tumor fragment into the pocket (Figure D(c)),
burying it inside the prostate tissue (Figure D(d)). Take hold of the free end of the needle attached to the
9-0 suture, and make a second suture on the other side of the implant (Figure D(e)). Ideally, the suture
should cross over the middle of the pocket containing the implant. Finally, take hold of both free ends of
the suture and draw the two ends together (Figure D(f)). The tissue to each side of the implant should
come together (arrows). Secure with a knot, as depicted in Figure D(g) and D(h). A side view of this
procedure, before and after the implant is secured, is shown in Figure D(i) (beige - prostate; gray - tumor;
red - suture; arrow-head - needle).
After implanting the tumor, use surgical spears to push the visceral organs back into the abdomen. Close
the inner peritoneum layer using a row of 5-0 sutures. Drip buphrenephrine along the wound site, and
subsequently, close the overlying skin layer using a second row of 5-0 sutures. Wipe down the surgical
site with alcohol pads and return the mouse to its cage. Sterilize all tools by soaking in ethanol in
between mice. Check the health of implanted animals 24 and 48 hours post-surgery and, if needed,
apply additional buphrenephrine.
1 It is critically important that a minimal volume of avertin/tribomethanol is used, and that the
preparation is made fresh and filtered prior to use. Older stocks of anesthesia often precipitate,
and, following surgery, mice seem especially susceptible to intestinal dysfunction as a
consequence of using old or excessive avertin.
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Figure A
CD-1 nude mouse 3-4 weeks after injection
of a subcutaneous tumor.
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APPENDIX C. Preparation of Biotinylated cRNA from Prostate Tumors for Array Analysis
October 1, 2003
I. Preparation for RNA Extraction (Room Temp)
1. Wash the glass homogenizer and plunger 3X with de-ionized water
2. Wash the glass homogenizer and plunger 2X with distilled water (carboy)
3. Soak glass homogenizer and plunger >5" in 1-2 ml of RLT buffer with 10 ul P-ME/1 mL buffer
4. Lean the homogenizer sideways so that buffer/ME also contacts the bulb at the top
II. Thawing Flash Frozen Tumor Tissue and RNA Extraction (Room Temp)
Ideally, extract RNA from tumors of mass 130-250 mg, using the following volumes of RLT to
homogenize:
75-130 mg tissue .................. 2.5 mL RLT/P-ME
130-250 mg tissue ............ 4.5 mL RLT/1-ME
250-375 mg tissue ..................... 6.5 mL RLT/P-ME
RNA Extraction is done with Qiagen's RNeasy Midi isolation kit
1. Remove tumor from -135 freezer and keep on ice - do NOT allow to thaw completely
2. Tap Eppendorf to drop tumor into the RLT buffer already in the glass homogenizer ASAP
3. Push in pestle 15X, rotating the plunger halfway with each push
4. Check for large tumor pieces that might later clog the column
5. Pour the lysate into a 15 mL Falcon tube
6. Shear genomic DNA in the lysate with a 20 g. syringe, 1 OX
7. Centrifuge the lysate at 4000 g. for 10"
8. Transfer lysate to a new 15 mL Falcon tube, keeping 1 mL of pellet at the bottom of the tube
(e.g. if 4.5 mL RLT/P-ME was used above, transfer 3.5 mL RLT/P-ME)
9. Add 1 volume of 70% EtOH-DEPC to the lysate and mix thorougly.
10. Complete the standard Qiagen RNeasy Midi instructions, spinning at 4000 g for each step.
11A. For 75-130 mg tissue: Elute the sample with 125 ul DEPC-water, pass it through 2X
11 B. For 130-250 mg tissue: Elute the sample with 250 ul DEPC-water, pass it through 2X
12. Dilute 3 ul sample into 200 ul water and take an initial OD260 (260/280 ratio will be bad)
(e.g. for 250 mg tissue sample, got OD260 = 0.26 at this dilution)
III. DNase Digestion
1A. For 130-250 mg tissue (elution volume = 250 ul), combine:
RNA: -200 ul actual volume
DNase buffer: 25 ul
Ambion DNase: 25 ul
Water
Final volume = 250 ul
1B: For 75-130 mg tissue (elution volume = 125 ul), combine:
RNA: -100 ul actual volume
DNase buffer: 15 ul
Ambion DNase: 15 ul
Water
Final volume = 150 ul
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2. Incubate for 2 hours at 37 degrees
IV. Cleaning Total RNA
1A. For 130-250 mg tissue (250 ul), split sample into 2, clean individually w/ Qiagen RNeasy Mini
2A. Elute the first tube using 30 ul DEPC-water, two passes
Take this liquid and elute the second, again with two passes (final volume = 30 ul)
1B. For 75-130 mg tissue (150 ul), clean with Qiagen's RNeasy Mini
2B. Elute using 20 ul DEPC-water, two passes
3. Dilute the sample 1:200 in water for quantitation, or 10 mM Tris-CI pH 7.5 to determine purity
(e.g. for 250 mg starting tissue, got concentration of > 3 ug/ul, 260/280 = 2.0)
(minimum concentration for reverse transcription = 1.77 ug/ul)
4. Run 1-3 ug of total RNA on a gel to check integrity
V. Reverse Transcription of Total RNA - First Strand Synthesis
1. For reverse transcription, it is preferred to use 16 ug total RNA + 2 ul Superscript II RT (later)
2. Combine the following for primer hybridization:
16 ug RNA + DEPC Water: 9 ul
50 pmol/ul T7-(dT)24 primer: 2 ul
3. Follow the Affymetrix protocols. Perform all incubations in PCR machines.
VI. Reverse Transcription of Total RNA - Second Strand Synthesis
1. Follow Affymetrix protocols. Incubation is performed at 16 degrees in the PCR machine
2. The final volume of the reaction = 162 ul
VII. cDNA Clean-Up
1. Clean up the RT reaction with Qiagen's PCR purification kit
2. Elute with 2 volumes of DEPC-water, 25 ul each (total = 50 ul)
3. Check the cDNA integrity by running 4 ul on a gel. A smear should be present.
It is critical to check for cDNA before proceeding to labelling reaction.
VIII. In vitro Transcription of Biotin-Labelled cRNA
1. From an elution volume of 50 ul from above, use 44% (22 ul) for IVT
2. Use the ENZO labelling kit, following Affymetrix protocols.
3. Incubate at 37 degrees for 4.5 hours, tapping the tube every 45 minutes, 5 secs each.
IX. cRNA Clean-Up
1. Clean the entire IVT sample (40 uL) with Qiagen's RNeasy Mini kit
2. Pass the initial sample through the column 2X
3. Elute the sample w/ 30 ul DEPC-water, using 2 passes (total 30 ul)
4. Dilute 1:100 and take spec
(e.g. for 250 mg tissue sample, got concentration of -2 ug/ul)
(minimum conc. for sample fragmentation is 0.6 ug/ul after adjustment - see below)
5. Calculate the adjusted cRNA yield:
Adjusted cRNA yield = (Amount cRNA measured after IVT) - (Total starting RNA)(% for IVT)
212
Appendix C
Example: Adjusted yield = (IX #5 above) - (16 ug)(44%)
(Does adjusted concentration exceed 0.6 ug/ul?)
X. Fragmentation
15 ug cRNA is sufficient for 1 test chip and 1 real chip.
1. Fragment with the following protocol, keeping final cRNA concentration at 0.5 ug/ul:
15 ug cRNA + DEPC-water: 24 ul
5X Frag buffer: 6 ul
2. Incubate at 94 degrees for 35 minutes. Place on ice afterwards.
3. Submit for hybridization upstairs in Biopolymers facility.
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APPENDIX D. STAINING BLOOD AND LYMPHATIC VESSELS IN ZINC-FIXED TUMOR SECTIONS
Sunny Wong (syw5@mit.edu) / May 22, 2003 / revised December 1, 2006
Anti-Mouse Antibodies
Rat anti-CD31 (PECAM) Pan-endothelial; Pharmingen stock: 15.625 ug/ml
Rat anti-CD34 (RAM34) Blood vessel-specific; Pharmingen stock: 0.5 mg/ml
Goat anti-VEGFR3 (FIt4) Expressed in lymphatics and in some tumor blood vessels; R&D (AF743)
Rabbit anti-LYVE-1 Expressed in lymphatics and on some macrophages; Ruoslahti Lab
Rat anti-CD1 lb (Macl-a) Expressed on macrophage and some stromal cells; Pharmingen
Rat anti-F4/80 Expressed on mouse macrophages; Serotec
Secondary Antibodies
Rabbit anti-Rat (Vector Laboratories)
Pig anti-Rabbit (DAKO-Cytomation)
Rabbit anti-Goat
Dilutions and Treatments
CD31: Dilute stock 1:3. No specific treatments necessary after de-waxing. Antigen retrieval
inhibits staining of antibody
CD34: Dilute stock 1:25. Antigen retrieval necessary only.
VEGFR3: Dilute stock 1:25. Antigen retrieval necessary only.
LYVE-1: Dilute stock 1:500. Antigen retrieval necessary only.
CD1 1 b: Dilute stock 1:25. Antigen retrieval necessary only.
F4/80: Dilute stock 1:10. Antigen retrieval AND detergent treatment necessary.
Antigen Retrieval: Prepare Retrievagen A pH 6.0 (BD) as described. Heat sections in Coplin Jar
containing Retrievagen A in microwave at full power until boiling begins (-1 min). Reduce power to
lowest level so that section simmers for an additional 9 min.
Detergent Treatment: Prepare 0.2% Triton X-100/PBS. Incubate at room temp, 10 min.
Trypsin Treatment: Prepare 0.2% trypsin/PBS. Incubate at room temp, 10-15 min.
Zinc Fixation: Immerse samples (no greater than 3 mm thick) in formalin-free IHC zinc-fixative (BD).
Incubate at room temperature for -48 hours.
Basic Protocol
1) De-wax slides in H20.
2) If necessary, perform antigen retrieval, 10" in microwave. Cool 15" and wash 2X 10" in PBS.
3) Treat with 3% fresh H202/PBS, 10". Wash 2X with 0.2% PBST, 1X with PBS.
4) If necessary, treat with trypsin or detergent.
5) Wash 2X with PBS, 10" each.
6) Block with 20% serum, 2% fish oil in PBS at 37 degrees, 30 min.
7) Add primary antibody diluted in 4% serum/PBS. Spin down antibody before use. Incubate o/n at
room temperature.
8) Wash 2X with PBST, 10 min each, and 1X with PBS.
9) Add secondary antibody conjugated to biotin (1:200-1:250) diluted in 4% antibody-specific serum/4%
mouse serum/PBS. Spin down antibody before use. Incubate 45" at room temperature. Go to
step #10.
10) Prepare Vector ABC complex 30 minutes prior to usage. Add 1 drop solution A and 1 drop solution
B to 2.5 ml of PBS. Vortex.
11) Wash off antibody 2X with PBST and 1X with PBS, 5-10 minutes each.
12) Add ABC complex and incubate 30" at room temperature.
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13) Wash off ABC 3X with PBS, 5 minutes each.
14) Prepare VIP substrate following manufacturer's protocols immediately prior to usage. To 1.67 ml
PBS, add single drops from bottles 1-4, vortexing between each drop.
15) Add VIP to sections and incubate for color development.
For VEGFR3, develop < 5 minutes
For LYVE-1, develop 7 minutes
For CD34, develop 45 minutes
16) Stop the reaction by washing with H20.
17) Counterstain sections with Methyl Green, treat with xylenes and mount.
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Up In: Features Descriptions Score Feature P Feature P k Feature P RFDR(BH) Q Value FWE  Vo•d Change
PC3-78 220784 s at UTS2 5.1643 0.168317 0.1137632 0.2148486 0.654556 0.59655 0.89 14.3743928
PC3-78 209839_at DNM3 3.6162 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 7.019521346
PC3-78 200665 s at SPARC 16.322 0.168317 0.1137632 0.2148486 0.654556 0.59655 0 4.975622193
PC3-78 205523 at HAPLN1 8.1191 0.168317 0.1137632 0.2148486 0.654556 0.59655 0.41 3.576273213
PC3-78 212667 at SPARC 4.8488 0.168317 0.1137632 0.2148486 0.654556 0.59655 0.89 3.14958413
PC3-78 208116 s at MANIA1 1.4517 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 3.005262602
PC3-78 209035 at MDK 1.778 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 2.901220789
PC3-78 211675 s at MDFIC 5.2915 0.168317 0.1137632 0.2148486 0.654556 0.59655 0.89 2.894841435
PC3-78 204818 at HSD17B2 9.6754 0.168317 0.1137632 0.2148486 0.654556 0.59655 0.145 2.78993694
PC3-78 201667 at GJA1 3.1996 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 2.769417986
PC3-78 204749 at NAP1L3 1.7738 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 2.751849435
PC3-78 204751 x at DSC2 2.75 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 2.705844334
PC3-78 211776 s at EPB41L3 2.5414 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 2.628950507
PC3-78 213273 at ODZ4 2.4929 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 2.477097985
PC3-78 217771 at GOLPH2 2.6035 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 2.453879353
PC3-78 206224 at CST1 0.9388 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 2.443805056
PC3-78 206710 s at EPB41L3 3.1969 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 2.417085756
PC3-78 212681 at EPB41L3 4.4666 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 2.39869006
PC3-78 219327 s at GPRC5C 6.8678 0.168317 0.1137632 0.2148486 0.654556 0.59655 0.745 2.341216218
PC3-78 211549 s at HPGD 2.2273 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 2.322029774
PC3-78 221618 s at TAF9L 1.0294 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 2.312163627
PC3-78 211959 at IGFBP5 2.2227 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 2.261722464
PC3-78 204597 x at STC1 2.645 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 2.257505637
PC3-78 207276 at CDR1 0.2336 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 2.239631474
PC3-78 201362 at IVNSIABP 2.0252 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 2.213315964
PC3-78 203980 at FABP4 2.6097 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 2.20271242
PC3-78 217787 s at GALNT2 1.4545 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 2.189504934
PC3-78 205524 s at HAPLN1 8.7701 0.168317 0.1137632 0.2148486 0.654556 0.59655 0.265 2.18521569
PC3-78 217028 at CXCR4 1.4871 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 2.185152878
PC3-78 202272 s at FBXO28 3.2684 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 2.158452953
PC3-78 206214 at PLA2G7 0.7626 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 2.120698385
PC3-78 213423 x at TUSC3 2.2272 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 2.088766124
PC3-78 207387 s at GK 2.5415 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 2.084715936
PC3-78 209205 s at LMO4 2.8209 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 2.078286093
PC3-78 202626_s at LYN 4.9796 0.168317 0.1137632 0.2148486 0.654556 0.59655 0.89 2.067309256
PC3-78 211599.x at MET 2.1288 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 2.052376041
PC3-78 201363 s at IVNS1ABP 2.825 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 2.035030506
PC3-78 215977 x at GK 4.7305 0.168317 0.1137632 0.2148486 0.654556 0.59655 0.89 2.028555021
PC3-78 201858 s at PRG1 3.4071 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 2.024262954
PC3-78 212385 at TCF4 1.8438 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 2.01366347
PC3-78 203180 at ALDH1A3 4.4041 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 2.004540462
PC3-78 221805 at NEFL 3.1664 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.992443735
PC3-78 203914 x at HPGD 2.0852 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.984662871
PC3-78 206424 at CYP26A1 1.927 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.982335275
PC3-78 218000 s at PHLDA1 1.2494 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.98100496
PC3-78 200796 s at .MCL1 1.2741 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.976668998
PC3-78 212382 at TCF4 1.372 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.976621705
PC3-78 221731 x at !CSPG2 4.3009 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.976038223
PC3-78 211161 s at COL3A1 1.5722 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.974729428
PC3-78 206033 s at DSC3 1.9475 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.954469774
PC3-78 209228 x at TUSC3 1.9532 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.949666278
PC3-78 217167 x at -GK 3.7414 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.948338481
PC3-78 209844 at HOXB13 1.2416 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.944701558
PC3-78 205500 at C5 3.3149 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.931438547
PC3-78 219140 s at 1RBP4 1.9428 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.928382524
PC3-78 214975 s at MTMR1 1.6525 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.928033193
PC3-78 213807 x at 'MET 2.0787 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.927315788
PC3-78 204404 at SLC12A2 2.5833 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.920968582
PC3-78 204475 at MMP1 3.4233 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.919141737
PC3-78 211548 s at HPGD 1.9605 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.916797635
PC3-78 1213865 at DCBLD2 1.6116 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.916558853
PC3-78 203913 s at HPGD 1.5239 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.908739374
PC3-78 201852 x at COL3A1 1.7526 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.900378258
PC3-78 218352 at RCBTB1 1.0544 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.900336863
PC3-78 206042 x at SNRPN/// SNL 2.5218 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.900059613
PC3-78 212098 at LOC151162 3.7945 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.891282684
PC3-78 206245 s at IVNS1ABP 8.2354 0.168317 0.1137632 0.2148486 0.654556 0.59655 0.41 1.885812547
PC3-78 211559 s at CCNG2 2.4519 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.875664841
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1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
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1
1
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1
1
1
1
1
1
1
1
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1
1
1
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1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
0.265
1
1
1
1
1
1
1
1
1
1
1
217
1.871597205
1.861140573
1.860351329
1.856812056
1.850837399
1.84680378
1.844995962
1.827883215
1.825766782
1.824699431
1.816434232
1.814475492
1.810175595
1.800543338
1.79823305
1.795956095
1.794772967
1.79232534
1.78050169
1.779117405
1.779012036
1.777807265
1.775113581
1.769963475
1.7623599
1.760833152
1.758642048
1.755510656
1.750829641
1.746497292
1.743185511
1.735338019
1.734753282
1.727076423
1.726112128
1.721942581
1.719118126
1.716551437
1.712490058
1.711980507
1.706415695
1.70360351
1.699380295
1.698556625
1.696446654
1.693121844
1.692122455
1.691984146
1.691717058
1.690614553
1.689129388
1.688066072
1.685914556
1.6843781
1.683317445
1.68265002
1.681399516
1.678388565
1.6775925
1.671207293
1.670393111
1.667842824
1.663095804
1.661433088
1.659277977
1.659277157
1.65872223
1.657842106
1.657045058
213447 at IPW
203716 s at DPP4
213325 at PVRL3
-78 !220738 s at :RPS6KA6
*78 218888_s at iNETO2
-78 '201058 s at MYL9
-78 208664 s at Tr-C3
-78 211812 s at iB3GALT3
-78 201116 s at CPE
-78 202271 at FBXO28
78
78
78
78
78
78
78
78
78
78
78
78
78
78
78
78
78
78
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78
78
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70
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PC3-78
PC3-78
PC3-78
PC3-78
206917 at
221428 s at
205808 at
202134 s at
219201 s at
201196 s at
202765 s at
215581 s at
218349 s at
209468 at
218113 at
209506 s at
202886 s at
208062 s at
209863 s at
203058 s at
201868 s at
211478 s at
211814 s at
204715 at
204352 at
207029 at
207992 s at
201341 at
209895 at
221638 s at
208930 s at
206172 at
200598 s at
208853 s at
209424_s~at
221760 at
202007 at
214581 x at
203176 s at
203429 s at
202625 at
212092 at
202438 x at
206631 at
210286 s at
219793 at
207172 s at
204995 at
219869 s at
204426 at
204128 s at
201043 s at
203799 at CD302
GNA13
TBL1XR1
ASPH
WWTR1
TWSG1
AMD1
FBN1
MCM3AP
ZWILCH
LRP5
TMEM2
NR2F1
PPP2R18B
NRG2
TP73L
PAPSS2
TBL1X
DPP4
CCNE2
PANX1
TRAF5
KITLG
AMPD3
ENC1
PTPN 11
STX16
ILF3
PC3-
PC3-
PC3-
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PC3-
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78 208459 s at
78 214684 at
78 212607 at
78 209456 s at
78 202132 at
78 207431 s at
78 210559 s at
78 200841
78 202651
78 210544
78 201073
78 202008
78 207781
s at
at
s at
s at
s
s
at
at
XPO7
MEF2A
AKT3
FBXW11
WWTR1
DEGS1
CDC2
EPRS
LPGAT1
ALDH3A2
SMARCC1
NID1
ZNF6
IL13RA2
TRA1
CANX
AMACR
MANlA1
NID1
TNFRSF21
TFAM
Clorf9
LYN
PEG10
IDS
PTGER2
SLC4A7
SNX16
CDH11
CDK5R1
SLC39A8
TMED2
RFC3
ANP32A
2.2916
1.7921
2.385
1.4343
1.5203
1.9514
3.3504
1.704
0.9197
1.0246
1.0563
1.4948
2.3535
0.9107
1.7593
0.514
1.1064
3.2405
0.7087
2.3298
1.8192
1.8749
2.3883
1.8784
1.2917
0.9862
0.6667
2.3464
1.6047
2.1439
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1.8369
1.7465
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0.8857
1.0784
1.1069
1.2573
1.17
1.1749
0.9353
4.9168
0.7932
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1.2351
2.252
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78 203214 x at ICDC2
78 !213256 at
78 212446 s at LASS6
78 209006 s at Clorf63
78 203570 at LOXL1
78 _87100_at ABHD2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
I
1
1
1
1
1
1.616736329
1.615330234
1.615290165
1.615186405
1.613409998
1.61323666
1.613147851
1.613072261
1.612117614
1.608468641
1.607344499
1.607146833
1.603199438
1.6028091
1.596936592
1.595449738
1.593689245
1.593415011
1.589774697
1.588320671
1.587443763
1.58717109
1.586587932
1.584660076
1.584066703
1.581590228
1.57923856
1.579022129
1.578097025
1.57555942
1.575403197
1.575090832
1.574439531
1.574410272
1.572466518
1.570213064
1.567233614
1.566081065
1.566022518
1.5635278E
1.562262159
1.560582536
1.559651568
1.558953967
1.556628458
1.554375946
11 1.553849766
1.656745843
1.656627974
1.656527683
1.654573456
1.653004169
1.65238692
1.65080993
1.650165574
1.649927251
1.647251702
1.64585352
1.642611386
1.639559891
1.638465142
1.636573063
1.630903682
1.62575046
1.623987902
1.623890807
1.62336878
1.621293537
1.617587146
4122 87
t 
ENSA
1.55437594
1
'------`
PC3-78 205732 s at NCOA2 1.6382 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.553717994
PC3-78 208663 s at TTC3 0.8902 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.552348878
PC3-78 204427 s at TMED2 1.6021 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.551988871
PC3-78 214930_at SLITRK5 1.6455 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.551957275
PC3-78 201646_at SCARB2 0.7791 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.548506017
PC3-78 208653 s at CD164 1.2671 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.545748247
PC3-78 213156 at --- 0.976 0.29703 0.2302494 0.3550604 0.772047 0.68489 1 1.545345015
PC3-78 212387 at TCF4 1.5402 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.54305473
PC3-78 207291_at PRRG4 2.0528 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.542843882
PC3-78 217997_at PHLDA1 1.9557 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.539234176
PC3-78 204454_at LDOC1 2.3339 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.539090767
PC3-78 211273 sat TBX1 0.186 0.475248 0.4017935 0.5389654 0.845043 0.74969 1 1.537682281
PC3-78 205920_at SLC6A6 3.5347 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.537312514
PC3-78 206483 at LRRC6 1.8198 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.535006779
PC3-78 209120 at NR2F2 1.6172 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.534452303
PC3-78 213158 at --- 0.9596 0.39604 0.3243521 0.4584289 0.814185 0.71485 1 1.531383515
PC3-78 218006 s at ZNF22 1.2136 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.528305939
PC3-78 210904 s at IL13RA1 2.1454 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.527640408
PC3-78 201476 s at RRM1 1.4518 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.527369605
PC3-78 203357 s at CAPN7 1.4021 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.527011649
PC3-78 213891 s at TCF4 1.5115 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.526701519
PC3-78 209426_s at AMACR 2.146 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.526328958
PC3-78 210457 x at HMGA1 0.9423 0.29703 0.2302494 0.3550604 0.772047 0.68489 1 1.526016635
PC3-78 200890 s at SSR1 1.0481 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.52444572
PC3-78 208955 at DUT 0.9858 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.524106711
PC3-78 205071 x at XRCC4 1.3823 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.52345566
PC3-78 201291 s at TOP2A 0.462 0.445545 0.3725421 0.5089743 0.841576 0.74674 1 1.522940375
PC3-78 203428 s at ASF1A 1.6015 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.522857655
PC3-78 203032 s at FH 1.236 0.316832 0.2488067 0.3759975 0.772047 0.68489 1 1.522131755
PC3-78 91816 f at RKHD1 2.165 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.522034985
PC3-78 212220 at PSME4 1.1101 0.316832 0.2488067 0.3759975 0.772047 0.68489 1 1.521419714
PC3-78 202514 at DLG1 0.9693 0.316832 0.2488067 0.3759975 0.772047 0.68489 1 1.521332562
PC3-78 211080 s at NEK2 1.4199 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.520578093
PC3-78 203294 s at LMAN1 1.6261 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.518051818
PC3-78 211019 s at LSS 0.8827 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.517768864
PC3-78 209817 at PPP3CB 2.732 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.517016691
PC3-78 217788 s at GALNT2 1.9706 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.516902983
PC3-78 220334 at RGS17 2.191 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.516119818
PC3-78 201879 at ARIHI 2.763 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.515387246
PC3-78 207469 s at PIR 2.2565 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.515155238
PC3-78 218005 at ZNF22 1.9121 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.513178292
PC3-78 205364 at ACOX2 1.639 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.511588177
PC3-78 203196 at ABCC4 1.0813 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.510458274
PC3-78 222146 s at TCF4 1.4844 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.509943824
PC3-78 217999 s at --- 0.7608 0.316832 0.2488067 0.3759975 0.772047 0.68489 1 1.509014915
PC3-78 212651 at RHOBTB1 1.6694 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.508185508
PC3-78 205923 at RELN 1.7901 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.508074818
PC3-78 222019 at HKE2 4.2358 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.508042512
PC3-78 212453 at KIAA1279 3.2783 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.507887197
PC3-78 201654 s at HSPG2 0.5052 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.507880104
PC3-78 219961 s at C20orfl9 1.2427 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.507448803
PC3-78 210148 at HIPK3 2.1113 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.507058569
PC3-78 1203753 at TCF4 1.1917 0.29703 0.2302494 0.3550604 0.772047 0.68489 1 1.506288759
PC3-78 215842 s at ATP11A 1.4252 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.505319148
PC3-78 200917 s at SRPR 0.9409 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.503176621
PC3-78 206748 s at iSPAG9 1.0937 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.502045906
PC3-78 208767 s at LAPTM4B 1.8364 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.501584899
PC3-78 212105 s at DHX9 1.9587 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.501384772
PC3-78 201663 s at SMC4L1 0.8751 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.501221297
PC3-78 201580 s at TXNDC13 2.0537 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.500652824
PC3-78 209121 x at NR2F2 1.4697 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.50031084
PC3-78 212218 s at FASN 0.7186 0.267327 0.2026906 0.3233796 0.772047 0.68489 1 1.499293441
PC3-78 210116 at SH2D1A 2.5578 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.498423895
PC3-78 203394 s at HES1 0.7563 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.498194139
PC3-78 203803 at PCYOX1 1.0251 0.29703 0.2302494 0.3550604 0.772047 0.68489 1 1.49768387
PC3-78 218589 at P2RY5 1.8161 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.497581694
PC3-78 220643 s at FAIM 1.3855 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.496376777
PC3-78 214908 s at TRRAP 1.4506 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.495605328
PC3-78 208839 s at CAND1 0.7202 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.495163002
PC3-78 217370 x at FUS 0.9639 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.495036538
PC3-78 220014 at LOC51334 1.0592 0.168317 0.1137632 0.2148486 0.654556 0.59655 1 1.494728957
PC3-82 204932 at TNFRSF11B -4.1977 0.009901 0 0.0147936 0.113315 0.19791 1 5.261552164
PC3-82 201110 sat THBS1 -5.4867 0.009901 0 0.0147936 0.113315 0.19791 0.89 4.831408115
PC3-82 214612 x at MAGEA6 -3.497 0.009901 0 0.0147936 0.113315 0.19791 1 4.407316704
PC3-82 204933 s at TNFRSF11B -4.492 0.009901 0 0.0147936 0.113315 0.19791 1 4.309530831
PC3-82 209942 x at MAGEA3 -7.7611 0.009901 0 0.0147936 0.113315 0.19791 0.41 4.233286822
PC3-82 201109 s at THBS1 -2.7305 0.009901 0 0.0147936 0.113315 0.19791 1 4.196244383
PC3-82 201884 at CEACAM5 -2.8697 0.009901 0 0.0147936 0.113315 0.19791 1 4.163698675
PC3-82 203021 at SLPI -4.3713 0.009901 0 0.0147936 0.113315 0.19791 1 3.539616523
PC3-82 211657 at CEACAM6 -1.4178 0.009901 0 0.0147936 0.113315 0.19791 1 3.260180324
PC3-82 201042 at TGM2 -2.3711 0.009901 0 0.0147936 0.113315 0.19791 1 3.142785598
PC3-82 203757 s at CEACAM6 -1.773 0.009901 0 0.0147936 0.113315 0.19791 1 2.970001386
PC3-82 210095 s at IGFBP3 -2.4807 0.009901 0 0.0147936 0.113315 0.19791 1 2.900522273
PC3-82 201108 s at THBS1 -4.2542 0.009901 0 0.0147936 0.113315 0.19791 1 2.89938604
PC3-82 209487 at RBPMS -3.0084 0.009901 0 0.0147936 0.113315 0.19791 1 2.873170687
PC3-82 211573_x at TGM2 -0.9845 0.009901 0 0.0147936 0.113315 0.19791 1 2.853109972
PC3-82 209488 s at RBPMS -7.7124 0.009901 0 0.0147936 0.113315 0.19791 0.545 2.829891835
PC3-82 204455 at DST -2.934 0.009901 0 0.0147936 0.113315 0.19791 1 2.805763282
PC3-82 201242 s at ATP1B1 -4.8635 0.009901 0 0.0147936 0.113315 0.19791 0.89 2.712985019
PC3-82 219936 s at GPR87 -7.4629 0.009901 0 0.0147936 0.113315 0.19791 0.545 2.711751637
PC3-82 203691 at PI3 -5.3318 0.009901 0 0.0147936 0.113315 0.19791 0.89 2.680088074
PC3-82 214292 at ITGB4 -1.5998 0.009901 0 0.0147936 0.113315 0.19791 1 2.604842701
PC3-82 204351 at S100P -0.6978 0.009901 0 0.0147936 0.113315 0.19791 1 2.593216084
PC3-82 205992 s at IL15 -1.0286 0.009901 0 0.0147936 0.113315 0.19791 1 2.553093039
PC3-82 203889 at SGNE1 -2.4597 0.009901 0 0.0147936 0.113315 0.19791 1 2.516567263
PC3-82 203918 at PCDH1 -1.9273 0.009901 0 0.0147936 0.113315 0.19791 1 2.487016398
PC3-82 41469 at PI3 -3.9739 0.009901 0 0.0147936 0.113315 0.19791 1 2.478560074
PC3-82 209016 s at KRT7 -2.8159 0.009901 0 0.0147936 0.113315 0.19791 1 2.439616212
PC3-82 205376 at INPP4B -2.6869 0.009901 0 0.0147936 0.113315 0.19791 1 2.394823668
PC3-82 218723 s at RGC32 -0.6472 0.009901 0 0.0147936 0.113315 0.19791 1 2.384602104
PC3-82 201243 s at ATP1B1 -2.5264 0.009901 0 0.0147936 0.113315 0.19791 1 2.304572792
PC3-82 214476 at TFF2 -2.6409 0.009901 0 0.0147936 0.113315 0.19791 1 2.260509744
PC3-82 205016 at TGFA -1.7361 0.009901 0 0.0147936 0.113315 0.19791 1 2.235132275
PC3-82 218804 at TMEM16A -2.6256 0.009901 0 0.0147936 0.113315 0.19791 1 2.232202342
PC3-82 202859 x at IL8 -2.4158 0.009901 0 0.0147936 0.113315 0.19791 1 2.227670292
PC3-82 206025 s at TNFAIP6 -1.545 0.009901 0 0.0147936 0.113315 0.19791 1 2.174025472
PC3-82 202672 s at ATF3 -0.9031 0.009901 0 0.0147936 0.113315 0.19791 1 2.140088878
PC3-82 209631 s at GPR37 -11.003 0.009901 0 0.0147936 0.113315 0.19791 0.145 2.137312471
PC3-82 211003 x at TGM2 -1.6288 0.009901 0 0.0147936 0.113315 0.19791 1 2.111381407
PC3-82 202411 at IFI27 -0.9692 0.009901 0 0.0147936 0.113315 0.19791 1 2.076565547
PC3-82 203851 at IGFBP6 -2.3217 0.009901 0 0.0147936 0.113315 0.19791 1 2.065813514
PC3-82 205552 s at OAS1 -1.1705 0.009901 0 0.0147936 0.113315 0.19791 1 2.062107176
PC3-82 201473 at JUNB -1.5469 0.009901 0 0.0147936 0.113315 0.19791 1 2.051192084
PC3-82 210827 s at ELF3 -1.4138 0.009901 0 0.0147936 0.113315 0.19791 1 2.032826702
PC3-82 204990 s at ITGB4 -3.9353 0.009901 0 0.0147936 0.113315 0.19791 1 1.997688199
PC3-82 207574 s at GADD45B -2.0077 0.009901 0 0.0147936 0.113315 0.19791 1 1.964067208
PC3-82 207850 at CXCL3 -2.1982 0.009901 0 0.0147936 0.113315 0.19791 1 1.960282348
PC3-82 200878 at EPASI -4.2236 0.009901 0 0.0147936 0.113315 0.19791 1 1.95114435
PC3-82 220468 at ARF7 -2.4171 0.009901 0 0.0147936 0.113315 0.19791 1 1.95086702
PC3-82 219209 at IFIH1 -1.8359 0.009901 0 0.0147936 0.113315 0.19791 1 1.946175795
PC3-82 204748_at PTGS2 -1.7386 0.009901 0 0.0147936 0.113315 0.19791 1 1.922670646
PC3-82 214385 s at MUC5AC -1.6848 0.009901 0 0.0147936 0.113315 0.19791 1 1.913011062
PC3-82 202869 at OAS1 -1.1822 0.009901 0 0.0147936 0.113315 0.19791 1 1.911311112
PC3-82 213418 at HSPA6 -0.1752 0.009901 0 0.0147936 0.113315 0.19791 1 1.911245129
PC3-82 209183 s at Cl0orf10 -1.0122 0.089109 0.0477178 0.1229598 0.654556 0.59655 1 1.90879553
PC3-82 ;208937 s at ID1 -1.7101 0.009901 0 0.0147936 0.113315 0.19791 1 1.903939696
PC3-82 217546 at MT1M -2.9978 0.009901 0 0.0147936 0.113315 0.19791 1 1.900745102
PC3-82 206026 s at TNFAIP6 -1.8251 0.009901 0 0.0147936 0.113315 0.19791 1 1.893361102
PC3-82 203789 s at SEMA3C -0.6938 0.009901 0 0.0147936 0.113315 0.19791 1 1.890395019
PC3-82 202149 at NEDD9 -3.4852 0.009901 0 0.0147936 0.113315 0.19791 1 1.884959272
PC3-82 213134 x at BTG3 -3.4059 0.009901 0 0.0147936 0.113315 0.19791 1 1.876810143
PC3-82 213711 at KRTHB1 -2.6485 0.009901 0 0.0147936 0.113315 0.19791 1 1.8748312
PC3-82 204682 at LTBP2 -3.5913 0.009901 0 0.0147936 0.113315 0.19791 1 1.870217023
PC3-82 208078 s at SNF1LK -1.1452 0.009901 0 0.0147936 0.113315 0.19791 1 1.867663119
PC3-82 205869 at PRSS1 -1.2771 0.009901 0 0.0147936 0.113315 0.19791 1 1.854357593
PC3-82 211564 s at PDLIM4 -2.0663 0.009901 0 0.0147936 0.113315 0.19791 1 1.854221876
PC3-82 211506 s at IL8 -1.5132 0.009901 0 0.0147936 0.113315 0.19791 1 1.851528519
PC3-82 205366 s at HOXB6 -4.859 0.009901 0 0.0147936 0.113315 0.19791 0.89 1.850382427
PC3-82 209160 at AKR1C3 -1.5109 0.009901 0 0.0147936 0.113315 0.19791 1 1.843714511
PC3-82 222108 at AMIGO2 -4.6016 0.009901 0 0.0147936 0.113315 0.19791 0.89 1.83797613
PC3-82 219371_s at KLF2 -1.2703 0.158416 0.1051867 0.2036806 0.654556 0.59655 1 1.819544114
PC3-82 203632_sat GPRC5B -9.6873 0.009901 0 0.0147936 0.113315 0.19791 0.145 1.818833229
PC3-82 206508 at TNFSF7 -4.9798 0.009901 0 0.0147936 0.113315 0.19791 0.89 1.808769363
PC3-82 213258 at TFPI -0.6435 0.009901 0 0.0147936 0.113315 0.19791 1 1.798947994
PC3-82 221009 s at ANGPTL4 -0.6032 0.009901 0 0.0147936 0.113315 0.19791 1 1.790994464
PC3-82 212099 at RHOB -1.3629 0.009901 0 0.0147936 0.113315 0.19791 1 1.770553594
PC3-82 201289 at CYR61 -2.9714 0.009901 0 0.0147936 0.113315 0.19791 1 1.755235577
PC3-82 210999 s at GRB10 -1.7471 0.009901 0 0.0147936 0.113315 0.19791 1 1.754550234
PC3-82 218543 sat PARP12 -1.412 0.009901 0 0.0147936 0.113315 0.19791 1 1.752992513
PC3-82 201061 s_at STOM -2.2993 0.009901 0 0.0147936 0.113315 0.19791 1 1.749881682
PC3-82 204512 at HIVEP1 -1.6047 0.009901 0 0.0147936 0.113315 0.19791 1 1.744202213
PC3-82 215243_s_at GIB3 -3.1653 0.009901 0 0.0147936 0.113315 0.19791 1 1.738502334
PC3-82 205807 s at TUFT1 -3.3936 0.009901 0 0.0147936 0.113315 0.19791 1 1.728400969
PC3-82 209774 x at CXCL2 -2.3825 0.009901 0 0.0147936 0.113315 0.19791 1 1.727453976
PC3-82 219352 at HERC6 -1.4488 0.009901 0 0.0147936 0.113315 0.19791 1 1.725394645
PC3-82 203153 at IFIT1 -1.702 0.009901 0 0.0147936 0.113315 0.19791 1 1.722735357
PC3-82 206114 at EPHA4 -3.0531 0.009901 0 0.0147936 0.113315 0.19791 1 1.721844205
PC3-82 214974 x at CXCL5 -0.5937 0.009901 0 0.0147936 0.113315 0.19791 1 1.721260612
PC3-82 201502 s at NFKBIA -2.4875 0.009901 0 0.0147936 0.113315 0.19791 1 1.71835573
PC3-82 204989 s at ITGB4 -1.2814 0.009901 0 0.0147936 0.113315 0.19791 1 1.717823281
PC3-82 212242 at TUBA1 -3.156 0.009901 0 0.0147936 0.113315 0.19791 1 1.71690428
PC3-82 205490 x at GJB3 -2.6502 0.009901 0 0.0147936 0.113315 0.19791 1 1.71614472
PC3-82 205009 at TFF1 -2.1042 0.009901 0 0.0147936 0.113315 0.19791 1 1.705570815
PC3-82 212268 at SERPINB1 -1.1464 0.009901 0 0.0147936 0.113315 0.19791 1 1.702156497
PC3-82 203726 s at LAMA3 -1.8461 0.009901 0 0.0147936 0.113315 0.19791 1 1.698279027
PC3-82 212647 at RRAS -2.5527 0.009901 0 0.0147936 0.113315 0.19791 1 1.697643694
PC3-82 211006 s at KCNB1 -3.6497 0.009901 0 0.0147936 0.113315 0.19791 1 1.69501591
PC3-82 219010 at Clorfl06 -3.6581 0.009901 0 0.0147936 0.113315 0.19791 1 1.69379636
PC3-82 202086 at MX1 -0.9811 0.158416 0.1051867 0.2036806 0.654556 0.59655 1 1.693175829
PC3-82 209270 at LAMB3 -1.7127 0.009901 0 0.0147936 0.113315 0.19791 1 1.691713168
PC3-82 213572 s at SERPINB1 -0.8857 0.009901 0 0.0147936 0.113315 0.19791 1 1.690300382
PC3-82 210665 at TFPI -1.2713 0.009901 0 0.0147936 0.113315 0.19791 1 1.689862079
PC3-82 209949 at NCF2 -2.3185 0.009901 0 0.0147936 0.113315 0.19791 1 1.680796101
PC3-82 205780 at BIK -1.8876 0.009901 0 0.0147936 0.113315 0.19791 1 1.680383454
PC3-82 212530 at NEK7 -0.9195 0.009901 0 0.0147936 0.113315 0.19791 1 1.677658992
PC3-82 201540 at FHL1 -0.7354 0.009901 0 0.0147936 0.113315 0.19791 1 1.677314797
PC3-82 219529 at CLIC3 -1.4255 0.009901 0 0.0147936 0.113315 0.19791 1 1.676805624
PC3-82 204337 at RGS4 -2.0788 0.009901 0 0.0147936 0.113315 0.19791 1 1.676249917
PC3-82 202052 s at RAI14 -1.8535 0.009901 0 0.0147936 0.113315 0.19791 1 1.674871953
PC3-82 210689 at CLDN14 -2.7382 0.009901 0 0.0147936 0.113315 0.19791 1 1.674066352
PC3-82 1203438 at STC2 -0.5796 0.009901 0 0.0147936 0.113315 0.19791 1 1.67143366
PC3-82 202863 at SP100 -1.6145 0.009901 0 0.0147936 0.113315 0.19791 1 1.67137622
PC3-82 205798 at IL7R -2.8162 0.009901 0 0.0147936 0.113315 0.19791 1 1.669780507
PC3-82 210002 at GATA6 -2.1431 0.009901 0 0.0147936 0.113315 0.19791 1 1.668120788
PC3-82 218573 at MAGEH1 -2.8453 0.009901 0 0.0147936 0.113315 0.19791 1 1.666554227
PC3-82 213793 s at HOMER1 -2.4371 0.009901 0 0.0147936 0.113315 0.19791 1 1.666097644
PC3-82 207836 s at RBPMS -2.4429 0.009901 0 0.0147936 0.113315 0.19791 1 1.664938464
PC3-82 212923 s at C6orfl45 -2.0895 0.009901 0 0.0147936 0.113315 0.19791 1 1.663808237
PC3-82 210664 s at TFPI -1.6055 0.009901 0 0.0147936 0.113315 0.19791 1 1.654580799
PC3-82 217572_at --- -1.0611 0.009901 0 0.0147936 0.113315 0.19791 1 1.654510836
PC3-82 205463 s at PDGFA -3.3303 0.009901 0 0.0147936 0.113315 0.19791 1 1.649643329
PC3-82 214303 x at MUC5AC -1.1773 0.009901 0 0.0147936 0.113315 0.19791 1 1.649369961
PC3-82 202864 s at SP100 -1.5082 0.009901 0 0.0147936 0.113315 0.19791 1 1.648698874
PC3-82 202150 s at NEDD9 -1.8527 0.009901 0 0.0147936 0.113315 0.19791 1 1.648171358
PC3-82 201012 at ANXA1 -1.576 0.009901 0 0.0147936 0.113315 0.19791 1 1.647561318
PC3-82 212143 s at IGFBP3 -1.7884 0.009901 0 0.0147936 0.113315 0.19791 1 1.644993559
PC3-82 209304 x at GADD45B -1.3841 0.009901 0 0.0147936 0.113315 0.19791 1 1.642731474
PC3-82 206884_s at SCEL -6.7554 0.009901 0 0.0147936 0.113315 0.19791 0.745 1.635582291
PC3-82 209761 s at SP110 -1.6133 0.009901 0 0.0147936 0.113315 0.19791 1 1.635477686
PC3-82 214175 x at PDLIM4 -2.5342 0.009901 0 0.0147936 0.113315 0.19791 1 1.632209509
PC3-82 205856 at SLC14A1 -1.2843 0.009901 0 0.0147936 0.113315 0.19791 1 1.629023804
PC3-82 215617 at --- -0.5151 0.009901 0 0.0147936 0.113315 0.19791 1 1.628866275
PC3-82 '202409 at LOC492304 -1.2903 0.009901 0 0.0147936 0.113315 0.19791 1 1.625352309
PC3-82 _1202504 at TRIM29 -3.0079 0.009901 0 0.0147936 0.113315 0.19791 1 1.619549293
PC3-82 209762 x at SP110 -1.9885 0.009901 0 0.0147936 0.113315 0.19791 1 1.617509509
PC3-82 218611 at IER5 -1.443 0.009901 0 0.0147936 0.113315 0.19791 1 1.613354089
PC3-82 203824 at TSPAN8 -2.3822 0.009901 0 0.0147936 0.113315 0.19791 1 1.611770218
PC3-82 207517 at LAMC2 -2.1025 0.009901 0 0.0147936 0.113315 0.19791 1 1.611443001
PC3-82 212256 at GALNT10 -2.7903 0.009901 0 0.0147936 0.113315 0.19791 1 1.609638013
PC3-82 208012 x at SP110 -1.9761 0.009901 0 0.0147936 0.113315 0.19791 1 1.608860958
PC3-82 216060 s at DAAM1 -1.1838 0.009901 0 0.0147936 0.113315 0.19791 1 1.605334575
PC3-82 215206 at EXT1 -0.9203 0.009901 0 0.0147936 0.113315 0.19791 1 1.604850616
PC3-82 206277 at P2RY2 -3.0564 0.009901 0 0.0147936 0.113315 0.19791 1 1.60416036
PC3-82 213001 at ANGPTL2 -2.5011 0.009901 0 0.0147936 0.113315 0.19791 1 1.60290644
PC3-82 220180 at SE57-1 -2.0144 0.009901 0 0.0147936 0.113315 0.19791 1 1.602253147
PC3-82 205548 s at BTG3 -2.2756 0.009901 0 0.0147936 0.113315 0.19791 1 1.600089089
PC3-82 209493 at PDZK3 -0.9119 0.009901 0 0.0147936 0.113315 0.19791 1 1.594394157
PC3-82 220104 at ZC3HAV1 -0.9118 0.009901 0 0.0147936 0.113315 0.19791 1 1.590647022
PC3-82 202458 at PRSS23 -2.1909 0.009901 0 0.0147936 0.113315 0.19791 1 1.590549428
PC3-82 205173 x at CD58 -0.6022 0.009901 0 0.0147936 0.113315 0.19791 1 1.58080049
PC3-82 204612 at PKIA -2.3202 0.009901 0 0.0147936 0.113315 0.19791 1 1.578759272
PC3-82 204338 s at RGS4 -2.2911 0.009901 0 0.0147936 0.113315 0.19791 1 1.578482608
PC3-82 221884 at EVIl -1.3923 0.009901 0 0.0147936 0.113315 0.19791 1 1.578174402
PC3-82 201641 at BST2 -0.8124 0.158416 0.1051867 0.2036806 0.654556 0.59655 1 1.577828795
PC3-82 204151 x at AKR1C1 -1.6504 0.009901 0 0.0147936 0.113315 0.19791 1 1.577581805
PC3-82 200904 at HLA-E -0.9498 0.009901 0 0.0147936 0.113315 0.19791 1 1.574261028
PC3-82 202267 at LAMC2 -1.8057 0.009901 0 0.0147936 0.113315 0.19791 1 1.57343645
PC3-82 202481 at DHRS3 -1.05 0.009901 0 0.0147936 0.113315 0.19791 1 1.571988156
PC3-82 209969 s at STAT1 -0.7681 0.376238 0.3052793 0.4380074 0.809472 0.70959 1 1.57096365
PC3-82 202410 x at IGF2 -0.3327 0.009901 0 0.0147936 0.113315 0.19791 1 1.567222451
PC3-82 213004 at ANGPTL2 -2.3953 0.009901 0 0.0147936 0.113315 0.19791 1 1.563848817
PC3-82 213089 at LOC153561 -1.9258 0.009901 0 0.0147936 0.113315 0.19791 1 1.560811029
PC3-82 203592 s at FSTL3 -1.4473 0.009901 0 0.0147936 0.113315 0.19791 1 1.559133248
PC3-82 213644 at MGC33887 -0.6071 0.009901 0 0.0147936 0.113315 0.19791 1 1.5567953
PC3-82 201506 at TGFBI -3.2381 0.009901 0 0.0147936 0.113315 0.19791 1 1.554635662
PC3-82 203939 at NT5E -1.3086 0.009901 0 0.0147936 0.113315 0.19791 1 1.55458718
PC3-82 204326 x at MT1X -1.4526 0.009901 0 0.0147936 0.113315 0.19791 1 1.550475269
PC3-82 218456 at C1QDC1 -3.1403 0.009901 0 0.0147936 0.113315 0.19791 1 1.548549581
PC3-82 209409 at GRB10 -2.621 0.009901 0 0.0147936 0.113315 0.19791 1 1.544106919
PC3-82 200696 s at GSN -1.5853 0.009901 0 0.0147936 0.113315 0.19791 1 1.543961016
PC3-82 215248 at GRB10 -1.3539 0.009901 0 0.0147936 0.113315 0.19791 1 1.543177739
PC3-82 219165 at PDLIM2 -2.7221 0.009901 0 0.0147936 0.113315 0.19791 1 1.540358694
PC3-82 201250 s at SLC2A1 -0.8316 0.009901 0 0.0147936 0.113315 0.19791 1 1.539143619
PC3-82 218986 s at FLJ20035 -1.5991 0.009901 0 0.0147936 0.113315 0.19791 1 1.53747311
PC3-82 211905 s at ITGB4 -0.4268 0.009901 0 0.0147936 0.113315 0.19791 1 1.536227258
PC3-82 221765 at UGCG -1.4488 0.009901 0 0.0147936 0.113315 0.19791 1 1.535322558
PC3-82 212444 at GPCR5A -2.5073 0.009901 0 0.0147936 0.113315 0.19791 1 1.53527282
PC3-82 205659 at HDAC9 -1.0563 0.009901 0 0.0147936 0.113315 0.19791 1 1.534789977
PC3-82 216442 x at FN1 -2.225 0.009901 0 0.0147936 0.113315 0.19791 1 1.533721545
PC3-82 205660 at OASL -1.7796 0.009901 0 0.0147936 0.113315 0.19791 1 1.532941133
PC3-82 210764 s at CYR61 -1.3965 0.009901 0 0.0147936 0.113315 0.19791 1 1.53243383
PC3-82 202071 at SDC4 -1.1506 0.158416 0.1051867 0.2036806 0.654556 0.59655 1 1.531429332
PC3-82 212488 at COL5A1 -0.5875 0.009901 0 0.0147936 0.113315 0.19791 1 1.527337776
PC3-82 209800 at KRT16 -1.4388 0.009901 0 0.0147936 0.113315 0.19791 1 1.526383915
PC3-82 202177 at GAS6 -2.3575 0.009901 0 0.0147936 0.113315 0.19791 1 1.526274175
PC3-82 215717 s at FBN2 -0.5072 0.237624 0.1754954 0.2913356 0.770626 0.68347 1 1.523549453
PC3-82 204345 at COL16A1 -0.8745 0.009901 0 0.0147936 0.113315 0.19791 1 1.523182755
PC3-82 217764 s at RAB31 -2.0261 0.009901 0 0.0147936 0.113315 0.19791 1 1.523052057
PC3-82 204114 at NID2 -0.9521 0.009901 0 0.0147936 0.113315 0.19791 1 1.522445732
PC3-82 201841 s at HSPB1 -0.5312 0.138614 0.0882631 0.1811164 0.654556 0.59655 1 1.522182827
PC3-82 214453 s at !IFI44 -1.0579 0.158416 0.1051867 0.2036806 0.654556 0.59655 1 1.519056152
PC3-82 219691 at SAMD9 -1.0819 0.09901 0.0555734 0.134841 0.654556 0.59655 1 1.517564229
PC3-82 204439 at IFI44L -1.2557 0.158416 0.1051867 0.2036806 0.654556 0.59655 1 1.514477111
PC3-82 217683 at HBE1 -0.5688 0.009901 0 0.0147936 0.113315 0.19791 1 1.514142517
PC3-82 204148_s at ZP3///POMZF -2.6643 0.009901 0 0.0147936 0.113315 0.19791 1 1.51337432
PC3-82 213526 s at PSENEN///F2 -0.7208 0.009901 0 0.0147936 0.113315 0.19791 1 1.513311602
PC3-82 216594 x at :AKR1C1 -1.8227 0.009901 0 0.0147936 0.113315 0.19791 1 1.513099524
PC3-82 202796 at SYNPO -1.9355 0.009901 0 0.0147936 0.113315 0.19791 1 1.512643554
PC3-82 210511 s at INHBA -2.0763 0.009901 0 0.0147936 0.113315 0.19791 1 1.511347257
PC3-82 211653 x at 'AKR1C2 -2.4678 0.009901 0 0.0147936 0.113315 0.19791 1 1.511110678
PC3-82 203108 at GPRC5A -1.1125 0.009901 0 0.0147936 0.113315 0.19791 1 1.510251648
PC3-82 201482 at QSCN6 -0.8971 0.158416 0.1051867 0.2036806 0.654556 0.59655 1 1.509984372
PC3-82 205402 x at PRSS2 -0.5254 0.009901 0 0.0147936 0.113315 0.19791 1 1.509878394
PC3-82 201466 s at JUN -1.0354 0.009901 0 0.0147936 0.113315 0.19791 1 1.506635015
PC3-82 221911 at ETV1 -0.9633 0.079208 0.0400305 0.1109139 0.654556 0.59655 1 1.506498603
PC3-82 204675_at SRD5A1 -2.2267 0.009901 0 0.0147936 0.113315 0.19791 1 1.505271434
PC3-82 217591 at SKIL -1.512 0.009901 0 0.0147936 0.113315 0.19791 1 1.503326439
PC3-82 206027 at S100A3 -5.1148 0.009901 0 0.0147936 0.113315 0.19791 0.89 1.498578549
PC3-82 210740 s at ITPK1 -2.8412 0.009901 0 0.0147936 0.113315 0.19791 1 1.498179993
PC3-82 213930 at --- -2.261 0.009901 0 0.0147936 0.113315 0.19791 1 1.498100296
PC3-82 218677 at S100A14 -0.9996 0.009901 0 0.0147936 0.113315 0.19791 1 1.498037515
PC3-82 215495 s at SAMD4 -1.5774 0.009901 0 0.0147936 0.113315 0.19791 1 1.497517067
PC3-82 214321 at NOV -1.2855 0.009901 0 0.0147936 0.113315 0.19791 1 1.496948607
PC3-82 212096 s at MTUS1 -5.5705 0.009901 0 0.0147936 0.113315 0.19791 0.89 1.496818331
PC3-82 211719 x at FN1 -1.4436 0.009901 0 0.0147936 0.113315 0.19791 1 1.496013118
PC3-82 204646 at DPYD -0.4358 0.009901 0 0.0147936 0.113315 0.19791 1 1.495408843
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Abstract
Dissemination to draining lymph nodes is a frequent first step
in prostate cancer metastasis. Although tumors metastasize to
lymph nodes via the lymphatics, the importance of lymphangio-
genesis in mediating the process remains controversial. Here,
we inhibit intratumoral lymphangiogenesis in s.c. and surgical
orthotopic implantation mouse models of human prostate
cancer using several strategies. Stable expression of small
interfering RNAs (siRNA) targeted against human vascular
endothelial growth factor-C (VEGF-C) in PC-3 cells reduced
intratumoral lymphatics by 99% in s.c. tumors, indicating that
tumor-secreted VEGF-C is necessary for lymphangiogenesis.
Expression of siRNAs against human VEGF-A somewhat
reduced tumor lymphangiogenesis. Secretion of a soluble VEGF
receptor-3/Flt4 fusion protein by PC-3 cells reduced intra-
tumoral lymphatics by 100% in s.c. tumors. Combination of
soluble Flt4 and VEGF-C siRNA yielded >92% reduction of
intratumoral lymphatics in orthotopic prostate tumors. How-
ever, metastasis to lymph nodes was not significantly affected
regardless of intratumoral lymphatic vessel density. The
abundance of marginal lymphatics at the tumor-stromal
interface was unchanged in orthotopic tumors whose intra-
tumoral lymphatics were inhibited, suggesting that these
marginal vessels could be sufficient for lymph node metastasis.
Hematogenous metastasis (blood tumor burden, lung metas-
tasis) correlated with degree of lymph node invasion. We also
analyzed the lymphatics in spontaneous transgenic adenocar-
cinomas of the mouse prostate which metastasize to lymph
nodes. Progression from well-differentiated prostate intra-
epithelial neoplasia to metastatic, undifferentiated adenocar-
cinoma was accompanied by loss of lymphatics. These results
suggest that tumor-secreted VEGF-C and, to a lesser extent,
VEGF-A, are important for inducing prostate cancer intra-
tumoral lymphangiogenesis but are unnecessary for lymph
node metastasis. (Cancer Res 2005; 65(21): 9789-98)
Introduction
In prostate cancer, metastasis to regional lymph nodes is a
frequent early event that is correlated with poor clinical prognosis
Note: Supplementary data for this article are available at Cancer Research Online
(http://cancerres.aacrjournals.org/).
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(1, 2). Typically, pelvic lymphadenectomy is done prior to radical
prostatectomy to assess lymph node status. In patients with lymph
node-positive prostate cancer, 75% will possess bone metastases
within 5 years regardless of treatment (2).
Analysis of metastasis patterns in human prostate cancer (1, 3) as
well as lymphatic mapping studies using tracking dyes in breast and
melanoma (4, 5) have shown that the pattern of tumor-to-lymph
node dissemination is nonrandom. Tumors first invade draining
(sentinel) lymph nodes before seeding more distant nodes (6). If the
sentinel node is free of metastasis, other lymph nodes will also likely
be uninvaded (7). Therefore, lymphatic vessels within or in proximity
to tumors mediate dissemination to draining lymph nodes, which
may then allow further seeding to more distant sites.
Although lymphatic vessels can be detected in prostate cancer
(8-10), the role of intratumoral lymphatics in mediating lymph node
metastasis has been controversial. While numerous clinical studies
have correlated lymphatic vessel density (LVD) with lymph node
metastasis in various cancers, nearly as many have failed to detect
such associations (for a summary of clinical data, see ref. 11). In
prostate cancer, increased LVD has been correlated both with lymph
node metastasis (9, 10) and with higher Gleason score (8, 9), an
indicator of more aggressive tumors. Consequently, it is unclear
whether tumoral lymphatics actually facilitate lymph node metas-
tasis, or are simply markers of tumors prone to disseminate
regardless of LVD.
Tumor lymphangiogenesis is thought to rely on preexisting
lymphatics (12). The major lymphangiogenic cytokines are vascular
endothelial growth factors-C and -D (VEGF-C and VEGF-D),
although platelet-derived growth factor-BB has also recently been
implicated (13). VEGF-C and VEGF-D primarily bind VEGF
receptor-3 (VEGFR-3, or Flt4) on the surface of lymphatic
endothelial cells (14). Levels of VEGF-C/D have generally correlated
with lymph node metastasis in human patients (13), and
experimental overexpression of VEGF-C (15-17), VEGF-D (18),
and platelet-derived growth factor-BB (19) in cell lines has resulted
in increased tumor LVD and lymph node metastasis in tumor
implantation models. Similar results were also obtained when
VEGF-C was overexpressed in spontaneous Rip-Tag tumors (20).
Whether the effects are due to increased lymphatic permeability or
activation and/or increased abundance of intratumoral and/or
peritumoral lymphatics remains unclear (13, 21).
Other studies have suggested that intratumoral lymphatics may
be nonfunctional (17, 22, 23), or display abnormal function at the
periphery (24), implying that lymphangiogenesis plays little role in
facilitating primary tumor dissemination. In contrast, others have
shown that interfering with ligand binding to VEGFR-3/Flt4 using a
soluble receptor can inhibit tumor lymphangiogenesis and reduce
lymph node metastasis (25-29). In most cases, both peritumoral
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and intratumoral lymphatic vessels were affected, although some
have speculated that the soluble receptor may have little or no effect
on preexisting lymphatics (28, 30). Consequently, the requirement
for tumor lymphangiogenesis, and the relative roles of intratumoral
and peritumoral-preexisting or induced-lymphatics in mediating
lymph node metastasis have remained controversial (13).
To address these questions, we investigated the contributions of
intratumoral, tumor-induced lymphatics and peritumoral lym-
phatics in facilitating lymph node metastasis by inhibiting
lymphangiogenesis in a surgical orthotopic implantation (SOI)
model of human prostate cancer. Our results show that, although
intratumoral lymphangiogenesis can be selectively ablated, this has
no effect on lymph node metastasis. We also found that
spontaneous transgenic adenocarcinoma of the mouse prostate
(TRAMP) tumors do not induce lymphangiogenesis but neverthe-
less metastasize to lymph nodes. These results argue that
peritumoral lymphatic vessels, perhaps preexisting at the tumor
margins-and not intratumoral lymphatics induced by lymphan-
giogenesis-are critical for mediating lymph node dissemination.
Materials and Methods
Cell culture and mice. A subline of the human prostate adenocarcinoma
cell line PC-3 (American Type Culture Collection, Manassas, VA) was derived
in our laboratory and used in these studies (designated PC3-#82). Cells were
cultured in F-12K medium (Kaign's modification; Life Technologies-Invitrogen,
Frederick, MD) containing 10% fetal bovine serum, glutamine, and antibiotics.
Small interfering RNA (siRNA) experiments used PC3-#82 cells expressing
ecotropic receptor (plasmid provided by H. Lodish, Biology, Massachusetts
Institute of Technology, Cambridge, MA). Immunodeficient CD-1 nude mice,
30 to 35 days old (Charles River Laboratories, Wilmington, MA), were used for
xenograft experiments. TRAMP mice (The Jackson Laboratory, Bar Harbor,
ME; ref. 31) in a C57BL/6 background were obtained from A. Bai, Biology,
Massachusetts Institute of Technology, Cambridge, MA.
Plasmids. PC3-#82 cells were transfected with Flt4-Ig expression plasmid
(originally "VEGFR-3-Ig/pEBS7", K. Alitalo, Biomedicum, University of
Helsinki, Helsinki, Finland; refs. 25, 32) using Effectene reagent (Qiagen,
Valencia, CA) and selected with hygromycin (100-200 plg/mL) for stable
expression. Ig-Neg control plasmid was made by removing the Flt4 coding
sequence. All siRNAs were inserted into the retroviral vector pSIRISP (W.C.
Hahn, Dana Farber Cancer Institute, Boston, MA; ref. 33). The siRNA
plasmids were transfected with Effectene into Phoenix cells (American Type
Culture Collection), and the secreted virus was subsequently used for stable
infection of PC3-#82 cells expressing ecotropic receptor. After infection,
cells were selected on puromycin (2.5 [tg/mL) for stable siRNA expression.
Please refer to Supplementary Materials for siRNA sequences.
Xenografts. s.c. tumors were obtained by injecting 2 x 106 cells into
CD-I nude mice anesthetized with avertin/tribomethanol. Tumors were
removed for analysis and/or used as donor material for SOI -3.5 weeks
after injection, as described previously (34, 35). Briefly, a peripheral portion
of the tumor was removed and sliced into -1 mm3 cubes under a
dissecting microscope. CD-1 mice were anesthetized, and the abdominal
regions exposed with an incision along the lower midline. A single tumor
fragment was embedded into the right dorsolateral capsule and secured
with 9-0 microsutures (Ethicon, Somerville, NJ). The peritoneum and
overlying skin were each closed with one set of 5-0 sutures (United States
Surgical, Norwalk, CT). The entire protocol was done in sterile conditions
inside a fume hood, in accordance with animal care guidelines. Mice were
analyzed when moribund, as judged by bladder/abdominal distension and/
or severe weight loss (typically 2-3 months after implantation). Primary
tumors were flash-frozen or fixed for immunohistochemistry. Lymph nodes
were removed, fixed, weighed, and sectioned. A lymph node set was
considered macroscopically invaded if its total mass exceeded 30 mg
(by histology, typically >80% of the node is tumor material at this size;
see Supplementary Table Sl).
Vascular endothelial growth factor-C and -A RNA quantitation. Total
RNA was extracted using RNeasy (Qiagen). RNA was digested with DNase
(Ambion, Austin, TX), then recleaned with RNeasy. One microgram of total
RNA was reverse-transcribed into cDNA using TaqMan reverse transcrip-
tion reagent (Applied Biosystems, Branchburg, NJ). cDNAs were analyzed by
quantitative PCR using SYBR Green PCR amplification kit (Applied
Biosystems), measured in a Bio-Rad iCycler (Bio-Rad, Richmond, CA).
Target gene message levels were normalized to glyceraldehyde-3-phosphate
dehydrogenase levels, and then to the control sample. See Supplementary
Materials for real-time PCR primer sequences.
Vascular endothelial growth factor-C and -A protein quantitation.
PC3-#82 cells (5 x 105) were plated into 10 cm 2 plates and grown for 72
hours. Medium was replaced, conditioned for the times specified,
collected, and spun to remove debris. Frozen s.c. and orthotopic tumors
were thawed and homogenized in 1 mL cold CelLytic-MT mammalian cell
lysis buffer (Sigma-Aldrich, St. Louis, MO) per gram of tumor material.
Lysis buffer contained protease inhibitors (Roche, Mannheim, Germany).
After homogenization, the lysate was chilled for >30 minutes, then spun to
remove debris. Total soluble protein was quantitated by bicinchoninic acid
protein assay (Pierce, Rockford, IL) to normalize ELISA results. The
supernatant was diluted 1:4 or 1:10 in PC-3 medium for ELISA. Diluted
tumor supernatant (200 ýIL) or undiluted conditioned medium was
analyzed by human VEGF-A Quantikine ELISA (R&D Systems, Minneap-
olis, MN); 100 tL of the same were analyzed by human VEGF-C ELISA
(IBL, Tokyo, Japan).
Immunoblotting. Soluble Flt4-Ig was detected by immunoprecipitating
conditioned medium with Protein A beads (Invitrogen, Carlsbad, CA). The
beads were spun, washed, and boiled in Laemmli SDS buffer containing 5%
V-mercaptoethanol. The protein was run on 8% SDS gel and detected with
goat anti-human VEGFR-3 antibody (clone AF349; 1:100 diluted; R&D
Systems) or rabbit anti-human antibody conjugated to horseradish
peroxidase (1:1,000 diluted; DAKO, Glostrup, Denmark). Tumor Flt4-Ig
was detected in tumors by homogenizing in CelLytic-MT lysis buffer, as
above, and running supernatant on SDS-PAGE.
Histology and immunohistochemistry. For immunohistochemistry,
2- to 3-mm-thick portions were removed near the periphery of the
anterior-facing end of the tumor. For wild-type and TRAMP prostates, the
dorsolateral lobes were dissected. In most cases, the tissue was fixed in
zinc (Becton Dickinson, San Diego, CA) for 48 hours. For short-term
orthotopic analysis, prostate tissue was fixed in 3.7% formaldehyde
overnight. Primary antibodies for immunohistochemistry included rabbit
anti-LYVE-1 (Ruoslahti lab; 1:450; ref. 36), goat anti-mouse VEGFR-3
(clone AF743, R&D Systems: 1:25) and rat anti-CD34 (clone RAM34, BD
PharMingen, San Diego, CA; 1:25). Sections were dewaxed, microwaved in
BD Retrievagen buffer, and stained using standard protocols. Biotin-
conjugated secondary antibodies included swine anti-rabbit immunoglob-
ulin (DAKO) and rabbit anti-rat immunoglobulin (Vector Labs, Burlin-
game, CA), both diluted 1:250. Staining was amplified with Vectastain ABC
kit (Vector Labs), developed with Vector VIP peroxidase substrate and
counterstained with methyl green. Lymphatic and blood vessels were
quantitated by counting the number of LYVE-1 or CD34-positive vessels,
respectively, in two random, low-power fields (2.25 x 1.7 mm) per tumor.
About 30% to 100% of the tumor area is covered with this approach, and
the LVD from a minimum of seven independent tumors was typically
quantitated for each cell line. In TRAMP and normal prostates, a single
low-power field was used for lymphatic quantitation, typically covering
70% to 100% of the sample. TRAMP tumor grading was based on a system
described by Hurwitz et al. (37). Two pathologists (M. Barry and R.
Bronson) independently graded H&E TRAMP sections, and then together
arrived at an agreed upon grade. For short-term SOI analysis, the length of
the tumor periphery at x 105 final magnification was quantitated in pixel
units by OpenLab software (Improvision Inc., Lexington, MA), and the
number of lymphatics at the periphery was normalized to a 1,000-pixel
perimeter. We defined "intratumoral" lymphatics as LYVE-1-positive
vessels completely surrounded by tumor cells, and "marginal" or
"peritumoral" lymphatics as vessels in contact with both tumor cells
and stroma.
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Statistics. All statistical comparisons were calculated with the unpaired
Student's t test. All error bars show ± SE.
Results
Stable small interfering RNAs specifically reduce vascular
endothelial growth factor-C or -A expression and protein
secretion. s.c. tumors formed by a subline of PC-3 prostate
cancer cells (designated PC3-#82) possessed abundant intra-
tumoral lymphatic vessels, as confirmed by immunohistochemical
staining for the lymphatic markers LYVE-1 and VEGFR-3/Flt4,
and absence of staining for the blood vessel marker CD34 (Fig. 1).
Because blood vessels in some tumors have been reported to
express VEGFR-3/Flt4 (38), we used LYVE-1 and CD34 for the rest
of these studies.
PC3-#82 cells expressed and secreted VEGF-C (Fig. 2A and B),
but not VEGF-D (data not shown). To examine the importance of
tumor-secreted VEGF-C in promoting lymphangiogenesis, we
stably expressed siRNAs against VEGF-C in PC3-#82 cells. We also
generated siRNAs against VEGF-A, a potent inducer of angiogen-
esis previously reported to stimulate lymphatic growth in the
mouse ear (39). C13 and C14 siRNAs knocked down VEGF-C
mRNA by 81% and 88%, respectively, relative to vector control
(Fig. 2A). A2 and A3 siRNAs reduced VEGF-A mRNA by 67% and
74%, respectively (Fig. 2A). Quantitative PCR showed that VEGF-C
siRNAs had little effect on VEGF-A expression, and vice versa.
C14-MM and A3-MM mismatch (MM) controls showed little
siRNA efficacy. Relative RNA message levels for VEGF-C/A were
reflected in their relative protein abundance in conditioned
medium, as assayed by ELISA (Fig. 2B). Cells expressing C14
siRNA accumulated virtually no VEGF-C in conditioned medium
after 72 hours, whereas cells expressing C13 showed modest
accumulation (Supplementary Fig. Si). VEGF-A secretion was not
significantly reduced by either C13 or C14 siRNAs, but was
slightly increased in C14-MM control.
As an additional approach for ablating lymphatics, we expressed
the soluble VEGFR-3/Flt4-human Fc-Ig fusion protein (Flt4-Ig) in
PC3-#82 cells, as described previously (25, 32). Protein secretion
was confirmed by immunoprecipitation from conditioned medium
and Western blot against VEGFR-3 (Fig. 2C).
Tumor-secreted vascular endothelial growth factor-C is
necessary for lymphangiogenesis. PC3-#82 cells expressing
siRNAs against VEGF-C or VEGF-A, or control siRNAs were
injected s.c. into CD-1 immunodeficient mice. We did not see
consistent tumor growth effects correlated with VEGF-C or
VEGF-A inhibition. Tumors were removed -3.5 weeks postin-
jection, sectioned and stained for LYVE-1 and CD34. PC3-#82
cells expressing C14 siRNA showed a >99% reduction in LVD
(Fig. 3A, c) relative to controls (Fig. 3A, a and b). Tumors
expressing C13, a less effective siRNA against VEGF-C, yielded
an 83% reduction in LVD relative to controls (Fig. 3B).
Interestingly, both siRNAs against VEGF-A (A2, A3) yielded a
nearly 50% reduction in LVD versus controls (Fig. 34A, d for A3
and data not shown for A2; combined P = 0.052). As both
VEGF-A siRNAs were only partially effective in reducing VEGF-A
gene expression, it is possible that more potent VEGF-A siRNAs
would have yielded greater reduction in LVD. LVD quantitation
of siRNA- or siRNA control-expressing tumors is shown in
Fig. 3B. In agreement with results by others (25, 26), expression
of soluble Flt4-Ig (Fig. 3A, f) yielded complete inhibition of
lymphangiogenesis versus Ig-Neg control (Fig. 3A, e and C). In
all cases, blood vessel density was not consistently affected
(Fig. 3B and C; images not shown), although C14-MM control
tumors had somewhat increased angiogenesis. Staining also
appeared slightly lighter in some tumors expressing siRNA.
Taken together, these results indicate that tumor-secreted VEGF-
C is necessary for intratumoral lymphangiogenesis. To a lesser
extent, tumor-secreted VEGF-A may also be important. The lack
of reduction in blood vessels, especially by A2 and A3, might
Figure 1. PC3-#82 cells form s.c. tumors with intratumoral lymphatic and blood vessels. Serial tumor sections probed with antibodies against LYVE-1 or CD34
show specific, nonoverlapping staining for lymphatics or blood vessels, respectively (top). In the merged image, lymphatics are colored white, and blood vessels black.
Serial sections probed with LYVE.1 and anti-mouse VEGFR-3/Flt4 show coincident staining (bottom).
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Figure 2. PC3-#82 cell expression and secretion of VEGF-C or VEGF-A can be reduced by siRNA. A, relative mRNA levels for VEGF-C (black) or VEGF-A (gray)
were measured by quantitative PCR, and normalized to pSIRISP vector control. C13 and C14 cells express siRNAs against VEGF-C. A2 and A3 cells express
siRNAs against VEGF-A. C14-MM and A3-MM (MM, mismatch) are siRNA specificity controls. siRNAs specifically down-regulated expression of the target gene and
reduced accumulation of either VEGF-C or VEGF-A protein in conditioned medium, as assessed by ELISA (B). Control samples typically secreted -2,000 pg
VEGF-C/mL conditioned mediun-/24 hours, and -200 pg VEGF-A/mL conditioned medium/24 hours. C, secretion of soluble VEGFR-3/Flt4-Ig fusion protein in
PC3-#82 cells was confirmed by immunoprecipitating fusion protein from conditioned medium and Western blot (**, P < 0.001).
reflect: the limited mRNA knock-down, and/or suggest that other
angiogenic factors are sufficient for inducing tumor angiogenesis.
Ablation of prostate intratumoral lymphatics does not
inhibit lymph node metastasis. PC-3 cells have been reported
to metastasize infrequently from s.c. tumors (40). In contrast,
prostate tumor cells introduced orthotopically metastasize in
patterns similar to human prostate cancer, including invasion of
lymph nodes, lung, and bone (34, 35). To model the early stages
of metastasis, where cells must detach from the primary tumor
before intravasating into vasculature, we used SOI to graft a
single piece of solid tumor into the dorsolateral prostate lobes of
CD-I mice (Fig. 4A). Graft material was derived from s.c. tumors.
As an advantage over other xenograft techniques, SOI minimizes
the artificial dispersal of cells away from the site of implan-
tation, as is often seen when tumor cells are injected as a
suspension (41). As expected, the tumors introduced by SOI
develop initially from a single focus in the interluminal spaces of
the prostate (Fig. 6A, a). Between 2 and 3 months after
implantation, - 50% of mice develop lymph node macrometa-
stases. We find that hematlogenous spread (circulating tumor
cells in blood and lung metastasis) is strongly associated with
lymphatic invasion (Supplementary Fig. S2), and primary tumors
possess abundant blood and lymphatic vessels (data not shown;
similar to Fig. 1).
To dletermine the metastatic effects of ablating lymphatic vessels
in orthotopic prostate tumors, we used SOI to transplant PC3-#82
tumors expressing either VEGF--C siRNA (C14), Flt4-Ig, or controls.
LVD was reduced by - 50% in both C14- and Flt4-Ig-expressing
tumors (Fig. 4B). Although statistically significant (P = 0.012 for C14
versus control; P = 0.0046 for Flt4-Ig versus control), this reduction
was far less severe than was seen in s.c. tumors. Expression of either
C14 siRNA or Flt4-Ig in orthotopic tumors did not affect the
incidence of macroscopic lymph node metastasis (Fig. 4C), the
average mass of macroscopically invaded lymph nodes (Fig. 4C;
P = 0.92), or the average size of the primary tumors (data not shown).
For lymph nodes without obvious macrometastases, histologic
analysis identified micrometastases in virtually all samples analyzed,
regardless of cell line (Supplementary Table SI).
To understand why inhibition of lymphangiogenesis was less
effective in orthotopic versus s.c. tumors, we used ELISA to
measure the human VEGF-C protein levels in s.c. and orthotopic
tumors expressing C14 or siRNA control. The concentration of
human VEGF-C protein in ('14 orthotopic tumors was increased
relative to C14 s.c. tumors and was correlated with LVD in both C14
and control tumors (Supplementary Fig. S3). Reduced siRNA-
mediated inhibition of VEGF-C secretion over the duration of the
experiment possibly accounted for less severe inhibition of tumor
lymphangiogenesis. In the case of Flt4-Ig-expressing tumors,
Western blot for VEGFR3/Flt4 indicated that, in some orthotopic
tumors, expression of the fusion protein was also severely reduced
(Supplementary Fig. S4).
To further ablate orthotopic intratumoral lymphatics, we
generated a derivative of PC3-#82 that combined expression of
VEGF-C siRNA and Flt4-Ig (Flt-C14), in addition to a cell line
expressing both empty-vector controls (Ig-pSIRISP). Specific knock-
down of VEGF-C mRNA and secretion of Flt4-Ig were again
confirmed (Fig. 5A). As expected, Flt-C14 s.c. tumors possessed
no lymphatic vessels, whereas Ig-pSIRISP control tumors had
abundant LYVE-1 staining (Fig. 5B). When implanted orthotopi-
cally, Flt-C14 tumors (n = 11) exhibited a 92% reduction in LVD
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versus controls (n = 8; P < 0.001). A single Flt4-C14 tumor
possessed moderate LVD, and without this outlier, inhibition of
LVD increases to 98% versus control. Interestingly, blood vessel
density was also reduced -35% in Flt-C14 tumors versus Ig-
pSIRISP control.
Despite a >92% reduction in intratumoral lymphatics, the
incidence of microscopic and macroscopic lymph node invasion,
and the mass of macroscopically invaded lymph nodes were again
largely unaffected in Flt-C14 tumors versus Ig-pSIRISP control
(Fig. 5C; P = 0.15), or other controls used in this study (Figs. 4C and
Fig. 5C). As before, nearly all local lymph nodes evaluated harbored
micro- or macrometastatic tumor invasion (Supplementary Table
S1). Also, we found no significant correlation between LVD and
lymph node metastasis in individual orthotopic tumors whose
lymphatics were ablated (Fig. 5D). Our data argue that intra-
tumoral lymphangiogenesis is unnecessary for prostate cancer
metastasis to lymph nodes.
Abundance of preexisting marginal lymphatics is unaffected
in Flt-CI4 orthotopic tumors. At least two possible explanations
could account for how orthotopic prostate tumors metastasized
efficiently to lymph nodes despite a >98% inhibition of intra-
tumoral lymphangiogenesis in 10 of 11 Flt-C14 tumors. Formally,
it is possible that a minority of lymphatic vessels (<2% of total) is
sufficient for metastasis. A more likely explanation is that
marginal lymphatic vessels at the tumor-stromal margin-and
not intratumoral lymphatics-are responsible for mediating
lymph node metastasis.
Because orthotopic tumors were analyzed 2 to 3 months after
implantation, the tumors tended to be large (- 1 g; see Fig. 4A) and
almost completely devoid of stromal tissue. To examine tumor
interaction with preexisting marginal lymphatics, we transplanted
Flt-C14 or control tumors using SOI and analyzed them 2 to 3
weeks after implantation. In most cases, tumors were not palpable
and were found by sectioning through the dorsolateral prostate
(Fig. 6A, a). As expected, primary tumors consistently arose from
a single focus.
We stained microscopic Flt-C14 or control orthotopic tumors
with LYVE-1 and found that both were in contact with lymphatics
located at the tumor-stromal margin (Fig. 6A, b-d; data not shown
for control tumors). In Flt-C14 tumors, all stages of lymphatic
invasion were observed, including tumor growth up against
individual lymphatic vessels without compression (Fig. 6A, b),
intravasation of tumor cells into lymphatics (Fig. 6A, c), and
crushing of vessels (Fig. 6A, d). Typically, these marginal
lymphatics delineated the exact region of contact between the
expanding tumor periphery and the surrounding prostatic stroma.
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Figure 4. SOI of PC3-#82 cells yields primary
tumors in the mouse prostate. Mouse urogenital
system (top left), with the site of implantation
indicated by an arrow (photograph courtesy
Dr. Anne Donjacour, UC Davis). Graft material
was labeled with CellTracker Green (bottom left),
implanted into the dorsal prostate and
immediately imaged under a fluorescence
dissecting microscope. Right, a typical orthotopic
primary tumor 2 to 3 months after implantation
(lower arrow), along with paralumbar lymph node
metastases (upper arrows). B, quantitation of
lymphatic (black) and blood vessels (gray) from
orthotopic tumors. C, metastasis to the draining
(lumbar) and more distant (renal) lymph nodes
were unaffected in all cases (for lumbar lymph
node mass; P = 0.92 for C14 versus pSIRISP;
P = 0.81 for Flt4-lg versus Ig-Neg; and similarly
not significant for renal lymph nodes; *, P < 0.02).
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Quantitation of marginal lymphatics revealed little difference
between Flt-C14 and control orthotopic tumors (Fig. 6B; P = 0.55).
However, intratumoral lymphatics were present in control tumors
but completely absent in Flt-C14 tumors (Fig. 6B). These results
indicate that a combination of VEGF-C siRNA and Flt4-Ig fusion
protein selectively inhibited intratumoral lymphangiogenesis
without affecting marginal, possibly preexisting, lymphatics, and
suggest that these vessels at the periphery are sufficient for
mediating lymph node metastasis.
Spontaneous TRAMP tumors do not induce lymphangio-
genesis. To extend our observations, we examined the lym-
phatics in spontaneous TRAMP tumors. TRAMP transgenic mice
express the SV40 large T antigen driven by the prostate-specific
rat probasin promoter (31.). Prostatic intraepithelial neoplasia
(PIN), a precursor of prostate cancer, appears as early as 10
weeks of age, and progresses to undifferentiated adenocarcinoma
(42). TRAMP prostates are graded 1 to 6 (1 being normal
prostate, and 6 being undifferentiated adenocarcinoma), based on
variables including cell differentiation and invasion through the
basement membrane (37, 43). By 28 weeks, 100% of TRAMP mice
were reported to harbor lymph node and/or lung metastases
(44). Importantly, local and distant dissemination is predomi-
nantly seen only in mice with primary tumors of grade 4 or
higher (37).
We examined the prostatic lymphatics in 8 normal C57BL/6
mice and 14 TRAMP mice at different ages and/or tumor stages.
The lymphatics in normal prostates were located in the
interluminal spaces outside individual ductal structures (Supple-
mentary Fig. S5), and their abundance and location did not differ
in mice between 15 and 35 weeks of age (data not shown). In
TRAMP prostates, PIN develops from the initial expansion of
luminal cells within ductal structures. As with wild-type
prostates, lymphatics in TRAMP prostates were consistently
located outside of ductal structures and did not infiltrate into
tumorigenic areas (Fig. 6C). Tumorigenic prostates graded from 1
to 4 did not exhibit significant differences in LVD versus normal
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prostates (Fig. 6D). In the most severe cases of prostate cancer stromal border prior to vessel compression and destruction.
(grades 5 and 6), the tumorigenic regions had overtaken the These results support our findings in the xenograft SOI model
surrounding stroma, and lymphatic density in the prostate was that intratumoral lymphangiogenesis is not required for lymph
reduced 7-fold versus either normal prostates or low-grade node metastasis.
tumorigenic prostates (Fig. 6C and D: P < 0.001). Because
metastasis to lymph nodes is predominantly seen only in high- Discussion
grade TRAMP tumors (37), it is likely that these spontaneous Lymph node status has traditionally been used as a prognostic
tumors also use preexisting lymphatics located at the tumor- indicator of prostate cancer aggressiveness, dissemination to
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Grades 5 to 6 TRAMP prostates possess significantly fewer lymphatic vessels than lower grade or normal (grade 1) prostates (P < 0.001).
distant sites and likelihood of recurrence after therapy (1-3, 45).
Although recent clinical studies have examined the abundance of
lymphatics and/or lymphatic growth factors in prostate cancer,
the results have been difficult to interpret. In most cases, VEGFR-
3/Flt4 was up-regulated in advanced or node-positive prostate
cancer (9, 10, 46, 47). One study found augmented tyrosine
phosphorylation of VEGFR-3/Flt4 in advanced versus early stage
(node-negative) prostate cancer (46), whereas another found up-
regulation of a truncated form of VEGFR3/Flt-4, but not full-length
receptor (48). Furthermore, VEGF-C was up-regulated in some
cases of metastatic prostate cancer (9, 10) but not in others
(46, 48). VEGF-D was also increased in node-positive versus node-
negative prostate cancer in some studies (46, 48) but was
unchanged in another (9).
Part of the complexity in analyzing these data arises from
the difficulty of distinguishing whether VEGFR-3/Flt4 was up-
regulated in tumor-associated lymphatics or in the tumor cells
themselves (46-48). Indeed, in vitro studies have shown that
prostate cancer cell lines can express the related receptors VEGFR-
1/Fltl (49, 50) and VEGFR-2/Flkl (49-51). Furthermore, staining
for VEGFR-3/Flt4 in one study of prostate cancer exclusively high-
lighted tumor and epithelial cells, but not endothelial vessels (46).
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In studies where VEGFR-3/FIt4 staining identified lymphatics
associated with prostate cancer, the localization of these vessels was
either reported to be peritumoral (10), or both peritumoral and
intratumoral (9). However, VEGFR-3/Flt4 has also been found to be
expressed in some tumor blood vessels (38). One clinical study of
prostate cancer reported lymphatics primarily in the tumor peri-
phery and nontumorigenic stromal regions (8). Because lymphatics
were significantly reduced in tumors, the authors speculated that
prostate cancer progression causes lymphatic destruction. LYVE-1-
positive vessels were also correlated with increased Gleason score
(8), but a detailed study comparing node-positive- with node-
negative prostate cancer using LYVE-1 has not been done.
Up-regulated VEGFR-3/Flt4, VEGF-C, and VEGF-D have also been
correlated with other variables of prostate cancer progression,
including Gleason score (9, 10, 47) and PSA level (10, 47). Conse-
quently, it is difficult to distinguish whether increased lymphatics
actually facilitate nodal metastasis or are simply markers of more
aggressive primary tumors. Similarly, in experimental mouse models,
whether lymphangiogenesis is required for lymph node metastasis
may depend on the innate aggressiveness of the tumor in question. It
is possible that for tumors already adept at colonizing distant sites,
preexisting lymphatics may be sufficient for lymph node metastasis,
whereas less aggressive cancers may require additional vessels to
disperse more cells and increase the probability of metastasis. This
may explain why overexpression of insulin-like growth factor receptor
I in pancreatic islet tumors by Hanahan's group yielded aggressive
tumors that metastasized to lymph nodes without significant
lymphangiogenesis [as reported by Alitalo et al. (ref. 52)].
Functional studies using assays for microlymphangiography and
interstitial fluid pressure have suggested that intratumoral lymphatics
may be nonfunctional (17, 22). Tumor compression of intratumoral
lymphatic vessels may be responsible for the absence of function,
although tumor-induced lymphatics may inherently be physiologi-
cally abnormal (23, 24). Although this apparent absence of function
has been interpreted to suggest that intratumoral lymphatics are
unimportant for metastasis, that hypothesis needs further testing.
In contrast with our results, work by others has shown that
inhibiting tumor lymphatics with soluble VEGFR-3/Flt4-Ig fusion
protein can reduce metastasis to lymph nodes both in xenograft
models (25, 26, 28, 53, 54) and in Rip-Tag spontaneous tumors (27). In
most studies, both peritumoral and intratumoral lymphatics were
inhibited, although some have suggested that Flt4-Ig may have no
effect on preexisting lymphatics (28, 30, 53, 54), or may inhibit
peripheral, but not intratumoral, lymphatics (27). The varying
effectiveness of Flt4-Ig may reflect how and when the inhibitor was
administered, its concentration, diffusion to surrounding tissues,
abundance of preexisting lymphatics, and local concentration of
VEGF-C/D ligands. Several articles report that high-level, systemic
expression of Flt4-lg fusion protein can suppress metastasis (27,
53, 54). Recent work by Pytowski et al. has suggested that VEGF-
C-mediated VEGFR-3 signaling might be unnecessary for the main-
tenance of preexisting lymphatics in the mouse tail (55). In any case,
the relative importance of peritumoral versus intratumoral lym-
phatics in mediating lymph node spread has remained unclear. In
addition, inhibiting lymphangiogenesis through the use of soluble
receptor, VEGFR-3/Flt4 antibody (29) or VEGF-D antibody (18), has
not distinguished between the ligands required for the process and/or
the source of the ligands. VEGF-C/D may be secreted by tumors or
from stromal sources including tumor-associated macrophages (56).
In this study, we have used the SOI model of human prostate
cancer to show that intratumoral lymphangiogenesis can be
inhibited in tumors (Flt-C14) without significantly affecting lymph
node metastasis. In early stage Flt-C14 tumors, we found that despite
the absence of intratumoral lymphangiogenesis, the abundance of
peritumoral lymphatics was not statistically different from controls,
and in all cases, tumor-intravasated lymphatic vessels were observed.
These data suggest that intratumoral lymphangiogenesis is unnec-
essary for lymph node metastasis in prostate cancer, and that
marginal, possibly preexisting, lymphatics are sufficient. He et al. (53)
reported that VEGF-C can promote dilation and sprouting in
preexisting lymphatics and that this could be inhibited by high levels
of systemic Flt4-lg, although the tumor cells still coopted the
preexisting lymphatics and lymph node metastases still occurred,
albeit at reduced levels. Those results could be reconciled with ours
if the high levels of Flt4-lg partially inhibited the intravasation of
tumor cells into preexisting lymphatics.
We have also obtained corroborative results using the TRAMP
spontaneous model of prostate cancer. In TRAMP, metastasis to
lymph nodes is primarily observed only in tumors of grade 4 or
higher (37). In TRAMP prostates, we found that lymphatics were
typically located outside the luminal acinar regions where PIN and
adenocarcinoma develop. Peritumoral, but not intratumoral,
lymphatics were seen and, as the tumors invaded through the
basement membrane into surrounding stromal regions (grades 5
and 6), significantly fewer lymphatics were observed, suggesting
the destruction of preexisting lymphatics and the absence of
lymphangiogenesis. This is similar to human clinical prostate
cancer (8), and also indicates that preexisting peritumoral
lymphatics are sufficient for lymph node metastasis.
It remains to be determined whether lymph node metastasis is
important for hematogenous dissemination. In our SOI model, we
observed that hematogenous metastasis was strongly associated with
lymph node invasion (Supplementary Fig. S2). These data mayindicate
that tumors enter the blood circulation indirectly via lymphatics, or
that blood and lymphatic vessel intravasation occur simultaneously.
Others have proposed that lymph nodes may act as bridgeheads where
tumor cells with limited metastatic capability can proliferate and
acquire additional mutations that allow further dissemination (57).
Whether this hypothesis is accurate remains to be seen.
In summary, we have shown that, in prostate cancer, lymph node
metastasis relies on peritumoral, and not intratumoral, lymphatics,
suggesting that the peritumoral lymphatics that preexist before
tumor development may be sufficient for disseminating tumor cells
to local and more distal lymph nodes. Our results also suggest that
inhibiting lymphangiogenesis may be easier than ablating preexisting
lymphatics. As targeting lymphatic vasculature has recently been
proposed as an antimetastatic approach for limiting the spread of
primary tumors (13), this study shows that the need to target the
surrounding marginal lymphatics is especially imperative.
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ABSTRACT
The formation of distant metastases is the deadliest phase of cancer progression.
Although numerous studies have identified genes and mechanisms that affect metastasis
after tumors have reached secondary sites, our knowledge about how cancer cells initially
gain access to systemic circulation is limited. Since tumors can enter the blood directly by
intravasating into venous capillaries or indirectly via lymphatics, it is important to evaluate
the relative contributions of both pathways as routes of egress from the primary site.
Insights into tumor and stromal factors governing the intravasation process may help
explain why certain tumors exhibit "preferred" pathways for metastatic dissemination,
both clinically and in experimental animal models.
WHICH TUMORS METASTASIZE?
What makes a tumor cell metastatic? Certainly, proliferative ability at a distant site is
essential for metastasis (Paget's "seed and soil" hypothesis), and difficulties in establishing
secondary growth might explain why fewer than 0.01% of circulating tumor cells actually
form metastases. 1-3 However, exactly what enables a cancer cell to complete the metastatic
process is not entirely clear. While recent gene expression studies have suggested that distant
metastases resemble their primary tumors of origin,4 '5 other studies have indicated that the
expression of specific genes is altered in metastatic cells. 6-8 A model combining both these
observations has speculated that cells derived from metastases and from their corresponding
primary tumors share an overall gene expression signature that confers the ability to
complete some, but not all, of the steps required for metastasis.7'9 On top of this, the
altered expression of a limited number of additional genes may render a sub-population of
cells fully competent for metastasis, without changing its overall similarity with the primary
tumor.
Although metastasis is widely regarded as an inefficient process, most cancer patients
die from metastases rather than from their primary tumors. Metastatic inefficiency is likely
overcome by the sheer number of tumor cells that enter the systemic circulation daily,
estimated in one study to be up to -4 x 106 tumor cells released per gram of primary
tumor. 10 Consequently, it is important that we gain a detailed understanding of how
tumors complete the earliest steps of metastasis, including intravasation into vasculature.
In order to metastasize, cancer cells must first detach from the primary tumor and
invade blood vessels or lymphatics. This may be a passive process where cells are simply
sloughed off from the primary tumor or an active one involving directed migration.11,12
Almost certainly, a tumor's cell of origin and its accompanying differentiation program will
affect its metastatic proclivity. 13 Cells from connective tissue tumors such as fibrosarcomas
and gliomas tend to migrate individually, for instance, whereas those from melanomas and
carcinomas often migrate collectively.14 In addition, highly differentiated epithelial tumors
may initially display collective migration, only to de-differentiate and exhibit single cell
invasion, a process termed epithelial-to-mesenchymal-transition (EMT).1 5 Indeed, genes
that promote EMT-including Twist;8 Slug and Snail transcription factors; 16 and com-
ponents of the TGF-P signaling pathway7,18-have all been reported to enhance the
earliest stages of metastasis. E-cadherin, which is often lost during EMT, is thought to
suppress cell migration and tumor progression. 19 Finally, stromal cells such as fibroblasts
and macrophages have also been reported to affect metastasis by contributing growth
factors (e.g., EGF, FGF-1), matrix metalloproteinases and chemotactic/pro-migratory
factors (e.g., SF/HGF, chemokines).12,14
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BLOOD VESSEL OR LYMPHATIC
DISSEMINATION?
Once a migratory cell(s) has detached from the
primary tumor, it may intravasate into blood
vessels or lymphatics. Either route of dissemination
can lead to venous circulation, as lymphatics drain
into blood, most commonly through the left
lymphatic duct (thoracic duct) or the right
lymphatic duct, and then subsequently into the
subclavian veins. Along the way, lymphatic fluid is
filtered by lymph nodes.
In the absence of overt metastases, hematoge-
nous dissemination of tumors is assayed by
detecting cancer cells in the peripheral blood of Figure 1. Tumor.
patients or from bone marrow aspirates. 20 The Experimental ablaEliminating or inhpresence of circulating tumor cells and ly phatic spreadlymphatic spread
micrometastases can be determined by RT-PCR that nevertheless
or immunohistochemistry (IHC), particularly for lymphatics media
cytokeratins in the case of epithelial tumors. VEGFR3; adeno,
Lymphatic spread is also assayed by IHC and/or
RT-PCR following surgical removal of regional lymph nodes. Tumors
almost invariably invade lymph nodes in sequence, starting with the
nearest (sentinel or draining) node, followed by increasingly distal
ones. 21 If the draining lymph node is uninvaded, other lymph nodes
are also likely free of metastases. 22
Metastatic bias is illustrated by the fact that carcinomas and
melanomas tend to develop lymph node metastases more frequently
than sarcormas,1 4 although it is unclear whether this disparity is due
to differences in intravasation and/or growth. Lymph nodes are often
the first site of metastasis in a variety of cancers, and are critical for
tumor staging and prognosis.22 In prostate cancer, for instance, 75%
of patients bearing lymph node metastases at the time of diagnosis
will possess bone metastases within 5 years, regardless of treatment. 23
The presence of tumor cells in the bone-marrow is also predictive of
distant metastases in a variety of tumors, particularly carcinomas.220
On the other hand, the prognostic value of circulating tumor cells in
the blood is debated, as current techniques for detection suffer from
problems such as low sensitivity and high rates of false positives. 24,25
However, recent studies using an automated platform for detecting
tumor cells in the blood, called CellSearch, have reported significant
correlations between the presence of circulating tumor cells and poor
clinical outcome for breast cancer patients. 26
The decision to intravasate into either blood or lymphatic vessels
may rest largely on physical restrictions imposed on invasive tumors,
although active mechanisms for attracting cells to specific types of
vasculature have also recently been proposed (see below). Lymphatic
capillaries lack the tight interendothelial junctions typically seen in
blood vessels, as well as the surrounding layers of pericytes/smooth
muscle cells and basement membranes.27 This inevitably renders
lymphatics "leaky" relative to blood vessels, thus lowering the barriers
for tumor intravasation. In addition, tumor cell survival may benefit
from the passive, low-shear system of fluid transport characteristic of
lymphatics.
Accessibility of blood and lymphatic vasculature may also influence
the pathway taken for metastasis. Induction of angiogenesis, the
growth of blood vessels, has been shown to be necessary for tumors
growing beyond 0.4 mm in diameter.2 8,29 Lymphangiogenesis, the
growth of lymphatic vessels, has: been inhibited by us30 and others31-37
in experimental mouse cancer models without affecting primary
mor
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tion of intratumoral lymphatics does not inhibit lymph node metastasis (top).30
ibiting the activation of peritumoral lymphatics has been shown to reduce
'bottom). 32,37,47 In addition, intratumoral lymphatics are absent in many tumors
metastasize to lymph nodes.51 These observations imply that peritumoral
te the majority of tumor cell dissemination. (FIt4-Ig, soluble Flt4 receptor/
adenoviral delivery).
tumor growth. Because blood and lymphatic vessels share a common
embryonic origin, and respond to many similar growth factors-
VEGF-A, VEGF-C, VEGF-D, FGF2, PDGF-B, HGF and others38
-tumors might be expected to induce lymphangiogenesis concomi-
tant with angiogenesis. But f~or reasons unclear, this is often not the
case. While proliferating intratumoral lymphatics have been detected
in human melanomas, 39 as well as in head and neck squamous cell
carcinomas, 40 evidence for lymphangiogenesis in other cancers has
been less well documented. The presence of anti-lymphangiogenic
factors may be one reason why proliferating intratumoral lymphat-
ics are not more commonly found in human clinical tumors,41
though the identity of these proposed factors is currently unknown.
Nonetheless, intratumoral lymphatics may provide a possible
escape route from the primary tumor to draining lymph nodes, and
indeed, several studies have reported that inhibition of lymphangio-
genesis in xenograft tumor models can significantly reduce lymph
node metastasis.3 1-33,36 However, other studies have suggested that
intratumoral lymphatics are compressed and nonfunctional.42-45
This apparent absence of functional intratumoral lymphatics would
imply that tumor cells intravasated into these vessels will encounter
blockages and dead ends that actually impede metastasis. The fact
that many tumors metastasize to local lymph nodes despite absence
of lymphangiogenesis or functional intratumoral lymphatics, has led
some to propose that it is the peripheral, peritumoral lymphatics
that mediate tumor cell dissemination.37'46 We recently obtained
results consistent with this hypothesis by selectively ablating
intratumoral, but not peritumoral, lymphatics in a prostate cancer
orthotopic model and showing that lymph node metastasis was not
significantly altered.30 Other studies that ablated peritumoral
lymphatics or inhibited their "activation"-local vessel sprouting,
dilation and permeability-were successful at reducing metastasis
(Fig. 1).32"37 ,47 It is possible that the studies reporting metastatic
inhibition associated with ablation of intratumoral lymphatics
3 1-33
,
36
may actually reflect interference with tumor cell intravasation into
peritumoral lymphatics. Recent clinical and spontaneous animal tumor
studies have also reported that prostate,48 breast 49,50 and pancreatic
tumors51 develop lymphatic metastases in the absence of intratumoral
lymphangiogenesis.
adano-Fl-g
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Figure 2. After surgical orthotopic implantation of human prostate PC-3 cells into nude mice, associations
were observed among lymph node metastasis, circulating tumor cells and lung micrometastases. Left,
significant numbers of circulating tumor cells in the blood were detected only in mice that bore macrometas-
tases in both the lumbar and renal lymph nodes. Middle, similarly, most lung metastases were seen in mice
with both lymph node sites invaded. Right, lung metastases were correlated with the presence of circulating
tumor cells in the blood. (Reproduced with permission from ref. 30).
Perhaps the best approach for studying blood and lymphatic vessel
intravasation is to observe the process in real time, using in vivo
intravital microscopy. Wyckoff et al imaged rat mammary adenocar-
cinomas and discovered that metastatic cells were more likely to
polarize towards blood vessels than were nonmetastatic cells.
11
,52
Interestingly, polarization of metastatic cells was explained by increased
expression of EGF receptor, which made the cells chemotactic to
EGF released by macrophages lining blood vessels. Furthermore,
individual metastatic cells were seen intravasating into blood vessels
using an amoeboid form of movement. Nonmetastatic cells, however,
often fragmented upon crossing endothelial junctions. Consequently,
the authors speculated that inrravasation was a rate-limiting step for
metastasis.
Although this work dealt with a limited number of established
cell lines and did not examine lymphatics, it does raise several
important considerations about the intravasation process. These
considerations include the mode of cell migration utilized (individual
amoeboid or fibroblastic movement, versus collective sheet/nest
migration); the role of stromal cells in promoting polarized move-
ment; and the effect of hemodynamic shear forces on cell viability-
all of which may influence a tumor's preference for disseminating via
blood vessels or lymphatics.
The type of cell movement undertaken is affected, in large part,
by the surrounding extracellular matrix (ECM) and by the integrity
of cell-cell juncrions."14 Mesenchymal, or fibroblast-like, single cell
migration tends to occur when mature, integrin-containing focal
contacts develop in the presence of dense matrix networks.
Amoeboid migration is favored under less adhesive conditions, as is
often seen in vivo or in three-dimensional cultures, when focal
contacts are lacking.53 The speed of amoeboid migration is about
10-30 times faster than mesenchymal migration and is protease-
independent. 14 '53 Given that lymphatic vessels lack basement
membranes, and that ECM networks are likely less dense around
peritumoral lymphatics than around intratumoral blood vessels, this
would scem to favor rapid and efficient amoeboid-type intravasation
814 Cell
into lymphatic circulation. Lymphatic
permeability may also allow passage of cell
aggregates that have retained expression
of homotypic cell-cell adhesion receptors
such as cadherins.54
In addition, active recruitment of
tumor cells towards lymphatics may occur
via EGF-EGFR-mediated chemotaxis,
since macrophages have been found in
proximity to lymphatic vessels.55' 56 In one
study, macrophages were even reported
to transdifferentiate into lymphatics in
response to inflammation in an eye
cornea model,57 though the generality of
this finding remains to be determined.
Lymphatic stromal cells have also been
reported to be a source of EGF and
IGF-I. 58 In addition, lymph node
secretion of chemokines such as SCL/
CCL21 and CCL1 may attract tumor
cells that express the receptors CCR7 and
CCR8, respectively.5 9 Overexpression
of CCR7 in B16 melanoma cells has
been shown to increase lymph node
metastasis,60 and others have reported
that breast cancer cells or melanomas expressing CXCR4 may actively
home to lymph nodes containing CXCL12/SDF-1 ligand.6 1 Activated
cancer-associated fibroblasts may also secrete chemokines that
enhance tumor growth and invasion.62
Lastly, although intravasation into lymphatics may seem to be
favored due to reduced shear stress inflicted upon the cell, increased
hemodynamic flow rate may also help dislodge individual cells from
the primary tumor. Disaggregation of cells under flow has been
reported to be affected, at least in part, by levels of E-cadherin
expression.
HOW DO TUMOR CELLS REACH SYSTEMIC CIRCULATION?
Viable tumor cells have been isolated in the blood of patients
bearing nearly all types of cancer, including the most common forms
of carcinomas. 63 Although the amount of time a tumor cell spends
circulating throughout the body is believed to be short, the sheer
number of cells potentially available for seeding distant metastases
makes it imperative for us to understand how tumors gain initial
access to systemic circulation.
In many clinical studies involving different human tumors, a
positive association between lymphatic and hematogenous metastasis
has generally been observed. For instance, Bubendorf et al reported
that 84% of patients with node-positive prostate cancer bore evidence
of hematogenous dissemination, as opposed to 16% of patients
without local lymph node spread.64 In breast cancer, lymph node
metastasis has been linked with poor prognosis and distant metasta-
sis,65 and similar observations have also been noted in pancreatic
cancer,66 ovarian cancer,67 and head and neck cancer,68 among others.
Recently, we observed a strong correlation between lymphatic
and hematogenous dissemination in a mouse orthotopic xenograft
model of prostate cancer (Fig. 2).30 As expected, the lymph nodes
directly draining the prostate, the para-aortic/sub-lumbar lymph
nodes, were invaded first by the tumors, followed by the more distant
sub-renal lymph nodes. Mice that bore tumors which had not
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formed macroscopic metastases in the lumbar
lymph nodes (-50% of mice) also did not possess
renal lymph node macro-metastases. Not surpris-
ingly, the appearance of lung micrometastases was
well-correlated with the detection of viable circu-
lating tumor cells in the blood. Interestingly,
however, significant numbers of lung metastases
and circulating cells were found only in mice that
possessed both renal and lumbar lymph node
metastases, regardless of primary tumor size.
These clinical and experimental correlations
can be interpreted in at least a couple of ways
(Fig. 3). It is possible that some tumors may be
unable to intravasate directly' into blood vessels;
thus they must establish satellite lymph node
metastases first to disperse metastatic cells via the
I ~ ~ ~ ~ ~ ·• , I .. •
thoracic duct. Another possbilifty is that the
primary tumors may be completely noninvasive
until somehow triggered to metastasize via both caFiguncer, h mtog
lymphatics and blood vessels simultaneously. (1) The tumors mi
Either possibility would potentially yield an enter venous circ
apparent correlation between lymphatic and completely nonm4
hematogenous spread. But in the case of human routes at the sam
patients, those with node-positive tumors at the
time of diagnosis might be free of distal metastases in the first scenario
but not in the second.
In support of the former possibility, Sleeman has noted that the
physiology of lymph nodes may actually favor formation of local
metastases that could serve as "bridgeheads" for further dissemina-
tion. 6' The low shear flow of lymphatic fluid coupled with the
filtering of cells into a confined space-the subcapsular sinuses-
may increase the local concentration of tumor cell aggregates in the
node. This would be in contrast to the "scatter-shot" dispersal of
individual tumor cells into large capillary beds such as the lung,
where metastatic progression after seeding is known to be highly
inefficient. Indeed, increased cell aggregation has been previously
found to enhance formation of experimental metastases. 70
Furthermore, according to Sleeman, tumor cells that have arrived in
the subcapsular sinuses would not need to extravasate. 69
Others have proposed that lymph nodes may act as initial "selec-
tion" sites where tumor cells with partial metastatic competence
could seed and expand, while selecting for increasingly malignant
variants that could later spread to more distant sites.32 This would
agree with hypotheses previously set forth that metastatic cells are
similar to, but also different from, their primary tumors of origin.7 '9
If entrance into systemic circulation were dependent on lymphatics,
experimental inhibition of lymph node metastasis should also inhibit
hematogenous spread. But, while some have indeed reported such
results, 32,343 6 others found that inhibiting lymph node metastasis
had no effect on lung metastasis. 31,37,7 1 These findings are likely
attributable to differences in the cell lines utilized and whether the
cells were implanted orthotopically or ectopically. In another study,
resection of MT- 100-TC mammary carcinomas along with draining
lymph nodes prevented metastatic recurrence, but removal of the
primary tumors alone did not.72 This would suggest that MT-100-
.TC cells reached systemic circulation via lymphatics, a progression
the authors termed "metachronous seeding."
In contrast, the presence of hematogenous metastases in the
absence of'lymphatic spread would clearly indicate direct dispersal of
tumor cells into blood vessels. This is a likely scenario for patients
ssible pathways for metastasis could explain why, in a mouse model of prostate
nous spread is observed only in the presence of significant lymphatic spread.
ght be incapable of intravasating directly into blood vessels, so metastatic cells
ulation indirectly via lymphatics ("metachronous seeding"). Or, the tumor is
etastatic until mobilized to metastasize via both lymphatic and hematogenous
e time 12).
harboring bone marrow micrometastases in the absence of other
detectable signs of spread, which has been reported to occur in
20-40% of carcinomas.7 3 Interestingly, comparative genomic
hybridization (CGH) analyses have suggested that malignant cells
may disseminate through the blood very early in breast cancer.74 '75
These cells were also found to be distinct from lymph node metastases
by CGH, thus arguing against metachronous seeding.7 4
Lastly, in patients harboring both lymphatic and hematogenous
metastases, assessing the order of events remains difficult. One possible
experimental approach to determine whether distant metastases arise
directly from the primary tumor or indirectly from lymph nodes
might be to construct a detailed time course tracking the relative
temporal appearance of tumor cells in the blood and lymph nodes.
If hematogenous spread occurs via lymphatics, for instance, malignant
cells should appear in lymph nodes before blood. Such an approach
could be coupled with methods such as CGH74 or gene expression
profiling7 6 to track dispersed tumor cells. Detailed genomic analyses
comparing primary tumors with micrometastases isolated from
lymph nodes and/or distant sites should be able to distinguish the
pathways undertaken for metastasis.
CONCLUSIONS
A confluence of factors likely influences whether primary tumors
metastasize via blood vessel or lymphatic routes and, related to that,
how tumor cells reach the systemic circulation. Differentiation
programs innate to the cell of origin of each tumor may predetermine
the metastatic phenotype, though additional genetic or epigenetic
changes may also affect a cell's ability to intravasate. Morphological
differences between blood vessels and lymphatics will almost certainly
affect the initial route of spread, and in this regard, peritumoral
lymphatics might be considered a default pathway for tumors
incapable of crossing blood endothelial boundaries. However, active
mechanisms for attracting tumor cells towards one type of vasculature
versus another cannot be discounted. In addition, the roles played by
inflammatory 77 and host hematopoietic precursor cells78 in affecting
the process will need to be further examined.
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At the same time, improved imaging techniques should allow
simultaneous visualization of blood vessel and lymphatic intravasation
within the same tumor, allowing direct measurements of the relative
frequencies of each occurrence. In addition, genomic approaches
combined with clustering algorithms should be able to elucidate
molecular relationships between disseminated tumor cells and cells
derived from the primary tumor and/or lymph node metastases.
'T'hese studies will likely yield detailed information about how and
when merastatic cells leave the primary tumor. Lastly, identification
and validation of genes and proteins that affect the intravasation
process and perhaps specify whether a tumor invades via blood
vessel or lymphatic routes, as has been recently proposed,79 will have
valuable clinical implications for prognosis and treatment.
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Abstract Metastasis to lymph nodes is a common feature of many human tumors and may facilitate dissemination to
other parts of the body. Peritumoral lymphatics, which are located at the periphery of a primary tumor, appear to be
anything but peripheral for metastasis, as recent studies have highlighted their critical role in disseminating tumor cells to
local lymph nodes. The metastatic process, including lymphangiogenesis, is likely governed by a complex series of
interactions among tumor cells, endothelial cells, and non-endothelial stromal components. Therefore, a detailed
understanding of the biology of the tumor microenvironment, particularly as it pertains to peritumoral lymphatics near the
tumor-stromal junction, may someday translate into clinical approaches that target metastasis at the invasive front. J. Cell.
Biochem. 9999: 1 -11, 2006. © 2006 Wiley-Liss, Inc.
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There are numerous ways in which a tumor
cell could succeed at metastasis but also many
ways in which it could fail. In order to
metastasize, a tumor cell must possess or
acquire the ability to surmount a variety of
obstacles-challenges that include de-adhesion
from the primary tumor, intravasation into
blood or lymphatic vessels, survival in circula-
tion, extravasation, and growth at a secondary
site. With so many barriers that need to be
overcome, it is almost a wonder that tumors ever
succeed at metastasis. One theme that has
emerged is that tumors probably do not perform
the feat alone but instead, receive significant
input from the surrounding microenvironment.
Another theme, as will become evident, is that
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different tumors solve the metastatic problem
in different ways.
Lymph nodes are the most common sites of
metastasis for many cancers, including carci-
nomas [Sleeman, 2000]. There are likely to be
several reasons for this. Tumors reach the
draining lymph nodes via lymphatic vessels,
which themselves appear to be ideal conduits for
metastasis. Unlike blood vessels, lymphatics
lack a basement membrane and are not sur-
rounded by pericytes, thus making them rela-
tively permeable to invading tumors. The low-
pressure flow of lymphatic fluid also likely
favors the survival of circulating tumor cells.
And, upon reaching the node, metastatic cells
are filtered into a confined space-the subcap-
sular sinuses-which may encourage the for-
mation of aggregates that could protect against
cell death [Sleeman, 2000].
These considerations offer a mechanistic,
albeit incomplete, view of lymphatic metastasis,
especially in light of recent studies that have
identified other factors, particularly those
extrinsic to the tumor cell that could affect the
metastatic switch in profound ways. In order to
examine the metastatic process thoroughly, one
must also consider the contextual cues provided
by a tumor's microenvironment. This microen-
vironment, or stroma, is comprised of a complex
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mixture of fibroblasts, immune cells, endothe-
lial cells, and endothelial-associated cells. Each
cell type could potentially communicate with
others, or with tumor cells, through secretion of
a variety of signals, including growth factors,
matrix molecules, chemokines, and protei-
nases. Indeed, the perception of metastasis as
a solitary journey embarked upon by a single
rogue cell can be regarded as overly simplistic
and, these days, even antiquated. In this article,
we will consider how different pair-wise cellular
interactions might potentially affect a tumor's
ability to metastasize to lymph nodes.
TUMOR-TO-LYMPHATIC ENDOTHELIAL
CELL SIGNALING
Recent studies have suggested several possi-
ble scenarios by which tumors could directly
affect the physiology of nearby lymphatics in
ways that would favor metastasis. These possi-
bilities include tumor-induced lymphangiogen-
esis, lymphatic activation, and pre-conditioning
of lymph nodes prior to metastatic colonization.
Lymphatic Vessels
Although experimental results have lent sup-
port to each of these scenarios, it is important to
note that direct signaling between tumor cells
and lymphatic endothelial cells has not been
demonstrated conclusively in vivo. As will be
discussed later, immune cells such as macro-
phages might serve as important intermedi-
aries for tumor-induced lymphangiogenesis.
Overexpression studies using cancer xeno-
graft models have been instrumental in identi-
fying factors that can induce tumor
lymphangiogenesis and, oftentimes, enhance
lymph node metastasis (Fig. 1A). The first
demonstration of this involved tumor over-
expression of vascular endothelial growth fac-
tor-C (VEGF-C) and -D (VEGF-D), both of which
increased lymphatic metastasis [Skobe et al.,
2001; Stacker et al., 2001]. The predominant
lymphatic receptor for these cytokines is VEGF
receptor-3/Flt4, though proteolytic processing
of VEGF-C/D by plasmin or by proprotein
convertases can allow efficient binding to VEGF
receptor-2/Flkl [McColl et al., 2003; Siegfried
et al., 20031. Subsequent studies have also
r.
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Fig. 1. Signals and interactions within the tumor micro-
environment could potentially affect lymph node metastasis.
A: Tumor-secreted factors have been reported to induce
lymphangiogenesis, lymphatic activation, and pre-conditioning
of lymph nodes for metastasis. B: Tumor cells can activate their
surrounding stroma, while an activated stroma (fibroblasts,
immune cells, etc.) can also induce increased tumorigenicity
and metastasis in neoplastic cells. C: The stromal microenviron-
ment, particularly immune cells such as macrophages, can
induce lymphangiogenesis through a variety of signals. D: The
lymphatic endothelium and/or the lymph node can, in turn,
release factors that recruit tumor cells. MMPs, matrix metallo-
proteinases; ECM, extracellular matrix; ROS, reactive oxygen
species. [Color figure can be viewed in the online issue, which is
available at www.interscience.wiley.com.]
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identified additional lymphangiogenic factors,
including VEGF-A, FGF2, PDGF-B, HGF, and
others (reviewed in Alitalo et al., 2005). Because
lymphatics and blood vessels share a common
embryonic origin [Karkkainen et al., 2004],
it is not surprising that these factors have
previously been found to possess angiogenic
activity.
Transgenic Rip-Tag mice overexpressing
VEGF-C in the pancreas displayed de novo
generation of lymphatics near P-cell islets and
increased metastasis to the regional mesenteric
lymph nodes [Mandriota et al., 2001]. Similarly,
loss of the cell adhesion molecule N-CAM was
associated with upregulated VEGF-C in pan-
creatic tumors, again yielding increased lymph
node metastasis [Crnic et al., 2004]. The
opposite result-reduced lymphangiogenesis-
was commonly found when Flt4-mediated sig-
naling was blocked. This has been accomplished
by injecting antibodies against VEGF-D into
tumor-bearing mice [Stacker et al., 2001], by
adenoviral delivery of a truncated soluble
receptor for Flt4 [He et al., 20021, or by
expressing in tumor cells RNAi against VEGF-
C [Chen et al., 2005; Wong et al., 2005]. In many
cases, lymphatic spread was also concomitantly
inhibited.
Although the degree of tumor lymphangio-
genesis has been positively correlated with
lymph node metastasis in many experimental
models, others have observed that tumor-asso-
ciated lymphatics are physiologically abnormal
and non-functional for fluid drainage [Padera
et al., 20021. An important distinction needs to
be made in that, in some cases, xenografted
tumors have been found to induce both lympha-
tics within the tumor itself (intratumoral
lymphatics) and lymphatics at the periphery
(peritumoral lymphatics). We recently showed
in an orthotopic model of prostate cancer that
intratumoral lymphatics were unnecessary for
efficient metastasis to draining lymph nodes
[Wong et al., 2005]. This result is consistent
with the view that peritumoral, and likely pre-
existing, lymphatics at the invasive margin are
the predominant routes of egress from the
primary tumor [Padera et al., 2002]. This view
is also supported by clinical data showing that
the abundance of peritumoral, but not intratu-
moral, lymphatics correlated with metastasis in
breast and prostate cancer; and that lymphan-
giogenesis does not occur in many tumors that
nevertheless metastasize to lymph nodes,
including those of the breast, prostate and
pancreas (reviewed in Wong and Hynes, 2006).
In contrast, several clinical studies have corre-
lated intratumoral lymphatic vessel density
(LVD) with metastasis (reviewed by Stacker
et al., 2002 and Achen et al., 2005). Conse-
quently, the importance of tumor lymphangio-
genesis in regard to metastasis is debatable, and
may depend on the organ and/or experimental
model in question. However, increased LVD
might also merely be a marker of aggressive
tumors that secrete high levels of lymphangio-
genic cytokines and are poised to metastasize
regardless of lymphangiogenesis.
Aside from increasing the abundance of
lymphatic vessels in proximity to the tumor,
activation of local lymphatic vessels has also
been proposed as a way to enhance tumor cell
intravasation and lymph node metastasis. He
et al., recently noted that peritumoral lympha-
tics proximal to subcutaneous LNM35 lung
tumors often displayed an "activated" pheno-
type-that is, increased vessel sprouting, dila-
tion, and permeability [He et al., 2005]. Others
have speculated that activated lymphatics
might upregulate secretion of chemokines that
could attract tumor cells [Alitalo et al., 2004].
This activated phenotype can apparently be
reversed by adenoviral delivery of soluble Flt4
[He et al., 20051, an effect that is reminiscent of
tumor blood vessel normalization, which is seen
upon interference with VEGF-A- or Flkl-
mediated signaling [Tong et al., 2004].
In addition to affecting lymphatics in their
immediate vicinity, tumors have been reported
to pre-condition future sites of metastasis in the
lymph node. As observed by Hirakawa et al.
[20051, carcinogen-induced squamous cell car-
cinomas in transgenic mice overexpressing
VEGF-A in the skin displayed increased angio-
genesis and lymphangiogenesis, as well as
enhanced lymphatic and systemic metastasis.
Surprisingly, increased lymphangiogenesis
was also seen within draining lymph nodes
prior to, and after, metastatic colonization. This
suggests that tumors might somehow prepare
the lymph node for metastasis. Although the
exact mechanism underlying this phenomenon
remains unclear, lymph-node lymphangiogen-
esis could perhaps be mediated directly by
binding of VEGF-A to Flkl on the surface of
lymphatic endothelial cells. Or, VEGF-A might
increase the permeability of local blood vessels,
and the consequent extravasation of fluid might
aL~ a..
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serve as a lymphangiogenic signal. Interest-
ingly, lymphangiogenesis within lymph node
metastases was also proposed as a possible way
for tumors to disseminate further throughout
the lymphatic system and, subsequently, to
systemic sites. At present, however, the exact
implications and generalities of these novel
findings remain to be seen.
BI-DIRECTIONAL SIGNALING BETWEEN
TUMOR AND NON-ENDOTHELIAL
STROMAL CELLS
Tumor cell communication with the sur-
rounding non-endothelial stroma can likely tip
the balance towards the metastatic phenotype.
.Not only can malignant cells provoke changes
within their microenvironment, but abnor-
mal stroma has also been found to enhance
epithelial cell transformation and invasiveness.
A consequence of these interactions might be
induction of lymphangiogenic growth factors, in
addition to an increased propensity by tumors to
invade local lymphatics. Mobilization of inflam-
matory cells to the primary tumor is also likely
to be an important component of both lymphan-
giogenesis and angiogenesis.
Based on clinical observations, as well as
experimental studies in mice, it has long been
known that tumor-associated stroma is fre-
quently abnormal in appearance [Bhowmick
and Moses, 20051. In many cases, the usual
boundary separating the epithelium from the
stroma-the basement membrane-has been
disrupted, with a corresponding loss of normal
tissue architecture, altered extracellular
matrix (ECM) deposition, increased inflamma-
tion, and neovasculogenesis. Cancer-associated
fibroblasts (CAFs) often take on the appearance
of an activated, or myofibroblastic, phenotype
marked by the expression of a-smooth muscle
actin. When cultured in vitro, CAFs have been
reported to exhibit altered migratory properties
as well as abnormal expression of growth factors
and ECM [Cunha et al., 20031.
Importantly, transplantation/co-injection ex-
periments have demonstrated that CAFs
appear to be stably activated and can induce
de novo tumorigenic growth in non-tumorigenic
prostate epithelial cells [Olumi et al., 1999], or
increased tumorigenicity in human MCF-7
breast cancer cells [Orimo et al., 2005].
Although the mechanism by which tumors
activate their surrounding stroma is, at present,
not entirely clear, the process likely involves a
complicated exchange of paracrine signals
(Fig. 1B). One example of this complex dialog
is illustrated in studies where several carci-
noma cell lines, through secretion of IL-1,
bFGF, and/or PDGF, induced co-cultured
human skin fibroblasts to secrete HGF. HGF,
in turn, bound its receptor, c-Met, on the surface
of the tumor cells, which increased their growth,
scattering and invasiveness [Nakamura et al.,
19971. In another example, human HaCaT
keratinocytes, which are immortalized but
non-tumorigenic, were reported to signal to
fibroblasts in vitro through secretion of PDGF.
In response, the fibroblasts upregulated FGF-7,
which induced HaCaT cell proliferation and
tumorigenicity [Brauchle et al., 1994].
While epithelial cell transformation has long
been regarded as an initiating event for stromal
activation, several recent studies have also
shown that abnormal stroma may precede,
and even induce, a malignant epithelial pheno-
type. For instance, irradiated fibroblasts can
enhance tumorigenicity and/or invasiveness of
lung, mammary, or pancreatic epithelial cells
when co-injected in vivo, and similar effects
have been reported when senescent fibroblasts
were utilized (reviewed in Bhowmick et al.,
2004b). In addition, human prostate BPH-1
cells can be made tumorigenic in mice when
combined with hormone-activated urogenital
mesenchyme [Cunha et al., 20031. In many
cases, the HGF-c-Met signaling axis appears to
be crucial. Other stromally derived, paracrine
signals involved with malignancy have been
reported to include TGF-P, HGF, EGF, FGF,
IGF, and Wntl [Bhowmick et al., 2004b]. In the
case of TGF-(3, its upregulation in fibroblasts
has been shown to induce mammary carcino-
mas [Kuperwasser et al., 2004]. However,
genetic deletion of TGF-P type II receptor
specifically in fibroblasts was associated with
upregulated HGF and resulted in induction of
spontaneous prostate and forestomach carcino-
mas in mice [Bhowmick et al., 2004a]. Trans-
genic expression of constitutively active TGF-3
type I receptor in the mammary gland has also
been reported to increase tumor metastasis
[Siegel et al., 2003]. The dual effects seen with
TGF-P signaling-both as a positive and nega-
tive regulator of tumorigenesis-may largely be
context- and cell-type dependent.
A similar dual effect on tumor progression has
been observed in the case of matrix metallopro-
teinases (MMPs), which are secreted by both
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tumor and stromal cells. MMPs function to
degrade the surrounding ECM and can activate
latent cytokines as well as other MMPs.
Furthermore, MMPs can release matrix-bound
growth factors (e.g., VEGF-A and FGF) that can
induce angiogenesis and/or lymphangiogenesis,
though cryptic collagen IV fragments released
by MMP-9 can also possess potent anti-angio-
genic activity [Hamano et al., 2003]. Experi-
mentally, spontaneous mouse mammary tumor
formation was enhanced by fibroblasts that
overexpressed MMP-1 and MMP-7, but was
inhibited when fibroblasts had lost MMP-11
(reviewed in Lynch and Matrisian, 2002).
Transgenic expression of MMP-3 in mammary
tumors has also been reported to promote
epithelial-to-mesenchymal transition, a marker
of enhanced cancer aggressiveness, through
disruption of E-cadherin-P-catenin interactions
[Sternlicht et al., 19991. In addition, intravasa-
tion of human breast, prostate, and fibrosar-
coma tumor cells into blood vessels has been
shown to require the activity of MMP-9 and
urokinase plasminogen activator in a chicken
chorioallantoic membrane assay [Kim et al.,
1998].
Another important component of the stromal
microenvironnient, the inflammatory cells of
the innate immune system, is now regarded as a
critical, if not indispensable, mediator of tumor
progression [Coussens and Werb, 2002].
Immune cells are major sources of growth
factors and cytokines that can induce tumor
progression, invasiveness, angiogenesis, and
lymphangiogenesis. Tumor and/or stromal
fibroblastic secretion of chemokines and other
cytokines such as VEGF-A and monocyte colony
stimulating factor (M-CSF) are key to recruiting
specific leukocyte populations. Macrophages, in
particular, are chemotactic to VEGF-A, M-CSF,
and monocyte chemotactic protein chemokines,
and may be critical for lymphangiogenesis, as
discussed below [Cursiefen et al., 20041. Inter-
estingly, a subset of tumor-associated macro-
phages (TAMs) has been found to express Flt4,
and these may be recruited to tumors secreting
VEGF-C/D [Schoppmann et al., 2002]. In addi-
tion to macrophages, neutrophils are also
chemotactic to chemokines such as CXCL1/
MIP-2 and are important for angiogenesis
[Scapini et al., 2004]. Finally, natural killer
cells have also been found to aid progression of
pre-neoplastic mammary lesions through secre-
tion of MMPs [Bissell and Radisky, 2001].
The importance of bi-directional signaling for
inducing tumor cell invasion has been evi-
denced both in vivo and in vitro, in studies
examining interactions between mammary car-
cinomas and macrophages. Tumor-secreted
colony-stimulating factor 1 (CSF-1) was shown
to be a chemotactic signal for macrophages
expressing the CSF-1 receptor [Wang et al.,
2005]. These TAMs reciprocated by secreting
epidermal growth factor (EGF), which bound
surface receptors on the tumor cells and induced
a migratory gene expression program. The
consequences of this-increased tumor inva-
siveness-have been observed by intravital
microscopy, particularly at the periphery of
mammary tumors, where macrophages were
abundant. Furthermore, in CSF-1 knock-out
mice, which display severe reductions of macro-
phages in most tissues, the growth of sponta-
neous mammary tumors was not affected
relative to wild-type mice, but progression to
invasion and metastasis was impaired [Lin
et al., 2001].
In colorectal cancer, peak VEGF-C/-D expres-
sion was observed in tumor cells closest to the
invasive margins [Onogawa et al., 2004]. It is,
therefore, conceivable that soluble factors
secreted by activated stromal cells located at
the tumor-stromal interface may act on malig-
nant cells to upregulate expression of lymphan-
giogenic factors, thus aiding indirectly in the
metastatic process. Expression of VEGF-C is
known to be regulated by cytokines, and,
indeed, can be induced in a PI3-kinase-depen-
dent manner by IGF, EGF, and PDGF in tumor
cells [Tang et al., 2003]. Similarly, VEGF-C was
upregulated by heregulin in breast cancer [Tsai
et al., 2003] and by the inflammatory cytokines
IL- 1 /IL- and TNF-c [Ristimaki et al., 1998].
In many cases, activation of canonical signaling
pathways known to be important for epithelial
cell transformation, such as those mediated by
Ras and Akt, has been implicated in upregulat-
ing expression of VEGF-A [Tan et al., 20041.
Hypoxic conditions or the presence of reactive
oxygen species generated during the inflamma-
tory response may also induce VEGF-A, which
may then either stimulate lymphangiogenesis
directly, or perhaps indirectly, as one study has
suggested, by inducing squamous cell carcino-
mas to upregulate VEGF-C [Hirakawa et al.,
20051.
These studies have been critical for delineating
functionally important lines of communication
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between tumor cells and stroma, and it is likely
that other examples of bi-directional signaling
remain to be uncovered. Some of the latter
studies have also brought to center stage the
importance of TAMs for mediating not only
tumor progression to metastasis, but also likely,
as will be discussed in the next section, the
actual induction of angiogenesis and lymphan-
giogenesis.
NON-ENDOTHELIAL
STROMAL-TO-LYMPHATIC
ENDOTHELIAL CELL SIGNALING
The stromal fibroblasts and immune cells
that surround tumors can exert direct effects on
lymphatics by secreting growth factors, remo-
deling the ECM, and maybe even by incorporat-
ing into nascent lymphatic vessels (Fig. 1C).
Stromal contributions to neovascularization are
well documented and perhaps best observed in
transgenic mice made to express GFP under
control of the human VEGF-A promoter
[Fukumura et al., 1998]. When these mice were
crossed with the PyMT spontaneous mammary
tumor model, the fibroblasts surrounding the
neoplasm, but not the tumor cells themselves,
were GFP-positive, suggesting that the main
source of VEGF-A was stromally derived.
Although it is tempting to speculate that many
principles applying to tumor angiogenesis also
apply to lymphangiogenesis-and many have
indeed been shown to be relevant for both
processes-it is important to remember that
angiogenic tumors do not necessarily induce
lymphangiogenesis. Furthermore, lymphangio-
genesis has not often been seen in human
clinical tumors, even in those that metastasize
to lymph nodes. The reasons for this are unclear
but almost certainly rest in the molecular
differences between the two vessel types, as
exemplified by the specificity of thrombospon-
din-1 for inhibiting CD36-expressing blood
vessels but not lymphatics rHawighorst et al.,
2{02].
In addition to VEGF-A, activated fibroblasts
have been known to secrete many potential
lymphangiogenic factors, including VEGF-C,
FGF, HGF, IGF, and PDGF [Cunha et al., 2003].
In vitro stimulation of normal human skin
fibroblasts with TGF-P and EGF induced secre-
tion of both VEGF-C and VEGF-D, and
this effect may, in part, underlie the activa-
ted fibroblastic phenotype [Trompezinski
et al., 20041. CAFs in breast cancer were also
found to enhance angiogenesis and tumor
growth by secreting the chemokine SDF-1/
CXCL12 [Orimo et al., 2005]. This mobilized
and recruited endothelial precursor cells which
were derived from the bone marrow and
expressed the receptor CXCR4. SDF-1 has also
recently been found to be important for retain-
ing pro-angiogenic bone marrow-derived circu-
lating cells that associated near blood
vessels [Grunewald et al., 2006]. Whether these
phenomena occur in other tumors, and whe-
ther similar mechanisms are important for
inducing lymphangiogenesis, is still highly
controversial.
Since stromal fibroblasts secrete abundant
matrix proteins, their influence on the composi-
tion and ordering of the ECM microenviron-
ment likely serves as another signal for blood
vessels and lymphatics. During angiogenesis,
endothelial cell matrix receptors such as integ-
rins are upregulated and serve several impor-
tant capacities such as enhancing VEGF-
mediated signaling through direct association
with Flkl [Soldi et al., 1999]. In the case of
lymphatics, cell proliferation in vitro seems
dependent on the matrix molecule fibronectin,
which may be supplied in vivo by tumor cells,
fibroblasts, and/or endothelial cells [Zhang
et al., 20051. Lymphatic endothelial cell binding
to fibronectin leads to direct association
between the integrin i1 subunit and Flt4, which
may enhance VEGF-C/D signaling pathways
[Wang et al., 2001]. The integrin heterodimer
ca9pl has also been implicated in the develop-
ment of lymphatics and may act to bind ECM
components like fibronectin and/or, as recently
reported, VEGF-C and -D [Vlahakis et al.,
2005]. Lastly, fibroblast-mediated contraction
of the ECM, particularly of collagen networks, is
increased when those cells are activated, and
likely contributes to high tumor interstitial
fluid pressure (IFP) [Heldin et al., 2004]. While
high IFP is thought to signal the growth of new
lymphatics, overwhelming IFP, as is often seen
within tumors, can collapse intratumoral lym-
phatic vessels [Padera et al., 2002]. Thus,
fibroblasts can potentially regulate not just
the growth of new lymphatics, but also their
function.
As mentioned previously, the role of immune
cells in mediating angiogenesis and lymphan-
giogenesis has recently received great atten-
tion, leading to some valuable insights. Once
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recruited to tumors, leukocytes release an
abundant cache of cytokines and MMPs that
can directly affect lymphatics. In support of this
idea, the degree of inflammation in two studies
of human cervical cancer positively correlated
with both lymphatic vessel density and the
number of VEGF-C-expressing peritumoral
cells r[Schoppmann et al., 2001, 2002]. Many of
these cells were CD68+ macrophages that also
expressed VEGF-C/-D and FIt4. Increased
inflammatory response, however, was nega-
tively correlated with lymph node metastasis
[Schoppmann et al., 2001]. These findings
illustrate the complexities that shape the
metastatic tendencies of a tumor-how, for
instance, the stromal inflammatory reaction
might wield a double-edged sword, acting both
as a way to promote lymphangiogenesis and as
an anti-tumor response.
But what exactly is the mechanism for
inflammation-induced lymphangiogenesis?
Novel findings have been obtained from experi-
ments utilizing traditional xenograft models, as
well as de novo lymphangiogenesis models
involving either the murine cornea or Matrigel
plugs implanted into mice. Many of these
studies have confirmed the important role of
macrophages, which have been found to secrete
many potential lymphatic growth factors,
including VEGF-C, VEGF-D, VEGF-A, and
FGF [Cursiefen et al., 2004; Jin et al., 20061.
Expression of these factors seems to be induced
in these cells by chemotactic factors such as M-
CSF rEubank et al., 2003] and possibly by an
autocrine loop in a subpopulation that
expresses Flt4 [Schoppmann et al., 2002;
Eubank et al., 2003]. In addition, macrophage
secretion of proteinases such as MMP-9 could
remodel the ECM, thereby releasing additional
cytokines while providing a hospitable environ-
ment for lymphatic proliferation [Carmeliet and
Collen, 19981.
In the cornea, which is normally avascular,
inflammation can induce local formation of
blood and lymphatic vessels. Interestingly,
CDllb+/LYVE-l+ macrophages have been
reported to integrate into inflammation-
induced lymphatics in vivo and could also form
lymphatic-like tubes when cultured in vitro
[Maruyama et al., 2005]. These findings were
recently supported by studies in human renal
transplants that had exhibited immune rejec-
tion, chronic inflammation and lymphatic
proliferation rKerjaschki et al., 2006]. Circula-
ting lymphatic progenitors derived either from
a minor CD133+VEGFR-3 CD34+ subpopula-
tion or from a major CD14+VEGFR-3 +
CD31 VEGFR-2 monocyte population incor-
porated into lymphatics. However, this was
contrasted by findings in the same study where
circulating progenitor cells did not incorporate
into lymphatics associated with two cases of
human carcinomas, an observation that had
been similarly noted in tumor xenograft models
utilizing B16 melanoma or Lewis lung carci-
noma cells [He et al., 2004]. Therefore, at
present, these data seem to suggest that
proliferation of pre-existing lymphatics
accounts for tumor lymphangiogenesis, though
increased inflammation might coax macro-
phages to transdifferentiate into lymphatics.
Obviously, the generality of these recent find-
ings, while exciting, remains to be further
validated in different systems.
Other as-yet-unknown factors affecting lym-
phatic growth will almost certainly be eluci-
dated in future studies. For instance, CXC-
ERL+ chemokines can induce angiogenesis by
binding the receptors CXCR2/CXCR1 on blood
endothelial cells-do chemokines have any
direct or indirect effects on lymphatics, which
express SDF-1 and specifically express the
atypical, and perhaps non-signaling, chemo-
kine receptor D6 [Nibbs et al., 2001]? It is also
known that blood vessels are molecularly
heterogeneous, exhibiting tissue- and tumor-
specific patterns of gene expression [St. Croix
et al., 2000]. Most notably, sprouting angiogenic
vessels upregulate the integrins avD3 and avI5,
thereby possibly implicating specific matrix
molecules such as vitronectin in angiogenesis
[Carmeliet and Collen, 1998]. Since peritumoral
lymphatics often appear physiologically distinct
from normal lymphatics, these nascent lympha-
tics will almost certainly possess an altered
gene expression program, and consequently, a
unique reliance on different growth factors and
matrix molecules.
LYMPHATIC-TO-TUMOR CELL SIGNALING
It is likely that some of the signals involved
with homing circulating lymphocytes to lymph
nodes might also be directing tumor cells to
lymphatics. Among other components, there is
evidence that chemokine receptors, selectins,
integrins, as well as their respective ligands,
are critically important for both processes.
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However, circulating lymphocytes are recruited
from the blood and initially roll along the
luminal walls of the lymph node high endothe-
lial venules (HEVs) before extravasation. This
is dependent upon the binding of lymphocyte L-
selectin primarily to peripheral node addressins
on the HEVs. While malignant cells circulating
in the blood might also reach distal lymph nodes
by extravasating through HEVs, in most cases,
human clinical tumors have been observed to
invade lymph nodes in a step-wise fashion
[Sleeman, 2000]. The nearest draining lymph
node, or the sentinel node, is invaded first,
followed by more distal nodes. Therefore, rather
than reaching lymph nodes via HEVs, most
tumor cells likely arrive at the node directly via
afferent lymphatics.
Nevertheless, L-selectin has been shown to
enhance tumor dissemination to both local and
distal lymph nodes. Spontaneous RipTag pan-
creatic tumors overexpressing L-selectin metas-
tasized to the draining mesenteric lymph nodes
as well as to peripheral nodes, while tumors
without L-selectin did not metastasize [Qian
et al., 20011. Addressins are not expressed on
lymphatics but another L-selectin ligand, man-
nose receptor, is expressed and has been
reported to be important for tumor cell binding
to the lymphatic endothelium in lymph nodes
[Irjala et al., 20031. Normally, L-selectin inter-
action with mannose receptor regulates exit of
lymphocytes from lymph nodes via efferent
lymphatics [Irjala et al., 2001]; at present, it is
unclear whether a similar mechanism is
involved with tumor spread away from the node.
The finding that chemokines can home tumor
cells to specific organs, including lymph nodes,
suggests that a certain logic may underlie the
pattern of metastasis exhibited by a particular
tumor, and that this pattern can be deciphered,
at least in part, by analyzing the distribution of
specific chemokine receptor-ligand pairs
(Fig. ID). The first and most notable demonstra-
tion of this was performed by Muller et al.
[20011, who showed that CXCL12/SDF-1 was
preferentially expressed in the lymph nodes,
lung, liver, and bone marrow. These are all
common sites of metastasis for breast cancers,
which express the SDF-1 receptor CXCR4.
Inhibiting the interaction between this recep-
tor-ligand pair in vivo reduced the ability of
MDA-MB-231 breast cancer cells to metastasize
to both lung and lymph nodes. Furthermore, the
chemokine CCL21 was also found to be highly
expressed in lymph nodes, and its receptor,
CCR7, is often present on the surface of breast
cancer and melanoma cells. Indeed, work by
others has shown that overexpressing CCR7 in
B16 melanoma cells can augment lymph node
metastasis [Wiley et al., 2001]. Finally, acti-
vated lymphatic endothelial cells may secrete
increased levels of CCL1, which could possibly
be a chemotactic signal for CCR8-expressing
tumor cells [Alitalo et al., 20041.
Release of EGF and IGF-1 by lymphatic
stromal cells might serve as additional factors
that recruit tumor cells and/or enhance their
proliferation in lymph nodes [LeBedis et al.,
2002]. Also, tumors have recently been reported
to induce the formation of pre-metastatic niches
at future sites of metastasis [Kaplan et al.,
2005]. These niches were composed of
VEGFR1-t+ bone marrow-derived cells and
matrix secreted by fibroblast-like stromal cells,
and were important for metastatic colonization
of different organs. It will be important to learn
how signals originating from these niches, in
turn, attract tumor cells to them, and whether
conditioning of the lymph node might also
precede lymphatic metastasis. In many ways,
these findings have uncovered more questions
than answers. Clearly, a great deal remains to
be understood.
CONCLUSIONS
Lymph node metastasis is commonly seen for
a variety of tumors and often guides the
therapeutic course of action. While the presence
of lymphatic metastasis may serve as an early
warning sign for an aggressive primary tumor,
perhaps more importantly, it might also be
indicative of a cancer that has already spread to
more distant sites in the body. Since lymphatics
eventually connect with venous blood, lymph
nodes might actually serve as the primary
gateways for disseminating tumor cells into
hematogenous circulation. Inhibit lymph node
metastasis, so the reasoning goes, and distant
metastasis would also be stopped, or at least
severely hampered. Based on this view, it is
critical that we better understand the molecular
mechanisms that affect each of the steps
involved.
The findings discussed here have helped us
move away from the perception of metastasis as
a black box relying on chance events, in many
ways once thought to be unintelligible. They
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have also revealed the intricacies of a process
orchestrated by a multitude of players. Inflam-
matory cells, fibroblasts, endothelial cells, the
cancer cells themselves-untangling the web of
reciprocal and non-reciprocal signals that con-
tribute to tumor dissemination will be espe-
cially important. So too will be the need to better
understand the fundamental biology of the
lymphatic endothelium and the processes rele-
vant to metastasis, including lymphangiogen-
esis and other tumor-induced lymphatic
abnormalities. Despite the complexity of the
tumor microenvironment, there is good reason
to believe that the myriad of cellular interac-
tions that take place can be teased apart, broken
down, understood. Knowledge gained from
these and future studies will affect how we treat
metastatic disease, and perhaps someday, allow
us to prevent it altogether.
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